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Respiratory Therapy Techniques
Oxygen therapy
All crit ically i l l  patients should receive additional inspired oxygen on a ‘more not less is best’ phi losophy.
Principles
High flow, high concentration oxygen should be given to any acutely dyspnoeic or hypoxaemic patient unti l accurate
ti tration can be performed using arterial  blood gas analysis.
In general, maintain SaO2 >90%, though preferably >95%. Compromises may need to be made during acute on
chronic hypoxaemic respiratory fai lure, or prolonged severe ARDS, when lower values may suffice provided tissue
oxygen del ivery is maintained.
Al l patients placed on mechanical venti lation should initial ly receive a high FIO2 unti l  accurate t itration is performed
using arterial  blood gas analysis.
Apart from patients receiving hyperbaric O2 therapy (e.g. for carbon monoxide poisoning, diving accidents), there is
no need to maintain supranormal levels of PaO2.
Cautions
A small proportion of patients in chronic Type II (hypoxaemic, hypercapnic) respiratory fai lure wi l l  develop apnoea i f
their central hypoxic drive is removed by supplemental  oxygen. However, this is seldom (if ever) abrupt and a period
of deterioration and increasing drowsiness wil l  alert medical  and nursing staff to consider ei ther (i) FIO2 reduction if
overal l condit ion al lows, (i i ) non-invasive or invasive mechanical  venti lation i f fatiguing or (i i i) use of respiratory
stimulants such as doxepram. The corollary is that close supervision and monitoring is necessary in al l  crit ically i l l
patients.
A normal pulse oximetry reading may obscure deteriorating gas exchange and progressive hypercapnia.
Oxygen toxicity is described in animal  models. Normal  volunteers wil l  become symptomatic after several hours of
breathing pure oxygen. Furthermore, washout of ni trogen may lead to microatelectasis. However, the relevance and
relative importance of oxygen toxici ty compared to other forms of venti lator trauma in cri tical ly i l l  patients is sti l l  far
from clear. Efforts should nevertheless be made to minimise FIO2 whenever possible. Debate continues as to whether
FIO2 or other venti lator sett ings (e.g. PEEP, VT, inspiratory pressures) should be reduced fi rst. The authors' present
view is to minimise the risks of venti lator trauma.
Monitoring
An oxygen analyser in the inspiratory l imb of the venti lator or CPAP/BiPAP ci rcuit confi rms the patient is receiving a
known FIO2. Most modern venti lators have a bui lt-in calibration device.
Adequacy and changes in arterial  oxygen saturation can be continuously monitored by pulse oximetry and
intermittent or continuous invasive blood gas analysis.
Oxygen masks
Hudson-type masks or nasal ‘spectacles’ give an imprecise FIO2 and should only be used when hypoxaemia is not
a major concern. Hudson-type masks do allow del ivery of humidi fied gas (e.g. via an ‘Aquapak’). Valves fi tted to
the Aquapak system do not del iver an accurate FIO2 unless gas flow is at the recommended level.
Masks fitted with a Venturi  valve del iver a reasonably accurate FIO2 (0.24, 0.28, 0.35, 0.40, 0.60) except in
patients with very high inspiratory flow rates. These masks do not al low del ivery of humidi fied gas but are
preferable in the short term for dyspnoeic patients as they enable more precise monitoring of PaO2/FIO2 ratios.
A t ight-fitt ing anaesthetic mask and reservoir bag allows 100% oxygen to be del ivered.
See also:
Venti latory support—indications, p4; Continuous positive airway pressure, p26; Basic resuscitation, p270; Respiratory
fai lure, p282
Ventilatory support—indications
Acute ventilatory insufficiency
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Defined by an acute rise in PaCO2 and a signi ficant respiratory acidosis. PaCO2 is di rectly proportional  to the body's
CO2 production and inversely proportional  to alveolar venti lat ion (minute venti lation minus dead space venti lation).
Causes include:
Respiratory centre depression, e.g. depressant drugs or intracranial  pathology
Peripheral neuromuscular disease, e.g. Gui l lain–Barré syndrome, myasthenia gravis or spinal  cord pathology
Therapeutic muscle paralysis, e.g. as part of balanced anaesthesia, for management of tetanus or status
epi lepticus
Loss of chest wall  integrity, e.g. chest trauma, diaphragm rupture
High CO2 production, e.g. burns, sepsis or severe agitation
Reduced alveolar venti lat ion, e.g. ai rway obstruction (asthma, acute bronchi tis, foreign body), atelectasis,
pneumonia, pulmonary oedema (ARDS, cardiac fai lure), pleural pathology, fibrotic lung disease, obesi ty
Pulmonary vascular disease (pulmonary embolus, cardiac fai lure, ARDS)
Oxygenation failure
Hypoxaemia is defined by PaO2 <11kPa on FIO2≥0.4. May be due to:
Venti lation–perfusion mismatching (reduced venti lation in, or preferential  perfusion of, some lung areas), e.g.
pneumonia, pulmonary oedema, pulmonary vascular disease, extremely high cardiac output
Shunt (normal  perfusion but absent venti lation in some lung zones), e.g. pneumonia, pulmonary oedema
Diffusion l imitation (reduced alveolar surface area with normal  venti lat ion), e.g. emphysema; reduced inspired
oxygen tension, e.g. alti tude, suffocation
Acute venti latory insufficiency (as above)
To reduce intracranial pressure
Reduction of PaCO2 to approximately 4kPa causes cerebral vasoconstriction and therefore reduces intracranial
pressure after brain injury. Recent studies suggest this effect is transient and may impair an already cri tical cerebral
blood flow.
To reduce work of breathing
Assisted venti lat ion ± sedation and muscle relaxation reduces respiratory muscle activity and thus the work of
breathing. In cardiac fai lure or non-cardiogenic pulmonary oedema the resul ting reduction in myocardial  oxygen
demand is more easily matched to the supply of oxygen.
Indications for ventilatory support
Venti latory support (invasive or non-invasive) should be considered i f:
Respiratory rate >30/min
Vital capaci ty <10–15ml/min
PaO2 <11kPa on FIO2≥0.4
PaCO2 high with signi ficant respiratory acidosis (e.g. pH <7.2)
Vd/VT >60%
Qs/Qt >15–20%
Exhaustion
Confusion
Severe shock
Severe LVF
Raised ICP
See also:
Dyspnoea, p278; Airway obstruction, p280; Respiratory fai lure, p282; Atelectasis and pulmonary collapse, p284;
Chronic airflow l imitation, p286; Acute chest infection (1), p288; Acute chest infection (2), p290; Acute respiratory
distress syndrome (1), p292; Acute respiratory distress syndrome (2), p294; Asthma—general management, p296;
Asthma—venti latory management, p298; Inhalation injury, p306; Pulmonary embolus, p308; Heart
fai lure—assessment, p324; Heart fai lure—management, p326; Acute l iver fai lure, p360; Acute weakness, p368;
Agi tation/confusion, p370; Generalised seizures, p372; Intracranial haemorrhage, p376; Subarachnoid haemorrhage,
p378; Stroke, p380; Raised intracranial  pressure, p382; Guil lain–Barré syndrome, p384; Myasthenia gravis, p386;
ICU neuromuscular disorders, p388; Tetanus, p390; Botul ism, p392; Poisoning—general  principles, p452; Sedative
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poisoning, p458; Tricycl ic antidepressant poisoning, p460; Cocaine, p464; Inhaled poisons, p466; Organophosphate
poisoning, p472; Systemic inflammation/multi-organ fai lure, p484; Mult iple trauma (1), p500; Multiple trauma (2),
p502; Head injury (1), p504; Head injury (2), p506; Spinal  cord injury, p508; Burns—fluid management, p510;
Burns—general management, p512; Near-drowning, p526; Post-operative intensive care, p534
IPPV—description of ventilators
Classification of mechanical ventilators
These may be classified by the method of cycl ing from inspiration to expiration. This may be when a preset time has
elapsed (time-cycled), a preset pressure reached (pressure-cycled) or a preset volume delivered (volume-cycled).
Though the method of cycl ing is classi fied according to a single constant, modern venti lators allow a greater degree
of control. In volume-cycled mode with pressure l imitation, the upper pressure alarm l imit is set or the maximum
inspiratory pressure control led. The venti lator delivers a preset t idal volume (VT) unless the lungs are non-compliant
or airway resistance is high. This is useful  to avoid high peak ai rway pressures. In volume-cycled mode with a time
limit, the inspiratory flow is reduced; the venti lator delivers the preset VT unless impossible at the set respiratory
rate. If pressure l imitation is not available this is useful to l imit peak airway pressures. In t ime-cycled mode with
pressure control,  preset pressure is del ivered throughout inspiration (unlike pressure-cycled venti lat ion), cycl ing
being determined by t ime. VT i s dependent on respiratory compliance and airway resistance. Here, too, high peak
airway pressures can be avoided.
Setting up the mechanical ventilator
Tidal volume
Conventional ly set at 7–10ml/kg, though recent data suggest lower values (6–7ml/kg) may be better in severe acute
respiratory failure, reducing barotrauma and improving outcome. In severe airflow l imitation (e.g. asthma, acute
bronchit is) smaller VT and minute volume may be needed to allow prolonged expiration.
Respiratory rate
Usually set in accordance with VT to provide minute venti lation of 85–100ml/kg/min. In time-cycled or time-l imited
modes the set respiratory rate determines the timing of the venti lator cycles.
Inspiratory flow
Usually set between 40–80l/min. A higher flow rate is more comfortable for alert patients. This al lows for longer
expiration in patients with severe airflow l imitation but may be associated with higher peak ai rway pressures. The
flow pattern may be adjusted on most venti lators. A square waveform is often used but decelerating flow may reduce
peak airway pressure.
I:E ratio
A function of respiratory rate, VT, inspiratory flow and inspiratory time. Prolonged expiration is useful in severe
airflow l imitation while a prolonged inspiratory t ime is used in ARDS to al low slow reacting alveoli  time to fi l l .  Alert
patients are more comfortable with shorter inspiratory t imes and high inspiratory flow rates.
FIO2
Set according to arterial blood gases. Usual  to start at FIO2=0.6–1 then adjust according to arterial blood gases.
Airway pressure
In pressure-controlled or pressure-l imited modes the peak airway pressure (ci rcuit rather than alveolar pressure) can
be set (usually ≤35–40cmH2O). PEEP is usual ly increased to maintain FRC when respiratory compl iance is low.
Initial ventilator set-up
Check for leaks
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Check oxygen is flowing
   FIO2 0.6–1
   VT 5–10ml/kg
   Rate 10–15/min
   I:E ratio 1:2
   Peak pressure ≤35cmH2O
   PEEP 3–5cmH2O
Key trial
Acute Respiratory Distress Syndrome Network. Venti lation with lower tidal  volumes compared with traditional t idal
volumes for acute lung injury and the acute respiratory distress syndrome. N Engl  J Med 2000; 342:1301–8
See also:
IPPV—modes of venti lation, p8; IPPV—adjusting the venti lator, p10; IPPV—failure to tolerate venti lat ion, p12;
IPPV—complications of venti lation, p14; IPPV—weaning techniques, p16; IPPV—assessment of weaning, p18; High
frequency venti lat ion, p20; Posit ive end expiratory pressure (1), p22; Posit ive end expiratory pressure (2), p24; Lung
recruitment, p28; Non-invasive respiratory support, p32; CO2 monitoring, p92; Blood gas analysis, p100
IPPV—modes of ventilation
Controlled mechanical ventilation (CMV)
A preset number of breaths are delivered to supply al l  the patient's venti latory requirements. These breaths may be
at a preset VT (volume control led) or at a preset inspiratory pressure (pressure controlled).
Assist control mechanical ventilation (ACMV)
Patients can trigger the venti lator to determine the respiratory rate but, as with CMV, a preset number of breaths are
del ivered i f the spontaneous respiratory rate falls below the preset level .
Intermittent mandatory ventilation (IMV)
A preset mandatory rate is set but patients are free to breathe spontaneously between set venti lator breaths.
Mandatory breaths may be synchronised with patients' spontaneous efforts (SIMV) to avoid mandatory breaths
occurring during a spontaneous breath. This effect, known as ‘stacking’ may lead to excessive tidal  volumes, high
airway pressure, incomplete exhalation and ai r trapping. Pressure support may be added to spontaneous breaths to
overcome the work of breathing associated with opening the venti lator demand valve.
Pressure support ventilation (PSV)
A preset inspiratory pressure is added to the venti lator circui t during inspiration in spontaneously breathing patients.
The preset pressure should be adjusted to ensure adequate VT.
Choosing the appropriate mode
Pressure controlled venti lation avoids the dangers associated with high peak airway pressures, although it may resul t
in marked changes in VT i f compliance alters. Allowing the patient to make some spontaneous respiratory effort may
reduce sedation requirements, retrain respiratory muscles and reduce mean airway pressures.
Apnoeic patient
Use of IMV or ACMV in patients who are totally apnoeic provides the total minute volume requirement if the preset
rate is high enough (this is effectively CMV) but allows spontaneous respiratory effort on recovery.
Patient taking limited spontaneous breaths
A guaranteed minimum minute volume is assured with both ACMV and IMV depending on the preset rate. The work of
spontaneous breathing is reduced by supplying the preset VT for spontaneously triggered breaths with ACMV, or by
adding pressure support to spontaneous breaths with IMV. With ACMV the spontaneous tidal volume is guaranteed
whereas with IMV and pressure support spontaneous t idal volume depends on lung compl iance and may be less than
the preset t idal volume. The advantage of IMV and pressure support is that gradual reduction of preset rate, as
spontaneous effort increases, al lows a smooth transition to pressure support venti lation. Subsequent weaning is by
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reduction of the pressure support level.
See also:
IPPV—description of venti lators, p6; IPPV—adjusting the venti lator, p10; IPPV—failure to tolerate venti lat ion, p12;
IPPV—complications of venti lation, p14; IPPV—weaning techniques, p16; IPPV—assessment of weaning, p18; High
frequency venti lat ion, p20; Posit ive end expiratory pressure (1), p22; Posit ive end expiratory pressure (2), p24; Lung
recruitment, p28; Non-invasive respiratory support, p32
IPPV—adjusting the ventilator
Venti lator adjustments are usual ly made in response to blood gases, pulse oximetry or capnography, patient agitation
or discomfort, or during weaning. ‘Migration’ of the endotracheal  tube, ei ther distal ly to the carina or beyond, or
proximally such that the cuff is at vocal cord level, may resul t in agi tation, excess coughing and a deterioration in
blood gases. This, and tube obstruction, should be considered and recti fied before changing venti lator or sedation
dose sett ings.
The choice of venti lator mode depends upon the level  of consciousness, the number of spontaneous breaths being
taken, and the blood gas values. The spontaneously breathing patient can usually cope adequately with pressure
support venti lation alone. However, on occasion, a few intermittent mandatory breaths (SIMV) may be necessary to
assist gas exchange or slow an excessive spontaneous rate. The paralysed or heavily sedated patient wil l  require
mandatory breaths, ei ther volume- or pressure-controlled.
The order of change wi l l  be dictated by the severity of respiratory fai lure and individual  operator preference. Earl ier
use of increased PEEP is advocated to recruit collapsed alveoli  and thus improve oxygenation in severe respiratory
fai lure.
Low PaO2 considerations
Increase FIO2
Review VT  and respiratory rate
Increase PEEP (may raise peak ai rway pressure or reduce CO)
Increase I:E ratio
Increase pressure support/pressure control
CMV, increase sedation ± muscle relaxants
Consider tolerating low level (‘permissive hypoxaemia’)
Prone venti lation, inhaled nitric oxide
High PaO2 considerations
Decrease level of pressure control/pressure support i f VT adequate
Decrease PEEP
Decrease FIO2
Decrease I:E ratio
High PaCO2 considerations
Increase VT (if low and peak ai rway pressure allows)
Increase respiratory rate
Reduce rate i f too high (to reduce intrinsic PEEP)
Reduce dead space
CMV, increase sedation ± muscle relaxants
Consider tolerating high level  (‘permissive hypercapnia’)
Low PaCO2 considerations
Decrease respiratory rate
Decrease VT
See also:
IPPV—description of venti lators, p6; IPPV—modes of venti lation, p8; IPPV—failure to tolerate venti lat ion, p12;
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IPPV—complications of venti lation, p14; IPPV—weaning techniques, p16; IPPV—assessment of weaning, p18; High
frequency venti lat ion, p20; Posit ive end expiratory pressure (1), p22; Posit ive end expiratory pressure (2), p24; Lung
recruitment, p28; Non-invasive respiratory support
IPPV—failure to tolerate ventilation
Agitation or ‘ fighting the venti lator’ may occur at any time. Poor tolerance may also be indicated by hypoxaemia,
hypercapnia, venti lator alarms or cardiovascular instabil i ty.
Poor gas exchange during initial phase of ventilation
Increase FIO2 to 1.0 and start manual  venti lat ion.
Check endotracheal tube is correctly posit ioned and both lungs are being inflated. Consider tube replacement,
intratracheal obstruction or pneumothorax.
Check venti lator ci rcuit is both intact and patent and venti lator is functioning correctly. Check venti lator settings
including FIO2,  PEEP, I:E ratio, set tidal  volume, respiratory rate and/or pressure control. Check ‘pressure l imit’
settings as these may be set too low, causing the venti lator to time-cycle prematurely.
Poor tolerance after previous good tolerance
If agi tation occurs in a patient who has previously tolerated mechanical  venti lation, either the patient's condi tion has
deteriorated or there is a problem in the venti lator circuit (including artifi cial airway) or the venti lator itsel f.
The patient should be removed from the venti lator and placed on manual venti lation with 100% oxygen while the
problem is resolved. Resorting to increased sedation ± muscle relaxation in this ci rcumstance is dangerous unti l
the cause is resolved.
Check patency of the endotracheal tube (e.g. wi th a suction catheter) and re-intubate i f in doubt.
Consider malposi tion of the endotracheal  tube (e.g. cuff above vocal  cords, tube tip at carina, tube in main
bronchus).
Seek and treat and changes in the patient's condi tion, e.g. tension pneumothorax, sputum plug, pain.
Where patients are making spontaneous respiratory effort consider increasing pressure support or adding
mandatory breaths.
If patients fai l to synchronise with IMV by stacking spontaneous and mandatory breaths, increasing pressure
support and reducing mandatory rate may help; alternatively, the use of PSV may be appropriate.
See also:
IPPV—description of venti lators, p6; IPPV—modes of venti lation, p16; IPPV—adjusting the venti lator, p10;
IPPV—complications of venti lation, p14; IPPV—weaning techniques, p16; IPPV—assessment of weaning, p18; High
frequency venti lat ion, p20; Posit ive end expiratory pressure (1), p22; Posit ive end expiratory pressure (2), p24; Lung
recruitment, p28; Non-invasive respiratory support, p32; Sedatives, p238; Muscle relaxants, p240;
Agi tation/confusion, p370
IPPV—complications of ventilation
Haemodynamic complications
Venous return is dependent on passive flow from central veins to right atrium. As right atrial  pressure increases
secondary to the transmitted increase in intrathoracic pressure across compl iant lungs, there is a reduction in venous
return. This is less of a problem i f lungs are sti ff (e.g. ARDS) although i t wil l  be exacerbated by the use of inverse
I:E ratio and high PEEP. As lung volume is increased by IPPV the pulmonary vasculature is constricted, thus
increasing pulmonary vascular resistance. This wi l l  increase diastolic volume of the right ventricle and, by septal
shi ft, impedes fi l l ing of the left ventricle. These effects al l contribute to a reduced stroke volume. This reduction can
be minimised by reducing ai rway pressures, avoiding prolonged inspiratory times and maintaining blood volume.
Ventilator trauma
The term barotrauma relates to gas escape into cavi ties and intersti tial t issues during IPPV. Barotrauma is a
misnomer since it is probably the distending volume and high shear stress that is responsible rather than pressure. It
is most l ikely to occur with high VT and high PEEP. It occurs in IPPV and condi tions associated with lung overinflation
(e.g. asthma). Tension pneumothorax is l i fe threatening and should be suspected in any patient on IPPV who becomes
suddenly agi tated, tachycardic, hypotensive or exhibi ts sudden deterioration in their blood gases. An immediate chest
drainage tube should be inserted if tension pneumothorax develops. Prevention of venti lator trauma rel ies on
avoidance of high VT and high airway pressures.
Nosocomial infection
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
7 из 254 07.11.2006 1:04
P.15
P.16
Endotracheal  intubation bypasses normal  defence mechanisms. Cil iary activi ty and cellular morphology in the
tracheobronchial tree are altered. The requirement for endotracheal suction further increases susceptibi l ity to
infection. In addi tion, the normal heat and moisture exchanging mechanisms are bypassed requiring artifi cial
humidi fication of inspired gases. Failure to provide adequate humidi fication increases the risk of sputum retention
and infection. Maintaining venti lated patients at 30° upright head ti l t has been shown to reduce the incidence of
nosocomial pneumonia.
Acid–base disturbance
Venti lat ing patients with chronic respiratory fai lure or hyperventi lation may, by rapid correction of hypercapnia,
cause respiratory alkalosis. This reduces pulmonary blood flow and may contribute to hypoxaemia. A respiratory
acidosis due to hypercapnia may be due to inappropriate venti lator settings or may be desi red in an attempt to avoid
high VT and venti lator trauma.
Water retention
Vasopressin released from the anterior pi tui tary is increased due to a reduction in intrathoracic blood volume and
psychological stress. Reduced urine flow thus contributes to water retention. In addit ion, the use of PEEP reduces
lymphatic flow with consequent peripheral  oedema, especial ly affecting the upper body. High ai rway pressure reduces
venous return, again contributing to oedema.
Respiratory muscle wasting
Prolonged venti lat ion may lead to disuse atrophy of the respiratory muscles.
See also:
CO2 monitoring, p92; Blood gas analysis, p100; Central venous catheter—use, p114; Central  venous
catheter—insertion, p116; Bacteriology, p158; Acute chest infection (1), p288; Acute chest infection (2), p290; Acute
respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2), p294; Pneumothorax, p300
IPPV—weaning techniques
Patients may require al l  or part of their respiratory support to be provided by a mechanical  venti lator. Weaning from
mechanical venti lation may fol low several patterns. In patients venti lated for short periods (no more than a few days)
it is common to al low 20–30min breathing on a ‘T’ piece before removing the endotracheal  tube. For patients who
have received longer term venti lation i t is unl ikely that mechanical  support can be withdrawn suddenly; several
methods are commonly used to wean these patients from mechanical  venti lat ion. There is no strong evidence that any
technique is superior in terms of weaning success or rate of weaning.
Intermittent ‘T’ piece or continuous positive airway pressure (CPAP)
Spontaneous breathing is al lowed for increasingly prolonged periods with a rest on mechanical venti lation in between.
The use of a ‘T’ piece for longer than 30min may lead to basal  atelectasis since the endotracheal  tube bypasses the
physiological PEEP effect of the larynx. It is therefore common to use 5cmH2O CPAP as spontaneous breathing periods
get longer. In the early stages of weaning, mechanical  venti lat ion is often continued at night to encourage sleep,
avoid fatigue and rest respiratory muscles.
Intermittent mandatory ventilation (IMV)
The set mandatory rate is gradual ly reduced as the spontaneous rate increases. Spontaneous breaths are usual ly
pressure supported to overcome ci rcuit and venti lator valve resistance. With this technique it is important that the
patient's required minute venti lation is provided by the combination of mandatory breaths and spontaneous breaths
without an excessive spontaneous rate. The reduction in mandatory rate should be slow enough to maintain adequate
minute venti lat ion. It is also important that the patient can synchronise his own respiratory efforts wi th mandatory
venti lator breaths; many cannot, particularly where there are frequent spontaneous breaths, some of which may
‘stack’ with mandatory breaths causing hyperinflation.
Pressure support ventilation
Al l respiratory efforts are spontaneous but positive pressure is added to each breath, the level being chosen to
maintain an appropriate tidal  volume. Weaning is performed by a gradual reduction of the pressure support level
whi le the respiratory rate is <30/min. The patient is extubated or al lowed to breathe with 5cmH2O CPAP when
pressure support is minimal (<10–15cmH2O with modern venti lators).
Choice of ventilator
Modern venti lators have enhancements to aid weaning; however, weaning most patients from venti lation is possible
with a basic venti lator and the intermittent ‘T’ piece technique, provided an adequate fresh gas flow is provided. If
IMV and/or pressure support are used the venti lator should provide the features l isted opposite.
Key features in the choice of ventilator
Venti lator must al low patient triggering (i.e. not a minute volume divider)
Fresh gas flow must be greater than spontaneous peak inspiratory flow
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Minimum circuit resistance (short, wide bore, smooth internal lumen)
Low resistance-venti lator valves
Sensit ive pressure or flow trigger (ideal ly monitored close to the endotracheal tube)
Synchronised IMV (avoids ‘stacking’ mandatory on spontaneous breaths)
See also:
IPPV—modes of venti lation, p8; IPPV—adjusting the venti lator, p10; IPPV—assessment of weaning, p18; Continuous
posit ive ai rway pressure, p26; Non-invasive respiratory support, p32
IPPV—assessment of weaning
Assessment prior to weaning
Prior to weaning i t is important that the cause of respiratory failure and any compl ications arising have been
corrected. Sepsis should be eradicated as should other factors that increase oxygen demand. Attention is required to
nutri tional  status and fluid and electrolyte balance. The diaphragm should be al lowed to contract unhindered by
choosing the optimum position for breathing (si tting up unless the diaphragm is paralysed) and ensuring that
intra-abdominal  pressure is not high. Adequate analgesia must be provided. Sedatives are often withdrawn by this
point but may sti l l  be needed in specific si tuations, e.g. residual  agi tation, raised intracranial pressure. Weaning
should start after adequate explanation has been given to the patient. Factors predicting weaning success are
detailed in l i st opposi te. Spontaneous (pressure-supported) breathing should generally start as soon as possible to
allow reduction in sedation levels, and maintain respiratory muscle function. Weaning with the intention of removing
mechanical support is unlikely to be successful  while FIO2 >0.4.
Assessment during weaning
Continuous pulse oximetry and regular cl inical review are essential during weaning. Arterial blood gases should be
taken after 20–30min of spontaneous breathing. After short term venti lat ion, extubate i f arterial gases and
respiratory pattern remain satisfactory, the cough reflex is adequate and the patient can clear sputum. Patients being
weaned from longer term venti lation (>1 week) should generally be al lowed to breathe spontaneously with CPAP for
at least 24h before extubation.
Indications for re-ventilation
If spontaneous respiration is discoordinate or the patient is exhausted, agitated or clammy, the venti lator should be
reconnected. However, cl inical  monitoring should avoid exhaustion. Successful  weaning is more easi ly accomplished i f
excessive fatigue is not al lowed to set in. Tachypnoea (>30/min), tachycardia (>110/min), respiratory acidosis (pH
<7.2), rising PaCO2 and hypoxaemia (SaO2 <90%) should all  prompt reconnection of the venti lator.
Factors associated with weaning failure
Fai lure to wean is associated with:
Increased oxygen cost of breathing
Muscle fatigue (hypophosphataemia, hypomagnesaemia, hypokalaemia, malnutri tion, peripheral neuropathy,
myopathy and drugs, e.g. muscle relaxants, aminoglycosides)
Inadequate respiratory drive (alkalosis, opiates, sedatives, malnutri tion, cerebrovascular accident, coma)
Inadequate cardiac reserve and heart fai lure
In the latter case cardiac function should be monitored during spontaneous breathing periods. Any deterioration in
cardiac function should be treated aggressively (e.g. optimal f luid therapy, vasodi lators, inotropes).
Factors predicting weaning success
PaO2 >11kPa on FIO2=0.4 (PaO2/FIO2 ratio >27.5kPa)
Minute volume <12l/min
Vital capaci ty >10ml/kg
Maximum inspiratory force (PImax) >20cmH2O
Respiratory rate/tidal volume <100
Qs/Qt <15%
Dead space/tidal  volume <60%
Haemodynamic stabil ity
A ratio of respiratory rate to t idal volume (f/VT, shal low breathing index) ≤v105 has been shown to have a 78%
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posit ive predictive value for successful weaning.
Key trial
Yang KL, Tobin MJ. A prospective study of indexes predicting the outcome of trials of weaning from mechanical
venti lat ion. N Engl J Med 1991; 324:1445–50
See also:
IPPV—weaning techniques, p16; CO2 monitoring, p92; Blood gas analysis, p100; Electrolytes
, p146; Calcium, magnesium and phosphate, p148; Heart fai lure—assessment, p324; Acute weakness, p368; ICU
neuromuscular disorders, p388
High frequency ventilation
High frequency jet ventilation (HFJV)
A high pressure jet of gas entrains further fresh gas which is di rected by the jet towards the lungs. Respiratory rates
of 100–300/min ensure minute volumes of about 20l/min although tidal volume may be lower than dead space. CO2
elimination is usual ly more efficient than conventional IPPV. The method of gas exchange is not ful ly elucidated but
includes turbulent gas mixing and convection. Oxygenation is dependent on mean ai rway pressure. Peak ai rway
pressures are lower than with conventional  mechanical  venti lat ion but auto-PEEP and mean ai rway pressures are
maintained. SaO2 often fal ls when starting on HFJV, though usually improves with time. The high gas flow rates
employed require addi tional  humidification to be provided (30–100 ml/h); this is usually nebulised with the jet.
Indications
Bronchopleural  fistula is the only proven ICU indication for HFJV though i t has been used to assist weaning from
mechanical venti lation as the open circui t al lows spontaneous breaths without the drawbacks of demand valves. HFJV
also ensures adequate venti lat ion if the patient fai ls to breathe adequately. Reducing the driving pressure and
increasing the respiratory rate may faci l itate weaning further. In ARDS conventional venti lation can lead to venti lator
trauma if a high VT i s used. HFJV avoids problems associated with high VT but is often unable to provide adequate
venti lat ion in isolation for patients with severe ARDS.
Setting up HFJV
A jet must be provided via a modified endotracheal tube or catheter mount. Entrainment gas is provided via a ‘T’
piece. The t idal volume cannot be set directly. Rather it is set by adjusting jet size, I:E ratio, driving pressure and
respiratory rate from an in-buil t algorithm. The respiratory rate is usually set between 100–200/min. As respiratory
rate increases at a constant driving pressure the PaCO2 may increase as increasing PEEPi  increases the effective
physiological dead space. The I:E ratio is usual ly set between 1:3 and 1:2. VT  is determined by airway pressure and
I:E ratio. Driving pressure is usually set between 1–2bar. These pressures are much higher than the 60–100cmH2O
used in conventional venti lat ion. PEEPi  is related to the driving pressure, I:E ratio and respiratory rate. External PEEP
may be added to increase mean airway pressure should this be necessary to improve oxygenation.
Combined HFJV and conventional CMV
May be useful  in ARDS where HFJV alone cannot provide adequate gas exchange. Low frequency pressure l imited
venti lat ion with PEEP provides an adequate mean airway pressure to ensure oxygenation whi le CO2 clearance is
effected by HFJV. Care must be taken to avoid excessive peak ai rway pressure when HFJV and CMV breaths stack.
High frequency oscillation (HFO)
This technique can be applied externally (see ‘Non-invasive respiratory support’) or via the endotracheal tube. In the
latter instance high rates are appl ied and the driving pressure gradually increased. The FRC increases, recruiting
alveol i and improving oxygenation. The airway pressure can then be wound down, often without any significant
deterioration in oxygenation.
Adjusting HFJV according to blood gases
Increasing PaO2
Increase FIO2
Increase I:E ratio
Increase driving pressure
Add external  PEEP
Consider reducing respiratory rate
Decreasing PaCO2
Increase driving pressure
Decrease respiratory rate
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See also:
Venti latory support—indications, p4; Posit ive end expiratory pressure (1), p22; Posit ive end expiratory pressure (2),
p24; Acute respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2), p294
Positive end expiratory pressure (1)
Positive end expiratory pressure (PEEP) is a modali ty used in posi tive pressure venti lation to prevent the alveoli
returning to atmospheric pressure during expiration. It is routinely set between 3–5cmH2O; however, in severe
respiratory failure it wil l  often need to exceed 10cmH2O to be above the lower inflexion point of the pressure–volume
curve. This has been suggested as beneficial in patients with severe ARDS. It rarely needs to exceed 20cmH2O to
avoid cardiorespiratory compl ications and alveolar over-distension (see below). It does not prevent nor attenuate
ARDS, or reduce capi l lary leak or lung water.
Respiratory effects
PEEP improves oxygenation by recruit ing collapsed alveoli , redistributing lung water, decreasing A–V mismatch and
increasing FRC.
Haemodynamics
PEEP usually lowers both left and right ventricular preload and increases RV afterload. Though PEEP may increase
cardiac output in left heart fai lure and fluid overload states by preload reduction, in most other cases cardiac output
fal ls, even at relatively low PEEP levels. PEEP may also compromise a poorly functioning right ventricle. Improved
PaO2 result ing from decreased venous admixture may sometimes arise solely from reductions in cardiac output.
Physiological PEEP
A smal l degree of PEEP (2–3cmH2O) is usually provided physiologically by a closed larynx. It is lost when the patient
is intubated or tracheostomised and breathing spontaneously on a ‘T’ piece with no CPAP valve (see CPAP).
Intrinsic PEEP (auto-PEEP, air trapping, PEEPi)
Increased level  of PEEP due to insufficient t ime for expiration, leading to ‘air trapping’, CO2 retention, increased
airway pressures and increased FRC. Seen in pathological condit ions of increased airflow resistance (e.g. asthma,
emphysema) and when insufficient expiratory time is set on the venti lator. Used cl inically in inverse ratio venti lat ion
to increase oxygenation and decrease peak airway pressures. High levels of PEEPi can, however, slow weaning by an
increased work of breathing; use of extrinsic PEEP may overcome this. PEEPi can be measured by temporari ly
occluding the expiratory outlet of venti lator at end-expiration for a few seconds to al low equil ibration of pressure
between upper and lower airway and then reading the venti lator pressure gauge (or print-out).
‘Best’ PEEP
Ini tial ly described as the level  of PEEP producing the lowest shunt value. Now generally considered to be the lowest
level of PEEP that achieves SaO2≥90% allowing, wherever possible, lowering of FIO2 (ideal ly ≤0.6) though not at the
expense of peak airway pressures >35–40cmH2O or significant reductions in DO2.
See also:
IPPV—description of venti lators, p6; IPPV—modes of venti lation, p8; IPPV—adjusting the venti lator, p10;
IPPV—complications of venti lation, p14; Posit ive end expiratory pressure (2), p24; Continuous positive airway
pressure, p26; Lung recrui tment, p28
Positive end expiratory pressure (2)
Adjusting PEEP
Measure blood gases and monitored haemodynamic variables.1.
If indicated, alter level of PEEP by 3–5cmH2O increments.2.
Re-measure gases and haemodynamic variables after 15–20min.3.
Consider further changes as necessary (including addit ional changes in PEEP, fluid chal lenge or vasoactive
drugs).
4.
A number of cl inical  trials have adjusted PEEP levels according to FIO2 requirements (see table). Al though unlikely to
consti tute ‘optimal PEEP’ for an individual patient, this provides a useful approximation and starting point for further
ti tration of therapy.
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FIO2 0.3 0.4 0.4 0.5 0.5 0.6 0.7 0.7 0.7 0.8 0.9 0.9 0.9 1.0
PEEP
(cmH2O)
5 5 8 8 10 10 10 12 14 14 14 16 18 ≥18
Indications
Hypoxaemia requiring high FIO2
Optimisation of pressure–volume curve in severe respiratory fai lure
Hypoxaemia secondary to left heart fai lure
Improvement of cardiac output in left heart fai lure
Reduced work of breathing during weaning in patients with high PEEPi
Neurogenic pulmonary oedema (i.e. non-cardiogenic pulmonary oedema fol lowing rel ief of upper ai rway
obstruction)
Complications
Reduced cardiac output. May need addi tional  fluid loading or even inotropes. This should generally be avoided
unless higher PEEP is necessary to maintain adequate arterial oxygenation. Caution should be exercised in
patients with myocardial  ischaemia.
Increased ai rway pressure (and potential  risk of venti lator trauma).
Overinflation leading to ai r trapping and raised PaCO2. Use with caution in patients with chronic ai rflow
limitation or asthma. In pressure- control led venti lation overdistension is suggested when an increase in PEEP
produces a significant fal l  in tidal volume.
High levels wil l  decrease venous return, raise intracranial  pressure and increase hepatic congestion.
PEEP may change the area of lung in which a pulmonary artery catheter t ip is posit ioned from West Zone III to
non-Zone III. This is suggested by a rise in wedge pressure of at least half the increase in PEEP and requires
resiting of the PA catheter.
See also:
IPPV—description of venti lators, p6; IPPV—modes of venti lation, p8; IPPV—adjusting the venti lator, p10;
IPPV—complications of venti lation, p14; Posit ive end expiratory pressure (1), p22; Continuous positive airway
pressure, p26; Lung recrui tment, p28; Pressure–volume relationship, p96; Blood gas analysis, p100; Inotropes, p196;
Fluid challenge, p274; Atelectasis and pulmonary collapse, p284; Raised intracranial pressure, p382
Continuous positive airway pressure
Continuous posi tive airway pressure (CPAP) is the addi tion of posi tive pressure to the expiratory side of the breathing
ci rcuit of a spontaneously venti lat ing patient who may or may not be intubated. This sets the basel ine upper ai rway
pressure above atmospheric pressure, prevents alveolar collapse and possibly recrui ts al ready col lapsed alveoli.  It is
usually administered in increments of 2.5cmH2O to a maximum of 10cmH2O and applied via ei ther a tight-fi tt ing face
mask (face CPAP), nasal  mask (nasal  CPAP) or expiratory l imb of a ‘T’ piece breathing circui t.  A high flow (i.e. above
peak inspiratory flow) inspired air-oxygen supply, or a large reservoir bag in the inspiratory circuit,  is necessary to
keep the valve open. CPAP improves oxygenation and may reduce the work of breathing by reducing the
alveolar-to-mouth pressure gradient in patients with high levels of intrinsic PEEP. Transient periods of high CPAP
(e.g. 40cm H2O for 40s) may be a useful manoeuvre for recruit ing collapsed alveoli  and improving oxygenation in
ARDS.
Indications
Hypoxaemia requiring high respiratory rate, effort and FIO2.
Left heart fai lure to improve hypoxaemia and cardiac output.
Weaning modal ity.
Reducing work of breathing in patients with high PEEPi (e.g. asthma, chronic ai rflow l imitation). NB: use with
caution and monitor closely.
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Complications
With mask CPAP there is an increased risk of aspiration as gastric di latation may occur from swallowed ai r.
Insert nasogastric tube, especial ly if consciousness is impaired or gastric moti l ity is reduced.
Reduced cardiac output due to reduced venous return (raised intra-thoracic pressure). May need addit ional fluid
or even inotropes.
Overinflation leading to ai r trapping and high PaCO2. Caution is urged in patients with chronic airflow l imitation
or asthma.
High levels wil l  reduce venous return and increase intracranial pressure.
Occasional poor patient compliance with tight-fi tt ing face mask due to feel ings of claustrophobia and discomfort
on bridge of nose.
Inspissated secretions due to high flow, dry gas.
Management
Measure blood gases, monitor haemodynamic variables and respiratory rate.1.
Prepare ‘T’ piece circui t with a 5cmH2O CPAP valve on the expiratory l imb. Connect inspiratory l imb to flow
generator/large volume reservoir bag. Adjust air-oxygen mix to obtain desired FIO2 (measured by oxygen
analyser in circui t). Use a heat–moisture exchanger to humidify the inhaled gas. If not intubated, consider either
nasal or face CPAP. Attach mask to face by appropriate harness and attach ‘T’piece to mask. Ensure no ai r leak
around mask. If using a nasal mask, encourage the patient to keep their mouth closed.
2.
Measure gases, respiratory rate, and haemodynamics after 15–20min.3.
Consider further changes in CPAP (by 2.5cmH2O increments)4.
Consider need for (i) fluid challenge (or vasoactive drugs) i f circulatory compromise and (i i) nasogastric tube if
gastric atony present.
5.
See also:
Positive end expiratory pressure (1), p22; Posit ive end expiratory pressure (2), p24; Inotropes, p196; Fluid
challenge, p274; Dyspnoea, p278; Airway obstruction, p280; Respiratory failure, p282; Atelectasis and pulmonary
col lapse, p284; Acute chest infection (1), p288; Acute chest infection (2), p290; Acute respiratory distress syndrome
(1), p292; Acute respiratory distress syndrome (2), p294; Post-operative intensive care, p534
Lung recruitment
There has been considerable interest in recent years in the concept of lung recruitment. The rationale is that
reopening of collapsed alveoli  wi l l  resul t in improved gas exchange, with result ing reductions in ai rway pressures and
FIO2. Timing is crucial  as collapsed alveoli  are more l ikely to be recrui table in the early stages of respiratory fai lure.
It appears that benefit is more l ikely in non-respiratory causes of ARDS, rather than in cases of direct pulmonary
pathology such as pneumonia. Some animal  studies suggest that recrui tment procedures may even be potential ly
injurious in the latter si tuation.
Consideration should be given to lung recrui tment soon after intuba-tion in patients with severe respiratory fai lure,
and procedures causing de-recrui tment, e.g. endotracheal  suction and ai rway disconnection.
Recruitment techniques
A number of techniques are described to recruit collapsed alveoli , such as applying 40cmH2O PEEP for 40s with no
venti lator breaths; del ivering a few large-volume, venti lator-delivered breaths; or by using a combination of varying
levels of PEEP and increasing pressure-del ivered breaths to obtain optimal  gas exchange.
Al though anecdotal  successes are reported, with occasionally dramatic improvements in lung compliance and gas
exchange, no comparative trials have been performed, and outcomes have not been assessed prospectively.
Haemodynamic compromise may occur during the procedure, though this usually recovers on cessation.
Key trial
Brower RG, et al  for the ARDS Clinical Trials Network. Effects of recrui tment maneuvers in patients with acute
lung injury and acute respiratory distress syndrome venti lated with high posi tive end-expiratory pressure. Cri t
Care Med 2003; 31:2592–7
Prone positioning
Prone positioning is used to treat patients with acute respiratory distress syndrome (ARDS) to improve gas exchange.
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A number of theories have been proposed to explain why the prone posit ion helps. These theories include: reduction
in compression atelectasis of dependent lung regions (temporary), reduction in chest wall  compl iance increasing
intrathoracic pressure and alveolar recruitment, better regional  diaphragmatic movement, better V/Q matching,
improved secretion clearance and less alveolar distension leading to better oxygenation.
Indications
Prone positioning may be considered when: PaO2 <8.5kPa, FIO2≥0.6, PEEP >10cmH2O despite optimisation of other
venti latory support.
Technique
Positioning the patient takes time and preparation. Four members of staff are required to turn the patient and one
person to secure the head and endotracheal  tube. The turn itsel f i s a two-stage procedure via the lateral posit ion.
The arm on which the patient is to be rol led is tucked under the hip with the other arm laid across the chest. Pi l lows
are placed under the abdomen and chest prior to rotation to the lateral position. If stable, turn may be completed to
prone. Pi l lows are placed under the shoulders and pelvis. The head of the bed is raised and one arm is extended at
the patient's side while the other is flexed with the head facing the opposite way.
Frequency of turns
The response to prone venti lat ion is di ffi cult to predict. Some patients may have no improvement in gas exchange;
others may have a temporary benefi t, requiring frequent turns, and others may have di fficul ty returning to a supine
posit ion. For compression atelectasis it is l ikely that benefi t wil l  last up to 2h before resumption of a supine posit ion
is required. For other condit ions, up to 18h prone posit ioning may be required. The head and arms should be
reposi tioned 2-hrly.
Complications
There are problems associated with posi tioning the patient prone including: facial oedema, incorrect posit ioning of
l imbs leading to nerve palsy and accidental removal  of drains and catheters, pressure necrosis, myosi tis ossi ficans.
These problems are preventable provided there is awareness of their potential.
Contraindications
There are two absolute contraindications to prone posi tion: severe head, spinal or abdominal injury and severe
haemodynamic instabil ity. Relative contraindications include:
Recent abdominal  surgery
Large abdomen
Pregnancy
Spinal  instabi l ity (though special beds are avai lable for turning affected patients)
Frequent seizures
Multiple trauma
Raised ICP
Key trial
Gattinoni L, et al for the Prone-Supine Study Group. Effect of prone positioning on the survival  of patients with acute
respiratory failure. N Engl J Med 2001; 345:568–73
See also:
Acute respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2), p294
Non-invasive respiratory support
Devices of varying sophistication are avai lable to augment spontaneous breathing in the compl iant patient by ei ther
assisting inspiration (inspiratory support) and/or providing CPAP. Non-invasive support is usually delivered by tight
fitting face or nasal  mask, though a helmet may be used and inspiratory support can be delivered by mouthpiece.
Some devices al low connection to an endotracheal  tube for the intubated but spontaneously breathing patient.
Indications
Hypoxaemia requiring high respiratory rate, effort and FIO2
Hypercapnia in a fatiguing patient
Weaning modal ity
To avoid endotracheal intubation where desi rable (e.g. severe chronic airflow l imitation, immunosuppressed
patients)
Reduces work of breathing in patients with high PEEPi (e.g. asthma, chronic airflow l imitation). Use with caution
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and monitor closely
Physiotherapy technique for improving FRC
Sleep apnoea
Inspiratory support (IS)
A preset inspiratory pressure is given which is triggered by the patient's breath. This trigger can be adjusted
according to the degree of patient effort. Some devices wi l l  deliver breaths automatically at adjustable rates and the
I:E ratio may also be adjustable. The tidal  volume delivered for a given level of inspiratory support wil l  vary
according to the patient's respiratory compl iance. An example of an IS device is the Bird venti lator commonly used by
physiotherapists for improving FRC and expanding lung bases.
BiPAP (Bi-level Positive Airways Pressure)
This device del ivers adjustable levels of pressure support and PEEP. Del ivered breaths can be ei ther patient-triggered
and/or mandatory. Some BiPAP devices are driven by air; to increase the FIO2,  supplemental oxygen can be given via
a circui t connection or through a portal in the mask.
Management
Select type and del ivery mode of venti latory support.1.
Connect patient as per device instructions.2.
Use an appropriate sized mask that is comfortable and leak-free.3.
A delivered pressure of 10–15cmH2O is a usual start ing point which can be adjusted according to patient
response (respiratory rate, degree of fatigue, comfort, blood gases…).
4.
Expiratory pressure support levels are usual ly within the 5–12cmH2O range.5.
Patients in respiratory distress may have ini tial difficul ty in coping with these devices. Constant attention and
encouragement help to accustom the patient to the device and/or mask while di fferent levels of support, I:E
ratios etc. are being tested to find the optimal  setting. Cautious administration of low dose subcutaneous opiate
injections (e.g. diamorphine 2.5mg) may help to calm the patient without depressing respiratory drive. The
tight-fitting mask may be found increasingly claustrophobic after a few days' use. This should be pre-empted if
possible by allowing the patient regular breaks. Pressure areas such as the bridge of the nose should be
protected.
6.
Key trials
Brochard L, et al.  Noninvasive venti lat ion for acute exacerbations of chronic obstructive pulmonary disease. N
Engl  J Med 1995; 333:817–22
Antonell i  M, et al . A comparison of noninvasive posi tive-pressure venti lation and conventional mechanical
venti lation in patients with acute respiratory fai lure. N Engl  J Med 1998; 339:429–35
Extracorporeal respiratory support
These techniques have declined in populari ty over recent years after several trials fai led to demonstrate clear
outcome benefit in adults with very severe respiratory failure. Survival rates of 50–60% are reported but clear
superiority over conventional  venti lat ion has not yet been demonstrated in controlled studies. A large prospective
randomised study (the ‘CESAR’ trial ) is currently under way in the UK.
Extracorporeal CO2 removal (ECCO2R)
An extracorporeal  veno-venous circulation al lows CO2 clearance via a gas exchange membrane. Blood flows of
25–33% cardiac output are typical ly used which only al low for partial  oxygenation support. Low frequency (4–5/min)
posit ive pressure venti lat ion is usual ly used with ECCO2R with continuous oxygenation throughout inspiration and
expiration. The lungs are ‘held open’ with high PEEP (20–25cmH2O), l imited peak airway pressures (35–40cmH2O) and
a continuous fresh gas supply. Thus, oxygenation is effected with lung rest to aid recovery. Anticoagulation of the
extracorporeal  ci rcuit can be reduced by using heparin-bonded tubing and membranes.
Extracorporeal membrane oxygenation (ECMO)
An extracorporeal  veno-arterial circulation with high blood flows (approaching cardiac output) through a gas
exchange membrane enables most if not al l of the body's gas exchange requirements to be met. The main
disadvantages compared to ECCO2R are the need for large bore arterial  puncture with its consequent risks, and high
extracorporeal  blood flows with the potential  for cell  damage.
Indications
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Fai lure of maximum intensive therapy and venti latory support to sustain adequate gas exchange as evidenced by the
criteria below.
Contraindications
Chronic systemic disease involving any major organ system (e.g. irreversible chronic CNS disease, chronic lung
disease with FEV1 <1l, FEV1/FVC <0.3 of predicted, chronic PaCO2 >6.0kPa, emphysema or previous admission
for chronic respiratory insufficiency, incurable or rapidly fatal malignancy, chronic left heart fai lure, chronic
renal fai lure, chronic l iver fai lure, HIV related disease).
Lung failure for >7 days (al though treatment with extracorporeal  respiratory support may persist for longer than
14 days).
Burns (>40% of body surface).
More than 3 organ fai lures in addi tion to lung failure.
Criteria for ECCO2R/ECMO
Rapid fai lure of venti latory support: immediate use of these techniques should be considered in those meeting
the fol lowing criteria for a period >2h despi te maximum intensive care:
PaO2 <6.7kPa
FIO2 1.0
PEEP >5cmH2O
i.
Slow failure of venti latory support: consider use after 48h maximum intensive care for those meeting the
following gas exchange and mechanical  pulmonary function criteria for a period >12h:
PaO2 <6.7kPa PEEP >5cmH2O
Qs/Qt >30% on FIO2 = 1.0 FIO2 >0.6
PaO2/FIO2 <11.2kPa TSLC <30ml/cmH2O at 10ml/kg inflation
ii.
See also:
Anticoagulants, p248; Prostaglandins, p264; Acute respiratory distress syndrome (1), p292; Acute respiratory
distress syndrome (2), p294
Endotracheal intubation
Indications
An artif icial airway is necessary in the fol lowing ci rcumstances:
Apnoea—Provision of mechanical venti lat ion, e.g. unconsciousness, severe respiratory muscle weakness,
sel f-poisoning
Respiratory fai lure—Provision of mechanical venti lation, e.g. ARDS, pneumonia
Airway protection—Unconsciousness, trauma, aspiration risk, poisoning
Airway obstruction—Maintain ai rway patency, e.g. trauma, laryngeal  oedema, tumour, burns
Haemodynamic instabil ity—Facil itate mechanical venti lation, e.g. shock, cardiac arrest
Choice of endotracheal tube
Most adul ts require a standard high volume, low pressure cuffed endotracheal tube. The average sized adul t wi l l
require a size 8.0–9.0mm id tube (size 7.5–8.0mm id for females) cut to a length of 23cm (21cm for females).
Particular problems with the upper airway, e.g. trauma, oedema, may require a smal ler tube. In specific situations
non-standard tubes may be used, e.g. jet venti lat ion, armoured tubes to avoid external  compression and double
lumen tubes to isolate the right or left lung.
Route of intubation
The usual  routes of intubation are oro-tracheal and naso-tracheal. Oro-tracheal intubation is preferred. The
naso-tracheal route has the advantages of increased patient comfort and the possibi l ity of easier bl ind placement; it
is also easier to secure the tube. However, there are several  disadvantages. The tube is usual ly smaller, there is a
risk of sinusi tis and otit is media and the route is contraindicated with concurrent coagulopathy, CSF leak and nasal
fractures.
Difficult intubation
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If a diff icult intubation is predicted, i t should not be attempted by an inexperienced operator. Diff iculty may be
predicted in the patient wi th a smal l mouth, high arched palate, large upper incisors, hypognathia, large tongue,
anterior larynx, short neck, immobi le temporo-mandibular joints, immobi le cervical joints or morbid obesity. If a
difficul t intubation presents unexpectedly, the use of a stylet, a straight bladed laryngoscope or a fibreoptic
laryngoscope may help. It is important not to persist for too long; revert to bag and mask venti lat ion to ensure
adequate oxygenation.
Complications of intubation
Early complications
Trauma, e.g. haemorrhage, mediastinal  perforation
Haemodynamic col lapse, e.g. positive pressure venti lat ion, vasodilatation, arrhythmias or rapid correction of
hypercapnia
Tube malposit ion, e.g. fai led intubation or endobronchial  intubation
Later complications
Infection including maxi l lary sinusitis if nasally intubated
Cuff pressure trauma (avoid by maintaining cuff pressure <25cmH2O)
Mouth/l ip trauma
Equipment required
Suction (Yankauer tip)
Oxygen supply, rebreathing bag and mask
Laryngoscope (two curved blades and straight blade)
Stylet/bougie
Endotracheal  tubes (preferred size and smal ler)
Magi l l  forceps
Drugs (induction agent, muscle relaxant, sedative)
Syringe for cuff inflation
Tape to secure tube
Capnograph
See also:
Venti latory support—indications, p4; Opioid analgesics, p234; Sedatives, p238; Muscle relaxants, p240; Cardiac
arrest, p272; Airway obstruction, p280; Respiratory fai lure, p282; Acute chest infection (1), p288; Acute chest
infection (2), p290; Acute respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2), p294;
Asthma—general  management, p296; Asthma—venti latory management, p298; Poisoning—general principles, p452;
Post-operative intensive care, p534
Tracheotomy
Indications
To provide an arti fic ial airway in place of oro- or naso-tracheal intubation. This may be to provide better patient
comfort, to avoid vocal cord, mouth or nasal trauma or, in an emergency, to bypass acute upper ai rway obstruction.
The optimal time to perform a tracheotomy in an intubated patient is not known; current practice suggests 10–16
days, or sooner if prolonged intubation is predicted, especial ly in cases of difficul t intubation. Avoiding the risks of
vocal cord damage may provide some advantage for a tracheostomy. The reduced need for sedation, the potential to
eat, drink and speak and the faci l itation of mouth care are all  defini te advantages.
Percutaneous tracheotomy
A more rapid procedure with less tissue trauma and scarring than the standard open surgical  technique. It can be
performed in the ICU, avoiding the need to transfer patients to theatre. Coagulopathy should be excluded or treated
first. Subcutaneous tissues are infi l trated with 1% lidocaine and epinephrine (adrenaline). After a 1–1.5cm midl ine
skin crease incision, the subcutaneous tissue is blunt dissected to the anterior tracheal wall . The endotracheal  tube
tip is wi thdrawn to the level of the vocal  cords. The trachea is then punctured in the midline with a 14G needle
between the 1st and 2nd tracheal carti lages (or lower), al lowing guide wire insertion. The stoma is created by
dilatation to 32–36Fr (Ciaglia technique) or by a guided forceps di lating tool  (Schachner–Ovil l  technique). In the
former case, the tracheostomy tube is introduced over an appropriate sized dilator and in the latter through the open
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dilating tool. End-tidal CO2 monitoring confi rms adequate venti lat ion during the procedure. Fibreoptic bronchoscopy
may be used to confirm correct tracheal  placement and no trauma to the posterior tracheal wal l, though this may
compromise venti lation.
Complications
The main early complication is haemorrhage from vessels anterior to the trachea. This is usually control led with
direct pressure or, occasionally, sutures. Bleeding into the trachea may result in clot obstruction of the airway;
endotracheal  suction is usual ly effective. Paratracheal placement should be rare but promptly recognised by inabi l i ty
to venti late the lungs. Later compl ications include tracheostomy displacement, stomal  infection and tracheal stenosis.
Stenosis is often related to low grade infection and is claimed to be more common with open tracheotomy. Rare
complications include tracheo-oesophageal  fistula due to trauma or pressure necrosis of the posterior tracheal  wall ,
or erosion through the lateral tracheal wall  into a blood vessel.
Maintenance of a tracheotomy
Since the upper ai r passages have been bypassed, artif icial  humidification is required. Cough is less effective without
a functioning larynx so regular tracheal suction wil l  be necessary. Furthermore, the larynx provides a smal l amount of
natural PEEP that is lost with a tracheostomy. The risk of basal atelectasis can be overcome with CPAP or attention to
respiratory exercises that promote deep breathing. A safe fistula forms within 3–5 days, al lowing replacement of the
tracheotomy tube.
Tracheotomy tubes
Standard high volume, low pressure cuff
Fenestrated with or without cuff
Useful  where ai rway protection is not a primary concern. May be closed during normal  breathing while providing
intermittent suction access.
Fenestrated with inner tube
As above but with an inner tube to faci l itate closure of the fenestration during intermittent mechanical  venti lation.
Fenestrated with speaking valve
Inspiration al lowed through the tracheostomy to reduce dead space and inspiratory resistance. Expiration through the
larynx, via the fenestration, al lowing speech and the advantages of laryngeal PEEP.
Adjustable flange
Accommodates extreme variations in skin to trachea depth whi le ensuring the cuff remains central  in the trachea.
Pitt speaking tube
A non-fenestrated, cuffed tube for continuous mechanical venti lation and ai rway protection with a port to di rect
airflow above the cuff to the larynx. When airflow is directed through the larynx some patients are able to vocalise.
Passy–Muir speaking valve
This is an expiratory occlusive valve placed onto the tracheostomy tube that permits inspiration through the
tracheostomy and expiration through the glott is. The tracheostomy tube cuff must be first deflated. The valve al lows
phonation, faci l i tates swal lowing and may reduce aspiration. Smal l studies have suggested that it may reduce the
work of breathing. The potential tidal volume drop through cuff deflation makes this valve only suitable in those
patients requiring no (or relatively low level) invasive venti latory support.
Silver tube
An uncuffed tube used occasionally in ENT practice to maintain a tracheostomy fistula.
See also:
Venti latory support—indications, p4; Opioid analgesics, p234; Sedatives, p238; Muscle relaxants, p240; Cardiac
arrest, p272; Airway obstruction, p280; Respiratory fai lure, p282; Acute chest infection (1), p288; Acute chest
infection (2), p290; Acute respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2), p294;
Asthma—general  management, p296; Asthma—venti latory management, p298; Poisoning—general principles, p452.
Post-operative intensive care, p534
Minitracheotomy
A 4mm diameter uncuffed plastic tube inserted through the cricothyroid membrane under local anaesthetic.
Indications
Removal  of retained secretions, usual ly if patient's cough is weak
Emergency access to lower ai rway i f upper airway obstructed
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Contraindications/cautions
Coagulopathy
Non-compliant, agitated patient (unless sedated)
Technique
Some commercial  ki ts rely on blind insertion of a blunt introducer; others use a Seldinger technique where a
guidewire is inserted via the cricothyroid membrane into the trachea. An introducer passed over the wire di lates the
track allowing easy passage of the tube.
Use aseptic technique. Cleanse si te with antiseptic. Locate cricothyroid membrane (midl ine ‘spongy’ area
between cricoid and thyroid carti lages).
1.
Infi ltrate local skin and subcutaneous tissues with 1% l idocaine ± epinephrine (adrenal ine). Advance needle into
deeper tissues, aspirating to confirm absence of blood then infi ltrating with l idocaine unti l cricothyroid
membrane is pierced and air can be easily aspirated.
2.
(If using Seldinger technique insert guidewire through membrane into trachea.) Tether thyroid carti lage with one
hand, incise skin and tissues vertical ly in midline (alongside wire) with short-bladed guarded scalpel provided
with pack. Insert scalpel to blade guard level to make adequate hole through cricothyroid membrane. Remove
scalpel.
3.
Insert blunt introducer through incision si te into trachea (or over guidewire). Angle caudal ly. Relatively l ight
resistance wil l  be felt during correct passage—do not force introducer if resistance proves excessive.
4.
Lubricate plastic tube with gel. Sl ide tube over introducer into trachea.5.
Remove introducer (+ wire), leaving plastic tube in situ.6.
Confirm correct posit ion by placing own hand over tube and feeling airflow during breathing. Suction down tube
to aspirate intratracheal contents (check pH if in doubt). Cap opening of tube. Suture to skin.
7.
Perform CXR (unless very smooth insertion and no change in cardio-respiratory variables).8.
O2 can be entrained through the tube, or an appropriate connector (provided in pack) placed to al low bagging,
use of the Bird venti lator and/or short term assisted venti lation.
9.
Complications
Puncture of blood vessel at cricothyroid membrane may cause significant intratracheal or external bleeding.
Apply local pressure if this occurs after blade incision. If bleeding continues, insert minitracheotomy tube for a
tamponading effect. If bleeding persists, insert deep sutures either side of mini tracheotomy; if this fai ls, contact
surgeon for assistance
Perforation of oesophagus
Mediastinitis (rare)
Pneumothorax
See also:
Chest physiotherapy, p48; Atelectasis and pulmonary collapse, p284; Acute chest infection (1), p288; Acute chest
infection (2), p290
Chest drain insertion
Indications
Drainage of air (pneumothorax), fluid (effusion), blood (haemothorax) or pus (empyema) from the pleural  space.
Insertion technique
Use 28Fr drain (or larger) for haemothorax or empyema; 20Fr wil l  suffice for a pure pneumothorax.
Seldinger-type drains with an integral guidewire are now also avai lable. The drain is usually inserted through
the 5th intercostal space in the mid-axil lary l ine, fi rst anaesthetising skin and pleura with 1% l idocaine. Ensure
that ai r/fluid/blood/pus is aspirated.
1.
Make a 1–1.5cm skin crease incision, create a track with gloved finger (or forceps) to separate muscle fibres and
open pleura.
2.
Insert drain through open pleura with trochar withdrawn to ensure tip is blunt to avoid lung damage. Angle and
insert drain to correct posit ion (towards lung apex for a pneumothorax and lung base for a
haemothorax/effusion). Connect drain to the underwater seal . CT scan or ul trasound may be useful  for directing
placement for focal/small  col lections.
3.
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Secure drain to chest wall by properly placed sutures.4.
Perform CXR to ensure correct sit ing and lung reinflation.5.
Place on 5–10cmH2O (0.5–1.3kPa) negative pressure (low pressure wall  suction) if lung has not ful ly expanded.6.
Subsequent management
Drains should not be clamped prior to removal , or transport of patient.
Drains may be removed when the lung has re-expanded and there is no air leak (no respiratory swing in fluid
level or air leak on coughing).
Unless long term venti lation is necessary, a drain inserted for a pneumothorax should usually be left in situ
during IPPV.
Remove drain at end-expiration. Cover hole with thick gauze and Elastoplast; a purse-string suture is not usually
necessary. Repeat CXR i f indicated by deteriorating cl inical  signs or blood gas analysis.
Complications
Morbidity associated with chest drainage may be up to 10%.
Puncture of intercostal vessel  may cause significant bleeding. Consider (i) correcting any coagulopathy, (i i )
placing deep tension sutures around drain or (i i i) removing drain, inserting a Foley catheter, inflating the
bal loon and applying traction to tamponade bleeding vessel . If these measures fai l , contact (thoracic) surgeon.
Puncture of lung tissue may cause a bronchopleural f istula. If chest drain suction (up to 15–20cmH2O) fai ls,
consider (i) pleurodesis (e.g. with tetracycl ine), (i i ) high frequency jet venti lation ± double-lumen endobronchial
tube, or (i i i) surgery. Extubate i f feasible.
Perforation of major vessel (often fatal)—clamp but do not remove drain, resusci tate with blood, contact
surgeon, consider double-lumen endotracheal  tube.
Infection—take cul tures; antibiotics (staphylococcal ± anaerobic cover); consider removing/resit ing drain.
Local discomfort/pain from pleural i rritation may impair cough. Consider simple analgesia, subcutaneous
lidocaine, insti l l ing local anaesthetic, local  or regional  anaesthesia, etc.
Drain dislodgement—if needed, replace/resi te new drain, depending on cleanl iness of site. Don't advance old
drain (infection risk).
Lung entrapment/infarction—avoid milking drain in pneumothorax.
See also:
IPPV—complications of venti lation, p14; High frequency venti lat ion, p20; Pleural aspiration, p44; Basic resuscitation,
p270; Pneumothorax, p300; Haemothorax, p302
Pleural aspiration
Drainage of fluid from the pleural space using either a needle, cannula or flexible small -bore drain. Increasingly
being performed under ul trasound guidance. Blood/pus usually requires large-bore drain insertion.
Indications
Improvement of blood gases
Symptomatic improvement of dyspnoea
Diagnostic ‘tap’
Contraindications/Cautions
Coagulopathy
Complications
Puncture of lung or subdiaphragmatic viscera
Bleeding
Fluid protein level
Protein >30g/l (this should be viewed in the context of the plasma protein level)-exudate—causes: inflammatory e.g.
pneumonia, pulmonary embolus, neoplasm, col lagen vascular diseases
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Protein <30g/l-transudate—causes: (i ) increased venous pressure (e.g. heart fai lure, fluid overload), (i i) decreased
col loid osmotic pressure (e.g. crit ical i l lness leading to reduced plasma protein from capi l lary leak and hepatic
dysfunction, hepatic fai lure, nephrotic syndrome)
Technique
Confirm presence of effusion by CXR or ul trasound.1.
Select drainage si te either by maximum area of stony dullness under percussion or under ul trasound guidance.2.
Use aseptic technique. Clean area with antiseptic and infi ltrate local skin and subcutaneous tissues with 1%
lidocaine. Advance into deeper tissues, aspirating to confi rm absence of blood then infi ltrating with local
anaesthetic unti l pleura is pierced and fluid can be aspirated.
3.
Advance drainage needle/cannula/drain slowly, applying gentle suction, through chest wal l and intercostal  space
(above upper border of rib to avoid neurovascular bundle) unti l fluid can be aspirated.
4.
Withdraw 50ml for microbiological  (M, C&S, TB stain, etc.), biochemical (protein, glucose, etc.) and
histological/cytological (pneumocystis, malignant cel ls, etc.) analysis as indicated.
5.
Either leave drain in situ connected to drainage bag or connect needle/cannula by 3-way tap to drainage
apparatus.
6.
Continue aspiration/drainage unti l no further fluid can be withdrawn or if patient becomes symptomatic
(pain/dyspnoea). Dyspnoea or haemodynamic changes may occur due to removal of large volumes of fluid
(>1–2l) and subsequent fluid shifts; if this is considered to be a possibi l ity, remove no more than 1l at a t ime
either by clamping/declamping drain or repeating needle aspiration after an equil ibration interval  (e.g. 4–6h).
7.
Remove needle/drain. Cover puncture si te with firmly applied gauze dressing.8.
See also:
Chest drain insertion, p42; Acute chest infection (1), p288; Acute chest infection (2), p290; Pulmonary embolus,
p308; Heart fai lure—assessment, p324; Heart fai lure—management, p326; Rheumatic disorders, p492; Vasculi tides,
p494
Fibreoptic bronchoscopy
Indications
Diagnostic
Collection of microbiological ± cytological specimens (by broncho- alveolar lavage, protected brush specimen,
biopsy).
Cause of bronchial obstruction (e.g. clot, foreign body, neoplasm).
Extent of inhalation injury.
Diagnosis of ruptured trachea/bronchus.
Therapeutic
Clearance of secretions, inhaled vomitus, etc.
Removal  of lumen-obstructing matter (e.g. mucus plug, blood clot, food, tooth). Proximal obstruction rather than
consol idation is suggested by the radiological appearance of a col lapsed lung/lobe and no air bronchogram.
Cleansing—removing soot or other toxic materials, i rrigation with saline.
Directed physiotherapy ± saline to loosen secretions.
Directed placement of bal loon catheter to arrest pulmonary bleeding.
To aid difficul t endotracheal intubation.
Contraindications/cautions
Coagulopathy
Severe hypoxaemia
Complications
Hypoxaemia—from suction, loss of PEEP, partial  obstruction of endotracheal tube and non-del ivery of t idal
volume.
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Haemodynamic disturbance including hypertension and tachycardia (related to hypoxaemia, agi tation, tracheal
stimulation, etc.).
Bleeding.
Perforation (unusual though more common i f biopsy taken).
Procedure
It is di ffi cul t to perform fibreoptic bronchoscopy in a nasally intubated patient. A narrow-lumen scope can be used but
suction is l imited.
Pre-oxygenate with FIO2 1.0. Monitor with pulse oximetry.1.
Increase pressure alarm limit on venti lator.2.
Lubricate scope with lubricant gel/sal ine.3.
If unintubated, apply l idocaine gel to nares ± spray to pharynx.4.
Consider short-term IV sedation ± paralysis.5.
Insert scope nasal ly (in a non-intubated patient) or through catheter mount port in an intubated patient. An
assistant should support the endotracheal tube during the procedure to minimise trauma to both trachea and
scope.
6.
Inject 2% lidocaine into trachea to prevent coughing and haemodynamic effects from tracheal/carinal
stimulation.
7.
Perform thorough inspection and any necessary procedures. If SpO2 ≤85% or haemodynamic disturbance occurs,
remove scope and al low re-oxygenation before continuing.
8.
Bronchoalveolar lavage is performed by insti l lat ion of at least 60ml of (preferably warm) isotonic sal ine into
affected lung area without suction, fol lowed by aspiration into a steri le catheter trap. All  bronchoscopic samples
should be sent promptly to the lab.
9.
Reduction of effective endotracheal  tube lumen and suction may affect the t idal volume, leading to hypoxaemia
and/or hypercapnia.
10.
After procedure, reset venti lator as appropriate.11.
Chest physiotherapy
The aim is to expand col lapsed alveol i,  mobil ise chest secretions or re-inflate col lapsed lung segments. No scienti fic
val idation of effectiveness has been reported. The current view is that routine ‘prophylactic’ suctioning/ bagging
should be avoided in the critically i l l .
Indications
Mobi l isation of secretions.
Re-expansion of collapsed lung/lobes.
Prophylaxis against alveolar collapse and secondary infection.
Contraindications/cautions
Aggressive hyperinflation in already hyperinflated lungs, e.g. asthma, emphysema—though can be very useful  in
removing mucus plugs.
Undrained pneumothorax.
Raised intracranial pressure.
Techniques
Hyperinflation
Hyperinflating to 50% above venti lator-del ivered VT, aiming to expand col lapsed alveoli and mobil ise secretions. VT
is rarely measured, so either excessive or inadequate hyperinflations may be given depending on lung compl iance and
operator technique. Pressure-l imiting devices (‘blow-off valves’) or manometers can avoid excessive airway
pressures. A recommended technique is slow inspiration, a 1–2s plateau phase and then rapid release of the bag to
simulate a ‘huff’ and mobil ise secretions. Pre-oxygenation may be needed as PEEP may be lost and the delivered VT
may be inadequate. Cardiac output often fal ls with variable blood pressure and heart rate responses. Sedation may
blunt the haemodynamic response. Ful l deflation avoids ai r trapping.
Suction
Removing secretions from trachea and main bronchi (usually right). A cough reflex may be stimulated to mobil ise
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secretions further. Tenacious secretions may be loosened by insti l lation of 2–5 ml 0.9% saline. Fal ls in SaO2 and
cardiovascular disturbance may be avoided by pre-oxygenation.
Percussion and vibration
Drumming and shaking actions over chest wall to mobil ise secretions.
Inspiratory pressure support (Bird ventilator)
The aim is to increase FRC and expand collapsed alveoli .
Postural drainage
Patient posi tioning to assist drainage—depends on affected lung area(s).
See also:
Endotracheal  intubation, p36; Chest physiotherapy, p48; Atelectasis and pulmonary collapse, p284; Haemoptysis,
p304; Inhalation injury, p306
Complications
Hypoxaemia—from suction, loss of PEEP, etc.
Haemodynamic disturbance affecting cardiac output, heart rate and blood pressure which may be related to high
VT,  ai rway pressure, hypoxaemia, agitation, tracheal  stimulation, etc.
Direct trauma from suctioning.
Barotrauma/volutrauma including pneumothorax.
General
Adequate humidi fication avoids tenacious sputum and mucus plugs.
Pain rel ief is important to encourage good chest excursion and cough.
Mobi l i sation and encouraging deep breathing may avoid infection.
When to request urgent physiotherapy
Collapsed lung/lobe with no air bronchogram visible, i .e. suggesting proximal obstruction rather than
consol idation.
Mucus plugging causing subsegmental col lapse e.g. asthma.
When not to request urgent physiotherapy
Clinical signs of chest infection with no secretions being produced.
Radiological  consolidation with air bronchogram but no secretions present.
See also:
Venti latory support—indications, p4; Endotracheal intubation, p36; Tracheotomy, p38; Minitracheotomy, p40;
Fibreoptic bronchoscopy, p46; Atelectasis and pulmonary collapse, p284; Acute chestinfection (1), p288; Acute chest
infection (2), p290
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Cardiovascular Therapy Techniques
Defibrillation
Electrical conversion of a tachyarrhythmia to restore normal sinus rhythm. This may be an emergency procedure
(when the ci rculation is absent or severely compromised), semi-elective (when the ci rculation is compromised to a
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lesser degree), or elective (when synchronised cardioversion is performed to restore sinus rhythm for a
non-compromising supraventricular tachycardia). Synchronisation requires initial connection of ECG leads from the
patient to the defibri l lator so that the shock is del ivered on the R wave to minimise the risk of ventricular fibri l lat ion.
Newer, biphasic defibri l lators require approximately half the energy setting of monophasic defibri l lators.
Indications
Compromised circulation, e.g. VF, VT
Restoration of sinus rhythm and more effective cardiac output
Lessens risk of cardiac thrombus formation
Contraindications/cautions
Aware patient
Severe coagulopathy
Caution with recent thrombolysis
Digoxin levels in toxic range
Complications
Surface burn
Pericardial tamponade
Electrocution of bystanders
Technique
(see algorithm opposi te).
The chances of maintaining sinus rhythm are increased in elective cardioversion i f K+ >4.5mmol/l  and plasma
Mg2+ levels are normal .
Prior to defibri l lat ion, ensure sel f and onlookers are not in contact wi th patient or bed frame.
To reduce the risk of superficial  burns, replace gel/gelled pads after every 3 shocks.
Consider resiting paddle posit ion (e.g. anteroposterior) if defibri l lat ion fails.
The risk of intractable VF fol lowing defibri l lation in a patient receiving digoxin is small  unless the plasma
digoxin levels are in the toxic range or the patient is hypovolaemic.
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Figure. No Caption Available.
See also:
Chronotropes, p206; Sedatives, p238; Cardiac arrest, p272; Tachyarrhythmias, p316; Hypokalaemia, p422
Temporary pacing (1)
When the heart's intrinsic pacemaking abi l i ty fai ls, temporary internal or external pacing can be insti tuted. Internal
electrodes can be endocardial (inserted via a central  vein) or epicardial (placed on the external surfaceof the heart at
thoracotomy). The endocardial wire may be placed under fluoroscopic control  or ‘bl ind’ using a bal loon flotation
catheter. External  pacing can be rapidly performed by placement of two electrodes on the front and rear chest wall
when asystole or third degree heart block has produced acute haemodynamic compromise. It is often used as a bridge
to temporary internal  pacing. It can also be used as a prophylactic measure, e.g. for Mobitz Type II second-degree
heart block.
Indications
Third-degree heart block
Mobitz Type II second-degree heart block when the ci rculation iscompromised or an operation is planned
Overpacing (rarely; more successful with internal pacing)
Asystole
Complications
Internal pacing
As for central venous catheter insertion
Arrhythmias
Infection (including endocardi tis)
Myocardial  perforation (rare)
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External pacing
Discomfort
Troubleshooting
Fai lure to pace may be due to:
No pacemaker spikes seen—check connections, check battery.1.
No capture (pacing spikes but no QRS complex fol lowing)—poor positioning/dislodgement of wire. Temporari ly
increase output as this may regain capture. Reposit ion/replace internal pacing wire.
2.
General
Check threshold dai ly as it wi l l  rise slowly over 48–96h, probably due to fibrosis occurring around the
electrodes.
1.
Overpacing is occasional ly indicated for a tachycardia not responding to antiarrhythmic therapy or cardioversion.
For SVT, pacing is usual ly attempted with the wire sited in the right atrium. Pace at rate 20–30bpm above
patient's heart rate for 10–15s, then ei ther decrease rate immediately to 80bpm or slowly, by 20bpm every
5–10s.
2.
If overpacing fails, underpacing may be attempted with the wire situated in either atrium (for SVT) or, usual ly,
ventricle (for either SVT or VT). A paced rate of 80–100bpm may produce a refractory period sufficient to
suppress the intrinsic tachycardia.
3.
Epicardial pacing performed during cardiac surgery requires siting of either two epicardial  electrodes or one
epicardial and one skin electrode (usual ly a hypodermic needle). The pacing threshold of epicardial  wires rises
quickly and may become ineffective after 1–2 days.
4.
In asystole, an electrical rhythm produced by pacing does not guarantee an adequate cardiac output is being
generated.
5.
See also:
Temporary pacing (2), p56; Chronotropes, p206; Cardiac arrest, p272; Bradyarrhythmias, p318
Temporary pacing (2)
Technique (for endocardial electrode placement)
If using fluoroscopy, move patient to X-ray suite or place lead shields around bed area. Place patient on
‘screening table’.  Staff should wear lead aprons.
1.
Use aseptic technique throughout. Insert 6Fr sheath in internal  jugular or subclavian vein. Suture in posit ion.2.
Connect pacing wire electrodes to pacing box (black = negative polarity = distal, red = posi tive polari ty =
proximal). Set pacemakerto demand. Check box is working and battery charge adequate. Turn pacing rate to
≥30bpm above patient's intrinsic rhythm. Set vol tage to 4V.
3.
Insert pacing wire through sheath into central vein. If using bal loon catheter, insert to 15–20cm depth then
inflate balloon. Advance catheter, viewing ECG monitor for change in ECG morphology and capture of pacing
rate. If using screening, direct wire toward the apex of the right ventricle. Approximate insertion depth from a
neck veinis 35–40cm.
4.
If pacing impulses not captured, (deflate balloon), withdraw wire to 15cm insertion depth then repeat step 4.5.
Once pacing captured, decrease vol tage by decrements to determine threshold at which pacing is no longer
captured. Ideal  posit ion determined by a threshold ≤0.6V. If not achieved, re-posi tion wire.
6.
If possible, ask patient to cough to check that wire does not dislodge.7.
Set vol tage at 3 × threshold and set desired heart rate on ‘demand’ mode. Tape wire securely to patient to
prevent dislodgement.
8.
Technique (for external pacing)
Connect pacing wire gelled electrodes to pacemaker. Place black (= negative polarity) electrode on the anterior
chest wall  to the left of the lower sternum and red (= posi tive polari ty) electrode to the corresponding posi tion
on the posterior hemithorax.
1.
Connect ECG electrodes from ECG monitor to external pacemaker and another set of electrodes from pacemaker
to patient
2.
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Set pacemaker to demand. Turn pacing rate to ≥30bpm above patient's intrinsic rhythm. Set current to 70mA.3.
Start pacing. Increase current (by 5mA increments) unti l  pacing rate captured on monitor.4.
If pacing rate not captured at current of 120–130mA resite electrodes and repeat steps 3–4.5.
Once pacing captured, set current at 5–10mA above threshold.6.
See also:
Temporary pacing (1), p54; Chronotropes, p206; Cardiac arrest, p272; Bradyarrhythmias, p318
Intra-aortic balloon counterpulsation
Principle
A 30–40ml balloon is placed in the descending aorta. The bal loon is inflated with helium during diastole, thus
increasing diastolic blood pressure above the balloon. This serves to increase coronary and cerebral  perfusion. The
bal loon is deflated during systole, thus decreasing peripheral  resistance and increasing stroke volume. No
pharmacological  technique exists which can increase coronary blood flow whi le reducing peripheral  resistance.
Intra-aortic balloon counterpulsation may improve cardiac performance in situations where drugs are ineffective.
Indications
The most obvious indication is to support the circulation where a structural  cardiac defect is to be repaired surgically.
However, it may be used in acute circulatory fai lure in any situation where resolution of the cause of the cardiac
dysfunction is expected. In acute myocardial infarction, resolution of peri-infarct oedema may allow spontaneous
improvement in myocardial function; the use of intra-aortic bal loon counterpulsation may provide temporary
ci rculatory support and promote myocardial heal ing by improving myocardial  blood flow. Other indications include
acute myocardit is and poisoning with myocardial  depressants. Intra-aortic bal loon counterpulsation should not be
used in aortic regurgitation since the increase in diastol ic blood pressure would increase regurgitant flow.
Insertion of the balloon
The usual  route is via a femoral artery. Percutaneous Seldinger catheterisation (with or without an introducer sheath)
provides a rapid and safe technique with minimal  arterial trauma and bleeding. Open surgical  catheterisation may be
necessary in elderly patients with atheromatous disease. The balloon posit ion should be checked on a CXR to ensure
that the radio-opaque tip is at the level of the 2nd intercostal space. Ensure the left radial pulse is not lost.
Anticoagulation
The presence of a large foreign body in the aorta requires systemic anticoagulation to prevent thrombosis. The
bal loon should not be left deflated for longer than a minute whi le in situ otherwise thrombosis may occur despite
anticoagulation.
Control of balloon inflation and deflation
Hel ium is used to inflate the bal loon, its low density faci l itating rapid transfer from pump to balloon. Inflation is
commonly timed to the ‘R’ wave of the ECG, although timing may be taken from an arterial pressure waveform. Minor
adjustment may be made to the t iming to ensure that inflation occurs immediately after closure of the aortic valve
(after the dicrotic notch of the arterial  pressure waveform) and deflation occurs at the end of diastole. The fi l l ing
volume of the balloon can be varied up to the maximum balloon volume. The greater the fi l l ing volume, the greater
the ci rculatory augmentation. The rate at which bal loon inflation occurs may coincide with every cardiac beat or
every 2nd or 3rd cardiac beat. Slower rates are necessary in tachyarrhythmias. Weaning of intra-aortic balloon
counterpulsation may be achieved by reducing augmentation or the rate of inflation.
See also:
Hypotension, p312; Heart fai lure—assessment, p324; Heart fai lure—management, p326; Post-operative intensive
care, p534
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Renal Therapy Techniques
Haemo(dia)filtration (1)
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These are al ternatives to dialysis that require a pressurised, puri fied water supply, more expensive equipment and
operator expertise, and a greater risk of haemodynamic instabil ity due to rapid fluid and osmotic shi fts.
Haemo(dia)fi l tration can be arteriovenous, using the patient's blood pressure to drive blood through the haemofi lter,
or pumped veno-venous. The latter is advantageous in that it is not dependent on the patient's blood pressure and
the pump system incorporates alarms and safety features. Veno-venous haemo(dia)fi ltration is increasingly the
technique of choice. Blood is usual ly drawn and returned via a 10–12Fr double lumen central venous catheter.
Indications
Azotaemia (uraemia)
Hyperkalaemia
Anuria/ol iguria; to make space for nutrition
Severe metabolic acidosis of non-tissue hypoperfusion origin
Fluid overload
Drug removal
Hypothermia/hyperthermia
Techniques
Numerous including haemofi l tration, haemodiafi l tration, ul trafi l tration, continuous ultrafi l tration with intermittent
dialysis (CUPID). Fi l trate is usual ly removed at 1–2l/h and fluid balance adjusted by varying the fluid replacement
rate. High volume haemofi ltration involves much higher clearances (e.g. 35l  in a 4h period) though variable outcomes
are reported in randomised studies.
Creatinine and potassium clearances are higher with diafi ltration though fi l tration alone is usually sufficient provided
an adequate ultrafi ltrate volume is achieved (1000ml/h = creatinine clearance of 16ml/min).
Membranes
Usually polyacryloni tri le, polyamide or polysulphone. May be hollow fibre or flat-plate in design. Surface area usual ly
0.6–1m2.
Replacement fluid
A buffered balanced electrolyte solution is given to buffer acidaemia and achieve the desi red fluid balance. Buffers
include lactate (metabol ised by l iver to bicarbonate), acetate (metabolised by muscle), and bicarbonate. Acetate
causes the most haemodynamic instabi l ity and is rarely used in the crit ical ly i l l .  Bicarbonate solutions may be more
efficient than lactate at reversing severe metabolic acidosis, but outcome benefi t has yet to be demonstrated from its
use and care is needed with co-administered calcium since calcium bicarbonate may crystal l ise. In l iver fai lure a
lactate buffer may not be adequately metabol ised. Similarly, in poor perfusion states, the muscle may not be able to
metabolise an acetate buffer.
An increasing metabolic alkalosis may be due to excessive buffer. In this case, use a ‘ low lactate’ (i .e. 30mmol/l )
replacement fluid. Potassium can be added, if necessary, to maintain normokalaemia. Having 20mmol KCl  in a 4.5l
bag provides a concentration of 4.44mmol/l . K+ clearance is increased by decreasing the concentration within the
replacement fluid or the dialysate.
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Figure. No Caption Available.
Key trials
Ronco C, et al. Effects of different doses in continuous veno-venous haemofi l tration on outcomes of acute renal
fai lure: a prospective randomised trial. Lancet 2000; 356:26–30
Bouman CS, et al. Effects of early high-volume continuous venovenous hemofi ltration on survival and recovery of
renal function in intensive care patients with acute renal fai lure: a prospective, randomized trial.
Cri t Care Med 2002; 30:2205–11
See also:
Haemo(dia)fi l tration (2), p64; Coagulation monitoring, p156; Anticoagulants, p248; Ol iguria, p330; Acute renal
fai lure—diagnosis, p332; Acute renal  fai lure—management, p334; Metabol ic acidosis, p434; Metabolic alkalosis,
p436; Poisoning—general principles p324; Metabolic acidosis, p434; Metabol ic alkalosis, p436; Poisoning—general
principles, p452; Rhabdomyolysis, p528
Haemo(dia)filtration (2)
Anticoagulation
Anticoagulation of the circui t is usually wi th unfractionated heparin (200–2000IU/h), or a prostanoid
(prostacyclin or PGE1) at 2–10ng/kg/min, or a combination of the two. Li tt le experience is avai lable on the use
of low molecular weight heparin, citrate and other anticoagulants such as hirudin.
No anticoagulant may be needed i f the patient is auto-anticoagulated.
Premature clott ing may be due to mechanical  kinking/obstruction of the ci rcuit, insufficient anticoagulation,
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inadequate blood flow rates or to lack of endogenous anticoagulants (antithrombin III, heparin cofactor II).
Usual f i l ter l i fespan should be at least 2 days but is often decreased in septic patients due to decreased
endogenous anticoagulant levels. In this situation, consider use of fresh frozen plasma, a synthetic protease
inhibi tor such as aprotinin, or antithrombin III replacement (costly).
Filter blood flow
Flow through the fi lter is usual ly 100–200ml/min. Too slow a flow rate promotes clotting. Too high a flow rate wil l
increase transmembrane pressures and decrease fi lter l i fespan without significant improvement in clearance of
‘middle molecules’ (e.g. urea).
Complications
Disconnection leading to haemorrhage.
Infection risk (steri le technique must be employed).
Electrolyte, acid–base or fluid imbalance (excess input or removal).
Haemorrhage (vascular access si tes, peptic ulcers) related to anticoagulation therapy or consumption
coagulopathy. Heparin-induced thrombocytopenia may rarely occur.
Cautions
Haemodynamic instabil ity related to hypovolaemia (especial ly at start).
Vasoactive drug removal by the fi l ter (e.g. catecholamines).
Membrane biocompatibi l ity problems (especial ly with cuprophane).
Drug dosages may need to be revised (consult pharmacist).
Amino acid losses through the fi l ter.
Heat loss leading to hypothermia.
Masking of pyrexia
Peritoneal dialysis
A slow form of dialysis, uti l ising the peri toneum as the dialysis membrane. Slow correction of fluid and electrolyte
disturbance may be better tolerated by cri tical ly i l l  patients and the technique does not require complex equipment.
However, treatment is labour intensive and there is considerable risk of peri toneal  infection. It has been largely
superseded by haemofi ltration in most intensive care uni ts.
Peritoneal access
For acute peritoneal dialysis a trochar and cannula are inserted through a small  skin incision under local  anaesthetic.
The skin is prepared and draped as for any steri le procedure. The commonest approach is through a smal l midl ine
incision 1cm below the umbi l icus. The subcutaneous tissues and peritoneum are punctured by the trocar which is
withdrawn sl ightly before the cannula is advanced towards the pouch of Douglas. In order to avoid damage to
intra-abdominal  structures 1–2l warmed peritoneal dialysate may be infused into the peritoneum by a standard, short
intravascular cannula prior to placement of the trocar and cannula system. If the midl ine access site is not avai lable
an alternative is to use a lateral approach, lateral to a l ine joining the umbil icus and the anterior superior i l iac spine
(avoiding the inferior epigastric vessels).
Dialysis technique
Warmed peritoneal dialysate is infused into the peritoneum in a volume of 1–2l  at a t ime. During the acute phase,
fluid is flushed in and drained continuously (i .e. wi th no dwel l time). Once biochemical control is achieved i t is usual
to leave fluid in the peritoneal cavity for 4-6h before draining. Heparin (500IU/l) may be added to the first 6 cycles
to prevent fibrin catheter blockage. Thereafter, it i s only necessary i f there is blood or cloudiness in the drainage
fluid.
Peritoneal dialysate
The dialysate is a steri le balanced electrolyte solution with glucose at 75mmol/l for a standard fluid or 311mmol/l for
a hypertonic fluid (used for greater fluid removal). The fluid is usually potassium free since potassium exchanges
slowly in peri toneal  dialysis, although potassium may be added if necessary.
Complications
Fluid leak
Poor drainage
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Steroid therapy
Obese or elderly patient
Catheter blockage
Bleeding
Omental  encasement
Infection
White cells >50/ml, cloudy drainage fluid
Hyperglycaemia
Absorption of hyperosmotic glucose
Diaphragm splinting
Treatment of infection
It is possible to steri l i se the peritoneum and catheter by adding appropriate antibiotics to the dialysate. Sui table
regimens include:
Cefuroxime 500mg/l for 2 cycles then 200mg/l  for 10 days
Gentamicin 8mg/l  for 1 cycle daily
See also:
Ol iguria, p330; Acute renal  fai lure—diagnosis, p332; Acute renal  fai lure—management, p334
Plasma exchange
Indications
Plasma exchange may be used to remove circulating toxins or to replace missing plasma factors. It may be used in
sepsis (e.g. meningococcaemia). In patients with immune mediated disease, plasma exchange is usually a temporary
measure while systemic immunosuppression takes effect. There are some immune mediated diseases (e.g.
Gui l lain–Barré syndrome, thrombotic thrombocytopenic purpura) where an isolated rather than a continuous
antibody–antigen reaction can be treated with early plasma exchange and no fol low-up immunosuppression. Most
diseases require a daily 3–4l  plasma exchange repeated for at least 4 further occasions over 5–10 days.
Techniques
Cell separation by centrifugation
Blood is separated into components in a centrifuge. Plasma (or other specific blood components) are discarded and a
plasma replacement fluid is infused in equal  volume. Centrifugation may be continuous where blood is wi thdrawn and
returned by separate needles, or intermittent where blood is wi thdrawn, separated and then returned via the same
needle.
Membrane filtration
Plasma is continuously fi l tered through a large pore fi l ter (molecular weight cut-off typically 1,000,000Da). The
plasma is discarded and replaced by infusion of an equal volume of replacement fluid. The technique is similar to
haemofi ltration and uses the same equipment.
Replacement fluid
Most patients wil l  tolerate replacement with a plasma substitute. Our preference is to replace plasma loss with equal
volumes of 6% hydroxy-ethyl starch and 5% albumin. However, some use partial crystalloid replacement and others
use al l albumin replacement. Some fresh frozen plasma wil l be necessary after the exchange to replace coagulation
factors. The only indication to replace plasma loss with al l fresh frozen plasma is where plasma exchange is being
performed to replace missing plasma factors.
Complications
Circulatory instabil ity
Intravascular volume changes
Removal of circulating catecholamines
Hypocalcaemia
Reduced intravascular COP
If replacement with crystalloid
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Infection
Reduced plasma opsonisation
Bleeding
Removal of coagulation factors
Indications
Autoimmune disease
Goodpasture's syndrome
Gui l lain–Barré syndrome
Myasthenia gravis
Pemphigus
Rapidly progressive glomerulonephri tis
SLE
Thrombotic thrombocytopenic purpura
Immunoproliferative disease
Cryoglobulinaemia
Multiple myeloma
Waldenstrom's macroglobulinaemia
Poisoning
Paraquat
Others
Meningococcal septicaemia (possible benefi t)
Sepsis (possible benefi t)
Reye's syndrome
See also:
Coagulation monitoring, p156; Anticoagulants, p248; Gui l lain–Barré syndrome, p384; Myasthenia gravis, p386;
Platelet disorders, p406; Poisoning—general principles, p452; Vasculi tides, p494
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Gastrointestinal Therapy Techniques
Sengstaken-type tube
Used to manage oesophageal variceal haemorrhage that continues despite pharmacological ± per-endoscopic therapy.
The device (Sengstaken– Blakemore or similar) is a large-bore rubber tube usually containing two balloons
(oesophageal  and gastric) and two further lumens (oesophageal  and gastric) that open above and below the bal loons.
This device works usually by the gastric bal loon alone compressing the varices at the cardia. Inflation of the
oesophageal bal loon is rarely necessary.
Insertion technique
The tubes are usually kept in the fridge to provide added stiffness for easier insertion.
The patient often requires judicious sedation or mechanical venti lation (as warranted by conscious state/level of
agi tation) prior to insertion.
1.
Check balloons inflate properly beforehand. Lubricate end of tube.2.
Insert via mouth. Place to depth of 55–60cm, i .e. to ensure gastric balloon is in stomach prior to inflation.3.
Inflate gastric balloon with water to volume instructed by manufacturer (usual ly ♠200ml). A smal l amount of4.
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
32 из 254 07.11.2006 1:04
P.73
P.74
radio-opaque contrast may be added. Negligible resistance to inflation should be felt. Clamp gastric balloon
lumen.
Pul l tube back unti l resistance is fel t, i.e. gastric balloon is at cardia. Fix tube in place by applying
counter-traction at the mouth. Old-fashioned methods, such as attaching the tube to a free-hanging l itre bag of
sal ine, have been superseded by more manageable techniques. For example, two wooden tongue depressors,
‘thickened’ by having Elastoplast wound around them, are placed either side of the tube at the mouth and then
attached to each other at both ends by more Elastoplast. The tube remains gripped at the mouth/cheek by the
attached tongue depressors but can be retracted unti l adequate but not excessive traction is being applied.
5.
Perform X-ray to check satisfactory posi tion of gastric balloon.6.
If bleeding continues (continued large aspirates from gastric or oesophageal lumens), inflate oesophageal
bal loon (approx 50ml).
7.
Subsequent management
The gastric bal loon is usually kept inflated for 12–24h and deflated prior to endoscopy ± sclerotherapy. The
traction on the tube should be tested hourly by the nursing staff. The oesophageal  lumen should be placed on
continuous drainage while enteral  nutri tion and administration of drugs can be given via the gastric lumen.
1.
If the oesophageal bal loon is used, deflate for 5–10min every 1–2h to reduce the risk of oesophageal pressure
necrosis. Do not leave oesophageal  balloon inflated for longer than 12h after sclerotherapy.
2.
The tube may need to stay in situ for 2–3 days though periods of deflation should then be allowed.3.
Complications
Aspiration
Perforation
Ulceration
Oesophageal necrosis
See also:
Upper gastrointestinal haemorrhage, p344; Bleeding varices, p346
Upper gastrointestinal endoscopy
Oesophago-gastro-duodenoscopy is identical  in venti lated and non-venti lated patients, though a protected airway ±
sedated status usually faci l i tates the procedure.
Indications
Investigation of upper gastrointestinal  signs/symptoms. e.g. bleeding, pain, mass, obstruction
Therapeutic, e.g. sclerotherapy for varices, local epinephrine (adrenaline) injection for discrete bleeding points,
e.g. in ulcer base
Placement of nasojejunal tube (when gastric atony prevents enteral feeding) or percutaneous gastrostomy (PEG)
ERCP—unusual in the ICU patient
Complications
Local trauma causing haemorrhage or perforation
Abdominal  distension compromising respiratory function
Contraindications/cautions
Severe coagulopathy should ideally be corrected
Procedure
Upper gastrointestinal endoscopy should be performed by an experienced operator to minimise the duration and
trauma of the procedure, and to minimise gaseous distension of the gut.
The patient is usually placed in a lateral  posit ion though can be supine if intubated.1.
Increase FIO2 and venti lator pressure alarm settings. Consider increasing sedation and adjusting venti lator
mode.
2.
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Monitor ECG, SPO2,  ai rway pressures and haemodynamic variables throughout. If patient is on pressure support
or pressure control venti latory modes also monitor tidal  volumes. The operator should cease the procedure, at
least temporari ly, if the patient becomes compromised.
3.
At the end of the procedure the operator should aspirate as much ai r as possible out of the gastrointestinal  tract
to decompress the abdomen.
4.
See also:
Pulse oximetry, p90; Upper gastrointestinal haemorrhage, p344; Bleeding varices, p346
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Nutrition—use and indications
Malnutri tion leads to poor wound healing, post-operative complications and sepsis. Adequate nutrit ional  support is
important for cri tical ly i l l  patients and should be provided early during the i l lness. Evidence for improved outcome
from early nutrit ional support exists for patients with trauma and burns. Enteral nutrit ion is indicated when
swallowing is inadequate or impossible but gastrointestinal function is otherwise intact. Parenteral  nutrition is
indicated where the gastrointestinal tract cannot be used to provide adequate nutri tional  support, e.g. obstruction,
i leus, high small  bowel  fistula or malabsorption. Parenteral nutrit ion may be used to supplement enteral  nutrition
where gastrointestinal function allows partial  nutri tional  support.
Consequences of malnutrition
Underfeeding Overfeeding
Loss of muscle mass
Reduced respiratory function
Reduced immune function
Poor wound healing
Gut mucosal atrophy
Reduced protein synthesis
Increased VO2
Increased VCO2
Hyperglycaemia
Fatty infiltration of liver
Calorie requirements
Various formulae exist to calculate the patient's basal metabolic rate but are misleading in crit ical i l lness. Metabolic
rate can be measured by indirect calorimetry but most patients are assumed to require 2000–2700Cal/ day, or less i f
starved or underweight.
Nitrogen requirements
Nitrogen excretion can be calculated in the absence of renal  fai lure according to the 24h urea excretion:
Nitrogen (g/24h) = 2 + Urinary urea (mmol/24h) ×  0.028
However, as with most formulae, this method lacks accuracy. Most patients require 7–14g/day.
Other requirements
The normal requirements of substrates, vi tamins and trace elements are tabled opposi te. Most long-term crit ically i l l
patients require fol ic acid and vitamin supplementation during nutritional support, e.g. Solvito. Trace elements are
usually supplemented in parenteral formulae but should not be required during enteral nutri tion.
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Normal daily requirements (for a 70kg adult)
Water 2100ml
Energy 2000–2700Cal
Nitrogen 7–14g
Glucose 210g
Lipid 140g
Sodium 70–140mmol
Potassium 50–120mmol
Calcium 5–10mmol
Magnesium 5–10mmol
Phosphate 10–20mmol
Vitamins
Thiamine 16–19mg
Riboflavin 3–8mg
Niacin 33–34mg
Pyridoxine 5–10mg
Folate 0.3–0.5mg
Vitamin C 250–450mg
Vitamin A 2800–3300iu
Vitamin D 280–330iu
Vitamin E 1.4–1.7iu
Vitamin K 0.7mg
Trace elements
Iron 1–2mg
Copper 0.5–1.0mg
Manganese 1–2µg
Zinc 2–4mg
Iodide 70–140µg
Fluoride 1–2mg
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Enteral nutrition
Routes include naso-gastric, naso-duodenal/jejunal, gastrostomy and jejunostomy. Nasal  tube feeding should be via a
soft, fine-bore tube to aid patient comfort and avoid ulceration of the nose or oesophagus. Prolonged enteral feeding
may be accomplished via a percutaneous/peroperative gastrostomy or peroperative jejunostomy. Enteral  feeding
provides a more complete diet than parenteral  nutri tion, maintains structural integri ty of the gut, improves bowel
adaptation after resection and reduces infection risk.
Feed composition
Most patients tolerate iso-osmolar, non-lactose feed. Carbohydrates are provided as sucrose or glucose polymers;
protein as whole protein or ol igopeptides (may be better absorbed than free amino acids in ‘elemental’  feeds); fats as
medium chain or long chain triglycerides. Medium chain triglycerides are better absorbed. Standard feed is
formulated at 1Cal/ml. Special  feeds are available, e.g. high fibre, high protein-calorie, restricted salt,  high fat or
concentrated (1.5 or 2Cal/ml) for fluid restrict ion. Immune-enhanced feeds (e.g. glutamine-enriched or Impact ®, a
formula supplemented with nucleotides, arginine and fish oi l) may reduce nosocomial infections but no evidence of
outcome benefit has been shown from large prospective studies.
Management of enteral nutrition
Once a decision is made to start enteral nutrit ion, 30ml/h ful l strength standard feed may be started immediately.
Starter regimens incorporating dilute feed are not necessary. After 4h at 30ml/h the feed should be stopped for
30min prior to aspiration of the stomach. Since gastric juice production is increased by the presence of a nasogastric
tube, it is reasonable to accept an aspirate of <200ml as evidence of gastric emptying and therefore to increase the
infusion rate to 60ml/h. This process is repeated unti l the target feed rate is achieved. Thereafter, aspiration of the
stomach can be reduced to 8hrly. If the gastric aspirate volume is >200ml the infusion rate is not increased but the
feed is continued. If aspirates remain at high volume despite measures to promote gastric emptying (e.g.
metoclopramide or erythromycin) then ei ther bowel rest, nasoduodenal/nasojejunal feeding or parenteral nutri tion
should be considered.
Complications
Tube placement: tracheobronchial intubation, nasopharyngeal perforation, intracranial penetration (basal  skull
fracture), oesophageal  perforation
Reflux
Pulmonary aspiration
Nausea and vomiting
Abdominal  distension is occasionally reported with features including a tender, distended abdomen and an
increasing metabol ic acidosis. Laparotomy and bowel  resection may be necessary in severe cases
Diarrhoea: large volume, bolus feeding, high osmolal ity, infection, lactose intolerance, antibiotic therapy, high
fat content
Constipation
Metabol ic: dehydration, hyperglycaemia, electrolyte imbalance
Key trial
Atkinson S, et al . A prospective, randomized, double-blind, control led cl inical  trial of enteral  immunonutri tion in the
critical ly i l l . Cri t Care Med 1998; 26:1164–72
See also:
Nutri tion—use and indications, p78; Electrolytes
, p146; Calcium, magnesium and phosphate, p148; Gut moti l i ty agents, p226; Vomiting/gastric stasis, p338;
Diarrhoea, p340; Bowel  perforation and obstruction, p348; Hypernatraemia, p416; Hyponatraemia, p418;
Hyperkalaemia, p420; Hypokalaemia, p422; Hypomagnesaemia, p424; Hypocalcaemia, p428; Hypophosphataemia,
p430
Parenteral nutrition
Feed composition
Carbohydrate is normally provided as concentrated glucose. 30–40% of total calories are usual ly given as l ipid (e.g.
soya bean emulsion). The nitrogen source is synthetic, crystal l ine L-amino acids which should contain appropriate
quanti ties of al l  essential and most non-essential  amino acids. Carbohydrate, l ipid and nitrogen sources are usually
mixed into a large bag in a steri le pharmacy uni t. Vi tamins, trace elements and appropriate electrolyte
concentrations can be achieved in a single infusion, thus avoiding multiple connections. Volume, protein and calorie
content of the feed should be determined on a dai ly basis in conjunction with the dieti tian.
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Choice of parenteral feeding route
Central venous
A dedicated catheter (or lumen of a multi-lumen catheter) is placed under steri le condi tions. For long-term feeding a
subcutaneous tunnel is often used to separate skin and vein entry sites. This probably reduces the risk of infection
and clearly identifies the special purpose of the catheter. Ideal ly, blood samples should not be taken nor other
injections or infusions given via the feeding lumen. The central venous route al lows infusion of hyperosmolar
solutions, providing adequate energy intake in reduced volume.
Peripheral venous
Parenteral nutrit ion via the peripheral route requires a solution with osmolali ty <800mOsmol/kg. Either the volume
must be increased or the energy content (particularly from carbohydrate) reduced. Peripheral  cannulae si tes must be
changed frequently.
Complications
Catheter related Misplacement
Infection
Thromboembolism
Fluid excess
Hyperosmolar hyperglycaemic state
Electrolyte imbalance
Hypophosphataemia
Metabolic acidosis Hyperchloraemia
Metabolism of cationic amino acids
Rebound hypoglycaemia
High endogenous insulin levels
Vitamin deficiency Folate
Thiamine
Vitamin K
Pancytopenia
Encephalopathy
Hypoprothrombinaemia
Vitamin excess Vitamin A
Vitamin D
Dermatitis
Hypercalcaemia
Fatty l iver
See also:
Nutri tion—use and indications, p78; Electrolytes
, p146; Calcium, magnesium and phosphate, p148; Hypernatraemia, p416; Hyponatraemia, p418; Hyperkalaemia,
p420; Hypokalaemia, p422; Hypomagnesaemia, p424; Hypocalcaemia, p428; Hypophosphataemia, p430; Metabol ic
acidosis, p434
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Special Support Surfaces
Special support surfaces
Pressure sores
Pressure sores occur due to compression of tissue between bone and the support surface and due to shearing forces,
frict ion and maceration of tissues against the support surface. The use of special beds attempts to reduce the
pressure at the contacting skin surface to a level  lower than the capil lary occlusion pressure. In the majority of cases
it is sufficient to minimise the time that the support surface contacts any one area of skin by position changes.
Factors suggesting the need for a special bed
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
37 из 254 07.11.2006 1:04
Patients with severely restricted mobil ity due to traction or cardiorespiratory instabil ity cannot be turned
frequently, i f at al l .
Patients with decreased skin integri ty, e.g. burns, pressure sores already present, chronic steroid use, diabetes
mell itus.
Patients on vasoactive drug infusions.
Types of special support surface
Air mattress
This either replaces or is placed on top of a standard hospi tal bed mattress. They provide minimum reduction in
contact pressure but should be considered as minimum support for any patient with the above factors.
Low air loss bed
These purpose-buil t pressure-rel ieving beds allow easier patient mobil i ty than other support surfaces. Contact
pressure may sti l l  be higher than capi l lary occlusion pressure so posi tioning is sti l l  required. Patients who are
haemodynamically unstable should usually be managed on a low air loss bed, particularly if receiving vasoconstrictor
drugs. The presence of pressure sores with intact skin is an indication for a low air loss bed. Rotational low ai r loss
beds allow automated lateral rotation at variable t ime intervals to faci l i tate chest drainage. These may also be useful
where manual  posit ioning is impractical.
Air fluidised bed
This is the only support surface that consistently lowers contact pressure to below capi l lary occlusion pressure.
Consequently, patients with severe cardiorespiratory instabil ity, who cannot be turned, and patients with pressure
sores with broken skin benefit most. The addi tional  abil i ty to control the temperature of the immediate environment
is an advantage in hypothermic patients and those with large surface area burns. Any exudate from the skin is
adsorbed into the si l icone beads on which the patient floats. This drying effect is particularly useful  in major burns
(al though it must be taken into account for fluid replacement therapy). The air fluidised bed also has a role in pain
rel ief.
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Respiratory Monitoring
Pulse oximetry
Continuous non-invasive monitoring of arterial oxygen saturation by placement of a probe emitt ing red and
near-infrared l ight over the pulse on digi t,  earlobe, cheek or bridge of nose. It is unaffected by skin pigmentation,
hyperbil irubinaemia or anaemia (unless profound).
Physics
The colour of blood varies with oxygen saturation due to the optical properties of the haem moiety. As the Hb
molecule gives up O2 it becomes less permeable to red l ight and takes on a blue tint. Saturation is determined
spectrophotometrical ly by measuring the ‘blueness’, uti l is ing the abil ity of compounds to absorb l ight at a specific
wavelength. The use of two wavelengths (650 and 940nm) permits the relative quantit ies of reduced and
oxyhaemoglobin to be calculated, thereby determining saturation. The arterial  pulse is used to provide t ime points to
allow subtraction of the constant absorption of l ight by tissue and venous blood. The accuracy of pulse oximetry is
within 2% above 70% SaO2.
Indications
Continuous monitoring of arterial  oxygen saturation.
Cautions
As only two wavelengths are used, pulse oximetry measures functional rather than fractional  oxyhaemoglobin
saturation. Erroneously high readings are given with carboxyhaemoglobin and methaemoglobin.
With poor peripheral perfusion or intense vasoconstriction the reading may be inaccurate (‘fai l  soft’) or, in newer
models, absent (‘fai l hard’).
Motion artefacts and high levels of ambient l ighting may affect readings.
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Erroneous signal may be produced by significant venous pulsation from tricuspid regurgitation or venous
congestion. Venous pulsati l ity accounts for differences between ear and finger SpO2 in the same subject.
Ensure a good LED signal  indicator or a pulse waveform (if available) is seen on the monitor.
Vital dyes (e.g. methylthioninium chloride (methylene blue), indocyanine green) may affect SpO2 readings.
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; IPPV—adjusting the venti lator, p10; Continuous positive
airway pressure, p26; Endotracheal  intubation, p36; Tracheotomy, p38; Fibreoptic bronchoscopy, p46; Chest
physiotherapy, p48; Upper gastrointestinal endoscopy, p74; Blood gas analysis, p100; Basic resuscitation, p270;
Dyspnoea, p278; Respiratory fai lure, p282; Acute chest infection (1), p288; Acute chest infection (2), p290; Acute
respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2), p294; Asthma—general
management, p296; Asthma—venti latory management, p298; Pneumothorax, p300; Poisoning—general principles,
p452; Post-operative intensive care, p534
CO2 monitoring
Capnography
For capnography, respiratory gases must be sampled continuously and measured by a rapid response device. Since
CO2 has an absorption band in the infrared spectrum, measurement is faci l i tated in gas mixtures. Other gases can
interfere with infrared absorption by CO2. This may be overcome by calibrating the instrument with known
concentrations of CO2 in the required measurement range, di luted with a gas mixture similar to exhaled gas.
The capnogram
The CO2 concentration of exhaled gas consists of 4 phases (see figure). The presence of significant concentrations of
CO2 in phase 1 implies rebreathing of exhaled gas. Fai lure of an expiratory valve to open is the most l ikely cause of
rebreathing during manual venti lation, al though an inadequate flow of fresh gas into a rebreathing bag is a common
cause. The slope of phase 3 is dependent on the rate of alveolar gas exchange. A steep slope may indicate
venti lat ion-perfusion mismatch since alveoli  that are poorly venti lated but well  perfused discharge late in the
respiratory cycle. A steep slope is seen in patients with significant auto-PEEP.
Colorimetric devices
The underlying principle is that the change in pH produced by different CO2 concentrations in solution wil l  change the
colour of an indicator. These are small  devices that fit onto an endotracheal tube or the venti lator circui t and respond
rapidly (up to 60 breaths/min). They can be affected by excessive humidity and general ly only work in the range
0–4% CO2.  They are useful  to confi rm tracheal intubation, during patient transfer and in the cardiac arrest si tuation.
End-tidal PCO2
End-tidal  PCO2 approximates PaCO2 in patients with normal  lung function. In ICU patients pulmonary function is
rarely normal, thus end-tidal  PCO2 i s a poor approximation of PaCO2. Large differences may represent an increased
dead space to t idal volume ratio, poor pulmonary perfusion or intrapulmonary shunting. A progressive rise in
end-tidal  PCO2 may represent hypoventi lation, ai rway obstruction or increased CO2 production due to increased
metabolic rate. End-tidal PCO2 fal ls wi th hyperventi lation and in low cardiac output states. It is absent with
venti lator disconnection and during cardiac arrest but rises with effective CPR or restoration of a spontaneous
ci rculation.
Dead space to tidal volume ratio
The arterial  to end-tidal PCO2 di fference may be used to calculate the physiological dead space to t idal volume ratio
via the Bohr equation:
In health a value between 30 and 45% should be expected.
The components of the normal capnogram
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Figure. No Caption Available.
Phase 1
During the early part of the exhaled breath anatomical  dead space and sampling device dead space gas are sampled.
There is negligible CO2 in phase 1.
Phase 2
As alveolar gas begins to be sampled there is a rapid rise in CO2 concentration.
Phase 3
Phase 3 is known as the alveolar plateau and represents the CO2 concentration in mixed expired alveolar gas. There
is normal ly a sl ight increase in PCO2 during phase 3 as alveolar gas exchange continues during expiration. Ai rway
obstruction or a high rate of CO2 production wil l  increase the slope. End-tidal PCO2 wil l  be less than the PCO2 of ideal
alveolar gas since the sampled exhaled gas is mixed with alveolar dead space gas.
Phase 4
As inspiration begins there is a rapid fal l  in sample PCO2.
See also:
Venti latory support—indications, p4; IPPV—adjusting the venti lator, p10; Endotracheal  intubation, p36; Tracheotomy,
p38; Fibreoptic bronchoscopy, p46; Blood gas analysis, p100; Basic resuscitation, p270
Pulmonary function tests
Few of the numerous pulmonary function tests currently available impact upon cl inical management of the crit ically
i l l , particularly i f the patient has to be moved to a laboratory. A number of other tests require highly special ised
equipment and fulf i l  a predominant research role.
Clinically relevant tests
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Measurement Test Common clinical use
PaO2, SaO2, PaCO2 Arterial blood gases
SpO2 Pulse oximetry
End-tidal PCO2 Capnography
Vital capacity, tidal
volume
Spirometry, electronic
flowmetry
Serial measurement of borderline
function (VC <10–15ml/kg) e.g.
Guillain–Barré syndrome
Peak expiratory flow
rate FEV1, FVC
Wright peak flow meter
Spirometry, electronic
flowmetry
(Spontaneous ventilation) asthma
(Spontaneous ventilation) asthma,
obstructive/restrictive disease
Lung/chest wall
compliance (see
equations opposite)
Pressure–volume curve Ventilator adjustments, monitoring
disease progression
Flow-volume loop,
pressure-volume loop
Pneumotachograph
manometry
Ventilator adjustments
Research tests (examples)
Measurement Test Research use
Diaphragmatic strength
(transdiaphragmatic pressure)
Gastric and oesophageal
manometry
Respiratory muscle function,
weaning
Pleural (intrathoracic)
pressure
Oesophageal manometry Ventilator trauma, work of
breathing, weaning
Functional residual capacity Closed circuit helium dilution,
(bag-in-a-box) open circuit
N2 washout
Lung volumes, compliance
Ventilation–perfusion
relationship
Multiple inert gas elimination
technique, isotope techniques
Regional lung
ventilation–perfusion,
pulmonary gas exchange
Pulmonary diffusing capacity Carbon monoxide uptake Pulmonary gas exchange
Notes
Compliance equals the change in pressure during a l inear increase of 1l in volume above FRC.
The alveolar–arterial  oxygen di fference is <2kPa in youth and <3.3kPa in old age.
The Bohr equation calculates physiological  deadspace, VD. The normal  value is below 30%.
The shunt equation estimates the proportion of blood shunted past poorly venti lated alveoli  (QS) compared to
total lung blood flow (QT).
These equations al low estimation of venti lation/perfusion mismatch:
V/Q=1, venti lat ion and perfusion are wel l-matched.
V/Q>1, increased deadspace (where alveoli  are poorly perfused but well venti lated).
V/Q<1, increased venous admixture or shunt (where alveol i are perfused but poorly venti lated).
The normal  range is <15%.
Lung volumes and capacity
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Equations
Alveolar gas equation
PAO2 = FIO2-(PaCO2/respiratory quotient) [RQ often approximated to 0.8]
Alveolar-arterial oxygen difference
(A-a) difference = FIO2 ×  94.8 - PaCO2 - PaO2
Bohr equation:
VD/VT  = (PaCO2 - expired PCO2)/PaCO2
Shunt equation
QS/QT=(CcO2-CaO2)/(CcO2-CvO2)
where CcO2 = end-capil lary O2 content, a = arterial,  v = mixed venous
See also:
Venti latory support—indications; IPPV—adjusting the venti lator; IPPV—weaning techniques; IPPV—assessment of
weaning; Pulse oximetry; CO2 monitoring; Blood gas analysis; Chronic ai rflow l imitation; Asthma—general
management; Asthma—venti latory management; Acute weakness; Guil lain–Barré syndrome; Myasthenia gravis;
Rheumatic disorders; Vascul it ides
Pressure–volume relationship
This is determined by the compliance of the lungs and chest wal l. The inspiratory pressure–volume relationship
contains three components: an ini tial increase in pressure with no significant volume change; a l inear increase in
volume as pressure increases (the slope of which represents respiratory system compl iance); and a further period of
pressure increase with no volume increase. These three phases are separated by two inflexion zones, the lower
representing the opening pressure of the system after flow resistance has been overcome in smaller airways and the
upper approximating to total lung capacity. The expiratory pressure–volume relationship should normal ly
approximate the inspiratory curve, returning to functional residual  capacity. In patients with small  ai rway collapse,
separation of the inspiratory and expiratory curves occurs (hysteresis) as gas is trapped in smaller ai rways at the end
of expiration.
Dynamic measurement
A pressure–volume loop may be viewed on most modern mechanical  venti lators. A square wave inspiratory waveform
(constant flow) and no inspiratory pause are necessary for waveform interpretation.
Static measurement
Small  incremental  lung volumes (200ml) are delivered with a cal ibrated syringe. The pressure measurement after
each increment is taken under zero flow condi tions, al lowing construction of a pressure–volume curve. A quasistatic
curve can be constructed by setting incremental  tidal  volumes (e.g. between 100 and 1000ml) for successive
venti lator breaths and measuring the pressure during an inspiratory pause.
Use of pressure volume curves
Since respiratory muscle activi ty can al ter intrathoracic pressure, the pressure volume curve is more easily obtained
in the relaxed, ful ly venti lated patient. Both static and dynamic respiratory system compliance can be determined as
the slope of the l inear portion of the curve, i.e. where incremental pressure inflates the lungs. Below the lower
inflexion zone the small  ai rways are closed and expiration does not reach functional  residual  capacity. The lower
inflexion zone therefore represents the appropriate sett ing for external PEEP to avoid gas trapping. Above the upper
inflexion zone the lungs cannot inflate further. The upper inflexion zone therefore represents the maximum setting for
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peak airway pressure.
Compliance: calculations
Lung compliance (l /cmH2O) = ΔVL/ΔPL where L, the l itre above FRC, is the slope of the l inear portion of the curve.
Total respiratory system compliance is derived from the equation:
(1/total compliance) = (1/lung compliance) + (1/chest wall compliance)
Total compliance can be calculated in well  sedated, venti lated patients as:
tidal  volume/(end-inspiratory pause pressure - PEEP).
Figure. No Caption Available.
See also:
Venti latory support—indications; IPPV—adjusting the venti lator, p10; Posi tive end expiratory pressure (1), p22;
Positive end expiratory pressure (2), p24; Chronic airflow l imitation, p286; Asthma—general management, p286;
Asthma—venti latory management, p298
Blood gas machine
A smal l amount of heparinised blood is either injected from a syringe or aspirated from a capil lary tube into the
machine. The blood comes into contact wi th three electrodes which measure pH, PO2 and PCO2.
pH—measured by the potential  across a pH-sensi tive glass membrane separating a sample of known pH and the
test sample.
PO2—the partial  oxygen pressure, is measured by applying a polarising voltage between a platinum cathode and
a si lver anode (Clark electrode). O2 is reduced, generating a current proportional to the PO2.
PCO2—the partial  pressure of carbon dioxide, uti l ises a pH electrode with a Teflon membrane (Severinghaus
electrode) which al lows through uncharged molecules (CO2) but not charged ions (H+). CO2 alone thus changes
the pH of a bicarbonate electrolyte solution, the change being l inearly related to the PCO2.
Hb—estimated photometrically; this is not as accurate as co-oximetry (see below).
Bicarbonate—calculated by the Henderson–Hasselbach equation
Actual  HCO3- includes bicarbonate, carbonate and carbamate.
Actual  base excess (deficit)—the difference in concentration of strong base (acid) in whole blood and that
titrated to pH 7.4, at PCO2 5.33kPa and 37°C.
Standard base excess (defici t)—a calculated in vivo base excess (defici t).
Standard bicarbonate—the plasma concentration of hydrogen carbonate equil ibrated at PCO2 5.33kPa, PO2
13.33kPa and temperature 37°C.
Blood gas values can be given either as ‘pHstat’ or ‘alphastat’, the former correcting for body temperature by shi ft ing
the calculated Bohr oxyhaemoglobin dissociation curve (hyperthermia to the right, hypothermia to the left). Alphastat
measures true blood gas levels in the sample.
Co-oximeter
This differs from a blood gas machine in that the blood is haemolysed to calculate (i ) total Hb and fetal Hb and (i i )
oxyHb, carboxyhaemoglobin (COHb), methaemoglobin and sulphaemoglobin by uti l i sing absorbance at six
wavelengths (535, 560, 577, 622, 636, 670nm).
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Taking a good blood gas sample
Use a 1ml syringe containing preferably a dry heparin sal t (if not, l iquid sodium heparin 1000iu/ml solution just
fi l l ing the hub). Take sample, expel  ai r, mix sample thoroughly and insert without delay.
Cautions
Too much heparin causes di lution errors and is acidic.
Nitrous oxide or halothane anaesthesia may give unreliable PO2 values.
Intravenous l ipid administration may affect pH values.
Abnormal (high/low) plasma protein concentrations affect base deficit.
See also:
Blood gas analysis, p100; Invasive blood gas monitoring, p102
Blood gas analysis
A heparinised (arterial , venous, capil lary) blood sample can be inserted into a blood gas machine and/or co-oximeter
for measurement of gas tensions and saturations, and acid–base status.
Measurements
Identi fication of arterial hypoxaemia and hyperoxia, hypercapnia and hypocapnia—enabl ing monitoring of disease
progression and efficacy of treatment. Venti lator and FIO2 adjustments can be made precisely.
pH, PaCO2 and base defici t (or bicarbonate) values can be reviewed in parallel for diagnosis of acidosis and
alkalosis, whether it is respiratory or metabol ic in origin, and whether any compensation has occurred. (See
figure opposi te).
Using a co-oximeter, accurate measurement can be made of haemoglobin oxygen saturation and also the total  Hb
level. The more sophisticated co-oximeters permit measurement of the fraction of metHb, COHb, deoxyHb and
fetal Hb.
Measurement of mixed venous oxygen saturation—for calculation of oxygen consumption and monitoring of
oxygen supply:demand balance.
Causes of acid–base disturbances
Respiratory acidosis—excess CO2 production and/or inadequate excretion, e.g. hypoventi lation, excess narcotic
Respiratory alkalosis—reduction in PaCO2 due to hyperventi lat ion
Metabol ic acidosis—usual ly lactic, keto, renal or tubular. Consider tissue hypoperfusion, ingestion of acids (e.g.
aspirin), loss of alkali  (e.g. diarrhoea, renal tubular acidosis), diabetic ketoacidosis and hyperchloraemia (e.g.
from excess normal sal ine administration)
Metabol ic alkalosis. Consider excess alkal i (e.g. bicarbonate or buffer infusion), loss of acid (e.g. large gastric
aspirates, renal), hypokalaemia, drugs (e.g. diuretics)
Normal values
pH 7.35–7.45
PCO2 4.6–6kPa
PO2 10–13.3kPa
HCO3- 22–26mmol/l
ABE -2.4 to +2.2
Arterial O2 saturation 95–98%
Mixed venous oxygen saturation 70–75%
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Figure. No Caption Available.
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; IPPV—adjusting the venti lator, p10; IPPV— assessment of
weaning, p18; Posi tive end expiratory pressure (1), p22; Posi tive end expiratory pressure (2), p24; Continuous
posit ive ai rway pressure, p26; Non-invasive respiratory support, p32; Extracorporeal respiratory support, p34;
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Peritoneal dialysis, p66; Parenteral nutrit ion, p82; Blood
gas machine, p98; Invasive blood gas monitoring, p102; Arterial  cannulation, p112; Pulmonary artery catheter— use,
p118; Gut tonometry, p130; Lactate, p170; Basic resuscitation, p270; Respiratory failure, p282; Chronic airflow
limitation, p286; Acute chest infection (1), p288; Acute chest infection (2), p290; Acute respiratory distress
syndrome (1), p292; Acute respiratory distress syndrome (2), p294; Asthma—general management, p296;
Asthma—venti latory management, p298; Heart fai lure—assessment, p324; General  acid–base management, p432;
Metabolic acidosis, p434; Metabol ic alkalosis, p436; Diabetic ketoacidosis, p442; Poisoning—general principles, p452
Sal icylate poisoning, p454; Inhaled poisons, p466; Post-operative intensive care, p534
Invasive blood gas monitoring
Continuous blood gas monitoring can be achieved via an intra-arterial  heparin-bonded catheter wi th on-l ine display of
directly measured and computed blood gas variables. Resul ts are updated every 20–30s. Recal ibration is generally
recommended at 12-hrly intervals.
Technology
Systems uti l ise ei ther electrode, tonometric or optode technology.
Electrode technology is similar to that described for blood gas machine measurement. Optical  sensors uti l i se
either absorbance or fluorescence spectrophotometry to measure the signal from the chemical  interaction
between the analyte (O2, CO2 and H+) and an indicator phase.
Problems
Damping of the arterial pressure waveform can occur through the presence of the catheter wi thin the arterial
cannula. A dedicated, non-tapering 20G cannula reduces this damping effect.
An increasing dri ft in accuracy is recognised after several  days.
See also:
Blood gas analysis, p100
Extravascular lung water measurement
Standard methods of assessing pulmonary oedema are indirect. The CXR allows quali tative assessment only and is
slow to change in response to cl inical  treatment. Assessment of cardiac fi l l ing pressures does not take into account
the degree of capi l lary permeabil ity or lymphatic adaptation. Consequently, a relatively low CVP or PAWP may be
associated with pulmonary oedema formation and high fi l l ing pressures in chronic heart fai lure may be associated
with no oedema and be entirely appropriate. Extravascular lung water (EVLW) measurement provides a technique for
quanti fying pulmonary oedema and monitoring the response to treatment.
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
45 из 254 07.11.2006 1:04
P.105
Measurement technique
The normal value of 4–7ml/kg for extravascular lung water has been derived by gravimetric techniques performed
post-mortem. A double indicator technique may be used in l iving patients. Two indicators are injected via a central
vein; one distributes within the vascular space and the other throughout the intra- and extravascular space. The
volume of distribution of the indicators is derived from the dilution curves detected at the femoral artery. Cooled 5%
glucose is used as a thermal indicator for intra- and extravascular volume and indocyanine green bound to albumin as
a colorimetric indicator for intravascular volume. Detection at the femoral artery is by a fibreoptic catheter with a
thermistor tip. The cardiac output is measured by thermodilution at the femoral artery. The rate of exponential  decay
of the thermodi lution curve al lows the derivation of the volume of distribution between the injection and detection
si tes (the heart and lungs).
Pulmonary thermal volume = thermodilution CO × rate of exponential decay of thermodilution curve (intra- and
extravascular volume)
Similar principles may be applied to the dye di lution curve produced on injection of indocyanine green which is
assumed to distribute within the vascular space only.
Pulmonary blood volume = dye di lution CO × rate of exponential  decay of dye di lution curve (intravascular volume)
EVLW may be calculated by subtracting pulmonary blood volume from pulmonary thermal volume.
Limitations of EVLW measurement
Since it is known that albumin can exchange across capil lary membranes, pulmonary blood volume is overestimated
by this technique and extravascular lung water is therefore underestimated. However, the corresponding error is
small  and not particularly signi ficant cl inically. A more serious drawback is in the l imitation of treatment options.
Treatment of pulmonary oedema by diuresis and ultrafi l tration has been shown to be less effective at reducing EVLW
in capil lary leak, compared to congestive heart fai lure. Similarly, the strategy of preventing oedema formation by
diuresis while maintaining the circulation with catecholamine infusions appears to be futi le; vasoconstriction so
produced increases EVLW.
See also:
Cardiac output—thermodi lution, p122; Cardiac output—other invasive, p124; Acute respiratory distress syndrome (1),
p292; Acute respiratory distress syndrome (2), p294; Heart fai lure—assessment, p324
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Cardiovascular Monitoring
ECG monitoring
Continuous ECG monitoring is routine in every intensive care unit. The standard technique is to display a three lead
ECG (commonly lead II). Other l imb leads may be used al though the electrodes are placed at the shoulders and left
side of the abdomen. Other lead configurations can be used for specific purposes:
Chest–Shoulder–V5 Early detection of left ventricular strain
Chest–Manubrium–V5 Early detection of left ventricular strain
Chest–Back–V5 P wave monitoring
Modern, continuous monitors include alarm functions for bradycardia and tachycardia monitoring, and software
routines for arrhythmia detection or ST segment analysis.
Causes of changes in heart rate or rhythm
Changes in heart rate or rhythm may be an indication of:
Sympathetic activi ty
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Circulatory insufficiency
Pain
Anxiety
Hypoxaemia
Hypercapnia
Adverse drug effects
Antiarrhythmics
Sedatives
Electrolyte imbalance
Fever
See also:
Defibri l lat ion, p52; Temporary pacing (1), p54; Temporary pacing (2), p56; Cardiac arrest, p272; Tachyarrthythmias,
p316; Bradyarrhythmias, p318; Acute coronary syndrome (1), p320; Acute coronary syndrome (2), p322;
Hyperkalaemia, p420; Hypokalaemia, p422; Poisoning—general  principle, p452; Tricycl ic antidepressant poisoning,
p460; Hypothermia, p518; Pain, p532
Blood pressure monitoring
Non-invasive techniques
Non-invasive techniques are intermittent but automated. They include oscil lotonometry (detection of cuff pulsation as
the systolic pressure), detection of arterial turbulence under the cuff, ultrasonic detection of arterial wal l motion
under the cuff and detection of blood flow distal  to the cuff. Any cuff system should use a cuff large enough to cover
two-thirds of the surface of the upper arm.
Invasive (direct) arterial monitoring
Blood pressure is most useful ly monitored from larger l imb arteries, e.g. femoral or brachial.  However, the potential
for damage to these arteries is considerable and most consider it safer to use the radial  or dorsalis pedis arteries,
the pressure in which is higher. The arterial cannula is connected to an appropriate transducer system via a short
length of non-compl iant manometer tubing. The transducer should be matched to the monitor, i.e. as recommended
by the manufacturer of the monitor. The transducer must be zeroed to atmospheric pressure. The transducer should
be positioned at the level of the 4th intercostal space in the mid-axil lary l ine. The transducer, manometer tubing and
cannula should be continuously flushed with 3ml/h heparinised sal ine (1000IU/l).
Damping errors
It is important that the monitoring system is correctly damped. An underdamped system wil l overestimate systol ic
and underestimate diastolic blood pressure. The converse is true for an overdamped system. Moreover, i t i s not
possible to correctly interpret waveform shape if damping is not correct. A correctly damped system wil l  return
immediately to the pressure waveform after flushing. Return is slow in an overdamped system and there is often
resonance around the baseline before return to the pressure waveform in an underdamped system.
Interpretation of waveform
The shape of the arterial pressure waveform gives useful qual itative information about the state of the heart and
circulation:
Short systol ic time
Hypovolaemia
High peripheral resistance
Marked respiratory swing
Hypovolaemia
Pericardial effusion
Airways obstruction
High intra-thoracic pressure
Slow systolic upstroke
Poor myocardial contracti l i ty
High peripheral resistance
Limitations of blood pressure monitoring
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It is important not to rely on arterial blood pressure monitoring alone in the cri tical ly i l l . A normal blood pressure
does not guarantee adequate organ blood flow. Conversely, a low blood pressure may be acceptable if perfusion
pressure and blood flow is adequate for al l organs. Measurement of cardiac output, in addi tion to blood pressure, is
necessary where there is doubt about the adequacy of the circulation.
Examples of arterial waveform shape
Figure. No Caption Available.
See also:
Arterial  cannulation, p112; Hypotension, p312; Hypertension, p314
Arterial cannulation
Indications
Performed correctly, arterial  cannulation is a safe technique allowing continuous monitoring of blood pressure and
frequent sampling of blood. It is indicated in any patient with unstable or potential ly unstable haemo-dynamic or
respiratory status.
Radial artery cannulation
The radial artery is most frequently chosen because it is accessible and has good collateral  blood flow. Al len's test,
used to confirm the ulnar arterial blood supply, is not rel iable.
Technique of cannulation
The wrist is hyperextended and the thumb abducted. After skin cleansing local  anaesthetic (1% plain l idocaine) is
injected into the skin and subcutaneous tissue over the most prominent pulsation. The course of the artery is noted
and a 20G Teflon cannula is inserted along the l ine of the vessel. The usual  technique is to enter the vessel  in the
same way as an intravenous cannula would be inserted. There is usually some resistance to skin puncture. To avoid
accidentally puncturing the posterior wal l of the artery, the skin and artery should be punctured as two distinct
manoeuvres. Alternatively, a smal l skin nick may be made to faci l i tate skin entry.
In the case of elderly patients with mobile, atheromatous vessels a technique that involves deliberate transfixation of
the artery may be used. The cannula is passed through the anterior and posterior wal ls of the vessel , thus
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immobi l ising i t. The needle is removed and the cannula withdrawn slowly into the lumen vessel , before being
advanced forward.
Seldinger-type ki ts are also avai lable for arterial cannulation. A guidewire is fi rst inserted through a rigid steel
needle. The indwel l ing plastic cannula is then placed over the guidewire.
The cannula should be connected to a continuous flushing device after successful puncture. Flushing with a syringe
should be avoided since the high pressures generated may lead to a retrograde cerebral embolus.
Alternative sites for cannulation
Brachial artery
End artery supplying a large volume of tissue. Thus thrombosis has potential ly severe consequences.
Ulnar artery
Should be avoided if the radial artery is occluded.
Femoral artery
May be di fficul t to keep clean. Also suppl ies a large volume of tissue. A longer catheter should be used to avoid
displacement.
Dorsalis pedis artery
Blood pressure wi l l  be at least 10–20mmHg higher than in the central  ci rculation.
Complications
Digital ischaemia due to arterial  spasm, thrombosis or embolus
Bleeding in cases with altered coagulation status
Infection is a risk in prolonged cannulation
False aneurysm
See also:
Blood gas analysis, p100; Invasive blood gas monitoring, p102; Blood pressure monitoring, p110; Routine changes of
disposables, p478
Central venous catheter—use
Types of catheter
Single, double, triple or quadruple lumen.
Sheaths for insertion of pulmonary artery catheter or pacing wire.
Tunnel led catheter for long term use.
Multi lumen catheters al low multiple infusions to be given separately ± continuous pressure monitoring.
Minimises accidental bolus risk.
Large-bore double lumen catheters used for venovenous dialysis/fi ltration.
Common routes are internal jugular, subclavian and femoral .
‘Long’ catheters can be inserted via brachial  or axil lary veins though are generally not used due to the risk of
thrombosis.
Uses
Invasive haemodynamic monitoring.
Infusion of drugs that can cause peripheral phlebit is or tissue necrosis i f t issue extravasation occurs (e.g. TPN,
epinephrine, amiodarone).
Rapid volume infusion. NB the rate of flow is inversely proportional to the length of the cannula.
Access, e.g. for pacing wire insertion.
Emergency access when peripheral circulation is ‘shut down’.
Renal replacement therapy, plasmapheresis, exchange transfusion.
Contraindications/cautions
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Coagulopathy.
Undrained pneumothorax on contralateral side.
Agi tated, restless patient.
Complications
Arterial  puncture.
Haemorrhage.
Arrhythmias.
Infection (usual ly skin, occasionally sepsis or endocardi tis).
Pneumothorax.
Air embol ism, venous thrombosis, haemothorax, chylothorax (rare).
Central venous pressure measurement
Use of an electronic pressure transducer is preferable to manometry which incorporates a three-way tap, a fluid
reservoir bag and a fluid-fi l led vertical  column, the height of which corresponds to CVP. The pressure transducer
should be placed and ‘zeroed’ at the level  of the left atrium (approximately mid-axil lary l ine) rather than the sternum
which is more affected by patient posit ion (supine/semi-erect/prone). Venous pulsation and some respiratory swing
should be seen in the trace but not a RV pressure waveform (i .e. catheter inserted too far).
Troubleshooting
Excessive bleeding at the insertion si te is usually controlled by direct compression. If not control led, correct any
coagulopathy, If post-thrombolysis, consider tranexamic acid.
The incidence of local infection (usual ly coagulase negative Staphylococci  or S. aureus) rises after 5 days. Routine
change of catheter at 5–7 days is not necessary though change over a wire may be sufficient if the patient develops
an unexplained pyrexia or neutrophil ia. However, removal ± change of site is needed i f the site is cellul iti c or blood
cul tures taken through the catheter are posi tive.
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Parenteral nutri tion, p82; Temporary pacing (1), p54;
Temporary pacing (2), p56; Central venous catheter—insertion, p116; Pulmonary artery catheter—insertion, p120;
Fluid challenge, p274; Routine changes of disposables, p478
Central venous catheter—insertion
Ultrasound-guided placement should be considered, especial ly for difficult placements. The technique with ultrasound
guidance is di fferent from the landmark technique; operators should to be able to identify a patent vein and
manipulate both probe and cannula simultaneously. There wil l  be many situations where an ultrasound device may be
unavai lable so placement using anatomical landmarks alone should sti l l  be learnt.
Landmarks
Various landmarks have been described. For example:
Internal jugular: Hal fway between mastoid process and sternal  notch, lateral  to carotid pulsation and medial  to
medial  border of sternocleidomastoid. Aim toward ipsi lateral nipple, advancing under body of
sternocleidomastoid unti l vein entered.
Subclavian: 3 cm below junction of lateral thi rd and medial two thi rds of clavicle. Turn head to contralateral
side. Aim for point between jaw and contralateral  shoulder tip. Advance needle subcutaneously to hit clavicle.
Scrape needle under clavicle and advance further unti l  vein entered.
Femoral: Locate femoral  artery in groin. Insert needle 3cm medially and angled rostrally. Advance unti l vein
entered.
Insertion technique
The Seldinger technique (described below) is safer than the ‘catheter-over-needle’ technique and should general ly be
used in ICU patients.
Use aseptic technique throughout. Clean area with antiseptic and surround with steri le drapes. Anaesthetise
local area with 1% lidocaine. Flush lumen(s) of catheter wi th saline.
1.
Use metal needle to locate central  vein.2.
Pass wire (with ‘J’  or floppy end leading) through needle into vein. Only minimal resistance at most should be
felt. If not, remove wire and confi rm needle tip is sti l l  located within vein lumen. Monitor for arrhythmias. If
3.
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these occur, wire is probably at tricuspid valve. Usually responds to retracting wire a few cm.
Remove needle leaving wire extruding from skin puncture si te.4.
Depending on size/type of catheter to be inserted, a rigid di lator (± preceded by a scalpel  incision to enlarge
puncture site) may be passed over the wire to form a track through the subcutaneous tissues to the vein.
Remove dilator.
5.
Thread catheter over wire. Ensure end of wire extrudes from catheter to prevent accidental loss of wire in vein.
Insert catheter into vein to depth of 15–20cm. Remove wire.
6.
Check for flashback of blood down each lumen and respiratory swing, then flush with saline.7.
Suture catheter to skin. Clean and dry area. Cover with steri le transparent semipermeable dressing.8.
A CXR is usually performed to veri fy correct position of tip (junction of superior vena cava and right atrium) and
to exclude a pneumothorax. Unless in an emergency situation, a satisfactory position should generally be
confirmed before use of the catheter.
9.
Pulmonary artery catheter—use
Though in cl inical use for 30 years, retrospective data analyses suggested an association between catheter use and
increased mortali ty that has not been confirmed by prospective trials. Studies have also found an inadequate
knowledge base regarding insertion and data interpretation so proper training in i ts use is mandated.
Uses
Pressure monitoring—RA, RV, PA, PAWP
Flow monitoring—(right ventricular) cardiac output
Oxygen saturation—‘mixed venous’ (i.e. in RV outflow tract/PA), determination of left to right shunts (ASD, VSD)
Derived variables—SVR, PVR, LVSW, RVSW, DO2, VO2,  O2ER
Temporary pacing
Right ventricular ejection fraction and end-diastol ic volume
Specialised catheters
Continuous mixed venous oxygen saturation measurement
Continuous cardiac output measurement
RV end-diastolic volume, RV ejection fraction calculation
Ventricular (±atrial ) pacing
Management
Monitor PA pressure continuously to recognise forward catheter migration and pulmonary arterial occlusion. If so,
correct immediately by partial catheter withdrawal  to prevent infarction.
The risk of local infection (usually Staph. aureus or coagulase negative staphylococci) rises after 5 days. A catheter
change over a guidewire may be sufficient i f unexplained pyrexia or neutrophil ia develops. Removal  ± change of si te
is needed if the site is cellul i ti c, or positive cul tures are grown from either l ine tip or blood.
Withdraw samples of pulmonary artery blood slowly from the distal lumen to prevent ‘arterial ization’, i.e. pulmonary
venous sampl ing.
Wedge pressure measurements
Inflate balloon slowly, monitoring the waveform to avoid overwedging and potential  vessel rupture especial ly if
elderly and/or pulmonary hypertensive. The trace should only ‘wedge’ after ≥1.3ml air has been injected.
Measure at end-expiration when intrathoracic pressure is closest to atmospheric pressure. For venti lated patients end
expiration ≡ lowest wedge reading; during spontaneous breathing end expiration ≡ highest reading. Measurement is
difficul t in the dyspnoeic patient; a ‘mean’ wedge reading may be used in this instance.
The PAWP cannot be higher than the PA diastol ic pressure.
CVP, PAWP and CO should not be measured during rapid volume infusion but after a period of equil ibration (5-10
min).
The PAWP does not equal the LVEDP in mitral stenosis.
In mitral regurgi tation measure PAWP at the end of the ‘A’ wave.
West's zones
The catheter tip should l ie in a zone III region where PA pressure >PV pressure >alveolar pressure and below left
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atrial level on a lateral CXR.
Suspect a non-zone III posi tion i f (i) fol lowing a rise in PEEP, the PAWP rises by >50% of the increment, (i i ) the
wedge trace shows no detectable cardiac pulsation and/or excess respiratory variation.
A non-zone III position is more l ikely with PEEP and/or hypovolaemia.
Normal values
Stroke volume 70–100ml
Cardiac output 4–6l/min
Right atrial pressure 0–5mmHg
Right ventricular pressure 20–25/0–5mmHg
Pulmonary artery pressure 20–25/10–15mmHg
Pulmonary artery wedge pressure 6–12mmHg
Mixed venous oxygen saturation 70–75%
Derived variables
Key trials and studies
Connors AF Jr et al . The effectiveness of right heart catheterization in the init ial care of critical ly i l l  patients. JAMA
1996; 276:889–97
Richard C et al . Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory
distress syndrome: a randomized control led trial. JAMA 2003; 290:2713–20
Iberti TJ et al . A multicenter study of physicians' knowledge of the pulmonary artery catheter. JAMA 1990;
264:2928–32
See also:
Positive end expiratory pressure (1), p22; Posit ive end expiratory pressure (2), p24; Blood gas analysis, p100;
Extravascular lung water measurement, p104; Central venous catheter—use, p114; Central  venous
catheter—insertion, p116; Pulmonary artery catheter—insertion, p120; Cardiac output—thermodilution, p122; Cardiac
output—other invasive, p124; Fluid chal lenge, p274; Heart fai lure—assessment, p324; Routine changes of
disposables, p478
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Pulmonary artery catheter—insertion
Insertion
Insert 8Fr central  venous introducer sheath under strict aseptic technique. Pulmonary artery catheterisation is
easier via internal jugular or subclavian veins.
1.
Prepare catheter pre-insertion—3-way taps on all lumens, flush lumens with crystalloid, inflate bal loon with
1.6ml air and check for concentric inflation and leaks, place transparent sleeve over catheter to maintain future
steri l ity, pressure transduce distal lumen and zero to a reference point (usually mid-axi l lary l ine). Depending on
catheter type, other pre-insertion calibration steps may be required, e.g. oxygen saturation.
2.
Insert catheter 15cm (i.e. beyond the length of the introducer sheath) before inflating bal loon. Advance catheter
smoothly through the right heart chambers. Pause to record pressures and note waveform shape in RA, RV and
PA. When a characteristic PAWP waveform is obtained, stop advancing catheter, deflate balloon and ensure that
PA waveform reappears. If not, withdraw catheter by a few cm.
3.
Slowly re-inflate bal loon, observing waveform trace. The wedge recording should not be obtained unti l at least
1.3ml of air has been injected into the bal loon. If not, wi thdraw catheter 1–2cm and repeat. If ‘overwedged’
(pressure continues to cl imb on inflation), catheter is inserted too far and balloon has inflated forward over
distal  lumen. Immediately deflate, wi thdraw catheter 1–2cm and repeat.
4.
After insertion, a CXR is usually performed to veri fy catheter position and to exclude pneumothorax.5.
Contraindications/cautions
Coagulopathy
Tricuspid valve prosthesis or disease
Complications
Problems of central  venous catheterisation
Arrhythmias (especial ly when traversing tricuspid valve)
Infection (including endocardi tis)
Pulmonary artery rupture
Pulmonary infarction
Knotting of catheter
Valve damage (do not withdraw catheter unless bal loon deflated)
Troubleshooting
Excessive catheter length in a heart chamber causes coil ing and a risk of knotting. No more than 15–20cm should be
passed before the waveform changes. If not, deflate balloon, withdraw catheter, repeat. A knot can be managed by
(i) ‘unknotting’ with an intraluminal wire, (i i ) pull ing taut and removing catheter + introducer sheath together, or
(i i i) surgical  or angiographic intervention.
If catheter fai ls to advance to next chamber, consider ‘stiffening’ catheter by injecting iced crystalloid through distal
lumen, rol l ing patient to left lateral  posit ion or advancing catheter slowly with bal loon deflated.
The catheter should never be withdrawn with the bal loon inflated.
Arrhythmias on insertion usually occur when the catheter tip is at the tricuspid valve. These usually resolve on
withdrawing the catheter or, occasional ly, after a slow bolus of 1.5mg/kg l idocaine.
Waveforms
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Figure. No Caption Available.
See also:
Central venous catheter—insertion, p116; Pulmonary artery catheter—use, p118; Pneumothorax, p300; Haemothorax,
p302; Tachyarrhythmias, p316
Cardiac output—thermodilution
Thermodilution is the technique uti l i sed by the pulmonary artery catheter to measure right ventricular cardiac output.
The principle is a modi fication of the Fick principle whereby a bolus of cooled 5% glucose is injected through the
proximal lumen into the central circulation (right atrium) and the temperature change is detected by a thermistor at
the catheter tip, some 30cm distal.  A modi fication of the Hamil ton–Stewart equation, uti l is ing the volume,
temperature and speci fic heat of the injectate, enables cardiac output to be calculated by an on-l ine computer from a
curve measuring temperature change in the pulmonary artery.
Continuous thermodilution measurement uses a modified catheter that emits heat pulses from a thermal fi lament
lying within the right ventricle and right atrium, 14–25cm from the tip. 7.5W of heat are added to the blood
intermittently every 30–60s and these temperature changes are measured by a thermistor 4cm from the tip. Though
updated frequently, the cardiac output displayed is usually an average of the previous 3–6min.
Thermodilution injection technique
The computer constant must be set for the volume and temperature of the 5% glucose used. 10ml of ice-cold glucose
provides the most accurate measure. 5ml of room temperature injectate is sufficiently precise for normal and high
output states however its accuracy does worsen at low output values.
Press ‘Start ’ button on computer.1.
Inject fluid smoothly over 2–3s.2.
Repeat at least twice more at random points in the respiratory cycle.3.
Average 3 measurements fal l ing within 10% of each other. Reject outputs gained from curves that are
irregular/non-smooth.
4.
Erroneous readings
Valve lesions—tricuspid regurgi tation wi l l  al low some of the injectate to reflux back into the right atrium. Aortic
incompetence produces a higher left ventricular output as a proportion wil l  regurgi tate back into the left
ventricle.
Septal  defects.
Loss of injectate. Check that connections are tight and do not leak.
Advantages
Most commonly used and famil iar ICU technique, computer warnings of poor curves.
Disadvantages
Non-continuous (by injection technique).
5–10% inter- and intraobserver variabil ity.
Erroneous readings with tricuspid regurgi tation, intracardiac shunts.
Frequently repeated measurements may result in considerable volumes of 5% glucose being injected.
See also:
Pulmonary artery catheter—use, p118; Cardiac output—other invasive, p124; Cardiac output—non-invasive (1), p146;
Cardiac output—non-invasive (2), p146; Fluid challenge, p274; Hypotension, p312; Heart fai lure—assessment, p324;
Systemic inflammation/multi-organ failure, p484; Burns—fluid management, p510
Cardiac output—other invasive
Dye dilution
Mixing of a given volume of indicator to an unknown volume of fluid al lows calculation of this volume from the degree
of indicator di lution. The time elapsed for the indicator to pass some distance in the cardiovascular system yields a
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cardiac output value, calculated as:
…where I is the amount of indicator injected, Cm is the mean concentration of the indicator and t is the total duration
of the curve. The tradit ional dye di lution technique is to inject indocyanine green into a central  vein fol lowed by
repeated sampling of arterial  blood to enable construction of a time–concentration curve with a rapid upstroke and an
exponential decay. Plott ing the dye decay curve semi logarithmically and extrapolating values to the origin produces
the cardiac output. The COLD-Pulsion device measures the concentration decay directly from an indwell ing arterial
probe, thus computing cardiac output. Alternatively, this device may use the thermodilution approach, avoiding
pulmonary artery catheterisation. The LiDCO device is based on a similar principle using l i thium as the ‘dye’.
Advantages
Reasonably accurate, less invasive than pulmonary artery catheter placement.
Disadvantages
Invasive, reci rculation of dye prevents mult iple repeated measurements, lengthy, underestimates low output values.
Inaccurate with moderate/ severe valvular regurgitation. Use of paralysing agents may interfere with l ithium
measurement.
Direct Fick
The amount of substance passing into a flowing system is equal to the difference in concentration of the substance on
each side of the system multipl ied by the flow within the system. Cardiac output is thus usually calculated by
dividing total  body oxygen consumption by the di fference in oxygen content between arterial  and mixed venous
blood. Al ternatively, CO2 production can be used instead of VO2 as the indicator. Arterial  CO2 can be derived
non-invasively from end-tidal CO2 whi le mixed venous CO2 can be determined by rapid rebreathing into a bag unti l
CO2 levels have equil ibrated.
Advantages
‘Gold standard’ for cardiac output estimation.
Disadvantages
For VO2: Invasive (requires measurement of mixed venous blood), requires leak-free open ci rcuit or an unwieldy
closed ci rcuit technique. Oxygen consumption measurements via metabol ic cart unrel iable if FIO2 i s high. Lung
oxygen consumption not measured by pulmonary artery catheter technique (may be high in ARDS, pneumonia…).
For CO2: Non-invasive but requires normal lung function and is thus not generally applicable in ICU patients.
See also:
CO2 monitoring, p92; Blood gas analysis, p100; Extravascular lung water measurement, p104; Pulmonary artery
catheter—use, p118; Cardiac output—thermodilution, p122; Cardiac output—non-invasive (1), p126; Cardiac
output—non-invasive (2), p128; Indirect calorimetry, p168; Fluid challenge, p274; Hypotension, p312; Heart
fai lure—assessment, p324; Systemic inflammation/multi-organ fai lure, p484; Burns—fluid management, p510
Cardiac output—non-invasive (1)
Doppler ultrasound
An ul trasound beam of known frequency is reflected by moving red blood corpuscles with a shift in frequency
proportional to the blood flow velocity. The actual  velocity can be calculated from the Doppler equation which
requires the cosine of the vector between the di rection of the ultrasound beam and that of blood flow. This has been
applied to blood flow in the ascending aorta and aortic arch (via a suprasternal approach), descending thoracic aorta
(oesophageal  approach) and intracardiac flow (e.g. transmitral from an apical approach). Spectral analysis of the
Doppler frequency shi fts produces velocity–time waveforms, the area of which represents the ‘stroke distance’, i.e.
the distance travelled by a column of blood with each left ventricular systole (see figure opposite). The product of
stroke distance and aortic (or mitral valve) cross-sectional area is stroke volume. Cross-sectional area can be
measured echocardiographically; however, as both operator expertise and equipment is required, this addi tional
measurement can be ei ther ignored or assumed from nomograms to provide a reasonable estimate of stroke volume.
Advantages
Quick, safe, minimally invasive, reasonably accurate, continuous (via oesophageal  approach), other information on
contracti l i ty, preload and afterload from waveform shape (see figure opposite).
Disadvantages
Non-continuous (unless via oesophagus), learning curve, operator dependent.
Echocardiography
Combines structural as wel l as dynamic assessment of the heart using ultrasound reflected off various interfaces.
Transthoracic or transoesophageal probes provide information on valve integri ty, global (diastolic and systol ic) and
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regional  ventricular function, wall  thickness, pericardial  fluid or thickening, aortic dissection, ventricular volumes and
ejection fraction, and pulmonary pressures. Often combined with integral Doppler ul trasound for cardiac output
estimation derived from combined measurement of aortic diameter plus flow at various si tes, e.g. left ventricular
outflow tract, aorta, transmitral. Analytic software or formulae can also enable computation of cardiac output from
estimations of ventricular volumes.
Advantages
Non-invasive, safe, relatively quick. Provides other useful information on cardiac structure and function.
Disadvantages
Expensive equipment, lengthy learning curve and interobserver variabil i ty. Body habitus or pathology (e.g.
emphysema) may impair image quality.
Doppler blood flow velocity waveform variables
Figure. No Caption Available.
Changes in Doppler flow velocity waveform shape
Figure. No Caption Available.
See also:
Cardiac output—thermodi lution, p122; Cardiac output—other invasive, p124; Cardiac output—non-invasive (2), p128;
Fluid challenge, p274; Hypotension, p312; Heart fai lure—assessment, p324; Systemic inflammation/multi-organ
fai lure, p484; Burns—fluid management, p510
Cardiac output—non-invasive (2)
Pulse contour analysis
The concept of this technique is that the contour of the arterial  pressure waveform is proportional to stroke volume.
However, it is also influenced by aortic impedance so another cardiac output measuring technique (e.g. commercial
devices uti l is ing COLD-Pulsion or LiDCO) must be used in tandem for ini tial cal ibration. Although i t can then be used
as a means of continuous cardiac output monitoring, frequent re-calibration should be performed against the
reference technique. This is particularly important when changes in impedance occur, e.g. wi th changes in cardiac
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output, vascular tone, body temperature.
Advantages
Continuous flow monitoring, uses data from arterial  cannula already in situ for pressure monitoring.
Disadvantages
Changes in vascular compliance wi l l  affect accuracy requiring frequent recalibration. Requires a good quali ty,
non-obstructed and non-damped arterial waveform. There is debate about the relative qual ity of signal from radial vs.
femoral artery.
Thoracic bioimpedance
Impedance changes originate in the thoracic aorta when blood is ejected from the left ventricle. This effect is used to
determine stroke volume from formulae uti l ising the electrical  field size of the thorax, baseline thoracic impedance
and fluctuation related to systole, and ventricular ejection t ime. A correction factor for sex, height and weight is also
introduced. The technique simply uti l i ses four pairs of electrodes placed in proscribed posit ions on the neck and
thorax; these are connected to a dedicated monitor which measures thoracic impedance to a low ampl itude, high
(70kHz) frequency 2.5mA current appl ied across the electrodes.
Advantages
Quick, safe, total ly non-invasive, reasonably accurate in normal, spontaneously breathing subjects.
Disadvantages
Discrepancies in critical ly i l l  patients (especial ly those with arrhythmias, tachycardias, intrathoracic fluid shi fts,
anatomical deformities, aortic regurgi tation), metal within the thorax, inabi l i ty to verify signal.
See also:
Cardiac output—thermodi lution, p122; Cardiac output—other invasive, p124; Cardiac output—non-invasive (1), p126;
Fluid challenge, p274; Hypotension, p312; Heart fai lure—assessment, p324; Systemic inflammation/multi-organ
fai lure, p484; Burns—fluid management, p510
Gut tonometry
A gas permeable si l i cone balloon attached to a sampling tube is passed into the lumen of the gut. Devices exist for
tonometry in the stomach or sigmoid colon. The tonometer al lows indirect measurement of the PCO2 of the gut
mucosa and calculation of the pH of the mucosa.
Indications
Gut mucosal hypoperfusion is an early consequence of hypovolaemia. Covert ci rculatory inadequacy due to
hypovolaemia may be detected as gut mucosal  acidosis and has been related to post-operative complications after
major surgery. In cri tical ly i l l  patients there is some evidence that prevention of gut mucosal  acidosis improves
outcome. The sigmoid colon tonometer is useful to detect ischaemic coli tis early (e.g. after abdominal  vascular
surgery).
Technique
Saline tonometry
In the original technique the tonometer balloon was prepared by degassing and fi l l ing with 2.5ml 0.9% sal ine. The
sal ine was withdrawn into a syringe connected to the sampling tube prior to insertion. After insertion the saline was
passed back into the bal loon. The PCO2 of the sal ine in the balloon equil ibrated with the PCO2 of the gut lumen over a
period of 30–90min. At steady state it was assumed that the PCO2 of the gut lumen and gut mucosa were in
equil ibrium. Time correction factors were derived for partial  equil ibration between the bal loon saline and the gut
lumen. The measurement was completed by sampling the saline from the balloon and an arterial blood sample for
measurement of arterial [HCO3-].
Gas tonometry
Using air in the tonometry bal loon allows more rapid equi l ibration between the tonometer and the luminal PCO2. A
modified capnometer automatically fi l l s the bal loon with ai r and samples the PCO2 after 5–10min equil ibration.
Subsequent cycles of bal loon fi l l ing do not use fresh ai r so CO2 equil ibration is quicker. Tonometric PCO2 may be
compared with end-tidal PCO2 (measured with the same capnometer) as an estimate of arterial PCO2. With a normal
capnogram, a balloon PCO2 significantly higher than end-tidal PCO2 impl ies gut mucosal  hypoperfusion.
pH versus regional PCO2
The pH of the gut mucosa (pHi) may be calculated using a modified Henderson–Hasselbach equation:
where K is the time dependent equi l ibration constant. However, most of the variation in the measurement is due to
variation in regional PCO2. Comparing regional  PCO2 with PaCO2 gives as much information as making the calculation
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of pHi  and overcomes the problematic assumption that arterial [HCO3-] is equivalent to mucosal  capil lary [HCO3-].
See also:
CO2 monitoring, p92; Blood gas analysis, p100
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Neurological Monitoring
Intracranial pressure monitoring
Indications
To confirm the diagnosis of raised intracranial  pressure (ICP) and monitor treatment. May be used in cases of head
injury particularly if venti lated, Glasgow Coma Score ≤8, or wi th an abnormal CT scan. Also used in encephalopathy,
post-neurosurgery and in selected cases of intracranial haemorrhage. Al though a raised ICP can be related to poor
prognosis after head injury, the converse is not true. Sustained reduction of raised ICP (or maintenance of cerebral
perfusion pressure) in head injury may improve outcome although large controlled trials are lacking.
Methods of monitoring intracranial pressure
Ventricular monitoring
A catheter is inserted into the lateral ventricle via a burr hole. The catheter may be connected to a pressure
transducer or may contain a fibreoptic pressure monitoring device. Fibreoptic catheters require regular calibration
according to the manufacturer's instructions. Both systems should be tested for patency and damping by temporari ly
raising intracranial pressure (e.g. wi th a cough or by occluding a jugular vein). CSF may be drained through the
ventricular catheter to reduce intracranial  pressure.
Subdural monitoring
The dura is opened via a burr hole and a hollow bolt inserted into the skul l. The bol t may be connected to a pressure
transducer or admit a fibreoptic or hi-fidel ity pressure monitoring device. A subdural bol t is easier to insert than
ventricular monitors. The main disadvantages of subdural  monitoring are a tendency to underestimate ICP and
damping effects. Again calibration and patency testing should be performed regularly.
Complications
Infection—particularly after 5 days
Haemorrhage—particularly with coagulopathy or diff icult insertion
Using ICP monitoring
Normal  ICP is <10mmHg. A raised ICP is usually treated when >25mmHg in head injury. As ICP increases, there are
often sustained rises in ICP to 50–100mmHg lasting for 5–20min, increasing with frequency as the basel ine ICP rises.
This is associated with a 60% mortal ity. Cerebral perfusion pressure (CPP) is the di fference between mean BP and
mean ICP. Treatment aimed at reducing ICP may also reduce mean BP. It is important to maintain CPP >50–60mmHg.
See also:
Intracranial haemorrhage, p376; Subarachnoid haemorrhage, p378; Raised intracranial pressure, p382; Head injury
(1), p504; Head injury (2), p506
Jugular venous bulb saturation
Retrograde passage of a fibre-optic catheter from the internal jugular vein into the jugular bulb enables continuous
monitoring of jugular venous bulb saturation (SjO2). This can be used in conjunction with other monitors of cerebral
haemodynamics such as middle cerebral blood flow, cerebral arteriovenous lactate di fference and intracranial
pressure to di rect management.
Principles of SjO2 management
Normal  values are approximately 65–70%. In the absence of anaemia and with maintenance of normal  SaO2 values,
values of SjO2 >75% suggest luxury perfusion or global  infarction with oxygen not being uti l i sed; values <54%
correspond to cerebral hypoperfusion while values <40% suggest global  ischaemia and are usual ly associated with
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increased cerebral lactate production. Knowledge of SjO2 al lows optimisation of brain blood flow to avoid (i) either
excessive or inadequate perfusion and (i i) iatrogenically induced hypoperfusion through treating raised intracranial
pressure aggressively with diuretics and hyperventi lation. Studies in trauma patients have found (i) a higher
mortal ity wi th episodes of jugular venous desaturation and (i i) a significant relationship between cerebral  perfusion
pressure (CPP) and SjO2 when the CPP was <70mmHg. A fal l ing SjO2 may be an indication to increase CPP though no
prospective randomised trial has yet been performed to study the effect on outcome.
Approximately 85% of cerebral venous drainage passes down one of the internal jugular veins (usually the right).
SjO2 usually represents drainage from both hemispheres and is equal on both sides; however, after focal  injury, this
pattern of drainage may alter.
Insertion technique
Insert introducer sheath rostral ly in internal  jugular vein.1.
Calibrate fibreoptic catheter pre-insertion.2.
Insert catheter via introducer sheath; advance to jugular bulb.3.
Withdraw introducer sheath.4.
Confirm (i ) free aspiration of blood via catheter, (i i) satisfactory l ight intensity reading, (i i i) satisfactory
posi tioning of catheter tip by lateral cervical  X-ray (high in jugular bulb, above level of 2nd cervical vertebra).
5.
Perform in vivo cal ibration, repeat cal ibration 12-hrly.6.
Troubleshooting
If the catheter is si ted too low in the jugular bulb, erroneous SjO2 values may resul t from mixing of intracerebral  and
extracerebral venous blood. This could be particularly pertinent when cerebral blood flow is low.
Ensure l ight intensi ty reading is satisfactory; i f too high the catheter may be abutting against a wall,  and i f low the
catheter may not be patent or have a smal l clot over the t ip. Before treating the patient, always confi rm the veracity
of low readings against a blood sample drawn from the catheter and measured in a co-oximeter.
Formulae
where SjO2 = jugular bulb oxygen saturation
SaO2(%) = arterial oxygen saturation
CMRO2 = cerebral metabolism of oxygen
CBF = cerebral blood flow
cerebral  perfusion pressure =mean systemic BP -intracranial  pressure
See also:
Intracranial pressure monitoring, p134; Other neurological monitoring, p140; Intracranial haemorrhage, p376;
Subarachnoid haemorrhage, p378; Raised intracranial  pressure, p382; Head injury (1), p504; Head injury (2), p506
EEG/CFM monitoring
EEG monitoring
The EEG reflects changes in cortical electrical function. This, in turn, is dependent on cerebral perfusion and
oxygenation. EEG monitoring can be useful to assess epilepti form activi ty as well  as cerebral  well -being in patients
who are sedated and paralysed. The conventional EEG can be used intermittently but data reduction and artefact
suppression are necessary to allow successful use of EEG recordings in the ICU.
Bispectral index (BIS) monitor
BIS is a statistical index derived from the EEG and expressed as a score between 0 and 100. Scores below 50 have
been reliably associated with anaesthesia-induced unconsciousness. Assessment in the cri tical ly i l l  patient may be
complicated by various confounding factors such as septic encephalopathy, head trauma and hypoperfusion. A low
score is related to deep or excessive sedation, and may al low dose reduction (or cessation) of sedative agents,
especial ly in paralysed patients.
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Cerebral function monitor (CFM)
The CFM is a single channel , fi ltered trace from 2 recording electrodes placed over the parietal  regions of the scalp. A
thi rd electrode may be used in the midl ine to help with interference detection. The parietal  recording electrodes are
usually placed close to watershed areas of the brain in order to allow maximum sensi tivity for ischaemia detection.
Vol tage is displayed against time on a chart running at 6–30cm/h.
Figure. No Caption Available.
Use of CFM
The CFM may detect cerebral ischaemia; burst suppression (periods of increasingly prolonged electrical si lence)
provide an early warning.
Sedation produces a fal l  in basel ine to <5µV, equivalent to burst suppression. This is equivalent to maximum
reduction in cerebral VO2 and no further benefit would be gained from addi tional  sedation.
Seizure activi ty may be detected in patients despi te apparently adequate cl inical control  or where muscle relaxants
have been used.
Typical CFM patterns
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Figure. No Caption Available.
Other neurological monitoring
Cerebral blood flow (CBF)
CBF can be measured by radioisotopic techniques uti l i sing tracers such as xenon-133 given intravenously or by
inhalation. This remains a research tool in view of the radioactivity exposure and the usual need to move the patient
to a gamma-camera. However, portable monitors are now available. Middle cerebral  artery (MCA) blood flow can be
determined non-invasively by transcranial  Doppler ultrasonography. The pulsati l ity index (PI) relates to
cerebrovascular resistance with a rise in PI indicating a rise in resistance and cerebral vasospasm.
Vasospasm can also be designated when the MCA blood flow velocity exceeds 120cm/s and severe vasospasm when
veloci ties >200cm/s. Low values of common carotid end-diastol ic blood flow and veloci ty have been shown to be
highly discriminating predictors of brain death. Impaired reactivi ty of CBF to changes in PCO2 (in normals 3–5% per
mmHg PCO2 change) is another marker of poor outcome.
Near-infra red spectroscopy (NIRS)
Near-infrared (700–1000nm) l ight propagated across the head is absorbed by haemoglobin (oxy- and de-oxy),
myoglobin and oxidised cytochrome aa3 (the terminal part of the respiratory chain involved in oxidative
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phosphorylation).
The sum of (oxy- + deoxy-) haemoglobin is considered an index of cerebral  blood volume (CBV) change, and the
difference as an index of change in haemoglobin saturation assuming no variation occurs in CBV. CBV and flow
can be quanti fied by changing the FIO2 and measuring the response.
Cerebral blood flow is measured by a modi fication of the Fick principle. Oxyhaemoglobin is the intravascular
non-diffusible tracer, i ts accumulation being proportional to the arterial  inflow of tracer. Good correlations have
been found with the xenon-133 technique.
Cytochrome aa3 cannot be quanti fied by NIRS but i ts redox status may be fol lowed to provide some indication of
mitochondrial function.
Movement artefact must be avoided and some devices require reduction of ambient l ighting.
Lactate
The brain normally uti l ises lactate as a fuel; however, in states of severely impaired cerebral perfusion the brain may
become a net lactate producer with the venous lactate rising above the arterial value. A lactate oxygen index can be
derived by dividing the venous–arterial lactate di fference by the arterio-jugular venous oxygen difference. Values
>0.08 are consistently seen with cerebral  ischaemia.
See also:
Lactate, p170; Intracranial haemorrhage, p376; Subarachnoid haemorrhage, p378; Raised intracranial  pressure,
p382; Head injury (1), p504; Head injury (2), p506; Brain stem death, p548
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Laboratory Monitoring
Urea and creatinine
Measured in blood, urine and, occasionally, in other fluids such as abdominal  drain fluid (e.g. ureteric disruption,
fistulae)
Urea
A product of the urea cycle resul ting from ammonia breakdown, i t depends upon adequate l iver function for its
synthesis and adequate renal function for its excretion. Low levels are thus seen in ci rrhosis and high levels in renal
fai lure. Uraemia is a cl inical syndrome including lethargy, drowsiness, confusion, pruritus and pericardi tis result ing
from high plasma levels of urea (or, more correctly, nitrogenous waste products—azotaemia).
The ratio of urine:plasma urea may be useful in dist inguishing oliguria of renal  or pre-renal origins. Higher ratios
(>10:1) are seen in pre-renal conditions, e.g. hypovolaemia, whereas low levels (<4:1) occur with direct renal
causes.
24-h measurement of urinary urea (or nitrogen) excretion has been previously used as a guide to nutritional protein
replacement but is currently not considered a useful routine tool .
Creatinine
A product of creatine breakdown, it is predominantly derived from skeletal muscle and is also renal ly excreted. Low
levels are found with malnutri tion and high levels wi th muscle breakdown (rhabdomyolysis) and impaired excretion
(renal  fai lure). In the latter case, a creatinine value >120 µmol/l suggests a creatinine clearance <25ml/min.
The usual  ratio for plasma urea (mmol/l ) to creatinine (µmol/l) is approximately 1:10. A much lower ratio in a
critical ly i l l  patient is suggestive of rhabdomyolysis whereas higher ratios are seen in ci rrhosis, malnutrition,
hypovolaemia and hepatic fai lure.
The ratio of urine:plasma creatinine may help distinguish between oliguria of renal  or pre-renal  origins. Higher ratios
(>40) are seen in pre-renal condit ions and low levels (<20) with di rect renal causes.
Creatinine clearance is a measure of glomerular fi l tration. Once fi l tered, only small  amounts of creatinine are
reabsorbed. Normal ly it exceeds 100ml/min.
Normal plasma ranges
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
62 из 254 07.11.2006 1:04
P.145
P.146
Urea 2.5–6.5mmol/l
Creatinine 70–120µmol/l (depends on lean body mass)
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Peritoneal dialysis, p6; Nutrit ion—use and indications;
Urinalysis, p166; Acute failure renal fai lure—diagnosis, p332; Acute renal fai lure—management, p334;
Rhabdomyolysis, p528
Electrolytes (Na+, K+, Cl-, HCO3-)
Measured accurately by direct-reading ion-speci fic electrodes from plasma or urine, though are sensit ive to
interference by excess l iquid heparin.
Sodium, potassium
Plasma levels may be elevated but poorly reflect intracel lular (approximately 3–5mmol/l  for Na+, 140–150mmol/l  for
K+) or total  body levels. Plasma potassium levels are affected by plasma H+ levels; a metabolic acidosis reduces
urinary potassium excretion while an alkalosis wil l  increase excretion.
Older measuring devices such as flame photometry or indirect-reading ion-specific electrodes gave spuriously low
plasma Na+ levels with concurrent hyperproteinaemia or hypertriglyceridaemia.
Urinary excretion depends on intake, total  body balance, acid–base balance, hormones (including anti–diuretic
hormone, aldosterone, corticosteroids, atrial natriuretic peptide), drugs (particularly diuretics, non-steroidal
anti-inflammatories and ACE inhibitors), and renal  function.
In oliguria, a urinary Na+ level <10mmol/l suggests a pre-renal cause whereas >20mmol/l is seen with direct renal
damage. This does not apply if diuretics have been given previously.
Chloride, bicarbonate
Bicarbonate levels vary with acid–base balance.
In the kidney, Cl-  reabsorption is increased when HCO3-  reabsorption is decreased, and vice versa. Plasma [Cl-] thus
tends to vary inversely with plasma [HCO3-], keeping the total anion concentration normal. A raised [Cl-] (producing
a hyperchloraemic metabolic acidosis) may be seen with administration of large volumes of isotonic sal ine or isotonic
sal ine-containing colloid solutions. Hyperchloraemia is also found with experimental sal t water drowning but rarely
seen in actual cases.
Anion gap
The anion gap is the difference between unestimated anions (e.g. phosphate, ketones, lactate) and cations.
In metabolic acidosis an increased anion gap occurs with renal  fai lure, ingestion of acid, ketoacidosis and
hyperlactataemia, whereas a normal  anion gap (usually associated with hyperchloraemia) is found with decreased
acid excretion (e.g. Addison's disease, renal tubular acidosis) and loss of base (e.g. diarrhoea, pancreatic/bi l iary
fistula, acetazolamide, ureterosigmoidostomy).
Normal plasma ranges
Sodium 135–145mmol/l
Potassium 3.5–5.3mmol/l
Chloride 95–105mmol/l
Bicarbonate 23–28mmol/l
Anion gap = plasma [Na+] + [K+] - [HCO3-] - [Cl-]
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Normal range 8–16mmol
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Peritoneal dialysis, p66; Nutri tion—use and indications,
p78; Urinalysis, p166; Crystal loids, p176; Diuretics, p212; Tachyarrhythmias, p316; Bradyarrhythmias, p318; Acute
renal fai lure—diagnosis, p332; Acute renal  fai lure—management, p334; Vomiting/gastric stasis, p338; Diarrhoea,
p340; Acute l iver fai lure, p360; Hypernatraemia, p416; Hyponatraemia, p418; Hyperkalaemia, p420; Hypokalaemia,
p422; Metabol ic acidosis, p434; Metabolic alkalosis, p436; Diabetic ketoacidosis, p442; Hyperosmolar diabetic
emergencies, p444; Hypoadrenal  crisis, p448; Poisoning—general principles, p452; Rhabdomyolysis, p528
Calcium, magnesium and phosphate
Calcium
Plasma calcium levels have been traditionally corrected to plasma albumin levels; this is now considered irrelevant,
particularly at the low albumin levels seen in cri tical ly i l l  patients. Measurement of the ionised fraction is now
considered more pertinent since it is the ionised fraction that is responsible for the extracellular actions of calcium,
with changes in the ionised fraction being responsible for the symptomatology.
High calcium levels occur with hyperparathyroidism, certain malignancies and sarcoidosis while low levels are seen in
renal fai lure, severe pancreatit is and hypoparathyroidism.
Magnesium
Plasma levels poorly reflect intracellular or whole body stores, 65% of which is in bone and 35% in cells. The ionised
fraction is approximately 50% of the total  level .
High magnesium levels are seen with renal fai lure and excessive administration; this rarely requires treatment unless
serious cardiac conduction problems or neurological complications (respiratory paralysis, coma) intervene.
Low levels occur fol lowing severe diarrhoea, diuretic therapy, alcohol abuse, and accompany hypocalcaemia.
Magnesium is used therapeutically for a number of conditions including ventricular and supraventricular arrhythmias,
eclampsia, seizures, asthma and after myocardial  infarction. Supranormal plasma levels of 1.5–2.0mmol/l are often
sought.
Phosphate
High levels are seen with renal fai lure and in the presence of an ischaemic bowel . Low levels (sometimes
<0.1mmol/l) occur with crit ical i l lness, chronic alcoholism and diuretic usage and may possibly result in muscle
weakness, fai lure to wean and myocardial  dysfunction.
Normal plasma ranges
Calcium 2.2–2.6mmol/l
Ionised calcium 1.05–1.2mmol/l
Magnesium 0.7–1.0mmol/l
Phosphate 0.7–1.4mmol/l
See also:
IPPV—assessment of weaning, p18; Plasma exchange, p68; Nutrit ion—use and indications, p78; Tachyarrhythmias,
p316; Pancreati tis, p354; General ised seizures, p372; Hypomagnesaemia, p424; Hypercalcaemia, p426;
Hypocalcaemia, p428; Hypophosphataemia, p430; Pre-eclampsia and eclampsia, p538
Cardiac function tests
The importance of biochemical markers of myocardial  necrosis has been emphasised by a consensus document from
the European Society of Cardiology and American Col lege of Cardiology. The diagnosis of myocardial infarction was
redefined as a typical rise and fal l  in troponin, or a more rapid rise and fal l in CK-MB, with at least one of the
fol lowing:
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Ischaemic symptoms
Development of pathological Q waves on ECG
ECG ST elevation or depression
Coronary intervention
Troponins
Troponins are bound to the actin fi lament within muscles and are involved in exci tation–contraction coupling. Both
cardiac troponin T and troponin I are coded by specific genes and are immunologically distinct from those in skeletal
muscle. Neither is detectable in normal heal thy individuals but both are released into the bloodstream from
cardiomyocytes damaged by necrosis, toxins and inflammation. They become detectable by 4–6h after myocardial
injury, peak at 14–18h, and persist for up to 12 days. Current assays are highly specific as they use recombinant
human cardiac tropinin T as a standard.
Due to their high sensi tivity, plasma levels rise with other cardiac insults, e.g. tachycardia (SVT/VT), pericardi tis,
myocardit is, sepsis, heart fai lure, severe exertion and pulmonary embol ism. The degree of rise post-MI or during
critical  i l lness correlates with a worse outcome.
A posi tive test is when the cardiac troponin T or I value exceeds the 99th percenti le of values for a control group on
≥1 occasion during the first 24h after the index cl inical event. For cardiac troponin T this is quoted as 0.05–0.1ng/ml
though many labs now consider values >0.03ng/ml as posi tive. Values for cardiac troponin I depend on the particular
assay used (usually >0.5–1.5ng/ml). The negative predictive value after an acute MI is probably strongest after 6h.
Sensi tivity peaks at 12h but at the expense of a lower specificity. With renal  dysfunction, higher levels are needed to
diagnose myocardial damage due to impaired excretion.
Cardiac enzymes
Creatine kinase (CK) is detectable in plasma within a few hours of myocardial  injury. The cardiac-speci fic isoform
(CK-MB) can be measured i f there is concurrent skeletal  muscle injury. CK and aspartate aminotransferase (AST)
peak by 24h and fal l over 2–3 days whereas the rise and subsequent fal l  in plasma lactate dehydrogenase takes 1–2
days longer.
Brain (or B-type) natriuretic peptide (BNP)
Cardiomyocytes produce and secrete cardiac natriuretic peptides. Plasma levels rise in a variety of conditions but
high levels are predominantly associated with heart fai lure, and increase in relation to severi ty. A sensi tivity of
90–100% is claimed, whereas speci ficity is approximately 70–80%. Numerous commercial  assays for B-type
natriuretic peptide (BNP) or proBNP are now avai lable, each with their own diagnostic range. They are useful  as a
screening tool  for patients presenting with dyspnoea, for prognostication, and for titration of therapy. Levels rise in
the elderly, in renal  fai lure, and in pulmonary diseases causing right ventricular overload (e.g. pulmonary embolus).
Figure. No Caption Available.
Key paper
Antman E et al.  Myocardial infarction redefined—a consensus document of The Joint European Society of
Cardiology/American College of Cardiology committee for the redefinit ion of myocardial infarction. J Am Coll  Cardiol
2000; 36:959–69
McCullough PA, et al.  B-type natriuretic peptide and cl inical  judgment in emergency diagnosis of heart fai lure:
analysis from Breathing Not Properly (BNP) Multinational  Study. Circulation 2002; 106:416–22
See also:
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
65 из 254 07.11.2006 1:04
P.152
P.153
Acute coronary syndrome (1), p320; Acute coronary syndrome (2), p322; Heart fai lure—assessment, p324
Liver function tests
Hepatic metabol ism proceeds via Phase I enzymes (oxidation and phosphorylation) and then subsequently to Phase II
enzymes (glucuronidation, sulphation, acetylation). Phase I enzyme reactions involve cytochrome P450.
Markers of hepatic damage
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Lactate dehydrogenase (LDH)
Patterns and ratios of various enzymes are variable and unreliable diagnostic indicators. Measurement of ALT alone is
usually sufficient. It is more l iver-specific but less sensit ive than AST and has a longer hal f-l i fe.
AST is not l iver-specific but is a sensi tive indicator of hepatic damage. The plasma level is proportional  to the degree
of hepatocel lular damage. Low levels occur in extrahepatic obstruction and inactive ci rrhosis.
LDH is insensi tive and non-speci fic. Isoenzyme electrophoresis is needed to distinguish cardiac, erythrocyte, skeletal
muscle and l iver injury.
Acute phase reactants such as C-reactive protein (CRP) are also produced by the l iver. Levels increase during crit ical
i l lness and fol lowing hepatocellular injury.
Markers of cholestasis
Bil irubin
Alkaline phosphatase
Gamma-glutamyl transferase (γ-GT)
Bi l irubin is derived from Hb released from erythrocyte breakdown and conjugated with glucuronide by the
hepatocytes. The conjugated fraction is water-soluble whereas the unconjugated fraction is l ipid-soluble. Levels are
increased with intra- and extrahepatic bi l iary obstruction (predominantly conjugated), hepatocellular damage and
haemolysis (usually mixed picture). Jaundice is detected when levels >45µmol/l .
Alkal ine phosphatase is released from bone, l iver, intestine and placenta. In the absence of bone disease (check Ca2+
and PO43-) and pregnancy, raised levels usual ly indicate bil iary tract dysfunction.
A raised γ-GT is a highly sensit ive marker of hepatobi l iary disease. Increased synthesis is induced by obstructive
cholestasis, alcohol , various drugs and toxins, acute and chronic hepatic inflammation.
Markers of reduced synthetic function
Albumin
Clotting factors
Chol inesterase
Albumin levels fal l during crit ical i l lness due to protein catabol ism, capi l lary leak, decreased synthesis, di lution with
artif icial col loids.
Coagulation factors II, VII, IX and X are l iver-synthesised. Over 33% of functional  hepatic mass must be lost before
any abnormal ity is seen.
Indicators of function
Lidocaine metaboli tes (MegX)
Indicators of hepatic blood flow
Indocyanine green clearance
Bromosulphthalein clearance
Normal plasma ranges
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Albumin 35–53g/l
Bilirubin 3–17µmol/l
Conjugated bilirubin 0–6µmol/l
Alanine aminotransferase 5–50U/l
Alkaline phosphatase 100–280U/l
Aspartate aminotransferase 11–55U/l
Cholinesterase 2.3–9.0KU/l
γ-glutamyl-transferase 5–37U/l
Lactate dehydrogenase 230–460U/l
See also:
Parenteral nutrit ion, p82; Jaundice, p358; Acute l iver fai lure, p360; Chronic l iver fai lure, p364; Paracetamol
poisoning, p456; HELLP syndrome, p540
Full blood count
Haemoglobin
A raised haemoglobin occurs in polycythaemia (primary and secondary to chronic hypoxaemia) and in
haemoconcentration. Anaemia may be due to reduced red cell  mass (decreased red cel l production or survival) or
haemodilution. The latter is common in critical ly i l l  patients. In severe anaemia there may be a hyperdynamic
ci rculation which, i f severe, may decompensate to cardiac fai lure. In this case, blood transfusion must be performed
with extreme care to avoid fluid overload, or in association with plasmapheresis. Di fferential diagnosis of anaemia
includes:
Reduced MCV
Iron deficiency (anisocytosis and poiki locytosis)
Raised MCV
Vitamin B12 or folate deficiency
Alcohol  excess
Liver disease
Hypothyroidism
Normal  MCV
Anaemia of chronic disease
Bone marrow failure (e.g. acute folate deficiency)
Hypothyroidism
Haemolysis (increased reticulocytes and bil irubin)
White blood cells
A raised white cel l count is extremely common in crit ical i l lness. Causes of changes in the di fferential count include:
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
67 из 254 07.11.2006 1:04
P.155
Neutrophilia Lymphocytosis Eosinophilia
Bacterial infection Brucellosis Asthma
Trauma and surgery Typhoid Allergic conditions
Burns Myasthenia gravis Parasitaemia
Haemorrhage Hyperthyroidism  
Inflammation Leukaemia  
Steroid therapy   
Leukaemia   
Neutropenia Lymphopenia  
Viral infections Steroid therapy  
Brucellosis SLE  
Typhoid Legionnaire's disease  
Tuberculosis AIDS  
Sulphonamide treatment   
Severe sepsis   
Hypersplenism   
Bone marrow failure   
Barrier nursing may be used for neutropenia <1.0 ×109/l .
Platelets
Correct interpretation of platelet counts requires blood to be taken by a venepuncture. Arterial blood is commonly
taken from an indwell ing cannula but is not ideal. Thrombocytopenia is due to decreased platelet production (bone
marrow failure, vi tamin B12 or folate deficiency), decreased platelet survival  (ITP, TTP, infection, hypersplenism,
heparin therapy), increased platelet consumption (haemorrhage, DIC) or in vivo aggregation giving an apparent
thrombocytopenia; this should be checked on a blood fi lm. Spontaneous bleeding is associated with platelet counts
<20 ×109/l  and platelet cover is required for procedures or traumatic bleeds at counts <50 ×109/l .
Normal ranges
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Haemoglobin 13–17g/dl (men), 12–16g/dl (women)
MCV 76–96fl
White cell count 4–11 ×109/l
Neutrophils 2–7.5 ×109/l
Lymphocytes 1.3–3.5 ×109/l
Eosinophils 0.04–0.44 ×109/l
Basophils 0–0.1 ×109/l
Monocytes 0.2–0.8 ×109/l
Platelets 150–400 ×109/l
See also:
Blood transfusion, p182; Blood products, p252; Haemothorax, p302; Haemoptysis, p304; Upper gastrointestinal
haemorrhage, p344; Bleeding varices, p346; Lower intestinal bleeding and col it is, p348; Bleeding disorders, p396;
Anaemia, p400; Sickle cell  disease, p402; Haemolysis, p404; Platelet disorders, p406; Neutropenia, p408;
Leukaemia, p410; Malaria, p490; Vasculi tides, p494; Multiple trauma (1), p500; Mult iple trauma (2), p502;
Burns—fluid management, p510; Post-partum haemorrhage, p542
Coagulation monitoring
Basic coagulation screen
The basic screen consists of a platelet count, prothrombin time, activated partial  thromboplastin time and thrombin
time. Close attention to blood sampl ing technique is very important for correct interpretation of coagulation tests.
Drawing blood from indwell ing catheters should, ideal ly, be avoided since samples may be diluted or contaminated
with heparin. The correct volume of blood must be placed in the sample tube to avoid dilution errors. Laboratory
coagulation tests are usual ly performed on ci trated plasma samples taken into glass tubes.
Specific coagulation tests
Activated clotting time (ACT)
Sample tube contains cel ite, a diatomaceous earth, which activates the contact system; thus the ACT predominantly
tests the intrinsic pathway. The ACT is prolonged by heparin therapy, thrombocytopenia, hypothermia, haemodi lution,
fibrinolysis and high dose aprotinin. Normal  is 100–140s.
Thrombin time (TT)
Sample tube contains lyophi l i sed thrombin and calcium. Thrombin bypasses the intrinsic and extrinsic pathways such
that the coagulation time tests the common pathway with conversion of fibrinogen to fibrin. The TT is prolonged by
fibrinogen depletion, e.g. fibrinolysis or thrombolysis, and heparin via antithrombin III dependent interaction with
thrombin. A high dose TT is more sensi tive to heparin anticoagulation than fibrinogen levels. Normal range is 12–16s.
Prothrombin time (PT)
Sample tube contains tissue factor and calcium. Tissue factor activates the extrinsic pathway. The PT is prolonged
with coumarin anticoagulants, l iver disease and vi tamin K deficiency. Normal range is 12–16s. The International
Normal ised Ratio (INR) relates PT to control and is normally 1.
Activated partial thromboplastin time (APTT)
Sample tube contains kaolin and cephalin as a platelet substitute to activate the intrinsic pathway. The APTT is
prolonged by heparin therapy, DIC, severe fibrinolysis, von Wil lebrand factor, factor VIII, factor X1 or factor XIII
deficiencies. Normal  range is 30–40s.
D-dimers and fibrin degradation products (FDPs)
Fibrin fragments are released by plasmin lysis. FDPs can be assayed by an immunological  method; they are often
measured in the crit ically i l l  to confirm disseminated intravascular coagulation. A level of 20–40µg/ml is common
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post-operatively, in sepsis, trauma, renal  fai lure and DVT. Raised levels do not distinguish fibrinogenolysis and
fibrinolysis. Assay of the d-dimer fragment is more specific for fibrinolysis, e.g. in DIC, since it is only released after
fibrin is formed.
Coagulation factor assays
Assays are avai lable for al l coagulation factors and may be used for diagnosis of speci fic defects. As heparins inhibit
factor Xa activity, the factor Xa assay is therefore the most specific method of controll ing low molecular weight
heparin therapy. Since this assay is not dependent on contact system activation, it also avoids the effects of
aprotinin when monitoring heparin therapy.
The coagulation cascade – new concept
Figure. No Caption Available.
The tradi tional coagulation cascade consisting of extrinsic, intrinsic and common pathways is now considered
outmoded, inconsistent with cl inical observations, and inadequate to explain the pathways leading to haemostasis in
vivo. This schema has been replaced recently by a cell -based model with the major ini tiating haemostasis event in
vivo being the action of factor VIIa and tissue factor (TF) at the site of injury.
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Anticoagulants, p248; Thrombolytics, p250; Blood
products, p252; Coagulants and antifibrinolytics, p254; Aprotinin, p256; Haemothorax, p302; Haemoptysis, p304;
Acute coronary syndrome (1), p320; Acute coronary syndrome (2), p322; Upper gastrointestinal haemorrhage, p344;
Bleeding varices, p346; Lower intestinal bleeding and col itis, p348; Acute l iver fai lure, p360; Bleeding disorders,
p396; Clotting disorders, p398; Platelet disorders, p406; Paracetamol poisoning, p456; Post-operative intensive care,
p534; HELLP syndrome, p540
Bacteriology
Microbiology samples should, if possible, be taken prior to commencement of antimicrobial  therapy. In severe
infections, broad spectrum antimicrobials should be started without await ing resul ts. Sampl ing sites include those
suspected cl inically of harbouring infection or, if a specific site cannot be identif ied cl inically, blood, urine and
sputum samples. In severe infection, indwell ing intravascular catheters should be replaced and the catheter t ips sent
for culture. Samples should be sent to the laboratory promptly to al low early incubation and to prevent potential ly
misleading growth. Swabs must be sent in the appropriate transport media.
Blood cultures
In order to avoid skin contamination, the skin should be cleaned with alcohol and al lowed to dry thoroughly before
venepuncture. A 5–20ml blood sample is withdrawn and divided into anaerobic and aerobic culture bottles. In
addition, cultures should be taken through indwell ing intravascular catheters i f catheter-related sepsis is suspected.
Al l samples must be clearly labelled. Cul ture bottles are incubated and examined frequently for bacterial growth.
Positive cul tures must be interpreted in l ight of the cl inical picture; an early pure growth from multiple bottles is
l ikely to be signi ficant, although cul tures from cri tical ly i l l  patients may appear later or not at al l due to antibiotic
therapy. Any Gram negative isolates or Staph. aureus are usually taken as significant.
Urine
Catheter specimens are usually obtained from the critically i l l .  The sampl ing site should be prepared aseptically prior
to sampling. The specimen should be sent to the laboratory immediately and examined microscopically for organisms,
casts and crystals. Urine is plated onto cul ture medium with a calibrated loop and incubated for 18–24h prior to
examination. Bacteria >108/l  (or a pure growth of 105/l) represent a signi ficant growth. Al l catheter specimens show
bacterial growth if the catheter has been in place for >2days. Isolation of the same organism from blood confirms a
signi ficant culture.
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Sputum
Sputum samples are easily contaminated during collection, particularly specimens from non-intubated patients.
Suction specimens from intubated patients can be taken via a steri le suction catheter, protected catheter brush or
from specific lung segments via a bronchoscope. Gram negative bacteria are frequently isolated from tracheal
aspirates of intubated patients; only deep suction specimens are significant. Blood cultures should accompany sputum
specimens in the diagnosis of pneumonia. Samples should be sent to the laboratory immediately.
Pus samples and wound swabs
Aspirated pus must be sent to the laboratory immediately or a swab sample may be taken and sent in transport
medium. Pus is preferable for bacterial  isolation.
Typical ICU-acquired nosocomial infections
Pneumonia due to Pseudomonas aeruginosa, Staph. aureus, Klebsiel la spp., Enterobacter spp.
Urinary infection with E. coli,  Ps. aeruginosa, Klebsiel la spp., Proteus spp.
Catheter related sepsis—Staph. aureus, coagulase negative staphylococci
See also:
Pleural aspiration, p44; Fibreoptic bronchoscopy, p46; Chest physiotherapy, p48; Virology, serology and assays,
p160; Urinalysis, p166; Antimicrobials, p260; Atelectasis and pulmonary col lapse, p284; Acute chest infection (1),
p288; Acute chest infection (2), p290; Abdominal sepsis, p350; Pancreatitis, p354; Meningi tis, p374; Tetanus, p390;
Neutropenia, p408; Infection—diagnosis, p480; Infection—treatment, p482; Sepsis and septic shock—treatment,
p486; HIV related disease, p488; Malaria, p490; Burns—general  management, p512; Pyrexia (1), p518; Pyrexia (2),
p520
Virology, serology and assays
Antibiotic assays
Antibiotic assays are usually performed for drugs with a narrow therapeutic range, such as aminoglycosides and
vancomycin. It is not usual  to request an assay on day 1 of treatment. Thereafter, samples are taken dai ly prior to
giving a dose and at 1h after an intravenous injection or infusion.
Serology
A clotted blood specimen al lows antibodies to vi ral and atypical antigens to be assayed. It is usual to send acute and
convalescent (14 days) serum to determine rising antibody ti tres. Single sample titres may be used to determine
previous exposure and carrier status.
Hepatitis B
Serology includes hepatitis B surface antigen as a screening test and hepatit is B core antigen to determine
infectivity. There is a 10% carrier rate in South East Asians. Serology should be sent in all high risk patients, e.g.
jaundice, IV drug abuse, homosexuals, prostitutes, those with tattoos or unexplained hepatic enzyme abnormal ities.
In addition, hepatit is B status should be known in staff who suffer accidental  exposure to body fluids, e.g. through
needlestick injury. Those who are not immune may be treated with immunoglobulin.
HIV
Since HIV posi tive status carries consequences for l i festyle and insurance, it should rarely be assessed without prior
counsell ing and consent. The CD4 count may be used to assess the l ikel ihood of symtomatology being AIDS-related,
although this wil l  fal l  further with acute cri tical i l lness; again, consent should usually be sought pre-testing. High risk
patients should be considered for testing, e.g. homosexual males, intravenous drug abusers, haemophil iacs, Central
African origin. In cri tical ly i l l  patients such consent can rarely be obtained and unconsented testing may be used
where management may change significantly with knowledge of the HIV status, or where organ donation is being
considered. Most AIDS-related infections can be adequately treated without knowledge of the HIV status. Patients or
staff who are recipients of a needlestick injury can be treated with anti retroviral  therapies i f risk is high.
Viral culture
Most commonly used for CMV. Samples of blood, urine or bronchial  aspirate may be sent for DEAFF (detection of early
antigen fluorescent foci). Herpes vi rus infections may be detected by electron microscopy of samples (including
pustule fluid) and adenovirus in immunosuppressed patients with a chest infection.
Fungi
Candida and Aspergil lus can be assessed by cul ture ± antigen tests. Cryptococcus can be detected by Indian ink stain
in biopsy samples.
Other tests
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Other tests available to make microbiological diagnoses include antigen testing for certain bacteria (e.g.
pneumococcus), and PCR (polymerase chain reaction) which ampli fies the microbial DNA. PCR is an extremely
sensi tive test for specific organisms. However, it is prone to environmental contamination (e.g. from airborne spores)
and it cannot dist inguish between colonisation and infection.
Common serology for critically ill patients
Hepati tis A
Hepati tis B
Hepati tis C
HIV
CMV
Mycoplasma pneumoniae
Legionella pneumophila
Antibiotic therapeutic levels
 Trough (mg/l) Peak (mg/l)
Amikacin <8 30
Gentamicin <2 4–10*
Tobramycin <2 4–10
Vancomycin <8 20–30
*Seek microbiological advice if once daily gentamicin is used
See also:
Bacteriology, p158; Urinalysis, p166; Antimicrobials, p260; Acute chest infection (1), p288; Acute chest infection (2),
p290; Jaundice, p358; Acute l iver fai lure, p360; Tetanus, p390; Botulism, p392; HIV related disease, p488; Pyrexia
(1), p518; Pyrexia (2), p520
Toxicology
Purpose
Samples taken from blood, urine, vomitus or gastric lavage (depending on drug or poison ingested) for:
Monitoring of therapeutic drug levels (usually plasma) and avoidance of toxicity, e.g. digoxin, aminoglycosides,
l ithium, phenytoin
Identi fication of unknown toxic substances (e.g. cyanide, amphetamines, opiates) causing symptomatology
and/or pathology. Always take a urine sample for analysis.
Confirmation of toxic plasma levels and monitoring of treatment effect, e.g. paracetamol, aspirin
Medicolegal, e.g. alcohol , recreational  drugs fol lowing road trauma
Samples
Confirm with chemistry laboratory ± local poisons uni t as to which, how, and when body fluid samples should be
taken for analysis, e.g. peak/trough levels for aminoglycosides, urine samples for out-of-hospital poisoning, repeat
paracetamol levels to monitor efficacy of treatment
See also:
Virology, serology and assays, p160; Poisoning—general  principles, p45
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Miscellaneous Monitoring
Urinalysis
Techniques
Biochemical/metabolic:
colorimetric ‘dipsticks’ read manual ly from reference chart or by automated machine within 15s—2min of
dipping in urine (see manufacturer's instructions). Usual ly performed at the bedside.
i.
sodium and potassium levels can be measured in most analysers used for plasma electrolyte measurement.
Recal ibration of the machine or special di lution techniques may be required.
ii.
laboratory analysisiii.
Haematological—either by dipstick or laboratory testing
Microbiological—microscopy, culture, sensit ivi ty; antigen tests
Renal disease—usual ly by microscopy + laboratory testing
Associated tests
Some of the above investigations are performed in conjunction with a blood test, e.g. urine:plasma ratios of urea,
creatinine and osmolali ty to distinguish renal  from pre-renal  causes of ol iguria, 24h urine collection plus plasma
creatinine for creatinine clearance estimation.
Cautions
White blood cel ls, proteinuria and mixed bacterial  growths are routine findings in catheterised patients and do
not necessari ly indicate infection.
A ‘positive’ dipstick test for blood does not di fferentiate between haematuria, haemoglobinuria or myoglobinuria.
Only conjugated bil irubin is excreted into the urine.
Urinary sodium and potassium levels are increased by diuretic usage.
Urinalysis tests
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Biochemical/metabolic:
pH dipstick
glucose dipstick
ketones dipstick
protein dipstick, laboratory
bilirubin dipstick
sodium, potassium electrolyte analyser, laboratory
urea, creatinine, nitrogen laboratory
osmolality laboratory
specific gravity bedside gravimeter, laboratory
myoglobin laboratory, positive dipstick to blood
drugs, poisons sent to Poisons Reference Laboratory
Haematological:
red blood cells microscopy, positive dipstick to blood
haemoglobin laboratory, positive dipstick to blood
neutrophils dipstick, laboratory
Microbiological:
bacteriuria microscopy, culture
TB microscopy, culture (early morning specimens)
Legionnaire's disease laboratory
Nephro-urological:
haematuria microscopy
granular casts microscopy
protein laboratory
sodium, potassium electrolyte analyser, laboratory
malignant cells cytology
See also:
Nutri tion—use and indications, p78; Bacteriology, p158; Virology, serology and assays, p160; Acute renal
fai lure—diagnosis, p332; Hypernatraemia, p416; Hyponatraemia, p418; Hyperkalaemia, p420; Hypokalaemia, p422;
Diabetic ketoacidosis, p442; Poisoning—general  principles, p452; Infection—diagnosis, p480; Rhabdomyolysis, p528
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Indirect calorimetry
Calorimetry refers to the measurement of energy production. Direct calorimetry is the measurement of heat
production in a sealed chamber but is impractical for crit ically i l l  patients. Indirect calorimetry measures the rate of
oxidation of metabolic fuels by detecting the volume of O2 consumed and CO2 produced. The ratio of CO2 production
to O2 uti l i sation (respiratory quotient or RQ) defines which fuels are being uti l i sed (see table). Knowledge of the
oxygen uti l i sation by the various fuels al lows the calculation of energy production. Carbohydrate and fat are oxidised
to CO2 and water producing 15–17 and 38–39kJ/g respectively. Protein is oxidised to CO2, water and nitrogen
(subsequently excreted as urea) producing 15–17kJ/g.
Technique of indirect calorimetry
Inspiratory and mixed expiratory gases must be sampled. O2 concentration may be measured by a fuel  cel l  sensor or
a fast response, paramagnetic sensor. CO2 is usually measured by infrared absorption. Sensors may be calibrated
with reference to known concentrations of standard gas or by burning a pure fuel with a predictable O2 consumption.
Measurements are usually made at ambient temperature, pressure and humidity prior to conversion to standard
temperature, pressure and humidi ty. In order to calculate metabol ic rate (energy expenditure) inspired and expired
minute volumes are required. It is common for one minute volume to be measured and the other derived from a
Haldane transformation:
The ni trogen concentrations are assumed to be the concentration of gas which is not O2 or CO2. Calculation of energy
expenditure uti l i ses a modification of the de Weir formula Energy expenditure = (3.94 VO2 + 1.11 VCO2) × 1.44
Although it is possible to calculate the rate of protein metabolism by reference to the urinary urea concentration, and
therefore to separate non-protein from protein energy expenditure, the resulting modification of the above formula is
not usual ly cl inical ly signi ficant.
Errors associated with indirect calorimetry
Underestimate VCO2 H+ ion loss, haemodialysis, haemofiltration
Overestimate VCO2 hyperventilation, HCO3- infusion
Underestimate VO2 free radical production, unmeasured O2 supply
FIO2 > 0.6 small difference between inspired and expired O2
Loss of volume circuit leaks, bronchopleural fistula
Use of indirect calorimetry
Helps to match nutri tional  intake to energy expenditure. It is important to feed critical ly i l l  patients appropriately,
avoiding both underfeeding and overfeeding (see table). Indirect calorimetry may also be used to assess the work of
breathing by assessing the change in VO2 during weaning from mechanical  venti lation. The VO2 change may also be
used to assess appropriate levels of sedation and analgesia.
Respiratory quotients for various metabolic fuels
Ketones 0.63
Fat 0.71
Protein 0.80
Carbohydrate 1.00
The whole body RQ depends on the fuel or combination of fuels being uti l i sed. Normally a combination of fat and
carbohydrate are uti l ised with a RQ of 0.8.
Lipogenesis associated with both sepsis and overfeeding may give a RQ of 1.1–1.3
See also:
IPPV—assessment of weaning, p18; Nutrit ion—use and indications, p78; Enteral  nutri tion, p80; Parenteral nutri tion,
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p82; CO2 monitoring, p92; Cardiac output—other invasive, p124; Opioid analgesics, p234; Non-opioid analgesics,
p236; Sedatives, p238; Pyrexia (1), p518; Pyrexia (2), p520; Pain, p532
Lactate
Measurement of blood lactate
Analysers are avai lable to al low rapid measurement of blood or plasma lactate on smal l samples, using enzyme-based
methods. The enzymatic conversion of lactate to pyruvate is an oxygen uti l is ing reaction. The extraction of oxygen
from the sample can be detected by a sensit ive oxygen fuel cel l sensor and is directly proportional  to the sample
lactate concentration. A whole blood sample (venous or arterial  since there is no practical difference) is col lected into
a heparin fluoride tube to prevent coagulation and glycolysis (lactate producing). Nitrite may be used in the sample
tube to convert haemoglobin to the met form, thus avoiding uptake of oxygen during the enzyme reaction. The
enzymatic method is specific for the L-isomer and wil l  not, therefore, detect D-lactate (e.g. in short bowel
syndrome). Normal arterial whole blood lactate concentration is <1.5mmol/l.  Lactate may also be measured from
regional  si tes as an aid to the assessment of regional  perfusion (e.g. arterial–jugular bulb di fference).
Biochemistry of lactate production
Pyruvate is the end product of glycolysis. Most is then metabol ised by pyruvate dehydrogenase to acetyl  CoA, the
major substrate for the Krebs cycle. However, in condi tions of mitochondrial dysfunction (e.g. cellular hypoxia,
sepsis) more pyruvate is converted to lactate by lactate dehydrogenase.
Lactate is a buffer not an acid so a high blood lactate is not, therefore, synonymous with lactic acidosis. In
continuous haemofi ltration the replacement fluid is usually buffered with lactate at 35–45mmol/l; thus blood lactate
levels wi l l  rise without acidosis.
Causes of lactic acidosis
Lactic acidosis occurs when production of lactic acid is in excess of removal . The major sources are skeletal muscle,
brain and red blood cells. Removal is mainly by metabol ism to glucose in the l iver and kidney. Hepatic removal is
impaired by poor perfusion and acidosis. Lactic acidosis is traditionally classif ied as type A or type B. Type A refers
to excess production when tissue oxygenation is inadequate. Type B occurs where there is no systemic t issue
hypoxia. Epinephrine therapy may cause accelerated aerobic glycolysis and pyruvate production in excess of
mitochondrial needs; this may produce an increasing metabolic acidosis often out of proportion to the patient's
cl inical  status. In sepsis, hyperlact ataemia is mainly due to increased muscle Na+K+-ATPase activi ty. Treatment of
metabolic acidosis with sodium bicarbonate solution may increase lactate production. A severe and persistent type A
lactic acidosis is associated with a poor outcome.
Identifying type A lactic acidosis
Evidence of poor t issue perfusion may be obvious cl inical ly. Calculation of arterial DO2 may confi rm inadequate t issue
oxygen del ivery but a normal  DO2 does not guarantee adequacy of supply.
Key trial
Totaro RJ, Raper RF. Epinephrine-induced lactic acidosis fol lowing cardiopulmonary bypass. Crit Care Med 1997;
25:1693–9
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Blood gas analysis, p100; Arterial  cannulation, p112;
Other neurological monitoring, p140; Metabolic acidosis, p434; Systemic inflammation/multiorgan fai lure, p484
Colloid osmotic pressure
Col loid osmotic pressure (COP) is the pressure required to prevent net fluid movement between two solutions
separated by a selectively permeable membrane when one contains a greater col loid concentration than the other.
The selectively permeable membrane should impede the passage of col loid molecules but not smal l ions and water.
COP is determined by number of molecules rather than type. However, most solutions exhibit non-ideal  behaviour due
to intermolecular interactions and electrostatic effects. Hence COP cannot be inferred from plasma protein
concentrations; i t must be measured.
Measurement of COP
In a membrane oncometer the plasma sample is separated from a reference 0.9% sal ine solution by a membrane with
a molecular weight exclusion between 10,000 and 30,000Da. The reference solution is in a closed chamber containing
a pressure transducer. Sal ine wi l l  pass to the sample chamber by col loid osmosis creating a negative pressure in the
reference chamber. When the negative pressure prevents any further flow across the membrane, i t i s equal to the
COP of the sample. Normal  plasma COP is 25–30mmHg.
Clinical use of COP measurement
Assessing significance of reduced plasma proteins
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Plasma albumin levels are almost invariably reduced in crit ical ly i l l  patients. Causes include interstit ial  leakage,
fai led synthesis and increased metabolism. However, the same group of patients often have raised levels of acute
phase proteins which contribute to COP. Since there is no evidence that correction of plasma albumin levels is
beneficial,  many cl inicians correct plasma volume defici t with arti fic ial  col loid. These wi l l  contribute to COP while
also reducing hepatic albumin synthesis. If COP is maintained >20mmHg i t is l ikely that reduced plasma albumin
levels are of no significance.
Avoiding pulmonary oedema
It has been suggested that a difference between COP and pulmonary artery wedge pressure >6mmHg minimises the
risk of pulmonary oedema. However, in the face of severe capil lary leak it is unlikely that pulmonary oedema can be
avoided i f plasma volumes are to be maintained compatible with circulatory adequacy. Conversely, a normal COP
would not necessari ly prevent pulmonary oedema in severe capi l lary leak; the contribution of COP to fluid dynamics
in this situation is much reduced.
Selection of appropriate fluid therapy
It is di ffi cul t not to support the use of colloid fluids in hypo-oncotic patients. In patients with renal fai lure the
repeated use of col loid fluid may lead to a hyperoncotic state. This is associated with tissue dehydration and fai lure
of glomerular fi l tration (thus prolonging the renal fai lure). Measurement of a high COP in patients who have been
treated with arti fic ial  col loids should direct the use of crystalloid fluids. It is important to note that excessive
diuresis may also lead to a hyper-oncotic state for which crystalloid replacement may be necessary.
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Liver function tests, p152; Fluid chal lenge, p274
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Fluids
Crystalloids
Types
Sal ine: e.g. 0.9% saline, Ringer's lactate, Hartmann's solution, 0.18% saline in 4% glucose
Glucose: e.g. 5%, 10%, 20%, 50%
Sodium bicarbonate: e.g. 1.26%, 8.4%
Uses
Crystal loid fluids – to provide the dai ly requirements of water and electrolytes. They should be given to critical ly
i l l  patients as a continuous background infusion to supplement fluids given during feeding, or to carry drugs.
Higher concentration glucose infusions – to prevent hypoglycaemia.
Potassium chloride – to supplement crystal loid fluids.
Sodium bicarbonate – for correction of metabol ic acidosis, urinary alkalinisation, etc
Routes
IV
Notes
A significant plasma volume deficit should be replaced with colloid solutions since crystalloids are rapidly lost from
the plasma, particularly during periods of increased capil lary leak, e.g. sepsis. As most plasma substi tutes are
carried in sal ine solutions, any addit ional  0.9% saline crystalloid infusion is only needed to replace excess sodium
losses.
The sodium content of 0.9% saline is equivalent to that of extracel lular fluid. A daily requirement of 70–80mmol
sodium is normal although there may be excess loss in sweat and from the gastrointestinal tract.
Ringer's lactate or Hartmann's solution have no practical advantage over 0.9% sal ine for fluid maintenance. They
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may, however, be useful i f large volumes of crystalloid are used to avoid hyperchloraemic acidosis. Hyperchloraemic
acidosis may adversly affect coagulation and renal function.
5% glucose is used to supply intravenous water requirements. The 50g/l glucose content ensures an isotonic solution
but only provides 200Cal/l.  Normal requirement is approximately 1.5–2l/day. Water loss in excess of electrolytes is
uncommon but occurs in excess sweating, fever, hyperthyroidism, diabetes insipidus and hypercalcaemia.
Potassium chloride must be given slowly since rapid injection may cause fatal arrhythmias. No more than 40mmol/h
should be given al though 20mmol/h is more usual. The frequency of infusion is dictated by plasma potassium
measurements.
Ion content of crystalloids (mmol/l)
 Na+ K+ HCO3- Cl- Ca2+
0.9% saline 150   150  
Hartmann's 131 5 29 111 2
0.18% saline in 4% glucose 30   30  
Ion content of gastrointestinal fluids (mmol/l)
 H+ Na+ K+ HCO3- Cl-
Gastric 40–60 20–80 5–20 150 100–150
Biliary  120–140 5–15 30–50 80–120
Pancreatic  120–140 5–15 70–110 40–80
Small bowel  120–140 5–15 20–40 90–130
Large bowel  100–120 5–15 20–40 90–130
See also:
Nutri tion—use and indications, p78; Urea and creatinine, p144; Electrolytes
, p146; Sodium bicarbonate, p178; Col loids, p180; Hypernatraemia, p416; Hyponatraemia, p418; Hyperkalaemia,
p420; Hypokalaemia, p422; Metabolic acidosis, p434; Diabetic ketoacidosis, p442; Hyperosmolar diabetic
emergencies, p444; Multiple trauma (1), p500; Multiple trauma (2), p502; Burns—fluid management, p510;
Post-operative intensive care, p534
Sodium bicarbonate
Types
Isotonic sodium bicarbonate 1.26%
Hypertonic sodium bicarbonate (1mmol/ml) 8.4%
Uses
Correction of metabolic acidosis.
Alkalinisation of urine.
Alkalinisation of blood, e.g. for treatment of tricycl ic antidepressant overdose.
Routes
IV
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Notes
Isotonic (1.26%) sodium bicarbonate may be used to correct acidosis associated with renal fai lure or to induce a
forced alkal ine diuresis. The hypertonic (8.4%) solution is rarely required in intensive care practice to raise blood pH
in severe metabolic acidosis. Bicarbonate therapy is inappropriate when tissue hypoperfusion or necrosis is present.
Administration may be indicated as either speci fic therapy (e.g. alkaline diuresis for salicylate overdose) or i f the
patient is symptomatic (usual ly dyspnoeic) in the absence of tissue hypoperfusion (e.g. renal  fai lure).
The PaCO2 may rise if minute volume is not increased. Bicarbonate cannot cross the cel l membrane without
dissociation so the increase in PaCO2 may result in intracellular acidosis and depression of myocardial  cel l function.
The decrease in plasma ionised calcium may also cause a decrease in myocardial  contracti l ity. Significantly worse
haemodynamic effects have been reported with bicarbonate compared to equimolar sal ine in patients with severe
heart fai lure.
Convincing human evidence that bicarbonate improves myocardial contracti l i ty or increases responsiveness to
ci rculating catecholamines in severe acidosis is lacking, though anecdotal success has been reported. Acidosis
relating to myocardial depression is related to intracellular changes that are not accurately reflected by arterial blood
chemistry.
Excessive administration may cause hyperosmolali ty, hypernatraemia, hypokalaemia and sodium overload.
Bicarbonate may decrease tissue oxygen avai labil ity by a left shift of the oxyhaemoglobin dissociation curve.
Sodium bicarbonate does have a place in the management of acid retention or alkali  loss, e.g. chronic renal fai lure,
renal tubular acidosis, fistulae, diarrhoea. Fluid and/or potassium deficits should be corrected first.
Ion content of sodium bicarbonate (mmol/l)
 Na+ K+ HCO3- Cl- Ca2+
1.26% sodium bicarbonate 150 150
8.4% sodium bicarbonate 1000 1000
See also:
Blood gas analysis, p100; Electrolytes
), p146; Crystal loids, p176; Cardiac arrest, p272; Metabolic acidosis, p434; Sal icylate poisoning, p454
Colloids
Types
Albumin: e.g. 4.5–5%, 20–25% human albumin solution
Dextran: e.g. 6% Dextran 70
Gelatin: e.g. 3.5% polygeline, 4% succinylated gelatin
Hydroxyethyl starch: e.g. 6% hetastarch, 6% hexastarch, 6 and 10% pentastarch, 6% tetrastarch
Uses
Replacement of plasma volume defici t/percentage
Short term volume expansion (gelatin, dextran)
Medium term volume expansion (albumin, pentastarch)
Longer term volume expansion (hetastarch)
Routes
IV
Side-effects
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Dilution coagulopathy
Anaphylaxis
Interference with blood cross-matching (Dextran 70)
Notes
Smaller volumes of colloid are required for resuscitation with less contribution to oedema. Maintenance of plasma
col loid osmotic pressure (COP) is a useful  effect not seen with crystalloids, but colloids contain no clott ing factors or
other plasma enzyme systems.
Albumin is the main provider of COP and has several  other roles. There is no evidence that maintaining plasma
albumin levels, as opposed to plasma COP with artif icial plasma substitutes, is better.
Albumin 20–25% and Pentaspan 10% are hyperoncotic and used to provide col loid where salt restriction is necessary.
This is rarely necessary in intensive care as plasma volume expansion is related to the weight of colloid infused
rather than the concentration. Arti fi cial col loids used with ul trafi l tration or diuresis are just as effective in oedema
states.
Polygeline is a 3.5% solution containing calcium (6.25mmol/l ). This prevents use of the same giving set for blood
transfusions. Succinylated gelatin is a 4% solution with a larger molecular size than polygeline giving a sl ightly
longer effect. This, and the lack of calcium in solution, make it more useful than polygel ine for short term plasma
volume expansion.
In patients with capi l lary leak albumin and smaller molecular weight colloids leak to the interstitium. In these cases
it is perhaps better to use larger molecular weight colloids such as hydroxyethyl starch, though conclusive evidence
is lacking.
Hetastarch and hexastarch are usually 6% solutions with a high degree of protection from metabol ism due to a high
degree of substitution (proportion of glucose units substituted with hydroxyethyl groups—DS) or a high ratio of C2 to
C6 carbon atoms substituted (C2:C6 ratio). The molecular weight ranges vary but molecular sizes are large enough to
ensure a prolonged effect. These are the most useful  colloids in capi l lary leak. Prolonged itching related to
intradermal  deposition and interference with coagulation are complications i f excessive doses are used.
Pentastarch and tetrastarch provide only a short term effect simi lar to succinylated gelatin.
Unique features of albumin
Transport of various molecules.
Free radical  scavenging.
Binding of toxins.
Inhibi tion of platelet aggregation.
Relative persistence of colloid effect
Albumin +++
Dextran 70 ++
Succinylated gelatin ++
Polygeline +
Hetastarch (high MW, high DS, low C2:C6 ratio) ++++
Hexastarch (medium MW, high DS, high C2:C6 ratio) ++++
Pentastarch (medium MW, low DS, low C2:C6 ratio) ++
Tetrastarch (low MW, low DS, high C2:C6 ratio) ++
Persistence is dependent on molecular size and protection from metabol ism.
High DS and high C2:C6 ratio protect hydroxyethyl  starch from metabolism.
All  arti fic ial  col loids are polydisperse (i .e. there is a range of molecular sizes).
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Key trial
The SAFE study investigators. A comparison of albumin and saline for fluid resusci tation in the intensive care unit. N
Engl J Med 2004; J50:2247-56.
See also:
Crystalloids, p176; Blood transfusion, p182; Blood products, p252; Basic resuscitation, p270; Fluid chal lenge, p274;
Diabetic ketoacidosis, p442; Systemic inflammation/multiorgan fai lure, p484; Sepsis and septic shock treatment,
p550; Anaphylactoid reactions, p496; Burns—fluid management, p510; Post-operative intensive care, p534
Blood transfusion
Blood storage
Blood cel ls are eventual ly destroyed due to oxidant damage during storage of whole blood. Since white cells and
plasma enzyme systems are of importance in this cel lular destruction, effects are correspondingly less severe for
packed red cells. Blood used for transfusion in most of Europe is now routinely leukodepleted. Microaggregate
formation is associated with platelets, white cells and fibrin and range in size from 20–170µm. The risk of
microaggregate damage is reduced with packed red cells. In addi tion to spherocytosis and haemolysis, prolonged
storage depletes ATP and 2,3-DPG levels thus increasing the oxygen affinity of the red cel ls. If whole blood is to be
used in cri tical ly i l l  patients i t should be as fresh as possible.
Compatibility
In an emergency, wi th massive blood loss that threatens l i fe, i t i s permissible to transfuse O negative packed cel ls
but a sample must be taken for grouping prior to transfusion. With modern laboratory procedures it is possible to
obtain ABO compatibi l i ty for group speci fic transfusion within 5–10min and a ful l cross-match in 30min.
Hazards of blood transfusion
Citrate toxicity—hypocalcaemia is rarely a problem and the prophylactic use of calcium supplementation is not
recommended.
Potassium load—potassium returns to cel ls rapidly but hyperkalaemia may be a problem if blood is stored at
room temperature.
Sodium load—from ci trate if the transfusion is massive.
Hypothermia—can be avoided by warming blood as it is transfused.
Jaundice—haemolysis of incompatible or old blood.
Pyrexia—immunological  transfusion reactions to incompatible red or white cells or platelets.
DIC—partial activation of clotting factors and destruction of stored cells, either in old blood or when transfusion
is incompatible.
Anaphylactoid reaction—urticaria is common and probably due to a reaction to transfused plasma proteins; if
severe it may be treated by slowing the transfusion and giving chlorpheniramine 10mg IV/IM. In severe
anaphylaxis, in addit ion to standard treatment, the transfusion should be stopped and saved for later analysis
and a sample taken for further cross-matching.
Transmission of disease—including vi ruses, parasites (malaria), prions.
Transfusion-related acute lung injury (TRALI) and other immune reactions.
A multicentre trial suggested l iberal  transfusion in the crit ical ly i l l  produced less favourable outcomes,
particularly in younger, less sick patients, than using a trigger haemoglobin of 7g/dl .
Key trial
Hebert PC, Wells G, Blajchman MA et al,  for the Tranfusion Requirements in Cri tical  Care Investigators. A
multicenter, randomized, control led cl inical trial of transfusion requirements in crit ical care. N Engl  J Med 1999;
340:409–17
See also:
Calcium, magnesium and phosphate, p148; Ful l blood count, p154; Coagulation monitoring, p156; Basic resuscitation,
p270; Haemothorax, p302; Haemoptysis, p304; Upper gastrointestinal  haemorrhage, p344; Bleeding varices, p346;
Lower intestinal bleeding and colit is, p348; Bleeding disorders, p396; Anaemia, p400; Haemolysis, p404; Malaria,
p490; Anaphylactoid reactions, p496; Post-operative intensive care, p534; Post-partum haemorrhage, p542
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Respiratory drugs
Bronchodilators
Types
β2 agonists: e.g. salbutamol, epinephrine, terbutal ine
Anticholinergics: e.g. ipratropium
Theophyll ines: e.g. aminophyll ine
Steroids: e.g. hydrocortisone, prednisolone
Others: e.g. ketamine, isoflurane, halothane
Uses
Rel ief of bronchospasm
Routes
Inhaled (salbutamol, epinephrine, terbutal ine, ipratropium, isoflurane, halothane)
Nebulised (salbutamol, epinephrine, terbutaline, ipratropium)
IV (salbutamol, epinephrine, terbutaline, ipratropium, aminophyll ine, hydrocortisone, ketamine)
PO (aminophyl l ine, prednisolone)
Side-effects
CNS stimulation (salbutamol, epinephrine, terbutal ine, aminophyll ine)
Tachycardia (salbutamol, epinephrine, terbutaline, aminophyl l ine, ketamine)
Hypotension (salbutamol, terbutal ine, aminophyll ine, isoflurane, halothane)
Hyperglycaemia (salbutamol, epinephrine, terbutaline, hydrocortisone, prednisolone)
Hypokalaemia (salbutamol, epinephrine, terbutaline, hydrocortisone, prednisolone)
Lactic acidosis (salbutamol)—rare
Notes
Selective β2 agonists are usually given by inhalation via a pressurised aerosol or a nebul izer. Inhalation often gives
rapid rel ief of bronchospasm, although the aerosol is of less benefit in severe asthma.
Nebulized drugs require a minimum volume of 4ml and a driving gas flow of 6–8l/min.
In extremis, epinephrine may be used IV, SC or injected down the endotracheal tube. As epinephrine is not selective,
arrhythmias are more l ikely. However, the α agonist effect may reduce mucosal swel l ing by vasoconstriction.
Ipratropium bromide has no systemic effects and does not depress mucocil l iary clearance. It is synergistic wi th β2
agonists but has a slower onset of action.
Aminophyl l ine is synergistic wi th β2 agonists. Dosages must be adjusted according to plasma levels (range
10–20mg/l) since toxic effects may be severe. Dose requirements are reduced by heart fai lure, l iver disease, chronic
airflow l imitation, fever, cimetidine, erythromycin. Dose requirements are increased in chi ldren, smokers and those
with a moderate to high alcohol intake.
See also:
Steroids, p262; Chronic airflow l imitation, p286; Asthma—general management, p296; Asthma—venti latory
management, p298
Drug dosages
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 Aerosol* Nebuliser* IV bolus IV infusion
Salbutamol 100–200µg 2.5–5mg  3–20µg/min
Terbutaline 250–500µg 5–10mg 1.5–5µg/min  
Epinephrine  0.5mg   
Ipratropium  250µg   
Aminophylline   5mg/kg over 20min 0.5mg/kg/h
Hydrocortisone   200mg qds  
*Aerosols and nebulisers are usually given 4–6 times daily but may be given more frequently if
necessary.
In extremis, epinephrine may be given as 0.1–0.5mg subcutaneously, injected down the endotracheal  tube or by IV
infusion.
Respiratory stimulants
Types
Drug antagonists: e.g. naloxone, flumazenil
CNS stimulants: e.g. doxapram
Almitrine
Uses
Acute respiratory fai lure due to fai lure of venti latory drive.
Drug induced venti latory failure, e.g. as a result of excessive sedation or post-operatively.
Routes
IV
Modes of action
Naloxone—short acting opiate antagonist.
Flumazenil—short acting benzodiazepine antagonist.
Doxapram—general ised central nervous system stimulant with predominant respiratory stimulation at lower
doses. Stimulation of carotid chemoreceptors at very low doses with increased tidal volumes.
Almitrine—increases the sensi tivity of carotid chemoreceptors to hypoxaemia and hypercapnia.
Side-effects
Seizures (flumazenil,  doxapram)
Tachyarrhythmias (naloxone, flumazeni l)
Hal lucinations (doxapram)
Notes
Respiratory stimulants are mainly used in patients with chronic airflow l imitation who develop acute hypercapnic
respiratory failure. Effects of doxapram are short-l ived so infusion is necessary. After about 12h infusion the effects
on venti latory drive are reduced.
Naloxone may be used in respiratory depression due to opiate drugs. Since i t reverses all  opiate effects, it may be
better to reverse respiratory depression with non-specific respiratory stimulants, leaving pain rel ief intact. It may
need to be repeated when long acting opiates are involved.
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As most benzodiazepines are long acting compared to flumazenil , repeated doses may be necessary.
Almitrine does not produce central respiratory stimulation but i t does improve venti lat ion–perfusion matching by
augmenting hypoxic pulmonary vasoconstrict ion. Effects continue for several  hours after injection.
Drug dosages
IV Infusion IV bolus IV
Naloxone 0.1–0.4mg  
Flumazenil 0.2mg over 15min (0.1mg/min to max 2mg)  
Doxapram 1–1.5mg/kg over 30s 2–3mg/min
Almitrine 0.25–0.5mg/kg over 30min  
Key paper
Greenstone M, Lasserson TJ. Doxapram for venti latory fai lure due to exacerbations of chronic obstructive pulmonary
disease. Cochrane Database Syst Rev. 2003; CD000223. Review
See also:
Opioid analgesics, p234; Sedatives, p238; Respiratory fai lure, p282; Sedative poisoning, p458; Post-operative
intensive care, p534
Nitric oxide
Nitric oxide is now recognised as a fundamental mediator in many physiological  processes. One of its most important
effects is smooth muscle relaxation; ni tric oxide is the major local  controller of vascular tone via effects on cycl ic
GMP.
Inhaled nitric oxide
Nitric oxide is provided for inhalation from cylinders (1000ppm nitric oxide in ni trogen). It is di luted with inspiratory
gases, ei ther at the gas supply to the venti lator or in the inspiratory l imb of the venti lator circuit,  to provide an
inhaled concentration of 1–40ppm, al though most patients require less than 20ppm. Inhalation produces
vasodi latation at the si te of gas exchange, and may improve venti lation–perfusion matching and reduce pulmonary
artery pressures. Randomised multi-centre studies in patients with acute lung injury have revealed no long-term
benefi t or outcome improvement.
Side-effects
Nitric oxide is immediately bound to haemoglobin ensuring local effects only. There is no tolerance but patients can
become dependent on continued inhalation with rebound pulmonary hypertension and hypoxaemia on withdrawal. For
this reason, wi thdrawal  must be gradual . Excessive humidi fication of inspired gases may form ni tric acid with NO; the
use of heat–moisture exchangers rather than water baths is recommended.
Monitoring
Nitric oxide and nitrogen dioxide concentrations may be monitored conveniently with portable fuel cel l analysers or
by chemiluminescence. It is important to monitor concentrations of both gases in the inspiratory l imb of the
venti lator circui t.  Monitoring of nitrogen dioxide is important to ensure that toxic doses are not formed with the
oxygen in the inspired gas and subsequently inhaled by the patient. Although i t is extremely rare to see toxic
nitrogen dioxide concentrations (>5ppm) it is possible to remove nitrogen dioxide from the inspired gas by using a
soda l ime adsorber. Methaemoglobin is formed when ni tric oxide binds to haemoglobin. Prolonged inhalation at higher
doses may rarely produce signi ficant methaemoglobinaemia (>5%) and this should therefore be monitored daily.
Achieving the correct dose
Approximately 50% of patients with severe respiratory fai lure respond to ni tric oxide. However, the most effective
dose varies. It is usual  to start at 1ppm for 10min and monitor the change in PaO2/FIO2 ratio. An increase should be
fol lowed by an increase in nitric oxide concentration to 5ppm for a further 10min. Thereafter, the dose is adjusted
according to response at 10min intervals unti l the most effective dose is found. Since the underlying pathophysiology
may change, i t is important to assess the dose response at daily intervals, aiming to keep the dose at the lowest
effective level .
Scavenging
Since the concentrations used are so smal l, di lution of exhaled gases into the atmosphere is unlikely to produce
important environmental  concentrations. In the air-condi tioned intensive care environment ai r changes are so
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frequent as to make scavenging unnecessary.
Key trials
Del l inger RP et al , for the Inhaled Nitric Oxide in ARDS Study Group. Effects of inhaled nitric oxide in patients with
acute respiratory distress syndrome: results of a randomized phase II trial.  Cri t Care Med 1998; 26:15–23
Lundin S et al , for the The European Study Group of Inhaled Nitric Oxide. Inhalation of ni tric oxide in acute lung
injury: results of a European multicentre study. Intensive Care Med 1999; 25:911–19
See also:
Vasodi lators, p198; Acute respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2), p294
Surfactant
In ARDS there is decreased surfactant production, biochemical  abnormal ity of the surfactant produced and inhibit ion
of surfactant function. The net result is alveolar and small  ai rway col lapse. Surfactant also contributes to host
defence against micro-organisms. Surfactant replacement would be expected to exert therapeutic effects on lung
mechanics, gas exchange and host defence.
Insti l lation of surfactant (either as a l iquid or nebul ised) via the endotracheal tube into the lungs is associated with
improved outcome in neonatal  respiratory distress syndrome. Potential indications in adults include ARDS,
pneumonia, chronic ai rflow l imitation and asthma. Multiple studies in ARDS have yet to demonstrate mortality
benefi t, though this may be related to the type of surfactant, the volume used, or the delivery system.
Studies have demonstrated improved oxygenation with recombinant surfactant protein C and a trend to improved
survival  in patients with direct lung injury. Further studies are underway using recombinant surfactant protein C with
phospholipids, and with surfactant proteins B and C. The surfactant is insti l led into the lungs via an endotracheal
catheter.
Complications of surfactant treatment have included increased cough, sputum production, bronchospasm, increasd
peak airway pressure and adverse effects on pulmonary function. These can be minimised by adequate sedation and
neuromuscular blockade before insti l l ing surfactant.
Key trial
Spragg RG, Lewis JF, Walmrath HD et al.  Effect of recombinant surfactant protein C-based surfactant on the acute
respiratory distress syndrome. N Engl J Med 2004; 351:884–92
See also:
Acute respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2), p294
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Cardiovascular Drugs
Inotropes
Types
Catecholamines: e.g. epinephrine, norepinephrine, dobutamine, dopamine
Phosphodiesterase (PDE) inhibi tors: e.g. mi lrinone, enoximone
Dopexamine
Calcium sensitisers: e.g. levosimendan
Cardiac glycosides: e.g. digoxin (weak)
Modes of action
Increase force of myocardial  contraction, either by stimulating cardiac β1 adrenoreceptors (catecholamines),
decreasing cAMP breakdown (PDE inhibi tors), increasing calcium sensi tivity (Ca sensitisers), di rectly increasing
contracti l i ty (digoxin), or inhibit ing neuronal  reuptake of noradrenaline (dopexamine). Al l agents except digoxin
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have, to greater or lesser degrees, associated di lator or constrictor properties via β1 and β1 adrenoreceptors,
dopaminergic receptors, or KATP channels.
Digoxin may cause splanchnic vasoconstrict ion and, for an inotropic effect, requires plasma levels at the top of
the therapeutic range.
The increase in cardiac work is partial ly offset in those drugs possessing associated dilator effects.
Other than epinephrine (when used for its vasoconstrictor effect in cardiopulmonary resuscitation) or digoxin (for
long term use in chronic heart fai lure), inotropes are usual ly given by continuous IV infusion titrated for effect.
Uses
Myocardial  fai lure, e.g. post-myocardial  infarction, cardiomyopathy
Myocardial  depression, e.g. sepsis
Augmentation of oxygen del ivery in high-risk surgical patients
Side-effects
Arrhythmias (usual ly associated with concurrent hypovolaemia)
Tachycardia (usual ly associated with concurrent hypovolaemia)
Hypotension (related to di lator properties ± concurrent hypovolaemia)
Hypertension (related to constrictor properties)
Anginal chest pain, or ST-segment and T-wave changes on ECG
Notes
Epinephrine, norepinephrine, dobutamine and dopamine should be given via a central vein as tissue necrosis may
occur secondary to peripheral  extravasation.
Drug dosages
Epinephrine Infusion starting from 0.05µg/kg/min
Norepinephrine Infusion starting from 0.05µg/kg/min
Dobutamine Infusion from 2.5–25µg/kg/min
Dopamine Infusion from 2.5–50µg/kg/min
Dopexamine Infusion from 0.5–6µg/kg/min
Milrinone Loading dose of 50µg/kg over 10min followed by infusion from
0.375–0.75µg/kg/min
Enoximone Loading dose of 0.5–1mg/kg over 10min followed by infusion from
5–20µg/kg/min
Digoxin 0.5mg given PO or IV over 10–20min. Repeat at 4–8h intervals until loading
achieved (assessed by clinical response). Maintenance dose thereafter is
0.0625–0.25mg/day depending on plasma levels and clinical response.
Levosimendan 12–24µg/kg over 10min followed by 0.1µg/kg/min for 24h
See also:
Intra-aortic balloon counterpulsation, p58; Cardiac output—thermodilution, p122; Cardiac output—other invasive,
p124; Cardiac output—non-invasive (1), p126; Cardiac output— non-invasive (2), p128; Basic resuscitation, p270;
Cardiac arrest, p272; Fluid challenge, p274; Hypotension, p312; Sepsis and septic shock—treatment, p486; Care of
the potential organ donor, p552
Vasodilators
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Types
Nitrates: e.g. glyceryl trini trate, isosorbide dinitrate
Angiotensin converting enzyme (ACE) inhibi tors: e.g. captopri l
Smooth muscle relaxants: e.g. sodium nitroprusside, hydralazine
α-adrenergic antagonists: e.g. phentolamine
β2-adrenergic agonists: e.g. salbutamol
Calcium antagonists: e.g. ni fedipine, di lt iazem
Dopaminergic agonists: e.g. dopexamine
Phosphodiesterase inhibi tors: e.g. enoximone, mil rinone, si ldenafi l
Prostaglandins: e.g. epoprostenol  (PGI2), alprostadi l (PGE1)
B-type natriuretic peptide analogues, e.g. nesirit ide
Modes of action
Increase cyclic GMP concentration (by nitric oxide donation or by inhibiting cGMP breakdown), or acts directly on
dopaminergic receptors leading to vasodilatation
Reduce (to varying degrees) ventricular preload and/or afterload.
Reduce cardiac work.
Uses
Myocardial  fai lure, e.g. post-myocardial  infarction, cardiomyopathy
Angina/ischaemic heart disease
Systemic hypertension (specific causes, e.g. phaeochromocytoma)
Vasoconstriction
Peripheral vascular disease/hypoperfusion
Splanchnic perfusion (dopexamine, dopamine)
Pulmonary hypertension (inhaled NO, prostaglandins, si ldenafi l )
Side-effects/complications
Hypotension (often associated with concurrent hypovolaemia)
Tachycardia (often associated with concurrent hypovolaemia)
Symptoms include headache, flushing, postural  hypotension
Renal fai lure (ACE inhibi tors)—especial ly with renal artery stenosis, hypovolaemia, non-steroidals
Notes
Glyceryl  trini trate and isosorbide dinitrate reduce both preload and afterload. At higher dose the afterload effect
becomes more prominent.
Tolerance to ni trates usually commences within 24–36h unless intermittent oral dosing is used. Progressive increases
in dose are required to achieve the same effect.
Prolonged (>24–36h) dose-related administration of sodium ni troprusside can rarely produce a metabolic acidosis
related to cyanide accumulation.
ACE inhibitor tablets can be crushed and given either SL or via a nasogastric tube.
Dopaminergic drugs improve splanchnic blood flow though cl inical  benefi ts are unproved.
Hydralazine has an unpredictable effect on blood pressure and, if given IV, should be used with caution.
Drug dosages
Nitrates Glyceryl trinitrate 2–40mg/h
Isosorbide dinitrate 2–40mg/h
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Sodium
nitroprusside
20–400µg/min
Hydralazine 5–10mg by slow IV bolus, repeat after 20–30min. Alternatively, by infusion
starting at 200–300µg/min and reducing to 50–150µg/min
ACE inhibitors Captopril: 6.25mg test dose increasing to 25mg tds
Enalapril: 2.5mg test dose increasing to 40mg od
Lisinopril: 2.5mg test dose increasing to 40mg od
Nifedipine: 5–20mg PO. Capsule fluid can be injected down nasogastric tube or given
sublingually
Phentolamine 2–5mg IV slow bolus. Repeat as necessary.
Dopexamine Infusion from 0.5–6µg/kg/min
Milrinone Loading dose of 50µg/kg over 10min followed by infusion from
0.375–0.75µg/kg/min
Enoximone Loading dose of 0.5–1mg/kg over 10min followed by infusion from
5–20µg/kg/min
Epoprostenol,
alprostadil
Infusion from 2–30ng/kg/min
Nitric oxide By inhalation: 2–40ppm
Nesiritide 2µg/kg bolus followed by infusion of 0.01–0.03µg/kg/min
Sildenafil 50mg tds PO
See also:
Blood pressure monitoring, p110; Cardiac output—thermodilution, p122; Cardiac output—other invasive, p124;
Cardiac output—non-invasive (1), p126; Cardiac output—non-invasive (2), p128; Hypotensive agents, p202;
Antianginal  agents, p208; Nitric oxide, p190; Basic resuscitation, p270; Fluid chal lenge, p274; Hypertension, p314;
Acute coronary syndrome (1), p320; Acute coronary syndrome (2), p322; Heart fai lure—assessment, p324; Heart
fai lure—management, p326; Pre-eclampsia and eclampsia, p538
Vasopressors
Types
α-adrenergic: e.g. norepinephrine, epinephrine, dopamine, ephedrine, phenylephrine, methoxamine
Drugs reducing production of cycl ic GMP (in septic shock): e.g. methylthioninium chloride (methylene blue)
Vasopressin or synthetic analogues, e.g. terl ipressin
Modes of action
Acting on peripheral α-adrenergic or vasopressin V1 receptors
Blocking cGMP production (methylene blue)
Increase afterload, mainly by arteriolar vasoconstriction and restoration of vascular reactivity
Venoconstriction
Uses
To increase organ perfusion pressures, particularly in high output, low peripheral  resistance states, e.g. sepsis,
anaphylaxis
To raise coronary perfusion pressures in cardiopulmonary resuscitation (epinephrine, vasopressin)
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Side-effects/complications
Increased cardiac work
Decreased cardiac output, especial ly wi th agents where pressor effects predominate
Myocardial  and splanchnic ischaemia
Increased myocardial irritabi l ity, especial ly with concurrent hypovolaemia, leading to arrhythmias and
tachycardia
Decreased peripheral perfusion and distal ischaemia/necrosis
Notes
Pressor agents should be avoided, if possible, in low cardiac output states as they may further compromise the
ci rculation.
Methoxamine and phenylephrine are the ‘purest’ pressor agents; other α-adrenergic agents have inotropic properties
to greater or lesser degrees. Ephedrine is simi lar to epinephrine but its effects are more prolonged as it is not
metabolised by monoamine oxidase.
Effects of pressor agents on splanchnic, renal and cerebral  ci rculations are variable and unpredictable.
Pulmonary vascular resistance is also raised by these agents.
Methyl thioninium chloride (methylene blue) inhibits the NO–cGMP pathway. It is currently unl icensed as a pressor
agent and its use has only been reported in a few small  case series. A multicentre study of a NO synthase inhibitor
(L-NMMA) was prematurely discontinued due to adverse outcomes.
Vasopressin (short half-l i fe, infusion needed) and terl ipressin (longer half-l i fe, can be given by bolus) may be
effective in treating catecholamine-resistant vasodilatory shock. Paradoxical ly, such patients respond to smal l doses
that have no pressor effect in healthy people. Multicentre outcome studies are ongoing.
Excessive dosing of any pressor agent may lead to regional  ischaemia, e.g. cardiac, splanchnic. Digital ischaemia
may respond to prompt administration of intravenous prostanoids (e.g. PGE1,  PGI2).
Drug dosages
Norepinephine Infusion starting from 0.05µg/kg/min
Epinephrine Infusion starting from 0.05µg/kg/min
Dopamine Infusion from 5–50µg/kg/min
Methoxamine 3–10mg by slow IV bolus (rate of 1mg/min)
Ephedrine 3–30mg by slow IV bolus
Methylthioninium chloride
(methylene blue)
1–2mg/kg over 15–30min
Vasopressin 0.01–0.04U/min
Terlipressin 0.25–0.5mg bolus, repeated at 30min intervals as necessary
to maximum 2mg.
Key paper
Lopez A, et al.  Multiple-center, randomized, placebo-control led, double-blind study of the ni tric oxide synthase
inhibi tor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32:21–30
Landry DW, et al . Vasopressin deficiency contributes to the vasodi lation of septic shock. Circulation 1997;
95:1122–5
Hypotensive agents
Types
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Vasodi lators
α- and β-adrenergic blockers
In routine ICU practice β-blockers are used relatively infrequently because most have a long half-l i fe and the
negative inotropic effects are generally undesirable. Exceptions are esmolol and labetalol , both of which have
short hal f-l ives and vasodilating properties.
Modes of action
Vasodi lators reduce preload and afterload to variable degrees depending on type and dose
β-blockers reduce the force of myocardial contracti l ity
Uses
Hypertension—systemic and pulmonary
Heart fai lure—to reduce afterload ± preload (caution with β-blockers)
Control  of blood pressure, e.g. dissecting aortic aneurysm
Side-effects/complications
Excessive hypotension
Heart fai lure (with β-blockers)
Peripheral hypoperfusion (with β-blockers)
Bronchospasm (with β-blockers)
Decreased sympathetic response to hypoglycaemia (with β-blockers)
Notes
In critical ly i l l  patients i t is often advisable to use short-acting β-blockers by infusion.
Drug dosages
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Nitrates Glyceryl trinitrate 2–40mg/h
Isosorbide dinitrate 2–40mg/h
Sodium
nitroprusside
20–400µg/min.
ACE inhibitors Captopril: 6.25mg test dose increasing to 25mg tds
Enalapril: 2.5mg test dose increasing to 40mg o.d
Lisinopril: 2.5 mg test dose increasing to 40mg o.d
Nifedipine: 5–20mg PO. Capsule fluid can be injected down nasogastric tube or given
sublingually.
Phentolamine 2–5mg IV slow bolus. Repeat as necessary
Esmolol A titrated loading dose regimen is commenced followed by an infusion rate of
50–200µg/kg/min.
Propranolol Initially given as slow IV 1mg boluses repeated at 2min intervals until effect is
seen (to maximum 5mg)
Labetalol 0.25–2mg/min
Hydralazine 5–10mg by slow IV bolus, repeat after 20–30min. Alternatively, by infusion
starting at 200–300µg/min and reducing to 50–150µg/min.
See also:
Blood pressure monitoring, p110; Cardiac output—thermodilution, p122; Cardiac output—other invasive, p124;
Cardiac output—non-invasive (1), p126; Cardiac output—non-invasive (2), p128; Vasodilators, p198; Basic
resuscitation, p270; Fluid challenge, p274; Hypertension, p314; Pre-eclampsia and eclampsia, p538
Antiarrhythmics
Only antiarrhythmics l ikely to be used in the ICU setting are described.
For supraventricular tachyarrhythmias:
adenosine, verapami l, amiodarone, digoxin, β-blockers, magnesium
For ventricular tachyarrhythmias:
amiodarone, l idocaine, flecainide, bretylium, β-blockers, magnesium
Uses
Correction of supraventricular and ventricular tachyarrhythmias which either compromise the ci rculation or could
potential ly do so.
Differentiation between supraventricular and ventricular arrhythmias using adenosine
Notes
Al l antiarrhythmic agents have side-effects; other than digoxin they are negatively inotropic to greater or lesser
degrees and may induce profound hypotension (e.g. verapamil , β-blockers) or bradycardia (e.g. β-blockers,
amiodarone, digoxin, l idocaine). β-blockers in particular should be used with caution because of these effects.
Al l A-V blockers are contraindicated in re-entry tachycardia (e.g. Wol ff–Parkinson–White syndrome).
Adenosine: very short-acting; may revert paroxysmal SVT to sinus rhythm. Ineffective for atrial f lutter and
fibri l lat ion, VT. Contraindicated in 2° and 3° heart block, sick sinus syndrome, asthma. May cause flushing,
bronchospasm and occasional  severe bradycardia.
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Amiodarone: effective against all types of tachyarrhythmia. Usually given by IV infusion for rapid effect but
requires ini tial loading dose. When converting from IV to oral  dosing, ini tial high oral  dosing (200mg tds) is sti l l
required. Contraindicated in patients with thyroid dysfunction. Has low acute toxicity, though may cause severe
bradycardia and both chronic and acute pulmonary fibrosis. Avoid with other Class III agents (e.g. sotalol). Must
be given via central vein as causes peripheral  phlebit is.
β-blockers: for SVT, esmolol  is preferred due to its short half-l i fe though may cause vasodilatation. Ini tial ly,
increasing loading doses required; an infusion may be needed thereafter. Propranolol can be given by slow IV
boluses of 1mg repeated at 2min intervals to a maximum of 5mg). Do not give β-blockers with verapamil.
Bretyl ium: may take 15–20min to take effect; now used predominantly for resistant VF/VT. CPR should be
continued for at least 20min.
Digoxin: slow-acting, requires loading (1–1.5g) to achieve therapeutic plasma levels which can be monitored.
Loading ideally given over 12–24h but can be done over 4–6h. Contraindicated in 2° and 3° heart block. May
cause severe bradycardia. Low K+ and Mg2+ and markedly raised Ca2+ increase myocardial  sensi tivity to digoxin.
Amiodarone raises digoxin levels.
Lidocaine: 10ml of 1% solution contains 100mg. No effect on SVT. Loading achieved by 1mg/kg slow IV bolus
fol lowed by infusion. Contraindicated in 2° and 3° heart block. May cause bradycardia and CNS side-effects, e.g.
drowsiness, seizures.
Verapamil: should not be given with β-blockers as profound hypotension and bradyarrhythmias may result.
Pretreatment with 3–5ml 10% calcium gluconate by slow IV bolus prevents the hypotensive effects of verapami l
without affecting i ts antiarrhythmic properties.
Modes of action (Vaughan-Williams classification)
Class Action Examples
I Reduces rate of rise of action potential:  
•Ia: increases action potential duration •Ia:
disopyramide
•Ib: shortens duration •Ib: lidocaine
•Ic: little effect •Ic: flecainide
II Reduces rate of pacemaker discharge β-blockers
III Prolongs duration of action potential and hence length of refractory
period
Amiodarone
Sotalol
IV Antagonises transport of calcium across cell membrane Verapamil
Diltiazem
Drug dosages
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Adenosine 3mg rapid IV bolus. If no response after 1min give 6mg. If no response after 1min
give 12mg.
Amiodarone 5mg/kg over 20min (or 150–300mg over 3min in emergency) then IV infusion of
15mg/kg/24h in 5% glucose via central vein. Reduce thereafter to 10mg/kg/24h
(approx. 600mg/day) for 3–7 days then maintain at 5mg/kg/24h (300–400mg/day)
β-blockers Esmolol: a titrated loading dose regimen is commenced followed by an infusion rate
of 50–200µg/kg/min.
Propranolol: Initially given as slow IV boluses of 1mg repeated at 2min intervals
until effect is seen to a maximum of 5mg.
Labetalol: 0.25–2mg/min
Bretylium In emergency 5mg/kg by rapid IV bolus. If no response after 5min, repeat or
increase to 10mg/kg.
Digoxin 0.5mg given IV over 10–20min. Repeat at 4–8h intervals until loading achieved
(assessed by clinical response). Maintenance dose thereafter is 0.0625–0.25mg/day
depending on plasma levels and clinical response.
Lidocaine 1mg/kg slow IV bolus for loading then 2–4mg/min infusion. Should be weaned
slowly over 24h.
MgSO4 10–20mmol over 1–2h. Can be given over 5min in emergency.
Verapamil 2.5mg slow IV. If no response repeat to a maximum of 20mg. An IV infusion of
1–10mg/h may be tried. 10% calcium gluconate solution should be readily available.
See also:
Defibri l lat ion, p52; ECG monitoring, p108; Basic resuscitation, p270; Cardiac arrest, p272; Tachyarrhythmias
Chronotropes
Types
Anticholinergic: e.g. atropine, glycopyrrolate
Modes of action
The antichol inergic drugs act by competit ive antagonism of acetylchol ine at peripheral  muscarinic receptors and
decrease atrioventricular conduction t ime.
Uses
All  types of bradycardia including 3° heart block.
High dose atropine is used in cardiopulmonary resusci tation protocols for treatment of asystole.
Side-effects/complications
Anticholinergic drugs produce dry mouth, reduction and thickening of bronchial secretions, and inhibit ion of
sweating. Urinary retention may occur but parenteral administration does not lead to glaucoma.
Notes
The antichol inergic agents are usually given by IV bolus, repeated as necessary.
They are frequently used as a bridge to temporary pacing but should not be considered a substi tute. External  or
internal  pacing should be readily accessible.
Atropine nebul isers have been used successfully in patients developing symptomatic bradycardia during endotracheal
suction.
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Neurological effects may be seen with atropine but not glycopyrrolate.
Drug dosages
Atropine 0.3–0.6mg IV bolus. 3mg is needed for complete vagal blockade.
Glycopyrrolate 0.2–0.4mg IV bolus.
See also:
Temporary pacing (1), p54; Temporary pacing (2), p56; ECG monitoring, p108; Basic resuscitation, p270; Cardiac
arrest, p272; Bradyarrhythmias, p318
Antianginal agents
Types
Vasodi lators: e.g. ni trates, calcium antagonists
β-blockers
Potassium channel openers: e.g. nicorandil
Aspirin, heparin, clopidogrel
Modes of action
Calcium channel  blockers cause competit ive blockade of cel l membrane and slow calcium channels leading to
decreased influx of calcium ions into cells. This leads to inhibi tion of contraction and relaxation of cardiac and
smooth muscle fibres result ing in coronary and systemic vasodilatation.
Nitrates may cause efflux of calcium ions from smooth muscle and cardiac cel ls and also increase cGMP synthesis
result ing in coronary and systemic vasodilatation.
β-blockers inhibit β-adrenoreceptor stimulation, reducing myocardial  work and oxygen consumption. This effect
is somewhat offset by compensatory peripheral vasoconstriction.
Potassium channel openers cause vasodilatation by relaxation of vascular smooth muscle. The potassium channel
opening action works on the arterial  ci rculation while a nitrate action provides addit ional vasodi latation.
Though aspirin, heparin and clopidogrel  have no direct antianginal  effect, patients with unstable angina benefi t
from the reduction in platelet aggregation and thrombus formation.
Uses
Angina pectoris
Side-effects/complications
See Di lators, Hypotensive agents.
Nicorandi l i s contraindicated in hypotension and cardiogenic shock. It should be avoided in hypovolaemia.
Headache and flushing are the major reported side-effects. Rapid and severe hyperkalaemia has been reported
after cardiac surgery.
Notes
Combination therapy involving intravenous nitrates, calcium antagonists, β-blockade and heparinisation has been
shown to be beneficial in unstable angina; thrombolytic therapy confers no added advantage.
Potassium channel openers belong to a new class of drug yet to be extensively evaluated in cri tical ly i l l  patients and
should be thus used with caution, especial ly when hyperkalaemia is a concern.
Angina may occasional ly be worsened by a ‘coronary steal’  phenomenon where blood flow is diverted away from
stenosed coronary vessels. This does not, however, occur with nicorandil .
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
94 из 254 07.11.2006 1:04
P.209
Drug dosages
Glyceryl
trinitrate
0.3mg sublingually, 0.4–0.8mg by buccal spray, 2–40mg/h by IV infusion.
Isosorbide
dinitrate
10-20mg tds orally, 2–40mg/h by IV infusion.
Nifedipine 5–20mg PO. The capsule fluid can be aspirated then injected down nasogastric
tube or given sublingually.
Propranolol Given either orally at doses of 10–100mg tds or IV as slow boluses of 1mg
repeated at 2min intervals to a maximum of 5mg until effect is seen. This can be
repeated every 2–4h as necessary.
Nicorandil 10–20mg PO bd.
Clopidogrel 75mg PO od.
Aspirin 75–150mg PO od.
See also:
Acute coronary syndorme (1), p146; Acute coronary syndrome (2), p322
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Renal Drugs
Diuretics
Types
Loop diuretics: e.g. furosemide, bumetanide
Osmotic diuretics: e.g. mannitol
Thiazides: e.g. metolazone
Potassium sparing diuretics: e.g. amiloride, spironolactone, potassium canrenoate
Uses
To increase urine volume
Control  of chronic oedema (thiazides, loop diuretics)
Control  of hypertension (thiazides)
To promote renal  excretion (e.g. forced diuresis, hypercalcaemia)
Routes
IV (mannitol , furosemide, bumetanide, potassium canrenoate)
PO (metolazone, furosemide, bumetanide, amiloride, spironolactone)
Modes of action
Osmotic diuretics—reduce distal tubular water reabsorption
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Thiazides—inhibit distal tubular Na+ loss and carbonic anhydrase and increase Na+ and K+ exchange. This
reduces the supply of H+ ions for exchange with Na+ ions producing and alkal ine natriuresis with potassium loss
Loop diuretics—inhibit Na+ and Cl-  reabsorption in the ascending loop of Henlé
Potassium sparing diuretics—inhibi t distal tubular Na+ and K+ exchange
Side-effects
Hypovolaemia
Hyponatraemia or hypernatraemia
Hypokalaemia
Oedema formation (mannitol)
Reduced catecholamine effect (thiazides)
Hyperglycaemia (thiazides)
Metabol ic alkalosis (loop diuretics)
Hypomagnesaemia (loop diuretics)
Pancreati tis (furosemide)
Notes
It is important to correct pre-renal causes of ol iguria before resorting to diuretic use.
Diuretics do not prevent renal fai lure but may convert ol iguric to polyuric renal fai lure.
If there is inadequate glomerular fi ltration, mannitol is retained and passes to the extracellular f luid to promote
oedema formation.
Bumetanide may be used in porphyria where thiazides and other loop diuretics are contraindicated.
Potassium sparing diuretics should be avoided with ACE inhibi tors as there is an increased risk of hyperkalaemia.
Drug dosages
 Oral IV Infusion
Mannitol  100g over 20min 6-hrly  
Metolazone 5–10mg od   
Furosemide 20–40mg 6–24-hrly 5–80mg 6–24-hrly 1–10mg/h
Bumetanide 0.5–1mg 6–24-hrly 0.5–2mg 6–24-hrly 1–5mg/h
Amiloride 5–10mg 12–24-hrly   
Spironolactone 100–400mg od   
K+ canrenoate  200–400mg od  
Dopamine
The effects of dopamine are dependent on the dose infused. Dopamine was used widely at low doses in an attempt to
secure preferential DA1 stimulation and increase renal  perfusion; however, a large multicentre randomised control led
study comparing ‘renal dose’ dopamine and diuretics showed no difference in the incidence of renal fai lure. The
widespread use of low dose dopamine (<3µg/kg/min) has thus diminished considerably in recent years. Higher doses
increase cardiac contracti l i ty via β1 st imulation and produce vasoconstrict ion via α st imulation. Where
vasoconstriction is inappropriate this wil l  reduce renal perfusion. There is, however, evidence of natriuresis and
diuresis by enhanced Na+ transport in the ascending loop of Henlé.  This effect is similar to that of a loop diuretic. In
addition to the renal  effects of DA1 stimulation there may be preferential perfusion of the splanchnic bed, though any
benefi ts to patients have yet to be shown.
Key trial
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
96 из 254 07.11.2006 1:04
P.219
Bel lomo R, for the Austral ian and New Zealand Intensive Care Society (ANZICS) Clinical  Trials Group. Low-dose
dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial.  Lancet 2000; 356:2139–43
See also:
Di luretics, p212; Oliguria, p330; Acute renal  fai lure—management, p334
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Gastrointestinal Drugs
H2 blockers and proton pump inhibitors
Types
H2 antagonists: e.g. rani tidine, cimetidine
Proton pump inhibi tors: e.g. omeprazole
Modes of action
These agents inhibit secretion of gastric acid, reducing both volume and acid content, ei ther by antagonism of the
histamine H2 receptor or by inhibit ing H+K+-ATPase which fuels the parietal cel l proton pump on which acid secretion
depends.
Uses
Peptic ulceration, gastrit is, duodenit is
Reflux oesophagi tis
Prophylaxis against stress ulceration
Upper gastrointestinal haemorrhage of peptic/stress ulcer origin
With non-steroidal  anti-inflammatory agents in patients with dyspepsia
Gastric tonometry measurement
Side-effects/complications
The major concern voiced against these agents is the increased risk of nosocomial pneumonia by removal of the
acid barrier. However, a multicentre RCT comparing ranitidine with sucralfate showed no di fference in
pneumonia rate and a lower incidence of GI bleeding.
H2 antagonists: rare but include arrhythmias, al tered l iver function tests, confusion (in the elderly).
Proton pump inhibi tors: altered l iver function tests.
Notes
Although l icensed and frequently used for stress ulcer prophylaxis, overwhelming supportive evidence is scanty.
Enteral nutrit ion has been shown to be as effective. No adequately powered study of proton pump inhibitors has yet
been performed in ICU patients.
Some studies have shown efficacy in upper gastrointestinal haemorrhage secondary to stress ulceration or peptic
ulceration.
Dosages should be modified in renal fai lure.
Cimetidine can affect metabolism of other drugs, in particular warfarin, phenytoin, theophyl l ine and l idocaine (related
to hepatic cytochrome P450-linked enzyme systems). This does not occur with ranit idine.
Omeprazole can delay el imination of diazepam, phenytoin and warfarin.
Drug dosages
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Ranitidine 50mg tds by slow IV bolus, 150mg bd PO
Cimetidine 200–400mg qds by slow IV bolus, 400mg bd PO
Omeprazole 40mg IV od (over 20–30min), 20–40mg PO
Key trial
Cook D, Guyatt G, Marshal l J, et al. A comparison of sucralfate and rani tidine for the prevention of upper
gastrointestinal bleeding in patients requiring mechanical  venti lation. Canadian Cri tical Care Trials Group. N Engl J
Med 1998; 338:791–7
See also:
Upper gastrointestinal endoscopy, p74; Sucral fate, p220; Antacids, p222; Upper gastrointestinal haemorrhage, p344;
Bleeding varices, p346; Bowel perforation and obstruction, p348
Sucralfate
Modes of action
Sucral fate is a basic aluminium sal t of sucrose octasulphate and is probably not absorbed from the
gastrointestinal tract.
Exerts a cytoprotective effect by preventing mucosal  injury. A protective barrier is formed both over normal
mucosa and any ulcer lesion providing protection against penetration of gastric acid, bi le and pepsin as wel l as
irritants such as aspirin and alcohol.
Directly inhibits pepsin activi ty and absorbs bi le salts.
Weak antacid activi ty.
Uses
Peptic ulceration, gastrit is, duodenit is
Reflux oesophagi tis
Prophylaxis against stress ulceration
Side-effects/complications
Constipation
Reduced bioavailabi l i ty of some drugs given orally, e.g. digoxin, phenytoin. Can be overcome by giving agents at
least 2h apart.
Use with caution in renal  fai lure due to risk of increased aluminium absorption.
Notes
Although l icensed and frequently used for stress ulcer prophylaxis, overwhelming supportive evidence is scanty.
Enteral nutrit ion and gastric acid blockers have been shown to be as effective.
Evidence for a reduced incidence of nosocomial pneumonia compared to H2 blocker therapy is also confl icting.
Signi ficant reduction in nosocomial  pneumonia has been shown compared to a combination of H2 blocker plus antacid
but not against H2 blocker alone. Indeed, a large multicentre RCT comparing ranit idine with sucral fate showed no
difference in pneumonia rate and a lower incidence of GI bleeding with rani tidine.
Antacids should not be given for 30min before or after sucralfate.
Drug dosages
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Sucralfate 1g six times a day PO or via ng tube.
Key trial
Cook D, Guyatt G, Marshal l J, et al. A comparison of sucralfate and rani tidine for the prevention of upper
gastrointestinal bleeding in patients requiring mechanical  venti lation. Canadian Cri tical Care Trials Group. N Engl J
Med 1998; 338:791–7
See also:
Upper gastrointestinal endoscopy, p74; H2 blockers and proton pump inhibi tors, p218; Antacids, p222; Upper
gastrointestinal haemorrhage, p344; Bleeding varices, p346; Bowel  perforation and obstruction, p348
Antacids
Types
Sodium bicarbonate
Magnesium-based antacids: e.g. magnesium trisi l i cate
Aluminium-based antacids: e.g. aluminium hydroxide (Aludrox)
Proprietary combinations: e.g. Gaviscon
Modes of action
Neutralises gastric acid
Provides protective coating on upper gastrointestinal  mucosa
Uses
Symptomatic rel ief of gastritis, duodenit is, oesophagi tis
Stress ulcer prophylaxis (contentious)
Side-effects/complications
Possible increased risk of nosocomial pneumonia
Aluminium toxicity (i f aluminium-containing antacids are used long-term in patients with renal dysfunction)
Diarrhoea (magnesium-based antacids)
Constipation (aluminium-based antacids)
Metabol ic alkalosis i f large amounts are administered
Milk-alkal i syndrome result ing in hypercalcaemia, metabol ic alkalosis and renal fai lure is very rare
Notes
As their main use is for symptomatic rel ief,  antacids are rarely needed in mechanically venti lated patients.
Continual  nasogastric infusion of a weak sodium bicarbonate solution has been used successful ly in treating stress
ulcer-related haemorrhage.
Drug dosages
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Magnesium trisilicate 10–30ml qds
Aluminium hydroxide 10–30ml qds
Gaviscon 10–30ml qds
See also:
Upper gastrointestinal endoscopy, p74; H2 blockers and proton pump inhibi tors, p218; Sucralfate, p220; Upper
gastrointestinal haemorrhage, p344; Bleeding varices, p346; Bowel  perforation and obstruction, p348
Anti-emetics
Types
Phenothiazines: e.g. prochlorperazine, chlorpromazine
Benzamides: e.g. metoclopramide
Antihistamines: e.g. cycl izine
5HT3 receptor antagonists: e.g. ondansetron, granisetron
Modes of action
Phenothiazines increase the threshold for vomiting at the chemoreceptor trigger zone via central
DA2-dopaminergic blockade; at higher doses there may also be some effect on the vomiting centre.
Metoclopramide acts central ly and by increasing gastric moti l i ty.
The exact mechanism of cycl izine action is unknown. It increases lower oesophageal  sphincter tone and may
inhibi t the midbrain emetic centre.
Ondansetron is a highly selective 5HT3 receptor antagonist; its precise mode of action is unknown but may act
both central ly and peripherally.
Uses
Nausea
Vomiting
Side-effects/complications
Dystonic or dyskinetic reactions, oculogyric crises (prochlorperazine, metoclopramide)
Arrhythmias (metoclopramide, prochlorperazine)
Headaches, flushing (ondansetron)
Urticaria, drowsiness, dry mouth, blurred vision, urinary retention (cycl izine)
Postural hypotension (prochlorperazine, cycl izine)
Rarely, neuroleptic malignant syndrome (prochlorperazine, metoclopramide)
Notes
The init ial  choice should fal l between prochlorperazine, metoclopramide or cycl izine. Prochlorperazine and cycl izine
are preferable when vomiting is related to drugs and metabol ic disturbances acting at the chemoreceptor trigger zone
whi le metoclopramide should be tried fi rst i f a gastrointestinal  cause is implicated.
Metoclopramide and prochlorperazine dosage should be reduced in renal  and hepatic fai lure.
Ondansetron dosage should be reduced in hepatic fai lure.
Drug dosages
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Prochlorperazine 5–10mg tds PO, 12.5mg qds IM or by slow IV bolus (note: not licensed for IV
use)
Metoclopramide 10mg tds by slow IV bolus, IM or PO
Cyclizine 50mg tds slow IV bolus, IM or PO
Ondansetron 4–8mg tds by slow IV bolus, IM or PO
Granisetron 1–3mg by slow IV bolus up to max 9mg/24h
See also:
Enteral nutrit ion, p80; Vomiting/gastric stasis, p338
Gut motility agents
Types
Metoclopramide
Erythromycin
Modes of action
Metoclopramide probably acts by blocking peripheral  DA2-dopaminergic receptors
Erythromycin is a moti l in agonist acting on antral  enteric neurones
Uses
Ileus, large nasogastric aspirates
Vomiting
Side-effects/complications
Dystonic or dyskinetic reactions, oculogyric crises (metoclopramide)
Arrhythmias (metoclopramide and erythromycin)
Cholestatic jaundice (erythromycin)
Notes
Metoclopramide dosing should be reduced in renal  fai lure and hepatic fai lure, while erythromycin dosing should be
reduced in hepatic fai lure.
Drug dosages
Metoclopramide 10mg tds by slow IV bolus, IM or PO
Erythromycin 250mg qds PO or IV
See also:
Enteral nutrit ion, p80; Vomiting/gastric stasis, p338; Bowel perforation and obstruction, p348
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Antidiarrhoeals
Types
Loperamide
Codeine phosphate
Modes of action
Loperamide and codeine phosphate bind to gut wall  opiate receptors, reducing propulsive peristalsis and increasing
anal sphincter tone
Side-effects/complications
Abdominal  cramps, bloating
Constipation (i f excessive amounts given)
Notes
Should not be used when abdominal distension develops, particularly with ulcerative colit is or pseudomembranous
col it is, or as sole therapy in infective diarrhoea.
Caution with loperamide in l iver fai lure, and codeine in renal  fai lure.
Drug dosages
Loperamide 2 capsules (20ml) initially, then 1 capsule (10ml) after every loose stool for
up to 5 days
Codeine
phosphate
30–60mg 4–6hrly PO, IM or by slow IV bolus
See also:
Enteral nutrit ion, p80; Diarrhoea, p340
Anticonstipation agents
Types
Laxatives: e.g. lactulose, propanthel ine, mebeverine, castor oi l
Bulking agents: e.g. dietary fibre (bran), hemicelluloses (methylcellulose, ispaghula husk)
Suppositories: e.g. glycerine
Enemata: e.g. warmed normal saline, ol ive oi l or arachis oi l retention enemata
Modes of action
Laxatives include
antispasmodic agents such as antichol inergics (e.g. propantheline) and mebeverine (a phenylethylamine
derivative of reserpine)
i.
non-absorbable disaccharides (e.g. lactulose) which soften the stool  by an osmotic effect and by lactic acid
production from a bacterial fermenting effect
ii.
i rri tants, such as castor oi l,  which is hydrolysed in the smal l intestine releasing ricinoleic acidiii.
Bulking agents are hydrophi l ic and thus increase the water content of the stool.
Side-effects/complications
Bloating and abdominal  distension
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Diarrhoea if excessive amounts given
Notes
Surgical  causes presenting as constipation such as bowel  obstruction must be excluded. Other measures should be
taken if possible to improve bowel  function, e.g. reducing concurrent opiate dosage, starting enteral  nutri tion.
The agent of choice is lactulose.
Larger doses of lactulose are used in hepatic fai lure as the pH of the colonic contents is reduced; this lowers
formation and absorption of ammonium ions and other nitrogenous products into the portal circulation. Proven benefit
in patients has not been shown.
Anthraquinone glycosides (e.g. senna) and l iquid paraffin are no longer recommended for routine use.
Drug dosages
Lactulose 15–50ml tds PO
See also:
Enteral nutrit ion, p80; Failure to open bowels, p342
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Neurological Drugs
Opioid analgesics
Types
Natural opiates: e.g. morphine, codeine
Semisynthetic: e.g. diamorphine, dihydrocodeine
Synthetic: e.g. pethidine, fentanyl, al fentani l,  remifentani l
Uses
Analgesia. Strong analgesics are extracts from opium or synthetic substances with simi lar properties. They are
useful  for continuous pain rather than sharp, intermittent pain.
Sedation
Mild vasodilatation in heart fai lure (diamorphine, morphine)
Antidiarrhoeal  (codeine)
Routes
IV (morphine, diamorphine, papaveretum, pethidine, fentanyl, alfentani l, remifentani l)
IM/SC (morphine, codeine, diamorphine, dihydrocodeine, pethidine)
PO (morphine, codeine, diamorphine, dihydrocodeine, pethidine)
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Epidural (morphine, diamorphine, fentanyl, al fentani l)
Side-effects
Respiratory depression
Central  nervous system depression
Addiction (rare in the cri tical ly i l l )
Withdrawal syndrome (withdraw slowly)
Stimulation of the vomiting centre
Appeti te loss
Dry mouth
Decreased gastric emptying and gut moti l ity
Histamine release and itching
Increased muscular tone
Notes
Morphine is poorly absorbed from the gastrointestinal  tract and is therefore usually administered parenterally. It is
metabolised to morphine-6-glucuronide in the l iver which is six t imes more potent than morphine and accumulates in
renal fai lure.
Codeine is a weak analgesic but is favoured by some in head injury since i t is less sedative than morphine.
Pethidine has local anaesthetic properties associated with cardiac depression and vasodi latation. It is metabolised to
norpethidine which may lead to seizures on accumulation. Respiratory depression occurs despi te maintenance of
respiratory rate.
Fentanyl and al fentani l are good, short-acting analgesics with poor sedative qual ity. They cause severe respiratory
depression and muscular rigidity. Remifentanil is ul tra-short-acting and the patient may suffer from rebound pain if
the infusion is stopped temporari ly.
Drug dosages
Intravenous
 Bolus Infusion
Morphine 0.1–0.2mg/kg 0.05–0.07mg/kg/h
Diamorphine 0.05–0.1mg/kg 0.03–0.06mg/kg/h
Pethidine 0.5mg/kg 0.1–0.3mg/kg/h
Fentanyl 5–7.5µg/kg 5–20µg/kg/h
Alfentanil 15–30µg/kg 20–120µg/kg/h
Remifentanil 1µg/kg 0.05–2µg/kg/min
Other routes
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Morphine 10mg IM/SC 4-hrly 5–20mg PO 4-hrly
Codeine 30–60mg IM 4-hrly 30–60mg PO 4-hrly
Diamorphine 5mg IM/SC 4-hrly 5–10mg PO 4-hrly
Dihydrocodeine 50mg IM/SC 4–6-hrly 30mg PO 4–6-hrly
Pethidine 25–100mg IM/SC 4-hrly 50–150mg PO 4-hrly
Note that the above doses are a guide only and may need to be altered widely according to
individual circumstances. The correct dose of an opiate analgesic is generally enough to ablate
pain.
See also:
IPPV—failure to tolerate venti lation, p12; Non-opioid analgesics, p236; Sedatives, p238; Pain, p532; Post-operative
intensive care, p534
Non-opioid analgesics
Types
Non-steroidal  anti -inflammatory drugs: e.g. aspirin, indomethacin, diclofenac
Paracetamol
Ketamine
Nitrous oxide
Local anaesthetics: e.g. l idocaine, bupivacaine
Uses
Pain associated with inflammatory condi tions (aspirin, indomethacin, diclofenac)
Post-operative pain and musculoskeletal pain (aspirin, indomethacin, diclofenac, paracetamol, ketamine, ni trous
oxide, l idocaine, bupivacaine)
Opiate sparing effect (aspirin, indomethacin, diclofenac used with strong analgesics)
Antipyretic (aspirin, paracetamol)
Routes
IV (ketamine)
IM (diclofenac)
PO (aspirin, indomethacin, diclofenac, paracetamol)
PR (aspirin, diclofenac, paracetamol)
Local /regional  (l idocaine, bupivacaine)
Inhaled (nitrous oxide)
Side-effects
Gastrointestinal bleeding (aspirin, indomethacin, diclofenac)
Renal dysfunction (indomethacin, diclofenac if any hypovolaemia)
Reduced platelet aggregation (aspirin, indomethacin, diclofenac)
Reduced prothrombin formation (aspirin, indomethacin, diclofenac)
Myocardial  depression (l idocaine, bupivacaine)
Hypertension and tachycardia (ketamine)
Seizures (l idocaine, bupivacaine)
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
105 из 254 07.11.2006 1:04
P.237
P.238
Hal lucinations and psychotic tendencies (ketamine—prevented by concurrent use of benzodiazepines or
droperidol)
Notes
Paracetamol overdose can cause severe hepatic fai lure due to the effects of alkylating metaboli tes. Though normal ly
removed by conjugation with glutathione, stores are rapidly depleted in overdose.
Non-steroidal anti -inflammatory agents should be generally avoided in patients with renal dysfunction, GI bleeding or
coagulopathy.
Ketamine is a derivative of phencycl idine used as an intravenous anaesthetic agent. In subanaesthetic doses it is a
powerful analgesic. It has several advantages over opiates in that it is associated with good ai rway maintenance,
allows spontaneous respiration and provides cardiovascular stimulation. It is also a bronchodi lator.
Nitrous oxide is a powerful , short acting analgesic used to cover short, painful  procedures. It may be useful when
del ivered via an intermittent posit ive pressure breathing system as an adjunct to chest physiotherapy. Nitrous oxide
should not be used in cases of undrained pneumothorax since i t may diffuse into the pneumothorax result ing in
tension.
Drug dosages
Aspirin 600mg PO/PR 4-hrly
Indomethacin 50–100mg PO/PR 12-hrly
Diclofenac 25–50mg PO 8-hrly, 100mg PR 12–24-hrly, 75mg IM 12-hrly
Ketorolac 10mg PO 4–6-hrly, 10–30mg IV, IM 4–6-hrly
Sulindac 200mg PO 12-hrly
Paracetamol 0.5–1g PO/PR 4–6-hrly
Ketamine 5–25µg/kg/min IV
Lidocaine Maximum 200mg
Bupivicaine Maximum 150mg*
*Local anaesthetic doses vary according to the area to be anaesthetised. Maximum doses may be
increased if epinephrine is used locally.
See also:
Opioid analgesics, p234; Sal icylate poisoning, p454; Rheumatic disorders, p492; Pyrexia (1), p518; Pyrexia (2),
p520; Pain, p532; Post-operative intensive care, p534
Sedatives
Types
Benzodiazepines: e.g. diazepam, midazolam, lorazepam
Major tranqui l l isers: e.g. chlorpromazine, haloperidol
Anaesthetic agents: e.g. propofol,  isoflurane
α2 agonists e.g. clonidine, dexmedetomidine
Uses
Sedation and anxiolysis
Routes
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IV (diazepam, midazolam, lorazepam, chlorpromazine, haloperidol , propofol, clonidine, dexmedetomidine)
IM (diazepam, chlorpromazine, haloperidol)
PO (diazepam, lorazepam, chlorpromazine, haloperidol , clonidine)
Inhaled (isoflurane)
Side-effects
Hypotension (diazepam, midazolam, chlorpromazine, haloperidol , propofol,  clonidine, dexmedetomidine)
Respiratory depression (diazepam, midazolam, chlorpromazine, haloperidol , propofol)
Arrhythmias (chlorpromazine, haloperidol)
Dry mouth (clonidine, dexmedetomidine)
Extrapyramidal disorder (chlorpromazine, haloperidol)
Fluoride toxici ty (isoflurane)
Notes
Sedation is necessary for most ICU patients. Whi le the appropriate use of sedative drugs can provide comfort, most
have cardiovascular and respiratory side-effects. Objective assessment of the depth of sedation is necessary to
ensure that comfort does not give way to excessively and dangerously deep levels of sedation. All  sedatives are
potential ly cumulative so doses must be kept to a minimum.
Benzodiazepines have the advantage of being amnesic. Diazepam is mainly administered as an emulsion in intralipid
as organic solvents are extremely irri tant to veins. Midazolam is shorter acting than diazepam although 10% of
patients are slow metabolisers. All  benzodiazepines accumulate in renal  fai lure; care must be taken to avoid
excessive dosage by regular reassessment of need. Some patients suffer unpredictable severe respiratory depression
with hypotension.
Propofol used in subanaesthetic doses is short-acting though effects are cumulative when infusions are prolonged or
with coexisting hepatic or renal  fai lure. It is given as an emulsion in 10% intral ipid so large volumes may contribute
signi ficantly to calorie intake.
As chlorpromazine and haloperidol antagonise catecholamines, they may cause vasodilatation and hypotension.
Dystonic reactions and arrhythmias are also occasionally seen.
α2 antagonists also provide analgesia and are synergistic with opiates. Dexmedetomidine causes minimal respiratory
depression and the patient is easily rousable. Bradycardia and hypotension may occur, especial ly with the loading
dose.
Isoflurane is largely exhaled unchanged and is therefore short acting. Cumulative effects have been recorded with
prolonged use, carrying the theoretical risk of fluoride toxicity. Exhaled isoflurane should be scavenged.
Drug dosages
 Bolus Infusion
Diazepam 0.05–0.15mg/kg Excessive half-life
Midazolam 50µg/kg 10–50µg/kg/h
Lorazepam 1mg PRN  
Propofol 0.5–2mg/kg 1–3mg/kg/h
Chlorpromazine 12.5–100mg Excessive half-life
Clonidine  100–150µg/min
Dexmedetomidine  Loading infusion of 6.0µg/kg/h over 10min, followed bymaintenance infusion of 0.2–0.7µg/kg/h.
Note that the above doses are a guide only and may need to be altered widely according to
individual circumstances.
Monitoring sedation
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Frequent, objective reassessment of sedation depth with corresponding adjustment of infusion doses is necessary to
avoid severe cardiovascular and respiratory depression. Simple sedation scores are available to aid assessment.
UCL Hospitals Sedation Score
Agitated and restless +3
Awake and uncomfortable +2
Aware but calm +1
Roused by voice, remains calm 0
Roused by movement -1
Roused by painful or noxious stimuli -2
Unrousable -3
Natural sleep A
Sedation doses are adjusted to achieve a score as close as possible to 0. Posit ive scores require increased sedation
doses and negative scores require reduced sedation doses.
See also:
IPPV—failure to tolerate venti lation, p12; Opioid analgesics, p234; Agitation/confusion, p370; Sedative poisoning,
p458; Post-operative intensive care, p534
Muscle relaxants
Types
Depolarising: e.g. suxamethonium
Non-depolarising: e.g. pancuronium, atracurium, vecuronium
Mode of action
Suxamethonium is structural ly related to acetylcholine and causes initial  st imulation of muscular contraction
seen cl inically as fasciculation. During this process, the continued stimulation leads to desensi tisation of the
post-synaptic membrane of the neuromuscular junction with efflux of potassium ions. Subsequent flaccid
paralysis is short acting (2–3min) and cannot be reversed (is actually potentiated) by anticholinesterase drugs.
Prolonged effects are seen where there is congeni tal  or acquired pseudocholinesterase deficiency.
Non-depolarising muscle relaxants prevent acetylcholine from depolarising the post-synaptic membrane of the
neuromuscular junction by competi tive blockade. Reversal of paralysis is achieved by antichol inesterase drugs
such as neostigmine. They have a slower onset and longer duration of action than the depolarising agents.
Uses
To faci l i tate endotracheal intubation.
To faci l i tate mechanical  venti lat ion where optimal sedation does not prevent patient interference with the
function of the venti lator.
Routes
IV
Side-effects
Hypertension (suxamethonium, pancuronium)
Bradycardia (suxamethonium)
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Tachycardia (pancuronium)
Hyperkalaemia (suxamethonium)
Notes
Modern intensive care practice and developments in venti lator technology have rendered the use of muscle relaxants
less common. Furthermore, i t i s rarely necessary to ful ly paralyse muscles to faci l itate mechanical venti lation.
Requirement for muscle relaxants should be reassessed frequently. Ideally, relaxants should be stopped
intermittently to al low depth of sedation to be assessed. If mechanical venti lation proceeds smoothly when relaxants
have been stopped they probably should not be restarted.
Suxamethonium is contraindicated in spinal neurological  disease, hepatic disease and for 5–50 days after burns.
Atracurium is non-cumulative and popular for infusion. Non-enzymatic (Hoffman) degradation al lows clearance
independent of renal or hepatic function, although effects are prolonged in hypothermia.
Drug dosages
 Bolus Infusion
Suxamethonium 50–100mg 2–5mg/min
Pancuronium 4mg 1–4mg/h
Atracurium 25–50mg 25–50mg/h
Vecuronium 5–7mg Excessive half-life
See also:
IPPV—failure to tolerate venti lation, p12; Endotracheal  intubation, p36; Sedatives, p238; Post-operative intensive
care, p534
Anticonvulsants
Types
Benzodiazepines: e.g. lorazepam, diazepam, clonazepam
Phenytoin
Carbamazepine
Sodium valproate
Magnesium sulphate
Thiopental
Uses
Control  of status epilepticus
Intermittent seizure control
Myoclonic seizures (clonazepam, sodium valproate)
Routes
IV (lorazepam, diazepam, clonazepam, phenytoin, sodium valproate, magnesium sulphate, thiopental)
PO (diazepam, clonazepam, phenytoin, carbamazapine, sodium valproate)
PR (diazepam)
Side-effects
Sedation (benzodiazepines, thiopentone)
Respiratory depression (benzodiazepines, thiopentone)
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Nausea and vomiting (phenytoin, sodium valproate)
Ataxia (phenytoin, carbamazapine)
Visual  disturbance (phenytoin, carbamazapine)
Hypotension (diazepam, thiopentone)
Arrhythmias (phenytoin, carbamazapine)
Pancreati tis (thiopentone)
Hepatic fai lure (sodium valproate)
Notes
Common insul ts causing seizures include cerebral ischaemic damage, space occupying lesions, drugs or drug/alcohol
withdrawal, metabolic encephalo-pathy (including hypoglycaemia), and neurosurgery. Anticonvulsants provide control
of seizures but do not replace removal of the cause where this is possible.
Onset of seizure control may be delayed by up to 24h with phenytoin but a loading dose is usually given during the
acute phase of seizures.
Magnesium sulphate is especial ly useful in eclamptic seizures (and in their prevention).
Phenytoin has a narrow therapeutic range and a non-l inear relationship between dose and plasma levels. It is
therefore essential to monitor plasma levels frequently. Enteral feeding should be stopped temporari ly while oral
phenytoin is administered. Intravenous use should only occur i f the ECG is monitored continuously.
Carbamazepine has a wider therapeutic range than phenytoin and there is a l inear relationship between dose and
plasma levels. It is not, therefore, crit ical to monitor plasma levels frequently.
Plasma concentrations of sodium valproate are not related to effects so monitoring of plasma levels is not useful.
Intravenous drug dosages
 Bolus Infusion
Lorazepam 4mg  
Diazepam 2.5mg repeated to 20mg  
Phenytoin 18mg/kg at <50mg/min 100mg 8hrly
Magnesium sulphate 20mmol over 10–20min 5–10mmol/h
Sodium valproate 400–800mg  
Clonazepam 1mg 1–2mg/h
Thiopental 1–3mg/kg Lowest possible dose
Key trial
Treiman VA for the Veterans Affai rs Status Epilepticus Cooperative Study Group. A comparison of four treatments
for generalized convulsive status epilepticus. N Engl  J Med 1998; 339:792–8
Magpie Trial  Col laboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium
sulphate? The Magpie Trial: a randomised placebo-controlled trial.  Lancet 2002; 359:1877–90
Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995;
345:1455–63
Neuroprotective agents
Types
Diuretics: e.g. mannitol , furosemide (frusemide)
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Steroids: e.g. dexamethasone
Calcium antagonists: e.g. nimodipine
Barbiturates: e.g. thiopental
Uses
Reduction of cerebral oedema (mannitol , furosemide, dexamethasone)
Prevention of cerebral  vasospasm (nimodipine)
Reduction of cerebral metabolic rate (thiopental)
Routes
IV
Notes
Cerebral protection requires generalised sedation and aboli tion of seizures to reduce cerebral  metabolic rate, cerebral
oedema and neuronal  damage during ischaemia and reperfusion.
Mannitol reduces cerebral intersti tial water by the osmotic load. The effect is transient and at i ts best where the
blood–brain barrier is intact. Intersti tial water is mainly reduced in normal areas of brain and this may accentuate
cerebral  shift. Repeated doses accumulate in the interstitium and may eventual ly increase oedema formation;
mannitol should only be given 4–5 times in 48h. In addition to its osmotic effect, there is some evidence of cerebral
vasoconstriction due to a reduction in blood viscosity and free radical  scavenging.
The loop diuretic effect of furosemide encourages salt and water loss. There may also be a reduction of CSF chloride
transport reducing the formation of CSF.
Dexamethasone reduces oedema around space occupying lesions such as tumours. Steroids are not currently
considered useful  in head injury or after a cerebrovascular accident but benefit has been shown if given early after
spinal  injury. Steroids encourage salt and water retention and must be withdrawn slowly to avoid rebound oedema.
Nimodipine is used to prevent cerebral  vasospasm during recovery from cerebrovascular insults. As a calcium channel
blocker i t also prevents calcium ingress during neuronal injury. This calcium ingress is associated with cel l death. It
is commonly used in the management of subarachnoid haemorrhage for 5–14 days.
Thiopental reduces cerebral metabol ism thus prolonging the time that the brain may sustain an ischaemic insul t.
However, it also reduces cerebral  blood flow, al though blood flow is redistributed preferential ly to ischaemic areas.
Thiopental acutely reduces intracranial pressure and this is probably the main cerebroprotective effect. Seizure
control is a further benefi t.  Despi te these effects, barbiturate coma has not been shown to improve outcome in
cerebral  insul ts of various causes.
Drug dosages
 Bolus Infusion
Mannitol 20–40g 6-hrly  
Furosemide  1–5mg/h
Dexamethasone 4mg 6-hrly  
Nimodipine  0.5–2.0mg/h
Thiopental 1–3mg/kg Lowest possible dose
Key trials
Al len GS et al . Cerebral arterial spasm—a control led trial  of nimodipine in patients with subarachnoid hemorrhage. N
Engl J Med 1983; 308:619–24
Bracken MB, et al.  Administration of methylprednisolone for 24 or 48 hours or ti ri lazad mesylate for 48 hours in the
treatment of acute spinal cord injury. Results of the Third National  Acute Spinal Cord Injury Randomized Controlled
Trial . National Acute Spinal  Cord Injury Study. JAMA 1997; 277:1597–604
See also:
Intracranial pressure monitoring, p134; Jugular venous bulb saturation, p136; EEG/CFM monitoring, p138; Other
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p376; Subarachnoid haemorrhage, p378; Raised intracranial  pressure, p382; Head injury (1), p504; Head injury (2),
p506
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Haematological Drugs
Anticoagulants
Types
Heparin
Low molecular weight (LMW) heparin: e.g. dal teparin, enoxiparin
Anticoagulant prostanoids: e.g. epoprostenol, alprostadi l
Sodium ci trate
Warfarin
Activated Protein C
Modes of action
Heparin potentiates natural ly occurring AT-III, reduces the adhesionof platelets to injured arterial  wal ls, binds to
platelets and promotes in vitro aggregation.
LMW heparin appears to speci fical ly influence factor Xa activi ty; its simpler pharmacokinetics al low for a smaller
(two thirds) dose to be administered to the same effect.
The effects of the prostanoids depend on the balance betweenTXA2 and PGI2.
Sodium ci trate chelates ionised calcium.
Warfarin produces a control led deficiency of vitamin K dependent coagulation factors (II, VII, IX and X).
Activated Protein C is the activated form of the endogenous anticoagulant, Protein C
Uses
Maintenance of an extracorporeal circulation
Prevention or treatment of thromboembolism
Severe sepsis (activated Protein C)
Routes
IV (heparins, anticoagulant prostanoids, sodium ci trate, activated Protein C, AT-III)
SC (heparins)
PO (warfarin)
Side-effects
Bleeding
Hypotension (anticoagulant prostanoids)
Heparin induced thrombocytopenia
Hypocalcaemia and hypernatraemia (sodium ci trate)
Notes
Alprostadil  has simi lar effects to epoprostani l but is less potent. As i t i s metabol ised in the lungs, systemic
vasodi latation effects are usually minimal . This may be an important advantage in the shocked patient. Major uses in
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intensive care are for anticoagulation of fi l ter circui ts, digital  vascul it is/ischaemia and pulmonary hypertension.
For extracorporeal  use citrate has advantages over heparin in that it has no known antiplatelet activi ty, is readi ly
fi l tered by a haemofi lter (reducing systemic anticoagulation), and is overwhelmed and neutral ised when returned to
central venous blood.
Warfarin is given orally and needs 48–72h to develop i ts effect. It can be reversed by fresh frozen plasma or low
doses (1mg) of vitamin K.
Activated Protein C has anti-inflammatory and pro-fibrinolytic properties in addit ion to its anticoagulant actions.
Drug dosages
Heparin
Dose requirement is variable to produce an APTT of 1.5–3 times control. This usually requires 500–2000IU/h with an
ini tial loading dose of 3000–5000IU.
Low molecular weight heparin
For deep vein thrombosis prophylaxis give 2500IU SC 12-hrly. For anticoagulation of an extracorporeal circui t a bolus
of 35IU/kg is given IV fol lowed by an infusion of 13IU/kg. The dose is adjusted to maintain anti-factor Xa activi ty at
0.5–1IU/ml (or 0.2–0.4IU/ml if there is a high risk of haemorrhage).
For pulmonary embol ism give 200IU/kg SC dai ly (or 100IU/kg bd if at risk of bleeding)
Anticoagulant prostaglandins
Usual range of 2.5–10ng/kg/min. If used for an extracorporeal  ci rculation the infusion should be started 30min prior
to commencement.
Sodium citrate
Infused at 5mmol per l itre of extracorporeal blood flow.
Warfarin
Start at 10mg/day orally for 2 days then 1–6mg/day according to INR. For DVT prophylaxis, pulmonary embolus,
mitral stenosis, atrial  fibri l lat ion and tissue valve replacements the INR should be maintained between2 and 3. For
recurrent DVT or pulmonary embolus and mechanical valve replacements the INR should be kept between 3 and 4.5.
Activated Protein C (Drotrecogin α activated)
For sepsis, an infusion of 24 µg/kg/h is given for 96h.
See also:
Extracorporeal  respiratory support, p34; Haemo(dia)fi ltration (2), p64; Plasma exchange, p68; Coagulation
monitoring, p156; Thrombolytics, p250; Pulmonary embolus, p308; Acute coronary syndrome (1), p320; Acute
coronary syndrome (2), p322; Clotting disorders, p398; Hyperosmolar diabetic emergencies, p444; Sepsis and septic
shock—treatment, p248; Post-operative intensive care, p534
Thrombolytics
Types
Alteplase (rt-PA)
Streptokinase
Urokinase
Modes of action
Activate plasminogen to form plasmin which degrades fibrin
Uses
Life threatening venous thrombosis
Life threatening pulmonary embolus
Acute myocardial infarction
To unblock indwell ing vascular access catheters
Routes
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IV
Side-effects
Bleeding, particularly from invasive procedures
Hypotension and arrhythmias
Embolisation from pre-existing clot as it is broken down
Anaphylactoid reactions (anistreplase, streptokinase, urokinase)
Contraindications (absolute)
Cerebrovascular accident in last 2 months
Active bleeding in last 10 days
Pregnancy
Recent peptic ulceration
Recent surgery
Contraindications (relative)
Systol ic BP >200mmHg
Aortic dissection
Prol iferative diabetic retinopathy
Notes
In acute myocardial infarction they are of most value when used within 12h of the onset. They may require adjuvant
therapy (e.g. aspirin with streptokinase or heparin with rt-PA) to maximise the effect in acute myocardial infarction.
rt-PA is said to be clot selective and is therefore useful where a need for invasive procedures has been identi fied.
Anaphylactoid reactions to streptokinase are not uncommon, particularly in those who have had streptococcal
infections, and patients should not be exposed twice between 5 days and 1 year of receiving the last dose.
Drug dosages
Alteplase
(rt-PA)
The dose schedule for acute myocardial infarction is 10mgin 1–2min, 50mg in 1h
and 40mg over 2h intravenously.
Anistreplase Single intravenous injection of 30U over 4–5min.
Streptokinase In acute myocardial infarction (1.5mu over 60min).In severe venous thrombosis
(250,000U over 30min followed by 100,000U/h for 24–72h).
Urokinase For unblocking indwelling vascular catheters 5000–37,500IU are instilled.
For thromboembolic disease 4400IU/kg is given over 10min followed by
4400IU/kg/h for 12–24h.
See also:
Coagulation monitoring, p156; Coagulants and anti fibrinolytics, p254; Pulmonary embolus, p308; Acute coronary
syndrome (1), p320
Blood products
Types
Plasma: e.g. fresh frozen plasma
Platelets
Concentrates of coagulation factors: e.g. cryoprecipitate, factor VIII concentrate, factor IX complex
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Uses
Vitamin K deficiency (fresh frozen plasma, factor IX complex)
Haemophil ia (cryoprecipi tate)
von Wil lebrand's disease (cryoprecipitate)
Fibrinogen deficiency (cryoprecipitate)
Christmas disease (factor IX complex)
Routes
IV
Notes
A uni t (150ml) of fresh frozen plasma is usually collected from one donor and contains al l  coagulation factors
including 200 uni ts factor VIII, 200 uni ts factor IX and 400mg fibrinogen. Fresh frozen plasma is stored at -30°C and
should be infused within 2h once defrosted.
Platelet concentrates are viable for 3 days when stored at room temperature. If they are refrigerated viabil ity
decreases. They must be infused quickly via a short giving set with no fi lter. Indications for platelet concentrates
include platelet count <10 × 109, or <50 × 109 with spontaneous bleeding, or to cover invasive procedures and
spontaneous bleeding with platelet dysfunction. They are less useful in condi tions associated with immune platelet
destruction (e.g. ITP).
A 15ml vial  of cryoprecipi tate contains 100 uni ts factor VIII, 250mg fibrinogen, factor XIII and von Wi l lebrand factor
and is stored at -30°. In haemophil ia, cryoprecipi tate is given to achieve a factor VIII level >30% of normal.
Factor VIII concentrate contains 300 units factor VIII per vial.  In severe haemorrhage due to haemophi l ia 10–15
units/kg are given 12-hrly.
Factor IX complex is rich in factors II, IX and X. It is formed from pooled plasma so fresh frozen plasma is preferred.
See also:
Coagulation monitoring, p156; Blood transfusion, p182; Anticoagulants, p248; Bleeding disorders, p396; Clotting
disorders, p398; Post-operative intensive care, p534; Post-partum haemorrhage, p542
Coagulants and antifibrinolytics
Types
Vitamin K
Protamine
Tranexamic acid
Activated factor VII (F VIIa)
Uses
To reverse a prolonged prothrombin time, e.g. malabsorption, oral anticoagulant therapy, β lactam antibiotics or
cri tical  i l lness (vi tamin K)
To reverse the effects of heparin (protamine)
Bleeding from raw surfaces, e.g. prostatectomy, dental extraction (tranexamic acid)
Bleeding from thrombolytics (tranexamic acid)
Bleeding from major trauma or haemophil ia (F VIIa)
Routes
IV (vi tamin K, protamine, tranexamic acid, F VIIa)
PO (vitamin K, tranexamic acid)
Notes
The effects of vitamin K are prolonged so i t should be avoided where patients are dependent on oral anticoagulant
therapy. A dose of 10mg is given oral ly or by slow intravenous injection daily. In l i fe threatening haemorrhage
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5–10mg is given by slow intravenous injection with other coagulation factor concentrates. If INR >7 or in less severe
haemorrhage 0.5–2mg may be given by slow intravenous injection with minimum lasting effect on oral anticoagulant
therapy.
Protamine has an anticoagulant effect of its own in high doses. Protamine 1mg neutral ises 100IU unfractionated
heparin i f given within 15min. Less is required i f given later since heparin is excreted rapidly. Protamine should be
given by slow intravenous injection according to the APTT. Total dose should not exceed 50mg. Protamine injection
may cause severe hypotension
Tranexamic acid has an anti fibrinolytic effect by antagonising plasminogen. The usual dose is 1–1.5g 6–12-hrly orally
or by slow intravenous injection.
Recombinant factor VIIa is l i censed for use in haemophil ia but a number of case series in major trauma, orthopaedic
and cardiac surgery report benefi t in severe, intractable bleeding that had not responded to standard measures. The
dose is 4500IU/kg over 2–5min, fol lowed by 3000–6000IU/kg depending on the severity of bleeding.
See also:
Coagulation monitoring, p156; Anticoagulants, p248; Thrombolytics, p250; Aprotinin, p256; Bleeding disorders, p396;
Clotting disorders, p398; Post-operative intensive care, p534;Post-partum haemorrhage, p542
Aprotinin
The role of serine protease inhibitors in coagulation and anticoagulation is compl icated due to their effects at various
points in the coagulation pathway. Aprotinin is a naturally occurring, non-specific serine protease inhibitor with an
elimination half-l i fe of about 2h. Prevention of systemic bleeding with aprotinin does not promote coagulation within
the extracorporeal  ci rculation and may even contribute to the maintenance of extracorporeal anticoagulation.
Modes of action
The effects of aprotinin on the coagulation cascade are dependent on the circulating plasma concentrations
(expressed as kall ikrein inactivation uni ts—kIU/ml) since the affini ty of aprotinin for plasmin is significantly greater
than that for plasma kal l ikrein. At a plasma level of 125kIU/ml aprotinin inhibi ts fibrinolysis and complement
activation. Inhibition of plasma kal l ikrein requires higher doses to provide plasma levels of 250–500kIU/ml.
Plasma kal l ikrein inhibi tion—reduces blood coagulation mediated via contact wi th anionic surfaces and, in the
cri tical ly i l l  patient, improves circulatory stabil ity via reduced kinin activation.
Prevention of inappropriate platelet activation—neutrophi l activation (complement or kall ikrein mediated) causes
a secondary activation of platelets. Important in this platelet–neutrophil  interaction is the release of Cathepsin
G by neutrophil  degranulation. It has been demonstrated recently that aprotinin can signi ficantly inhibi t the
platelet activation due to purified Cathepsin G, this mechanism forming a direct inhibition of inappropriate
neutrophi l mediated platelet activation.
Uses
The main role of aprotinin in the management of the extracorporeal circulation has been to prevent bleeding
associated with heparinisation. High dose aprotinin given during cardiopulmonary bypass procedures has been
shown to reduce post-operative blood loss dramatical ly.
Drug dosages
Aprotinin—loading dose of 2 × 106kIU followed by 500,000kIU/h
See also:
Extracorporeal  respiratory support, p34; Haemo(dia)fi ltration (2), p64; Anticoagulants, p248; Post-operative
intensive care, p534
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Miscellaneous Drugs
Antimicrobials
Types
Penici l l ins: e.g. benzylpenici l l in, flucloxaci l l in, piperaci l l in, ampici l l in
Cephalosporins: e.g. cefotaxime, ceftazidime, cefuroxime
Carbapenems: e.g. imipenem, meropenem
Aminoglycosides: e.g. gentamicin, amikacin, tobramycin
Quinolones: e.g. ciprofloxacin
Glycopeptides: e.g. teicoplanin, vancomycin
Macrol ides: e.g. erythromycin, clari thromycin
Other antibacterials:. e.g. cl indamycin, metronidazole, l inezolid, co-trimoxazole, ri fampicin
Antifungals: e.g. amphotericin, f lucytosine, fluconazole, caspofungin, voriconazole, i traconazole
Antivi rals: e.g. aciclovir, ganciclovi r
Uses
Treatment of infection.
Prophylaxis against infection, e.g. peri-operatively
Local choice of antimicrobial varies. However, as a guide, the fol lowing choices are common:
Pneumonia (hospi tal-acquired Gram negative)—ceftazidime, ciprofloxacin, meropenem or piperacil l in/tazobactam
(piptazobactam)
Pneumonia (community-acquired)—cefuroxime + clari thromycin
Systemic sepsis—cefuroxime ± gentamicin (+ metronidazole i f anaerobes l ikely)
Routes
Generally IV in crit ical ly i l l  patients.
Side-effects
Hypersensitivity reactions (al l)
Seizures (high dose penici l l ins, high dose metronidazole, ciprofloxacin)
Gastrointestinal disturbance (cephalosporins, erythromycin, cl indamycin, teicoplanin, vancomycin,
co-trimoxazole, ri fampicin, metronidazole, ciprofloxacin, amphotericin, flucytosine)
Vestibular damage (aminoglycosides)
Renal fai lure (aminoglycosides, teicoplanin, vancomycin, ciprofloxacin, ri fampicin, amphotericin, aciclovi r)
Erythema multiforme (co-trimoxazole)
Leucopenia (co-trimoxazole, metronidazole, teicoplanin, ciprofloxacin, f lucytosine, aciclovi r)
Thrombocytopenia (l inezol id)
Peripheral neuropathy (metronidazole)
Notes
Antimicrobials should be chosen according to microbial sensi tivities, usual ly based on advice from the microbiology
laboratory.
Appropriate empiric therapy for serious infections should be determined by l ikely organisms, taking into account
known community and hospi tal  infection and resistance patterns.
Up to 10% of penici l l in-allergic patients are also cephalosporin-allergic.
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Drug dosages (intravenous)
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Benzylpenicillin 1.2g 6-hrly (2-hrly for pneumococcal pneumonia)
Flucloxacillin 500mg–2g 6-hrly
Ampicillin 500mg–1g 6-hrly
Piptazobactam 4.5g 6–8-hrly
Cefotaxime 1–4g 8-hrly
Ceftazidime 2g 8-hrly
Ceftriaxone 1–4g daily
Cefuroxime 750mg–1.5g 8-hrly
Gentamicin 1.5mg/kg stat then by levels (usually 80mg 8-hrly)
Amikacin 7.5mg/kg stat then by levels (usually 500mg 12-hrly)
Tobramycin 5mg/kg stat then by levels (usually 100mg 8-hrly)
Erythromycin 500mg–1g 6–12-hrly
Metronidazole 500mg 8-hrly or 1g 12-hrly PR
Clindamycin 300–600mg 6-hrly
Ciprofloxacin 200–400mg 12-hrly
Co-trimoxazole 960mg 12-hrly in Pneumocystis carinii pneumonia
Imipenem 1–2g 6–8-hrly
Meropenem 500mg–1g 8-hrly
Rifampicin 600mg daily
Teicoplanin 400mg 12-hrly for 3 doses then 400mg daily
Vancomycin 500mg 6-hrly (monitor levels)
Linezolid 600mg 12-hrly
Chloramphenicol 1–2g 6-hrly
Amphotericin 250µg–1mg/kg daily
Flucytosine 25–50mg/kg 6-hrly
Fluconazole 200–400mg daily
Caspofungin 70mg stat then 50–70mg daily
Voriconazole 400mg 12-hrly on first day then 200–300mg 12-hrly
Itraconazole 200mg 12-hrly for 2 days then 200mg daily
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Common choices for specific organisms
Staph. aureus flucloxacillin
Methicillin-resistant Staph.
aureus
teicoplanin, vancomycin, linezolid
Strep. pneumoniae cefuroxime, benzylpenicillin
N. meningitidis ceftriaxone, cefotaxime, benzylpenicillin
H. influenzae cefuroxime, cefotaxime
E. coli ampicillin, ceftazidime, ciprofloxacin, gentamicin, ciprofloxacin,
gentamicin, imipenem, meropenem
Klebsiella spp. ceftazidime, ciprofloxacin, gentamicin, imipenem, meropenem
Ps. aeruginosa ceftazidime, ciprofloxacin, gentamicin, imipenem, meropenem,
piptazobactam
Steroids
Uses
Anti-inflammatory—steroids are often given in high dose for their anti-inflammatory effect, e.g. asthma, allergic
and anaphylactoid reactions, vasculi tic disorders, rheumatoid arthritis, inflammatory bowel  disease,
neoplasm-related cerebral  oedema, the fibro-proli ferative phase of ARDS, pneumococcal  meningit is,
pneumocystis pneumonia, laryngeal oedema (e.g. after repeated intubation) and after spinal cord injury. Benefi t
is unproved as yet in cerebral  oedema fol lowing head injury or cardiorespiratory arrest, and may be harmful in
cerebral malaria and sepsis (at high dose).
A multicentre trial has shown improved outcomes with ‘ low dose’ hydrocortisone (50mg qds for one week) in
septic shock patients with depressed adrenal function (subnormal plasma cortisol  response to ACTH, often
despite ‘normal ’ or raised plasma levels). Some patients with hypotension not responding to catecholamines wil l
improve with corticosteroid therapy.
Replacement therapy is needed for patients with Addison's disease and after adrenalectomy or pituitary surgery.
In the longer term, fludrocortisone is usual ly required in addition for its mineralocorticoid sodium-retaining
effect. Higher replacement doses are needed in chronic steroid takers (i .e. >2 weeks within the last year)
undergoing a stress, e.g. surgery, infection.
Immunosuppressive—after organ transplantation
Side-effects/complications
Sodium and water retention (especial ly with mineralocorticoids)
Hypoadrenal crisis if stopped abruptly after prolonged treatment
Immunosuppressive—possibly increased infection risk (q.v.)
Neutrophi l ia
Impaired glucose tolerance/diabetes mel l itus
Hypokalaemic alkalosis
Osteoporosis, proximal myopathy (long-term use)
Increased susceptibi l ity to peptic ulcer disease and GI bleeding
Notes
The perceived heightened risk of systemic infection appears exaggerated. Chronic steroid users general ly appear no
more affected than the general population; studies in ARDS and sepsis revealed no greater incidence of infection
post-steroid administration. Oral fungal  infection is relatively common with inhaled steroids but systemic and
pulmonary fungal infection is predominantly seen in the severely immunocompromised (e.g. AIDS,
post-chemotherapy) and not those taking high-dose steroids alone.
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The choice of corticosteroid for short-term anti-inflammatory effect is probably irrelevant provided the dose is
sufficient. Chronic hydrocortisone should be avoided for anti-inflammatory use because of its mineralocorticoid effect
but is appropriate for adrenal  replacement.
Prednisone and cortisone are inactive unti l metabolised by the l iver to prednisolone and hydrocortisone respectively.
Glucocorticoids antagonise the effects of antichol inesterase drugs.
Steroids are probably not l ikely to cause critical i l lness myopathy though this remains a contentious issue.
Relative potency and activity
Drug Glucocorticoid
activity
Mineralocorticoid
activity
Equivalent
anti-inflammatory dose
(mg)
Cortisone ++ ++ 25
Dexamethasone ++++ — 0.75
Hydrocortisone ++ ++ 20
Methylprednisolone +++ + 4
Prednisolone +++ + 5
Prednisone +++ + 5
Fludrocortisone + ++++ —
Drug dosages
Drug Replacement dose Anti-inflammatory dose
Dexamethasone — 4–20mg tds IV
Hydrocortisone 20–30mg daily 100–200mg qds IV
Methylprednisolone — 500mg–1g IV daily
Prednisolone 2.5–15mg mane 40–60mg od PO
Fludrocortisone 0.05–0.3mg daily —
Weaning
Acute use (<3–4 days) can stop immediately
Short-term use ≥3–4 days) wean over 2–5 days
Medium-term use (weeks) wean over 1–2 weeks
Long-term use (months/years) wean slowly (months to years)
Key papers
Annane D, Sebil le V, Charpentier C et al . Effect of treatment with low doses of hydrocortisone and fludrocortisone
on mortali ty in patients with septic shock. JAMA 2002; 288:862–71
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Bracken MB, et al. Administration of methylprednisolone for 24 or 48 hours or tiri lazad mesylate for 48 hours in
the treatment of acute spinal cord injury. Results of the Third National  Acute Spinal Cord Injury Randomized
Control led Trial. National Acute Spinal Cord Injury Study. JAMA 1997; 277:1597–604
Prasad K, Garner P. Steroids for treating cerebral malaria. Cochrane Database Syst Rev 2000; (2):CD000972.
Review.
de Gans J, van de Beek D; European Dexamethasone in Adulthood Bacterial  Meningit is Study Investigators.
Dexamethasone in adults with bacterial meningi tis. N Engl  J Med 2002; 347:1549–56
van de Beek D, et al . Corticosteroids in acute bacterial meningitis. Cochrane Database Syst Rev 2003;
(3):CD004305. Review.
Prostaglandins
Types
Epoprostenol  (prostacycl in, PGI2)
Alprostadil  (PGE1)
Modes of action
Stimulate adenyl cyclase thus increasing platelet cAMP concentration; this inhibits phospholipase and
cycloxygenase and thus reduces platelet aggregation (epoprostenol is the most potent inhibi tor known)
Reduces platelet procoagulant activi ty and release of heparin neutral ising factor
May have a fibrinolytic effect
Pulmonary and systemic vasodilator by relaxation of vascular smooth muscle
Uses
Anticoagulation, particularly for extracorporeal circui ts, ei ther as a substitute or in addit ion to heparin
Pulmonary hypertension
Microvascular hypoperfusion (including digital vascul it is)
Haemolytic uraemic syndrome
Acute respiratory fai lure (by inhalation)
Side-effects/complications
Hypotension
Bleeding (particularly at cannula sites)
Flushing, headache
Notes
Epoprostenol  is active on both pulmonary and systemic circulations.
Al though alprostadil  i s claimed to be metabolised in the lung and have only pulmonary vasodilating effects, fal ls in
systemic blood pressure are not uncommonly seen, especial ly if metabolism is incomplete.
Avoid extravasation into peripheral  tissues as solution has high pH.
Effects last up to 30min fol lowing discontinuation of the drug.
Prostaglandins may potentiate the effect of heparin.
Recent studies have shown improvement in gas exchange by selective pulmonary vasodi latation fol lowing inhalation
of epoprostenol  at doses of 10–15ng/kg/min. The efficacy appears similar to that of ni tric oxide inhalation but is not
as rapid.
Drug dosages
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
122 из 254 07.11.2006 1:04
P.266
P.267
Epoprostenol 2–20ng/kg/min
Alprostadil 2–20ng/kg/min
See also:
Haemo(dia)fi l tration (2), p64; Plasma exchange, p68; Vasodilators, p198; Nitric oxide, p190; Anticoagulants, p248;
Acute respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2), p294; Clotting disorders,
p398; Vascul it ides
Novel therapies in sepsis
Greater understanding of the pathophysiology of sepsis has stimulated the development and investigation of agents
that modulate different components of the inflammatory response. These drugs have been targeted at triggers (e.g.
endotoxin), cytokines (e.g. tumour necrosis factor, interleukin (IL)-1), and effector cells and their products (e.g.
neutrophi ls, free oxygen radicals, nitric oxide) or aim to boost a general anti-inflammatory response (e.g. steroids).
An increasing area of research is in replacement or augmentation of endogenous anti-inflammatory systems, e.g.
activated Protein C, antithrombin-III, IL-10, as there is an increasing realisation of the degree of disruption and
imbalance between pro- and anti -inflammatory substances.
Unfortunately, due to deficiencies in trial design and size, choice of appropriate patient, timing of drug
administration, dosage, and lack of standardisation of concurrent therapies, only two agents (‘low dose’
hydrocortisone and activated Protein C) have been shown to produce outcome benefit in reasonably sized multicentre
trials. For many other products, promising results from post-hoc subgroup analysis and from tightly controlled small
patient studies have not been reproduced. Concern over cost has highl ighted the potential budgetary implications of
any successful therapy though, in terms of l i fe years, the cost–benefit wil l  be relatively cheap.
Uses
Sepsis
Multiple-organ dysfunction
Activated Protein C
Activated Protein C has anti-inflammatory, anticoagulant and pro-fibrinolytic properties. Its beneficial effects in
sepsis are most l ikely to be related to its anti-inflammatory properties. A large prospective randomised control led
trial  demonstrated outcome benefi t for patients with severe sepsis treated within 48h of presentation with a 96h
infusion of 24µg/kg/h aPC. Most benefi t was seen in those with ≥2 organ dysfunctions. The major side effect was
bleeding so caution should be exercised in those at high risk of potential ly catastrophic bleeding, e.g. concurrent
coagulopathy, or a recent history of surgery, major trauma, head injury and/or peptic ulcer disease.
Corticosteroids
Large randomised multicentre studies of high dose methyl  prednisolone showed either no benefi t or a trend to harm.
However, subsequent studies with lower doses of corticosteroids (e.g. 50mg qds hydrocortisone) revealed earl ier
resolution of shock and improved survival in those patients with an impaired (<250nmol/l [9µg/dl]) rise in plasma
cortisol  to a synthetic ACTH challenge.
Examples of drugs investigated in multicentre studies
Corticosteroids (methylprednisolone, hydrocortisone)
Polyclonal  immunoglobulin
Anti-endotoxin antibody (HA-1A, E5)
Antitumour necrosis factor antibody
Tumour necrosis factor soluble receptor antibody
Interleukin-1 receptor antagonist
Platelet activating factor antagonists, PAF-ase
Bradykinin antagonists
Naloxone
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
123 из 254 07.11.2006 1:04
P.271
P.272
Ibuprofen
N-acetylcysteine, procysteine
L-N-mono-methyl-arginine (L-NMMA)
Antithrombin III
Tissue factor pathway inhibitor
Activated Protein C
Key trials
Bernard GR, for the PROWESS study group. Efficacy and safety of recombinant human activated protein C for severe
sepsis. N Engl  J Med 344:699–709
Annane D, et al . Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortali ty in patients
with septic shock. JAMA 2002; 288:862–71
See also:
Sepsis and septic shock—treatment, p486
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Resuscitation
Basic resuscitation
In any severe cardiorespiratory disturbance the order of priority should be to secure the ai rway, maintain respiration
(i.e. manual  venti lat ion if necessary), restore the ci rculation (with external cardiac massage if necessary) and
consider mechanical venti lation. Init ial  assessment of the patient should include patency of the airway, palpation of
the pulses, measurement of blood pressure, presumptive diagnosis and consideration of treatment of the cause.
Airway protection
The ai rway should be opened by l i fting the jaw forward and ti lting the forehead. The mouth and pharynx should be
cleared by suction and loose fitt ing dentures removed. If necessary an oropharyngeal  (Guedel) airway may be
inserted.
Manual ventilation
Once the airway is protected the patient who is not breathing requires manual venti lat ion with a self-inflating bag
and mask (Ambu bag). Oxygen should be del ivered in maximum concentration (FIO2 1.0 for manual venti lation, FIO2
0.6–1.0 for spontaneously breathing patients). If the patient breathes inadequately (poor arterial saturation,
hypercapnia, rapid shal low breathing) venti latory support should continue.
Circulation
If pulses are not palpable or are weak or i f the patient has a severe bradycardia external cardiac massage is required
and treatment should continue as for a cardiac arrest. Hypotension should be treated init ial ly with a fluid challenge
although l i fe-threatening hypotension may require bl ind treatment with epinephrine 0.05–0.2mg increments at
1–2min intervals intravenously unti l a satisfactory blood pressure is restored. Such treatment should not be
prolonged without ci rculatory monitoring to ensure adequacy of cardiac output as wel l as correction of hypotension.
Venous access
Venous access must be secured early during basic resusci tation. Large-bore cannulae are necessary, e.g. 14G. In
cases of haemorrhage two cannulae are required. Smal l peripheral veins should be avoided; forearm flexure veins are
appropriate if nowhere else is available. In very diff icult patients a Seldinger approach to the femoral  vein or a
central vein may be appropriate. The latter has the advantage of providing central  venous monitoring.
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; Endotracheal intubation, p36; Central venous
catheter—insertion, p116; Colloids, p180; Inotropes, p196; Vasopressors, p200; Fluid chal lenge, p274; Hypotension,
p312
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Cardiac arrest
As with basic resuscitation the order of priority is ai rway, breathing and circulation fol lowed by drug treatment. If the
cardiac arrest is wi tnessed a precordial  thump may revert ventricular tachycardia or ventricular fibri l lation. Initial
management of the airway and respiration is as for basic resuscitation. When intubation is attempted i t should be
effected after adequate pre- oxygenation and quickly to avoid hypoxaemia. If intubation is diff icult maintain manual
venti lat ion with an Ambu bag, mask and 100% oxygen.
Cardiac massage
External cardiac massage provides minimal  ci rculatory support during cardiac arrest. A compression rate of
80–100/min is l ikely to provide the optimum blood flow during cardiac massage with a manual  breath from an
assistant for every 5 compressions. Avoid massage during manual  inspiration i f the patient is not intubated (to avoid
gastric di latation); otherwise cardiac massage is more effective i f not synchronised to respiration.
Defibrillation
Defibri l lat ion should be performed urgently if VT or VF cannot be excluded. It is important to restart cardiac massage
immediately after defibri l lat ion without wai ting for the ECG to recover. Cerebral  damage continues whi le there is no
blood flow.
Drugs
Few drugs are necessary for fi rst l ine cardiac arrest management. Drugs should be given via a large vein since
vasoconstriction and poor flow create delay in injections given via smal l peripheral veins reaching the central
ci rculation. Access should be secured early during the resuscitation; if venous access cannot be secured double or
triple doses of drugs may be given via the endotracheal  tube.
Epinephrine
The α constrictor effects predominate during cardiac arrest, helping to maintain diastol ic blood pressure and thus
coronary and cerebral  perfusion. Epinephrine should be given i rrespective of rhythm at 1mg (10ml of 1:10,000
solution) every 10 CPR sequences.
Vasopressin
A recent randomized controlled trial comparing vasopressin and epinephrine showed improved outcomes with
vasopressin for patients in asystole.
Atropine
A single 3mg dose is given early in asystole.
Calcium chloride
Used in electromechanical dissociation i f there is hyperkalaemia, hypocalcaemia or calcium antagonist use. A dose of
10ml of a 10% solution is usual. The main disadvantage of calcium is the reduction of reperfusion of ischaemic brain
and promotion of cytosol ic calcium accumulation during cell  death.
Bicarbonate
Only used if resusci tation is prolonged to correct temporari ly a potential ly lethal pH. A dose of 50ml of 8.4% solution
is given. The main disadvantage is that intracel lular and respiratory acidosis are exacerbated unless venti lation is
increased and the cause of the metabolic acidosis is not corrected.
Key trial
Wenzel  V for the European Resuscitation Counci l Vasopressor during CPR study. A comparison of vasopressin and
epinephrine for out-of- hospital cardiopulmonary resuscitation. N Engl J Med 2004; 350:105–13
Fluid challenge
Hypovolaemia must be treated urgently to avoid the serious compl ication of organ fai lure. An adequate circulating
volume must be provided before considering other methods of circulatory support. Clinical  signs of hypovolaemia
(reduced skin turgor, low CVP, ol iguria, tachycardia and hypotension) are late indicators. Lift ing the legs of a supine
patient and watching for an improvement in the circulation is a useful indicator of hypovolaemia. A high index of
suspicion must be maintained; a normal heart rate, blood pressure and CVP do not exclude hypovolaemia and the CVP
is particularly unreliable in pulmonary vascular disease, right ventricular disease, isolated left ventricular fai lure and
valvular heart disease. The absolute CVP or PAWP are also di fficul t to interpret since peripheral  venoconstriction may
maintain these fi l l ing pressures despi te hypovolaemia; indeed, they may fal l in response to fluid. The response to a
fluid challenge is the safest method of assessment.
Choice of fluid
The aim of a fluid challenge is to produce a significant (200ml) and rapid increase in plasma volume. Colloid fluids
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are ideal; a gelatin solution is recommended for short term plasma volume expansion in simple hypovolaemia, and
hydroxyethyl  starch where there is a probabil ity of capil lary leak. Packed red cells have a high haematocrit and do
not adequately expand the plasma volume. Crystalloid fluids are rapidly lost from the circulation and do not give a
rel iable increase in plasma volume.
Assessing the response to a fluid challenge
Ideally, the response of CVP, or stroke volume and PAWP, should be monitored during a fluid challenge. Fluid
challenges should be repeated whi le the response suggests continuing hypovolaemia. However, i f such monitoring is
not available i t i s reasonable to assess the cl inical  response to up to two fluid chal lenges (200ml each).
CVP response
The change in CVP after a 200ml fluid chal lenge depends on the starting blood volume (see figure). A 3mmHg rise in
CVP represents a significant increase and is probably indicative of an adequate circulating volume. However, a
posit ive response may sometimes occur in the vasoconstricted patient wi th a lower blood volume. It is important to
assess the cl inical response in addit ion; i f inadequate, it i s appropriate to monitor stroke volume and PAWP before
further fluid challenges or considering further circulatory support.
Stroke volume and PAWP response
In the inadequately fi l led left ventricle a fluid challenge wi l l  increase the stroke volume. Failure to increase the
stroke volume with a fluid challenge may represent an inadequate challenge, particularly i f the PAWP fai ls to rise
signi ficantly (3mmHg). This indicates that cardiac fi l l ing was inadequate and the fluid chal lenge should be repeated.
Such a response may also be seen in right heart fai lure, pericardial  tamponade and mitral  stenosis. It is important to
monitor stroke volume rather than cardiac output during a fluid chal lenge. If the heart rate fal ls appropriately in
response to a fluid chal lenge the cardiac output may not increase despite an increase in stroke volume.
CVP and stroke volume response to fluid challenge
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Figure. No Caption Available.
See also:
Central venous catheter—use, p114; Pulmonary artery catheter—use, p118; Cardiac output—thermodilution, p122;
Cardiac output—other invasive, p124; Cardiac output—non-invasive (1), p126; Cardiac output—non-invasive (2),
p128; Lactate, p170; Colloids, p180; Hypotension, p312; Ol iguria, p330; Metabolic acidosis, p434; Diabetic
ketoacidosis, p442; Systemic inflammation/multiorgan fai lure, p484; Sepsis and septic shock—treatment, p486;
Burns—fluid management, p510; Post-operative intensive care, p534
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Respiratory Disorders
Dyspnoea
Defined as diff iculty in breathing. The respiratory rate may be increased or decreased, though the respiratory effort
is usual ly increased with the use of accessory muscles. The patient may show signs of progressive fatigue and
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impaired gas exchange.
Commoner ICU causes
Respiratory respiratory failure
Circulatory heart failure, hypoperfusion, pulmonary embolus, severe anaemia
Metabolic acidosis
Central stimulants, e.g. aspirin
Anaphylactic upper airway obstruction, bronchospasm
Psychiatric hysterical
Principles of management
O2 therapy to maintain SaO2 (ideal ly >90–95%)1.
Correct abnormal ity where possible2.
Support therapy unti l  recovery
mechanical , e.g. posit ive pressure venti lat ion, CPAP
pharmacological treatment, e.g. bronchodilators, vasodi lators
3.
Relieve anxiety4.
A psychiatric cause of dyspnoea is only made after exclusion of other treatable causes.
Dual co-existing pathologies should be considered, e.g. chest infection and hypovolaemia.
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; Airway obstruction, p280; Respiratory fai lure, p282;
Atelectasis and pulmonary col lapse, p284; Chronic ai rflow l imitation, p286; Acute chest infection (1), p288; Acute
chest infection (2), p290; Acute respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2),
p294; Asthma—general management, p296; Pneumothorax, p300; Pulmonary embolus, p308; Heart
fai lure—assessment, p324; Heart fai lure—management, p326; Acute weakness, p368; Sal icylate poisoning, p454;
Anaemia, p400; Post-operative intensive care, p534
Airway obstruction
Causes
In the lumen, e.g. foreign body, blood clot, vomitus, sputum plug
In the wal l, e.g. epiglotti tis, laryngeal oedema, anaphylaxis, neoplasm
Outside the wal l, e.g. trauma (facial , neck), thyroid mass, haematoma
Presentation
In spontaneously breathing patient: stridor, dyspnoea, fatigue, cyanosis
In venti lated patient (due to intraluminal  obstruction): raised ai rway pressures, decreased tidal volume,
hypoxaemia, hypercapnia
Diagnosis
Chest and lateral neck X-ray
Fibreoptic laryngoscopy/bronchoscopy
CT scan
Management
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Presentation outside ICU/operating theatre:
High FIO21.
If col lapsed or in extremis: immediate orotracheal intubation. If impossible, emergency cricothyroidotomy or
tracheostomy.
2.
If symptomatic but not in extremis: consider cause and treat as appropriate, e.g. fibreoptic or rigid
bronchoscopy for removal of foreign body, surgery for thyroid mass. Elective orotracheal  intubation or
tracheostomy may be required.
3.
With acute epiglottit is, the use of a tongue depressor or nasendoscopy may precipi tate complete obstruction so
should be undertaken in an operating theatre ready to perform emergency tracheostomy. The responsible
organism is usually Haemophilus influenzae and early treatment with chloramphenicol  should be begun. Acute
epiglotti tis is recognised in adults, even those of advanced age.
4.
Consider Hel iox (79%He/21%O2) alone or as a supplement to oxygen to reduce viscosity and improve airflow.5.
Presentation within ICU/operating theatre:
If intubated:
High FIO2
Pass suction catheter down the endotracheal  tube, assess ease of passage and the contents suctioned. If the
tube is patent, attempt repeated suction interspersed with 5ml boluses of 0.9% sal ine. Urgent fibreoptic
bronchoscopy may be necessary for diagnosis and, i f possible, removal of a foreign body. If this cannot be
removed by fibreoptic bronchoscopy, urgent rigid bronchoscopy should be performed by an experienced
operator. If the endotracheal  tube is obstructed, remove the tube, oxygenate by face mask then reintubate.
1.
If not intubated:
As for out-of-ICU presentation.
If recently extubated, consider laryngeal oedema. Post-extubation laryngeal oedema is unpredictable
though occurs more commonly after prolonged or repeated intubation; the incidence may be reduced by
proper tethering of the endotracheal tube and prevention of excessive coughing. If diagnosed (by
nasendoscopy), dexamethasone 4mg × 3 doses over 24h may reduce the swel l ing though re-intubation is
often necessary in the interim.
2.
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; Endotracheal intubation, p36; Tracheotomy, p38;
Minitracheotomy, p40; Fibreoptic bronchoscopy, p46; Bronchodilators, p186; Steroids, p262; Atelectasis and
pulmonary collapse, p284; Chronic ai rflow l imitation, p286; Asthma—general management, p296; Haemoptysis, p304
Respiratory failure
Defined as impaired pulmonary gas exchange leading to hypoxaemia and/or hypercapnia.
Commoner ICU causes
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Central Cerebrovascular accident, drugs (e.g. opiates, sedatives), raised
intracranial pressure, trauma
Brainstem/spinal
cord
Trauma (at or above phrenic level), tetanus, Pickwickian syndrome, motor
neurone disease
Neuropathy Guillain–Barré, critical illness polyneuropathy
Neuromuscular Muscle relaxants, organophosphorus poisoning, myasthenia gravis
Chest wall/muscular Flail chest, heart failure, myopathy (including critical illness and disuse
myopathy)
Airways Upper airways obstruction, airway disruption, asthma, anaphylaxis
Parenchymal Pneumonia, ARDS, fibrosis, pulmonary oedema
Extrapulmonary Pneumothorax, pleural effusion, haemothorax
Circulatory Pulmonary embolus, heart failure, Eisenmenger intracardiac shunt
Types of respiratory failure
Type I: Hypoxaemic—often parenchymal in origin
Type II: Hypoxaemic, hypercapnic—often mechanical  in origin
Principles of management
Ensure SaO2 compatible with survival  (i .e. usual ly >80%, preferably >90–95%)1.
Correct abnormal ity where possible, e.g. drain pneumothorax, rel ieve/bypass obstruction.2.
Support therapy unti l  recovery
Posi tive pressure venti lation
Non-invasive respiratory support
Pharmacological treatment, e.g. bronchodilators, antibiotics, opiate antagonists, respiratory stimulant
General  measures, e.g. hydration, airway humidi fication, removal  of secretions, physiotherapy,
bronchoscopy
3.
Unless the patient is symptomatic (e.g. drowsy, dyspnoeic) while being mechanically venti lated, the PaCO2 may
be left elevated to minimise venti lator trauma (permissive hypercapnia).Higher PaCO2 values may also be
tolerated if the patient is chronically hypercapnic (Type II respiratory fai lure).
4.
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; Continuous posit ive ai rway pressure, p26; Non-invasive
respiratory support, p32; Endotracheal intubation, p36; Pulse oximetry, p90; Blood gas analysis, p100; Respiratory
stimulants, p188; Opioid analgesics, p234; Sedatives, p238; Basic resuscitation, p270; Dyspnoea, p278; Airway
obstruction, p280; Atelectasis and pulmonary col lapse, p284; Chronic ai rflow l imitation, p286; Acute chest infection
(1), p288; Acute chest infection (2), p290; Acute respiratory distress syndrome (1), p292; Acute respiratory distress
syndrome (2), p294; Asthma—general management, p296; Pneumothorax, p300; Pulmonary embolus, p308; Acute
weakness, p368; Guil lain–Barré syndrome, p384; Myasthenia gravis, p386; ICU neuromuscular disorders, p388;
Poisoning—general  principles, p452; Sedative poisoning, p458; Organophosphate poisoning, p472; Systemic
inflammation/multiorgan fai lure, p484; HIV related disease, p488; Mult iple trauma (1), p500; Multiple trauma (2),
p502; Head injury (1), p504; Head injury (2), p506; Spinal  cord injury, p508; Near drowning, p526; Pain, p532;
Post-operative intensive care, p534
Atelectasis and pulmonary collapse
A col lapsed lobe or segment is usual ly visible on a CXR. Macroatelectasis is also evident as volume loss. In
microatelectasis the CXR may be normal but A-aDO2 wi l l  be high. Atelectasis reduces lung compliance and PaO2, and
increases work of breathing. This may result in poor gas exchange, increased airway pressures, reduced tidal  volume
and, i f severe, ci rculatory collapse.
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Causes
Collapsed lobe/segment—bronchial obstruction (e.g. sputum retention, foreign body, blood clot, vomitus,
misplaced endotracheal tube)
Macroatelectasis—air space compression by heavy, oedematous lung tissue, external  compression (e.g. pleural
effusion, haemothorax), sputum retention
Microatelectasis—inadequate depth of respiration, nitrogen washout by 100% oxygen with subsequent absorption
of oxygen occurring at a rate greater than replenishment.
Sputum retention
Excess mucous (sputum) normally stimulates coughing. If ci l iary clearance is reduced (e.g. smoking, sedatives) or
mucous volume is excessive (e.g. asthma, bronchiectasis, cystic fibrosis, chronic bronchitis) sputum retention may
occur. Sputum retention may also be the resul t of inadequate coughing (e.g. chronic obstructive lung disease, pain,
neuromuscular disease) or increased mucous viscosi ty (e.g. hypovolaemia, inadequate humidi fication of inspired
gas).
Preventive measures
Sputum hydration—maintenance of systemic hydration and humidi fication of inspired gases (e.g. nebul ized
sal ine/bronchodilators, heated water bath, heat moisture exchanging fi lter).
Cough—requires inspiration to near total lung capacity, glottic closure, contraction of abdominal  muscles and
rapid opening of the glottis. Dynamic compression of the airways and high velocity expiration expels secretions.
The process is l imited i f total lung capacity is reduced, abdominal muscles are weak, pain l imits contraction or
smal l airways collapse on expiration. It is usual to flex the abdomen on coughing and this should be simulated in
supine patients by drawing the knees up. This also l imits pain in patients with an upper abdominal wound.
Physiotherapy—postural drainage, percussion and vibration hyperinflation, intermittent posi tive pressure
breathing, incentive spirometry or manual hyperinflation.
Maintenance of lung volumes—increased VT  CPAP, PEEP, posit ioning to reduce compression of lung tissue by
oedema.
Management
Speci fic management depends on the cause and should be corrective. Al l measures taken for prevention should
continue. If there is lobar or segmental col lapse with obstruction of proximal airways, bronchoscopy may be useful  to
allow directed suction, foreign body removal and saline insti l lat ion. Patients with high FIO2 may deteriorate due to
the effects of excessive lavage or suction reducing minute venti lation.
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; IPPV—compl ications of venti lat ion, p14; Posi tive end
expiratory pressure (1), p22; Positive end expiratory pressure (2), p24; Continuous posi tive airway pressure, p26;
Non-invasive respiratory support, p32; Lung recruitment, p28; Endotracheal intubation, p36; Minitracheotomy, p40;
Fibreoptic bronchoscopy, p46; Chest physiotherapy, p48; Blood gas analysis, p100; Bronchodi lators, p186; Chronic
airflow l imitation, p286; Acute chest infection (1), p288; Acute chest infection (2), p290; Post-operative intensive
care, p534
Chronic airflow limitation
Many patients requiring ICU admission for a community acquired pneumonia have chronic respiratory fai lure. An
acute exacerbation (which may or may not be infection-related) results in decompensation and symptomatic
deterioration. Infections result ing in acute exacerbations include viruses, Haemophilus influenzae, Klebsiella and
Staph. aureus in addition to Strep. pneumoniae, Mycoplasma pneumoniae and Legionella pneumophila. Otherwise,
patients with coincidental  chronic ai rflow l imitation (CAL) are admitted for other reasons or as a prophylactic
measure in view of their l imited respiratory function, e.g. for elective post-operative venti lation.
Problems in managing CAL patients on the ICU
Disabi l i ty due to chronic i l l  health
Fatigue, muscle weakness and decreased physiological  reserve leading to earl ier need for venti latory support,
increased di fficul ty in weaning, and greater physical dependency on support therapies
Psychological dependency on support therapies
More prone to pneumothoraces
Usually have greater levels of sputum production
Right ventricular dysfunction (cor pulmonale)
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Notes
Decisions on whether or not to intubate should be made in consul tation with the patient (if possible), the family,
and a respiratory physician with knowledge of the patient. The patient should be given the benefit of the doubt
and intubated in an acute si tuation where a precise history and quali ty of l i fe is not known.
Trials of non-invasive venti latory support ± respiratory stimulants such as doxepram have shown considerable
success in avoiding intubation and mechanical  venti lat ion.
Accept lower target levels of PaO2
Accept higher target levels of PaCO2 i f patient is known or suspected to have chronic CO2 retention on the basis
of elevated plasma bicarbonate levels on admission to hospital.
Weaning the patient with CAL
An early trial of extubation may be worthwhile before the patient becomes venti lator-dependent.
Weaning may be a lengthy procedure. Daily trials of spontaneous breathing may reveal faster-than-anticipated
progress.
Provide plentiful encouragement and psychological support. Setting daily targets and early mobi l isation may be
advantageous.
Do not ti re by prolonged spontaneous breathing. Consider gradual ly increasing periods of spontaneous breathing
interspersed by periods of rest. Ensure a good night's sleep.
Use patient appearance and lack of symptoms (e.g. tachypnoea, fatigue) rather than specific blood gas values to
judge the duration of spontaneous breathing.
Early tracheostomy may benefit when di fficulty in weaning is expected.
The patient may cope better with a tracheostomy mask than CPAP.
Addition of extrinsic PEEP or CPAP may prevent early ai rways closure and thus reduce the work of breathing.
However, this should be done with caution because of the risk of increased ai r trapping.
Consider heart fai lure as a cause of difficulty in weaning.
Key trials
Brochard L, et al.  Noninvasive venti lat ion for acute exacerbations of chronic obstructive pulmonary disease. N
Engl  J Med 1995; 333:817–22
Antonell i  M, et al . A comparison of noninvasive posi tive-pressure venti lation and conventional mechanical
venti lation in patients with acute respiratory fai lure. N Engl  J Med 1998; 339:429–35
Epstein SK, Ciubotaru RL. Independent effects of etiology of fai lure and time to reintubation on outcome for
patients fai l ing extubation. Am J Respir Crit Care Med 1998; 158:489–93
Acute chest infection (1)
Patients may present to intensive care as a result of an acute chest infection or may develop infection as a
complication of intensive care management. Typical features include fever, cough, purulent sputum production,
breathlessness, pleurit ic pain and bronchial breathing. Urgent investigation includes arterial gases, CXR, blood count
and cultures of blood and sputum. In community acquired pneumonia, acute phase antibody titres should be taken.
Diagnosis and initial antimicrobial treatment
Basic resuscitation is required if there is cardiorespiratory compromise. Appropriate treatment of the infection
depends on CXR and cul ture findings, al though empiric ‘best guess’ antibiotic treatment may be started before cul ture
resul ts are available. Treatment includes physiotherapy and methods to aid sputum clearance.
Clear CXR
Acute bronchit is is associated with cough, mucoid sputum and wheeze. In previously healthy patients a vi ral  aetiology
is most l ikely and there is often an upper respiratory prodrome. Symptomatic rel ief is usual ly al l  that is required.
Likely organisms in acute on chronic bronchi tis include Strep. pneumoniae, H. in. uenzae or Staph. aureus.
Appropriate antibiotics include cefuroxime or ampici l l in and .ucloxacil l in. Viral pneumonia may be confused by the
presence of bacteria in the sputum but secondary bacterial infection is common.
Pulmonary cavitation on CXR
Cavitation should alert to the possibi l ity of anaerobic infection (sputum is often foul  smel l ing). Staph. aureus, K.
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pneumoniae or tuberculosis are also associated with cavi tation. Appropriate antibiotics include metronidazole or
cl indamycin for anaerobic infection, flucloxaci l l in for Staph. aureus and ceftazidime and gentamicin for K.
pneumoniae. A foreign body or pulmonary infarct should also be considered where there is a single abscess.
Consolidation on CXR
The recent history is important for deciding the cause of a pneumonia:
Hospital acquired pneumonia—enteric (Gram negative) organisms treated with ceftazidime and gentamicin,
Staph. aureus treated with ceftazidime and gentamicin, Staph. aureus treated with flucloxacil l in (or
teicoplanin/vancomycin i f mult iresistant).
Recent aspiration—anaerobic or Gram negative infection treated with cl indamycin or cefuroxime and
metronidazole.
Community acquired pneumonia in a previously heal thy individual—Strep. pneumoniae (often lobar, acute onset)
or atypical pneumonia (insidious onset, known community outbreaks, renal fai lure and electrolyte disturbance in
Legionnaire's disease). Appropriate antibiotic therapy is cefuroxime and clarithromycin.
Pneumonia complicating influenza—Staph. aureus treated with flucloxacil l in. Both Staph. aureus and H.
influenzae are common in those debil i tated by chronic disease (e.g. alcoholism, diabetes, chronic airflow
limitation or the elderly).
Immunosuppressed—opportunistic infections (e.g. tuberculosis, Pneumocystis carinii Herpes vi ruses, CMV or
fungi).
Antimicrobial treatment
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Drug Dose Organism
Acyclovir 10mg/kg 8-hrly IV Herpes viruses
Amphotericin B 250mg–1g 6-hrly IV Fungi
Ampicillin 500mg–1g 6-hrly IV H. influenzae
Gram negative spp.
Benzylpenicillin 1.2g 2–6-hrly IV Strep. pneumoniae
Ceftazidime 2g 8-hrly IV K. pneumoniae
Ps. aeruginosa
Gram negative spp.
Cefuroxime 750mg–1.5g 8-hrly IV Strep. pneumoniae
H. influenzae
Gram negative spp.
Clarithromycin 500mg 12-hrly IV (250–500mg 12-hrly
PO if less severe)
Atypical pneumonia Strep.
pneumoniae
Erythromycin 1g 6–12-hrly (500mg 6-hrly PO if less
severe)
Atypical pneumonia Strep.
pneumoniae
Clindamycin 300–600mg 6-hrly IV Anaerobes Gram negative spp.
Cotrimoxazole 120mg/kg/day IV Pneumocystis carinii
Flucloxacillin 2g 6-hrly IV (500mg–1g 6-hrly PO if
less severe)
Staph. aureus
Ganciclovir 5mg/kg 12-hrly IV (over 1h) CMV
Gentamicin 1.5mg/kg stat IV(thereafter by
levels—usually 80mg 8-hrly)
K. pneumoniae, Ps. aeruginosa Gram
negative spp.
Metronidazole 500mg 8-hrly IV or 1g 12-hrly PR Anaerobes
Teicoplanin 400mg 12-hrly for 3 doses then 400mg
daily
Methicillin-resistant Staph. aureus
Vancomycin 500mg 6-hrly (monitor levels) Methicillin-resistant Staph. aureus
Linezolid 600mg 12-hrly IV or PO Methicillin-resistant Staph. aureus
Key trial
Iregui  M et al.  Clinical  importance of delays in the init iat ion of appropriate antibiotic treatment for
venti lator-associated pneumonia. Chest 2002; 122: 262–8
Acute chest infection (2)
Laboratory diagnosis
The fol lowing samples are required for laboratory diagnosis:
Sputum (e.g. cough specimen, endotracheal tube aspirate, protected brush specimen, bronchoalveolar lavage
specimen)
Blood cul tures
Serology (in community acquired pneumonia)
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Urine for antigen tests (if Legionella, Candida or pneumococcus suspected)
In severe pneumonia, bl ind antibiotic therapy should not be withheld whi le awaiting resul ts. Specimens should,
however, be taken before starting antibiotics.
Microbiological yield is usually very low, especial ly i f antibiotic therapy has started before sampl ing.
Where cul tures are posi tive there is often multiple growth. Separating pathogenic organisms from colonising
organisms may be diff icult.
In hospital  acquired pneumonia, known nosocomial  pathogens are the l ikely source, e.g local Gram negative flora,
MRSA.
Continuing treatment
Antibiotics should be adjusted according to sensi tivities once avai lable. Failure to respond to treatment in 72h should
prompt consideration of infections more common in the immunocompromised or other diagnoses.
Hospital-acquired pneumonia requires treatment with appropriate antibiotics for 24h after symptoms subside (usual ly
3–5 days). After this period cul tures should be repeated (off antibiotics if there has been improvement). Some ICUs
wil l use longer courses—a recent multicentre study showed no difference in outcome between 8 and 15 days'
treatment.
In atypical  or pneumococcal  pneumonia, 10–14 days of antibiotic treatment is usual (though no evidence base exists
to indicate the optimal  duration of therapy).
Key trial
Chastre J, for the PneumA Trial  Group. Comparison of 8 vs 15 days of antibiotic therapy for venti lator-associated
pneumonia in adults: a randomized trial . JAMA 2003; 290:2588–98
Acute respiratory distress syndrome (1)
ARDS is the respiratory component of mult iple organ dysfunction. It may be predominant in the cl inical picture or be
of lesser cl inical importance in relation to dysfunction of other organ systems.
Aetiology
As part of the exaggerated inflammatory response fol lowing a major exogenous insul t which may be either di rect
(e.g. chest trauma, inhalation injury) or distant (e.g. peri tonit is, major haemorrhage, burns). Histology reveals
aggregation and activation of neutrophi ls and platelets, patchy endothel ial and alveolar disruption, intersti tial
oedema and fibrosis. Classical ly, the acute phase is characterised by increased capil lary permeabi l i ty and the
fibroproliferative phase (after 7 days) by a predominant fibrotic reaction. However, more recent data would suggest
such distinctions are not so clear-cut; there may be evidence of markers of fibrosis as early as day 1.
Definitions
Acute lung injury (ALI)
PaO2/FIO2≤300mmHg (40kPa)
Regardless of level  of PEEP
With bi lateral infi l trates on CXR
With pulmonary artery wedge pressure <18mmHg
Acute respiratory distress syndrome (ARDS)
As above but PaO2/FIO2≤200mmHg (26.7kPa)
Prognosis
Prognosis depends in part on the underlying insult, the presence of other organ dysfunctions and the age and chronic
health of the patient. Predominant single-organ ARDS carries a mortal ity of 30–50%; there does appear to have been
some improvement over the last decade.
Some deterioration on lung function testing is usually detectable in survivors of ARDS, even in those who are
relatively asymptomatic. Recent studies indicate that a significant proportion of survivors of ARDS have physical
and/or psychological sequelae at 1 year.
Key trials
Bernard GR for the The American–European Consensus Conference on ARDS. Definit ions, mechanisms, relevant
outcomes, and cl inical trial coordination. Am J Respir Cri t Care Med. 1994; 149:818–24
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Herridge MS, Cheung AM for the Canadian Cri tical  Care Trials Group. One-year outcomes in survivors of the acute
respiratory distress syndrome. N Engl J Med 2003; 348:683–93
Marshall  RP, et al . Fibroproli feration occurs early in the acute respiratory distress syndrome and impacts on outcome.
Am J Respir Cri t Care Med 2000; 162:1783–8
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; IPPV—compl ications of venti lat ion, p14; Posi tive end
expiratory pressure (1) Positive end expiratory pressure (2), p24; Continuous posi tive airway pressure, p26; Lung
recruitment, p28; Prone positioning, p30; Extracorporeal respiratory support, p34; Endotracheal  intubation, p36;
Blood gas analysis, p100; Bacteriology, p158; Virology, serology and assays, p160; Col loid osmotic pressure, p172;
Col loids, p180; Bronchodilators, p186; Nitric oxide, p190; Surfactant, p192; Antimicrobials, p260; Steroids, p262;
Prostaglandins, p264; Basic resusci tation, p270; Acute chest infection (1), p288; Acute chest infection (2), p290;
Acute respiratory distress syndrome (2), p294; Inhalation injury, p306; Infection—diagnosis, p480;
Infection—treatment, p482; Systemic inflammation/multiorgan fai lure, p484; Sepsis and septic shock—treatment,
p486; Multiple trauma (1), p500; Mult iple trauma (2), p502; Pyrexia (1), p518; Pyrexia (2), p520
Acute respiratory distress syndrome (2)
General management
Remove the cause whenever possible, e.g. drain pus, antibiotic therapy, fix long bone fracture.1.
Sedate with an opiate–benzodiazepine combination as mechanical venti lation is l ikely to be prolonged. Doses
should be kept to the lowest possible but consistent wi th adequate sedation.
2.
Muscle relaxation is indicated in severe ARDS to improve chest wal l compliance and gas exchange.3.
Haemodynamic manipulation with either fluid, di lators, pressors, diuretics and/or inotropes may improve
oxygenation. This may be achieved by either increasing cardiac output, and thus mixed venous saturation in low
output states, or by decreasing cardiac output thereby lengthening pulmonary transi t t imes in high output
states. Care should be taken not to compromise the ci rculation.
4.
Respiratory management
Maintain adequate gas exchange with increased FIO2 and, depending on severity, either non-invasive respiratory
support (e.g. CPAP, BiPAP) or posi tive pressure venti lation. Speci fic modes may be uti l ised, such as pressure
controlled inverse ratio venti lation. Whi le general agreement exists for minimising VT (6-7ml/kg) and plateau
inspiratory pressures (≤30cmH2O) i f possible, there is no consensus regarding the upper desired level of FIO2
and PEEP. Greater emphasis is currently placed on higher levels of PEEP (up to 20cm H2O) While the current
European view favours the use of higher FIO2 (up to 1.0), a common US approach is to keep the FIO2 ≤0.60 but
to maintain SaO2 wi th higher levels of PEEP. A recent study assessing higher levels of PEEP showed no outcome
benefit.
1.
Non-venti latory respiratory support techniques such as ECCO2R can be used in severe ARDS but have yet to show
convincing benefit over conventional  venti latory techniques.
2.
Blood gas values should be aimed at maintaining survival without striving to achieve normality. Permissive
hypercapnia, where PaCO2 values are allowed to rise, sometimes above 10kPa, has been associated with
outcome benefit.  Acceptable levels of SaO2 are controversial; in general, values ≥90–95% are targeted but in
severe ARDS this may be relaxed to 80–85% or even lower provided organ function remains adequate.
3.
Patient posi tioning may provide improvements in gas exchange. This includes kinetic therapy using special
rotational beds, and prone posi tioning with the patient being turned frequently through 180°. Care has to be
taken during prone posit ioning to prevent tube displacement and shoulder injuries.
4.
Inhaled ni tric oxide or epoprostenol  improves gas exchange in some 50% of patients, though no outcome benefit
has been shown.
5.
High dose steroids commenced at 7–10 days are beneficial in 50–60% of patients, at least in terms of improving
gas exchange.
6.
Surfactant therapy is currently not indicated for ARDS.7.
Venti lator trauma is ubiquitous. Multiple pneumothoraces are common and may require multiple chest drains.
They may be di fficult to diagnose by X-ray and, despi te the attendant risks, CT scanning may reveal
undiagnosed pneumothoraces and aid correct si ting of chest drains.
8.
Key trials
Acute Respiratory Distress Syndrome Network. Venti lation with lower tidal  volumes compared with traditional t idal
volumes for acute lung injury and the acute respiratory distress syndrome. N Engl  J Med 2000; 342:1301–8
Hickl ing KG, et al . Low mortal ity rate in adult respiratory distress syndrome using low-volume, pressure-l imited
venti lat ion with permissive hypercapnia: a prospective study. Cri t Care Med 1994; 22:1568–78
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Meduri  GU, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome:
a randomized controlled trial . JAMA 1998; 280:159–65
Gattinoni L, et al for the Prone-Supine Study Group. Effect of prone positioning on the survival  of patients with acute
respiratory failure. N Engl J Med 2001; 345:568–73
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; IPPV—compl ications of venti lat ion, p14; Posi tive end
expiratory pressure (1) Positive end expiratory pressure (2), p24; Continuous posi tive airway pressure, p26; Lung
recruitment, p28; Prone positioning, p30; Extracorporeal respiratory support, p34; Endotracheal  intubation, p36;
Blood gas analysis, p100; Bacteriology, p158; Virology, serology and assays, p160; Col loid osmotic pressure, p172;
Col loids, p180; Bronchodilators, p186; Nitric oxide, p190; Surfactant, p192; Antimicrobials, p260; Steroids, p262;
Basic resuscitation, p270; Acute chest infection (1), p288; Acute chest infection (2), p290; Acute respiratory distress
syndrome (2), p294; Inhalation injury, p306; Infection—diagnosis, p480; Infection—treatment, p482; Systemic
inflammation/multiorgan fai lure, p484; Sepsis and septic shock—treatment, p486; Multiple trauma (1), p500; Multiple
trauma (2), p502; Pyrexia (1), p518; Pyrexia (2), p520
Asthma—general management
Pathophysiology
Acute bronchospasm and mucus plugging, often secondary to an insul t such as infection. The patient may progress to
fatigue, respiratory fai lure and collapse. The onset may develop slowly over days, or occur rapidly within minutes to
hours.
Clinical features
Dyspnoea, wheeze (expiratory ± inspiratory), di ffi culty in talking, use of accessory respiratory muscles, fatigue,
agi tation, cyanosis, coma, col lapse.
Pulsus paradoxus is a poor indication of severity; a fatiguing patient cannot generate significant respiratory
swings in intrathoracic pressure.
A ‘si lent’ chest is also a late sign suggesting severely l imited ai rflow.
Pneumothorax and lung/lobar col lapse.
Management of asthma
Asthmatics must be managed in a well -monitored area. If cl inical features are severe, they should be admitted to an
intensive care uni t where rapid institution of mechanical venti lation is available. Monitoring should comprise, as a
minimum, pulse oximetry, continuous ECG, regular blood pressure measurement and blood gas analysis. If severe, an
intra-arterial  cannula ± central  venous access should be inserted.
High FIO2 (≥0.60) to maintain SpO2≥95%.1.
Nebulised β2-agonist (e.g. salbutamol)—may be repeated every 2–4h or, in severe attacks, administered
continuously
2.
IV steroids for 24h then oral prednisolone. Nebulised ipratropium bromide may give addi tional benefit.3.
IV bronchodi lators, e.g. salbutamol, magnesium sulphate.4.
Exclude pneumothorax and lung/lobar collapse.5.
Ensure adequate hydration and fluid replacement.6.
Commence antibiotics (e.g. cefuroxime ± clarithromycin) if strong evidence of bacterial chest infection. Green
sputum does not necessari ly indicate a bacterial  infection.
7.
If no response to above measures or in extremis consider:
IV salbutamol  infusion
Epinephrine SC or by nebuliser
Mechanical  venti lat ion
Anecdotal success has been reported with subanaesthetic doses of a volati le anaesthetic agent such as
isoflurane which both calms/sedates and bronchodi lates.
8.
Indications for mechanical ventilation
Increasing fatigue and obtundation
Respiratory fai lure—rising PaCO2 fal l ing PaO2
Cardiovascular col lapse
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Facilitating endotracheal intubation
Summon senior assistance. Pre-oxygenate with 100% O2. Perform rapid sequence induction with suxamethonium and
etomidate or ketamine. ‘Breathing down’ wi th an inhalational  anaesthetic (e.g. isoflurane) pre- intubation should only
be attempted by an experienced cl inician. To minimse barotrauma, care should be taken to avoid excess air trapping,
high airway pressures and high t idal volumes.
Drug dosage
Epinephrine 0.5ml 1:1000 solution SC or 2ml 1:10,000 solution by nebuliser
Hydrocortisone 100–200mg qds
Ipratropium bromide 250–500µg qds by nebuliser
Prednisolone 40–60mg od initially
Salbutamol 2.5–5mg by nebuliser 5–20µg/min by IV infusion
Magnesium sulphate 1.2–2.0g IV over 20min
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; Endotracheal intubation, p36; Pulse oximetry, p90; Blood
gas analysis, p100; Bacteriology, p158; Bronchodi lators, p186; Sedatives, p238; Steroids, p262; Dyspnoea, p278;
Asthma—venti latory management, p298; Anaphylactoid reactions, p496
Asthma—ventilatory management
Early period
Ini tial ly give low VT (5ml/kg) breaths at low rate (5–10/min) to assess degree of bronchospasm and air trapping.
Slowly increase VT  (to 7-8ml/kg) ± increase rate, taking care to avoid significant air trapping and high
inspiratory pressures. Low rates with prolonged I:E ratio (e.g. 1:1) may be advantageous. Avoid very short
expiratory t imes.Do not strive to achieve normocapnia.
1.
Administer muscle relaxants for a minimum 2–4h, unti l  severe bronchospasm has abated and gas exchange
improved. Al though atracurium may cause histamine release, i t does not appear cl inical ly to worsen
bronchospasm.
2.
Sedate with either standard medication or with agents such as ketamine or isoflurane that have bronchodilating
properties. Ketamine given alone may cause hal lucinations whi le isoflurane carries a theoretical  risk of fluoride
toxici ty.
3.
If significant air trapping remains, consider venti lator disconnection and forced manual  chest compressions every
10–15min
4.
If severe bronchospasm persists, consider injecting 1–2ml of 1:10,000 epinephrine down endotracheal  tube.
Repeat at 5min intervals as necessary.
5.
Maintenance
Ensure adequate rehydration.1.
Generous humidi fication should be given to loosen mucus plugs. Use a heat–moisture exchanger plus ei ther
hourly 0.9% saline nebul isers or insti l lation of 5ml 0.9% saline down the endotracheal tube.
2.
Physiotherapy assists mobil isation of secretions and removal  of mucus plugs. Hyperventi lat ion should be
avoided.
3.
With improvement, gradual ly normalise venti lator sett ings (VT,  rate, I:E ratio) to achieve normocapnia before
allowing patient to waken and breathe spontaneously
4.
Consider pneumothorax or lung/lobar collapse i f acute deterioration occurs.5.
If mucus plugging consti tutes a major problem, insti l lat ion of a mucolytic (N-acetyl  cysteine) may be considered
though this may induce further bronchospasm. Bronchoscopic removal  of plugs should only be performed by an
experienced operator.
6.
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Assessment of air trapping (intrinsic PEEP, PEEPi)
Measure PEEPi  by pressing end-expiratory hold button of venti lator.
No pause between expiratory and inspiratory sounds.
Disconnection of venti lator and timing of audible expiratory wheeze.
An increasing PaCO2 may respond to reductions in minute volume which wil l  lower the level of intrinsic PEEP.
Weaning
Bronchospasm may increase on l ightening sedation due to awareness of endotracheal tube and increased
coughing.
May need trial of extubation whi le st i l l  on high FIO2
Consider extubation under inhalational or short-acting IV sedation.
space out intervals between β2 agonist nebulisers. Convert other antiasthmatic drugs to oral  medication. Theophyl l ine
doses should be adjusted to ensure therapeutic levels.
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; Endotracheal intubation, p36; Pulse oximetry, p90; Blood
gas analysis, p100; Bacteriology, p158; Bronchodi lators, p186; Sedatives, p238; Steroids, p262; Dyspnoea, p278;
Asthma—general  management, p296; Anaphylactoid reactions, p496
Pneumothorax
Signi ficant collection of air in the pleural space that may occur spontaneously, fol lowing trauma (including
iatrogenic), asthma, chronic lung disease, and is a common sequel of venti lator trauma.
Clinical features
May be asymptomatic.
Dyspnoea, pain.
Decreased breath sounds, hyper-resonant, asymmetric chest expansion—may be diff icult to assess in a
venti lated patient.
Respiratory fai lure and deterioration in gas exchange.
Increasing airway pressures and diff iculty to venti late.
Cardiovascular deterioration with mediastinal  shift (tension).
Diagnosis
CXR—most easi ly seen on erect views where absent lung markings are seen lateral to a well -defined lung border.
However, venti lated patients are often imaged in a supine posi tion; pneumothorax may be easily missed as it
may be lying anterior to normal  lung giving the misleading appearance of lung markings on the radiograph.
Supine pneumothorax should be considered i f the fol lowing are seen:
Hyperlucent lung field compared to the contralateral  side
Loss of clari ty of the diaphragm outl ine
‘Deep sulcus’ sign, giving the appearance of an inverted diaphragm
A particular clear part of the cardiac contour
A lateral fi lm may help. Tension pneumothorax results in marked mediastinal shi ft away from the affected
side.
Ultrasound—may be helpful  but is highly operator dependent
CT scan—very sensit ive and may be useful in difficult si tuations, e.g. ARDS, and to direct drainage of
localised pneumothorax
Pneumothorax must be distinguished from bullae, especial ly with long-standing emphysema; inadvertent drainage of
a bulla may cause a bronchopleural f istula. Assistance should be sought from a radiologist.
Management
Increase FIO2 i f hypoxaemic.1.
If l i fe-threatening with ci rculatory collapse, needle aspirate pleura on affected side, fol lowed by formal  chest2.
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drain insertion.
Repeated needle aspiration may be sufficient in spontaneously breathing patients without respiratory fai lure;
however, this is not recommended i f the patient is venti lated.
3.
Chest drain insertion. This may be done under ultrasound or CT guidance, especial ly if localised due to
surrounding lung fibrosis.
4.
A smal l pneumothorax (<10% hemithorax) may be left undrained but prompt action should be insti tuted if
cardiorespiratory deterioration occurs. Patients should not be transferred between hospi tals, particularly by plane,
with an undrained pneumothorax. Drains may be removed i f not swinging/bubbling for several days.
Bronchopleural fistula
Denoted by continual drainage of air. Usually responds to conservative treatment with continual  application of 5kPa
negative pressure; this may take weeks to resolve. For severe leak and/or compromised venti lation, high frequency
jet venti lat ion and/or a double lumen endobronchial  tube may be considered. Surgical  intervention is rarely
necessary.
Chest X-ray appearance
Figure. No Caption Available.
See also:
IPPV—complications of venti lation, p14; High frequency venti lat ion, p20; Chest drain insertion, p42; Central  venous
catheter—insertion, p116; Basic resusci tation, p270; Respiratory fai lure, p282; Acute respiratory distress syndrome
(1), p292; Acute respiratory distress syndrome (2), p294; Multiple trauma (1), p500; Mult iple trauma (2), p502
Haemothorax
Usually secondary to chest trauma or fol lowing a procedure, e.g. cardiac surgery, chest drain insertion, central
venous catheter insertion. Spontaneous haemothorax is very rare, even in patients with clotting disorders.
Clinical features
Stony dul lness.
Decreased breath sounds.
Hypovolaemia and deterioration in gas exchange (i f large).
Diagnosis
Erect CXR—blunting of hemidiaphragm and progressive loss of basal lung field
Supine CXR—increased opacity of affected hemithorax plus decreased clari ty of cardiac contour on that side.
Large bore needle aspiration to confi rm presence of blood. A small  bore needle may be unable to aspirate a
haemothorax i f i t has clotted.
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Management
If smal l,  observe with serial X-rays and monitor for signs of cardiorespiratory deterioration.1.
Ensure any coagulopathy is corrected by administration of fresh frozen plasma and/or platelets as indicated.2.
Ensure that cross-matched blood is avai lable for urgent transfusion i f necessary.3.
If significant in size or patient becomes symptomatic, insert large bore chest drain, e.g. size 28 Fr. The drain
should be di rected postero-inferiorly toward the dependent area of lung and placed on 5kPa suction.
4.
If drainage exceeds 1000ml or >200ml/h for 3–4h despi te correcting any coagulopathy, contact thoracic surgeon.5.
Factor VIIa may be considered for intractable bleeding, though only anecdotal reports of benefit exist.6.
Drains inserted for a haemothorax may be removed after 1–2 days i f no further bleeding occurs.7.
Perforation of an intercostal vessel  during chest drain insertion may cause considerable bleeding into the pleura. If
deep tension sutures around the chest drain fai l  to stem blood loss, remove the chest drain and insert a Foley
urethral  catheter through the hole. Inflate the bal loon and apply traction on the catheter to tamponade the bleeding
vessel . If these measures fai l , contact a thoracic surgeon.
See also:
Chest drain insertion, p42; Central venous catheter—insertion, p116; Blood transfusion, p182; Blood products, p252;
Coagulants and antifibrinolytics, p254; Aprotinin, p256; Pneumothorax, p300; Bleeding disorders, p396
Haemoptysis
May range from a few specks of blood in expectorated sputum to massive pulmonary haemorrhage.
More l ikely to disrupt gas exchange before l i fe-threatening hypovolaemia ensues.
May be a presenting feature of a patient admitted to intensive care or may resul t from crit ical i l lness and its
treatment.
Causes
Massive haemoptysis
Disruption of a bronchial artery by acute inflammation or invasion (e.g. pulmonary neoplasm, trauma, cavitating
TB, bronchiectasis, lung abscess and aspergi l loma).
Rupture of arteriovenous mal formations and bronchovascular fistulae.
Pulmonary infarction secondary to prolonged pulmonary artery catheter wedging or pulmonary artery rupture.
Minor haemoptysis
Intrapulmonary inflammation or infarction (e.g. pulmonary embolus)
Endotracheal  tube trauma (e.g. mucosal erosion, balloon necrosis, trauma from the tube t ip, trauma to a
tracheostomy stoma, trauma from suction catheters).
Tissue breakdown in crit ically i l l  patients (e.g. tissue hypoperfusion, coagulopathy, poor nutritional state, sepsis
and hypoxaemia.)
Investigation and assessment
Urgent assessment of cardiorespiratory function and cardiorespiratory monitoring are required. Massive haemoptysis
may require resuscitation and urgent intubation. The diagnosis may be suggested by the history and a CXR may
identi fy a cavi tating lesion. Lower lobe shadowing on a CXR may be the resul t of overspi l l  of blood from elsewhere in
the bronchial tree. Early surgical  intervention should be prompted by a changing ai r-fluid level, persistent
opacification of a previous cavity or a mobile mass. Early bronchoscopy may identify the source of haemoptysis,
although only while bleeding is active. Blood in mult iple bronchial  orifi ces may be confusing but saline lavage may
leave the source visible. Rigid bronchoscopy is useful in massive haemoptysis al lowing oxygenation and wide bore
suction.
Management
Basic resuscitation (high FIO2,  endotracheal intubation and bloodtransfusion) is needed for cardiorespiratory
compromise.
Correction of coagulopathy is a priority.
Bronchoscopy al lows direct insti l lation of 1 in 200,000 epinephrine if the source of haemorrhage can be found or,
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alternatively, endobronchial tamponade with a bal loon catheter.
In cases of severe haemorrhage from one lung a double lumen endotracheal  tube may prevent some overspi l l  to
the other lung while defini tive treatment is organised.
Defini tive treatment may include radiological  bronchial artery embol isation, or surgical  resection.
Induced hypotension may be useful in bronchial  artery haemorrhage.
In cases of pulmonary artery haemorrhage, PEEP may be used with mechanical  venti lat ion to reduce pulmonary
bleeding.
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; Posi tive end expiratory pressure (1), p22; Posi tive end
expiratory pressure (2), p24; Continuous posi tive airway pressure, p26; Endotracheal intubation, p36; Fibreoptic
bronchoscopy, p46; Blood transfusion, p182; Blood products, p252; Coagulants and anti fibrinolytics, p254; Basic
resuscitation, p270; Acute chest infection (1), p288; Acute chest infection (2), p290; Pulmonary embolus, p308;
Bleeding disorders, p396; Amniotic f luid embolus, p544
Inhalation injury
Causes include smoke, steam, noxious gases and aspiration of gastric contents.
Clinical features
Dyspnoea, coughing
Stridor (if upper airway obstruction)
Bronchospasm
Signs of lung/lobar collapse (especial ly with aspiration)
Signs of respiratory fai lure
Cherry-red skin colour (carbon monoxide)
Agi tation, coma
ARDS (late)
General principles of management
100% O21.
Early intubation i f upper airway compromised or threatened.2.
Early bronchoscopy if inhalation of soot, debris, vomit suspected.3.
Specific conditions
Smoke inhalation
Smoke rarely causes thermal  injury beyond the level of bronchi as i t has a low specific heat content. However,
soot is a major irritant to the upper airways and can produce very rapid and marked inflammation.
Urgent laryngoscopy should be performed if soot is present in the nares, mouth or pharynx.
If soot is seen or the larynx appears inflamed, perform early endotracheal intubation. As the upper airway can
obstruct within minutes it is advisable to intubate as a prophylactic measure rather than as an emergency where
it may prove impossible.
After intubation, perform urgent bronchoscopy with bronchial  toi let using warmed 0.9% sal ine to remove as
much soot as possible.
Commence benzylpenici l l in 1.2g qds IV.
Specific treatment for poisons contained within smoke (e.g. carbon monoxide, cyanide)
Steam inhalation
Consider early/prophylactic intubation
Steam has a much higher heat content than smoke and can cause injury to the whole respiratory tract.
Consider early bronchoscopy and lavage with cool 0.9% saline.
Aspiration of gastric contents
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Early bronchoscopy and physiotherapy to remove as much particulate and l iquid matter as possible.
Either cefuroxime plus metronidazole, or cl indamycin for 3–5 days.
Steroid therapy has no proven benefit.
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; Endotracheal intubation, p36; Fibreoptic bronchoscopy,
p46; Blood gas analysis, p100; Antimicrobials, p260; Airway obstruction, p280; Inhaled poisons, p466; Burns—fluid
management, p510; Burns—general management, p512
Pulmonary embolus
Aetiology
Usually arises from a deep vein thrombosis in femoral or pelvic veins. The risk increases after prolonged
immobi l isation and with polycythaemia or hyperviscosity disorders.
Amniotic fluid embolus.
Fat embolus after pelvic or long bone trauma.
Right heart source, e.g. mural  thrombus.
Clinical features
Pleuri tic-type chest pain, dyspnoea, ± haemoptysis.
The patient with a major embolus often prefers to l ie flat. Dyspnoea improves due to increased venous return
and right heart loading.
Deterioration in gas exchange—may find a low PaO2 low or high PaCO2 and a metabolic acidosis. However, these
.ndings are inconsistent and non-diagnostic.
Cardiovascular features, e.g. tachycardia, low/high BP and collapse.
CXR: may be normal but a massive embolus may produce fewer vascular markings (pulmonary ol igaemia) in a
hemithorax ± a bulging pulmonary hilum. A wedge-shaped peripheral pulmonary infarct may be seen after a few
days fol lowing a smaller embolus.
ECG: acute right ventricular strain, i .e. S1 Q3T3, tachycardia, right axis deviation, right bundle branch block, P
pulmonale.
Echocardiogram: may reveal evidence of pulmonary hypertension and acute right ventricular strain.
D-dimers—though a raised level  is non-diagnostic, a normal value carries a high probabi l i ty of exclusion of a
pulmonary embolus.
Definitive diagnosis
CT scan with contrast—the investigation of choice for major embolus.
Pulmonary angiography
Venti lation–perfusion scan—degree of certainty is reduced i f area of non-perfused lung corresponds to any CXR
abnormali ty.
Fat globules or foetal  cel ls in pulmonary artery blood may be found in fat and amniotic f luid embolus,
respectively.
General management
FIO2 0.6–1.0 to maintain SaO2 ≥90–95%1.
Lie patient flat; improvement often fol lows increased venous return.2.
Fluid challenge to optimise right heart fi l l ing.3.
Epinephrine infusion if circulation sti l l  compromised.4.
Mechanical  venti lation may be needed if the patient tires or cannot maintain adequate oxygenation. Gas
exchange may worsen due to loss of preferential  shunting and decreases in cardiac output.
5.
Management of blood clot embolus
Start anticoagulation with low molecular weight heparin adjusted for weight. Consider thrombolysis if there is a major
embolus and cardiovascular compromise, and embolectomy if the patient remains moribund. Otherwise, at 24–48h
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commence warfarin but continue heparin for further 2–3 days after adequate oral  dosing.
Management of fat embolus
Other than general  measures including oxygenation, fluid resuscitation and right heart loading, treatment remains
controversial.  Various authorit ies advocate steroids, heparinisation or no specific therapy.
Low molecular weight heparin regimen
Subcutaneous low molecular weight heparin is given unti l  oral anticoagulant therapy is ful ly established.
Dalteparin
200 units/kg (max. 18,000units) every 24h (or 100units/kg twice dai ly if increased risk of haemorrhage)
Enoxaparin
1.5mg/kg (150units/kg) every 24h
Tinzaparin
175units/kg once daily
Thrombolytic regimens
rt-PA (100mg over 90min) should be given fol lowed by a heparin infusion (24,000–36,000units/day) to maintain the
partial thromboplastin time at 2–3 × normal. This is the treatment of choice if surgery or angiography is
contemplated.
Streptokinase (500,000units as a loading dose over 30min fol lowed by 100,000units/h for 24h).
NB: Central venous catheters should ideally be inserted prethrombolysis by an experienced operator to minimise the
risk of bleeding/haematoma.
Key trials
Konstantinides S, for the Management Strategies and Prognosis of Pulmonary Embol ism-3 Trial  Investigators.
Heparin plus al teplase compared with heparin alone in patients with submassive pulmonary embol ism. N Engl  J
Med 2002; 347:1143–50
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Cardiovascular Disorders
Hypotension
The overall principle in the management of hypotension is to maintain the minimum mean arterial pressure that wil l
ensure adequate tissue perfusion. A normal  blood pressure does not guarantee an adequate cardiac output and
circulatory support should aim to achieve adequate blood flow as well . In extremis, the .rst l ine treatment options
should include external  cardiac massage and epinephrine 0.05–0.2mg intravenous boluses (1mg in cardiac arrest).
Assessment of hypotension
Hypotension requires treatment i f the mean BP <60mmHg (higher i f the patient was previously hypertensive) with
signs of poor t issue perfusion (e.g. ol iguria, confusion, altered consciousness, cool peripheries, metabol ic acidosis).
Speci fic treatment should be considered for haemorrhage, acute myocardial infarction, arrhythmias, pulmonary
embolus, cardiac tamponade, pneumothorax, anaphylaxis, diarrhoea and vomiting, ketoacidosis, hypoadrenalism,
hypopi tui tarism and poisoning.
Initial treatment of hypotension
Most cases of hypotension require fluid as fi rst-l ine management to confirm an adequate ci rculating volume.
Exceptions may include acute heart fai lure, arrhythmias, cardiac tamponade and pneumothorax. In cases of
l i fe-threatening haemorrhage group specific or O negative blood should be used urgently.
Pharmacological treatment
If hypotension persists after an adequate circulating volume, rate and rhythm has been restored, the appropriate
choice of drug treatment depends on whether there is myocardial  fai lure (signs of low output or measured low stroke
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volume) or peripheral  vascular fai lure (warm, vasodilated periphery or measured normal stroke volume). A low stroke
volume should be treated with an inotrope (e.g. epinephrine, dobutamine) and peripheral vascular fai lure with a
vasopressor (e.g. norepinephrine).
Inotropic support
Epinephrine (started at 0.2µg/kg/min), dopamine or dobutamine (started at 5µg/kg/min) should be ti trated against
stroke volume (if monitored). Most hypotensive patients requiring inotropes should have a pulmonary artery catheter
inserted. The alternative is to titrate against blood pressure, but there is a danger of producing inappropriate
vasoconstriction. Dobutamine is safer in this respect but has the disadvantage of producing excessive vasodilatation
in some patients.
Vasopressors
Once stroke volume has been optimised, norepinephrine (started at 0.05µg/kg/min) should be titrated against mean
BP. In most patients, wi th previously normal  blood pressure, 60mmHg is an adequate target but may need to be
higher to ensure organ perfusion in the elderly and those with previous hypertension. Norepinephrine may reduce
cardiac output. This effect should be monitored and corrected by adjustment of dose. Vasopressin (or i ts synthetic
analogue, terl ipressin) is increasingly used for high output, catecholamine-resistant, vasodilatory shock. Care should
be taken to avoid excessive peripheral constrict ion or impairment of organ perfusion.
See also:
Intra-aortic balloon counterpulsation, p58; Blood pressure monitoring, p110; Arterial cannulation, p112; Pulmonary
artery catheter—use, p118; Pulmonary artery catheter—insertion, p120; Cardiac output—thermodi lution, p122;
Cardiac output—other invasive, p124; Cardiac output—non-invasive (1), p126; Cardiac output—non-invasive (2),
p128; Col loids, p180; Blood transfusion, p182; Inotropes, p196; Vasopressors, p200; Basic resusci tation, p270;
Cardiac arrest, p272; Fluid challenge, p274; Pneumothorax, p300; Haemothorax, p302; Pulmonary embolus, p308;
Tachyarrhythmias, p316; Bradyarrhythmias, p318; Acute coronary syndrome (1), p320; Acute coronary syndrome (2),
p322; Heart fai lure—assessment, p324; Heart fai lure—management, p326; Upper gastrointestinal haemorrhage, p344;
Bleeding varices, p346; Abdominal  sepsis, p350; Pancreatit is, p354; Oliguria, p330; Metabolic acidosis, p434;
Diabetic ketoacidosis, p442; Hypoadrenal  crisis, p448; Poisoning—general principles, p452; Systemic
inflammation/multiorgan fai lure, p484; Sepsis and septic shock—treatment, p486; Multiple trauma (1), p500; Multiple
trauma (2), p502; Spinal  cord injury, p508; Burns—fluid management, p510; Burns—general management, p512;
Pyrexia (1), p518; Pyrexia (2), p520; Hyperthermia, p522; Post-operative intensive care, p534; Post-partum
haemorrhage, p542; Care of the potential  organ donor, p552
Hypertension
Often defined in adul t patients as a diastolic pressure >95mmHg and a systolic pressure >180mmHg.
Common causes in intensive care
Idiopathic/essential
Agi tation/pain, especial ly where muscle relaxants are used
Excessive vasoconstriction, e.g. cold, vasopressor drugs
Head injury, cerebrovascular accidents
Drug-related
Dissecting aneurysm, aortic coarctation
Vascul itis, thrombotic thrombocytopenic purpura
(Pre-)eclampsia
Aortic coarctation (may present acutely in adulthood)
Endocrine, e.g. phaeochromocytoma (rare)
Renal fai lure, renal artery stenosis (rare)
Spurious—underdamped transducer system
Indications for acute treatment
Hypertensive encephalopathy, heart fai lure, eclampsia and acute dissecting aneurysm are the prime indications for
rapid and aggressive, albei t controlled, reduction of blood pressure.
In other condit ions, especial ly chronic hypertension and fol lowing acute neurological  events, e.g. head injury,
cerebrovascular accidents, a precipitate reduction in blood pressure may adversely affect perfusion leading to further
deterioration. Hypertension post-cerebral  event is not usually treated unless very high, e.g. mean BP
>140–150mmHg, systolic BP >220–230mmHg. In this instance, control led and partial  reduction is mandatory, e.g.
using sodium ni troprusside infusion with continuous invasive monitoring. In the presence of a raised ICP, a cerebral
perfusion pressure ≥60–70mmHg is usual ly targeted.
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Hypertensive crisis
This occurs when the patient becomes symptomatic (increasing drowsiness, seizures, papil loedema, retinopathy) in
the presence of elevated systemic pressures. The diastolic BP usually exceeds 120–130mmHg and the mean BP
>140–150mmHg, al though encephalopathy can occur at lower pressures.
Principles of management
Adequate monitoring (invasive BP, ECG, CVP, CO, urine output)1.
Consider pain, hypovolaemia, hypothermia and agitation, especial ly if paralysed.2.
Consider specific treatment for, e.g. phaeochromocytoma, thyroid crisis, aortic dissection, inflammatory
vascul itis
3.
Slow intravenous infusion of ni trate or ni troprusside. GTN is usually given first before considering sodium
nitroprusside. Other options include labetalol  or esmolol infusions, and hydralazine (IV or IM). Sublingual
nifedipine or IV hydralazine may sometimes produce precipitate fal ls in BP. Use cautiously and start with low
doses.
4.
Aim to reduce to mi ldly hypertensive levels unless a dissecting aneurysm is present where systolic BP should be
lowered <100–110mmHg. After certain types of surgery (e.g. cardiac, aortic), control of systol ic blood pressure
<100–120mmHg may be requested to reduce risk of bleeding.
5.
Longer term treatment, e.g. an oral ACE inhibitor, should be insti tuted with caution, starting at low doses.6.
Drug doses
Drug Dose
GTN 0.5–20mg/h
Sodium nitroprusside 0.5–1.5µg/kg/min, increased slowly to 0.5–8.0g/kg/min
Labetolol 50mg IV over 1min repeated every 5min to maximum 200mg
Esmolol 50–200µg/min
Hydralazine 5–10mg slow IV followed by 50–150µg/min
See also:
IPPV—failure to tolerate venti lation, p12; Blood pressure monitoring, p110; Intracranial  pressure monitoring, p134;
Vasodi lators, p198; Hypotensive agents, p202; Opioid analgesics, p234; Non-opioid analgesics, p236; Sedatives,
p238; Intracranial haemorrhage, p376; Subarachnoid haemorrhage, p378; Raised intracranial  pressure, p382; Pain,
p532; Pre-eclampsia and eclampsia, p538; HELLP syndrome, p540
Tachyarrhythmias
If pulses are not palpable or there is severe hypotension, a tachyarrhythmia requires cardiac massage and urgent DC
cardioversion. Otherwise, the initial  treatment prior to diagnosis includes correction of hypoxaemia, potassium (to
ensure a plasma K+ >4.5mmol/l) and magnesium (often to levels of 1.5–2mmol/l).
Causes of tachyarrhythmias
Where possible the cause of a tachyarrhythmia should be treated. Common causes for which speci fic treatment may
be required include hypovolaemia, hypotension (may also be due to the arrhythmia), acute myocardial infarction,
pain, anaemia, hypercapnia, fever, anxiety, thyrotoxicosis and digoxin toxicity.
Diagnosis of tachyarrhythmias
Broad complex tachycardia
Regular complexes with AV dissociation (fusion beats, capture beats, QRS>140ms, axis<-30°, concordance) suggest
ventricular tachycardia. If there is no AV dissociation the arrhythmia is probably supraventricular wi th aberrant
conduction; adenosine may be used as a diagnostic test since SVT may respond and VT wil l  not. Irregular broad
complexes are probably atrial fibri l lation with aberration. Torsades de pointes is a form of ventricular tachycardia
with a variable axis.
Narrow complex tachycardia
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The absence of P waves suggests atrial f ibri l lat ion. A P wave rate >150 is suggestive of SVT whereas slower P wave
rates may represent a sinus tachycardia or atrial flutter with block. The P waves are abnormal (flutter waves) in
atrial f lutter and QRS complexes may be irregular if the block is variable. Extremely fast SVT may be due to a
re-entry pathway with retrograde conduction and premature ectopic atrial  exci tation. In Wolff–Parkinson–White
syndrome the re-entry pathway inserts below the His bundle al lowing rapid AV conduction and re-entry
tachyarrhythmias. This may be diagnosed by a short PR interval and a delta wave.
Treatment of tachyarrhythmias
Ventricular tachycardia
Lidocaine, amiodarone or magnesium form the mainstay of drug treatment. Overdrive pacing may be used if a pacing
wire is in situ, capturing the ventricle at a pacing rate higher than the arrhythmia and gradual ly reducing the pacing
rate. Torsades de pointes may be exacerbated by antiarrhythmics so magnesium or overdrive pacing are safest.
Supraventricular tachycardia and atrial flutter
Carotid sinus massage may be used in patients with no risk of calcified atheromatous carotid deposi ts. Amiodarone,
adenosine or magnesium are usually the most useful drugs in the crit ically i l l .  Verapami l may be used if complexes
are narrow (no risk of misdiagnosed ventricular tachycardia) al though i t and other AV node blockers should be
avoided in re-entry tachycardias.
Atrial fibrillation
Acute or paroxysmal atrial  fibri l lation should be treated as for supraventricular tachycardia. Digoxin is more useful
for chronic atrial f ibri l lat ion and does not prevent paroxysmal episodes.
Drug doses and cautions
Adenosine 3mg IV as a rapid bolus. If no response in 1min give 6mg followed by 12mg.
Verapamil 2.5mg IV slowly. If no response repeat to a maximum of 20mg. An intravenous
infusion of 1–10mg may be used. 10ml CaCl 10% should be available to treat
hypotension associated with verapamil. Verapamil should be avoided in re-entry
tachyarrhythmias since ventricular response may increase. Life threatening
hypotension may occur in misdiagnosed ventricular tachycardia and life threatening
bradycardia may occur if the patient has been β-blocked.
Lidocaine 1mg/kg intravenously as a bolus followed by an infusion of 2–4mg/min.
Amiodarone 5mg/kg over 20min then infused at up to 15mg/kg/24h in 5% glucose via a central
vein. Avoid with other class III agents (e.g. sotalol) since QT interval may be
severely prolonged.
Magnesium 20mmol MgSO4 over 2–3h. In an emergency it may be given over 5min
See also:
Defibri l lat ion, p52; ECG monitoring, p108; Antiarrhythmics, p204; Basic resusci tation, p270; Cardiac arrest, p272;
Fluid challenge, p274; Hypotension, p312; Acute coronary syndrome (1), p320; Hyperkalaemia, p420; Hypokalaemia,
p422; Thyroid emergencies, p446; Tricycl ic antidepressant poisoning, p460; Anaemia, p400; Pyrexia (1), p518;
Pyrexia (2), p520; Pain, p532
Bradyarrhythmias
If peripheral pulses are not palpable a bradyarrhythmia requires external cardiac massage and treatment as for
asystole. For asymptomatic bradycardia treatment may not be required other than close monitoring and correction of
the cause. The exception to this is higher degrees of heart block occurring after an acute anterior myocardial
infarction where pacing may be required prophylactically.
Causes of bradyarrhythmias
Where possible the cause of a bradyarrhythmia should be treated. Common causes for which speci fic treatment may
be required include hypovolaemia, hypotension (may also be due to the arrhythmia), acute myocardial infarction,
digoxin toxici ty, β-blocker toxicity, hyperkalaemia, hypothyroidism, hypopituitarism and raised intracranial  pressure.
Digoxin toxici ty may require treatment with antidigoxin antibodies.
Diagnosis of bradyarrhythmias
Sinus bradycardia
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
147 из 254 07.11.2006 1:04
P.319
P.320
Slow ventricular rate with normal P waves, normal PR interval and 1:1 AV conduction.
Heart block
Normal  P waves, a prolonged PR interval and 1:1 AV conduction suggest 1° heart block. In 2° heart block the
ventricles fai l to respond to atrial contraction intermittently. This may be associated with regular P waves and an
increasing PR interval unti l ventricular depolarisation fails (Mobitz I or Wenkebach) or a normal  PR interval  with
regular fai led ventricular depolarisation (Mobitz II). In the latter case the AV conduction ratio may be 2:1 to 5:1. In
3° heart block there is complete AV dissociation with a slow, idioventricular rate.
Absent P wave bradycardia
Absent P waves may represent slow atrial f ibri l lat ion or sino-atrial  dysfunction. In the latter case there wi l l  be a
slow, idioventricular rate.
Treatment of bradyarrhythmias
Hypoxaemia must be corrected in all symptomatic bradycardias. First l ine drug treatment is usually atropine 0.3mg or
glycopyrrolate 200µg intravenously. If the arrhythmia fails to respond, 0.6mg fol lowed by 1.0mg atropine may be
given. Failure to respond to drugs requires temporary pacing. This may be accompl ished rapidly with an external
system if there is haemodynamic compromise or transvenously. Other indications for temporary pacing are shown
opposi te. Higher degrees of heart block after an anterior myocardial infarction wil l  usually require permanent pacing.
Indications for temporary pacing
Persistent symptomatic bradycardia
Blackouts associated with
3° heart block
2° heart block
RBBB and left posterior hemiblock
Cardiovascular col lapse
Inferior myocardial infarction with symptomatic 3° heart block
Anterior myocardial infarction with
3° heart block
RBBB and left posterior hemiblock
Alternating RBBB and LBBB
See also:
Temporary pacing (1), p54; Temporary pacing (2), p56; ECG monitoring, p108; Chronotropes, p206; Basic
resuscitation, p270; Cardiac arrest, p272; Acute coronary syndrome (1), p320; Thyroid emergencies, p446;
Hypothermia, p516
Acute coronary syndrome (1)
Principles of management of the uncomplicated myocardial infarct
Oxygen—to maintain SaO2≥98%
Good venous access
Continuous ECG monitoring
Adequate pain rel ief
Early thrombolysis plus aspirin (heparin if using rt-PA)
Early β blockade
Gradual mobi l isation
Complications of myocardial infarction
Cardiopulmonary arrest
Continuing chest pain—may be ischaemic or pericardi tic in origin
Pump failure
Hypotension—apart from cardiogenic shock consider hypovolaemia (e.g. post-diuretics) and a thrombolysis
reaction
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Tachyarrhythmias/bradyarrhythmias
Valve dysfunction—predominantly mitral
Pericardial tamponade (rare)
Ventricular septal defect (unusual, often presents 2–5 days post-infarct)
Complications of thrombolytic therapy—arrhythmias, bleeding, anaphylactoid reaction
Management of the complicated myocardial infarct
General
Oxygen to maintain SaO2≥98%
Appropriate and prompt monitoring and investigations as indicated, e.g. echocardiogram, pulmonary artery
catheter, angiography, ECG
Early thrombolysis should sti l l  be given. rt-PA fol lowed by heparin should be given in preference to streptokinase
if invasive procedures and/or surgery are contemplated.
Arterial  or central venous cannulation should not be delayed if cl inically indicated. These procedures should be
performed by an experienced operator to minimise the risk of bleeding. The subclavian route should be avoided.
Angioplasty or revascularisation surgery is beneficial i f performed early. The cardiologist should be informed
promptly if a patient is admitted in pump fai lure, continuing pain, or valvular dysfunction.
Specific
Cardiopulmonary arrest—cardiopulmonary resuscitation
Continuing chest pain:
If ischaemic—IV ni trate and heparin infusions, aspirin, clopidogrel , calcium antagonist and β-blocker (unless
contraindicated); consider urgent angiography.
If pericardi tic—consider non-steroidal  anti-inflammatory agent
Management of heart fai lure—also consider IABP
Tachyarrhythmia—antiarrhythmics, synchronised DC cardioversion
Bradycardias—chronotrope, consider temporary pacing
Valve dysfunction—heart fai lure management; consider surgery
Pericardial tamponade—pericardial  aspiration
Ventricular septal defect—heart fai lure management, consider surgery
Thrombolysis compl ications
Drug dosage
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
149 из 254 07.11.2006 1:04
P.322
Diamorphine 2.5mg IV. Repeat prn + anti-emetic
Streptokinase 1.5 million units in 100ml 0.9% saline IV over 1h
rt-PA
(alteplase)
100mg IV over 90min (15mg bolus, then 50mg over 30min, then 35mg over
60min
Reteplase 10units IV + further 10units IV 30min later
Aspirin 150mg PO od
Clopidogrel 75mg
Atenolol 50mg PO od (increase to 100mg od if not hypotensive and heart rate exceeds
70bpm) or 5mg slow IV bolus
Propranolol 10–40mg PO qds (titrate to heart rate of 60bpm)
Isosorbide
dinitrate
2–40mg/h IV
GTN 10–200µg/min IV or 0.5–1mg SL
Diltiazem 60mg PO tds
Nifedipine 5–10mg sublingual or PO tds
Atropine 0.3mg IV. Repeat to maximum of 2mg
Lidocaine 1mg/kg slow IV bolus then 2–4mg/min
Amiodarone 5mg/kg over 20min then infused up to 15mg/kg/day in 5% glucose via central
vein (in emergency give 150–300mg in 10–20ml 5% glucose over 3min)
Key papers
Task force or Management of acute myocardial infarction of the European Society of Cardiology. Management of acute
myocardial infarction in patients presenting with ST segment elevation. Eur Heart J 2003; 24:28–66
See also:
Defibri l lat ion, p52; Temporary pacing (1), p54; Temporary pacing (2), p56; Intra-aortic bal loon counterpulsation,
p58; ECG monitoring, p108; Blood pressure monitoring, p110; Central venous catheter—use, p114; Central  venous
catheter—insertion, p116; Pulmonary artery catheter—use, p118; Pulmonary artery catheter—insertion, p120; Cardiac
output—thermodi lution, p122; Cardiac output—other invasive, p124; Cardiac output—non-invasive (1), p126; Cardiac
output—non-invasive (2), p128; Inotropes, p196; Vasodi lators, p198; Vasopressors, p200; Antiarrhythmics, p204;
Chronotropes, p206; Anticoagulants, p248; Thrombolytics, p250; Basic resuscitation, p270; Cardiac arrest, p272;
Fluid challenge, p274; Hypotension, p312; Tachyarrhythmias, p316; Bradyarrhythmias, p318; Acute coronary
syndrome (2), p322; Heart fai lure—assessment, p324; Heart fai lure—management, p326; Pain, p532
Acute coronary syndrome (2)
Angina
Ischaemic or, rarely, spasmodic constriction of coronary arteries result ing in pain, usual ly precordial,  pressing or
crushing, and with or wi thout radiation to jaw, neck or arms. The sedated, venti lated patient wi l l  not usual ly
complain of pain but signs of discomfort may be apparent, e.g. sweating, hypertension, tachycardia. The ECG should
be regularly scrutinised for ST segment and/or T wave changes.
Unstable angina encompasses a spectrum of syndromes between stable angina and myocardial  infarction. Anginal
attacks may be increased in frequency and/or severity, persist longer, respond less to nitrates, and occur at rest or
after minimal exertion.
Pathophysiology
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Myocardial  oxygen supply–demand imbalance usually due to coronary artery atheroma ± disruption of plaque or
new non-occlusive thrombus formation. Spasm (Prinzmetal  angina) is uncommon.
Vasopressor drugs may compromise myocardial perfusion by further constrict ing an al ready stenosed vessel .
Vasodi lator drugs may also compromise myocardial  perfusion by a ‘coronary steal’ phenomenon where blood flow
is redistributed away from stenosed vessels.
Diagnosis
Symptoms, especial ly chest pain but also non-specific, e.g. sweating
ECG changes—ST segment elevation/depression, T wave inversion
No rise in cardiac enzymes or troponin above the myocardial infarction threshold
Dyskinetic areas of myocardium may be seen on echocardiography or angiography
Treatment
Ensure adequate oxygenation
Correct hypotension and tissue hypoperfusion
Consider drug causes, e.g. vasopressors
Glyceryl trini trate 0.5mg SL, or ni trol ingual spray (0.4–0.8mg) repeated as necessary
If symptoms are severe and/or persist ing, maintain bed rest
Aspirin 75mg od PO (unless contraindicated).
For continuing angina:
IV Nitrate infusion, e.g. glyceryl trinitrate, isosorbide trini trate
Consider calcium antagonist, e.g. di ltiazem though not alone
Consider β-blocker (unless contraindicated), e.g. propranolol, atenolol
LMW heparin and clopidogrel  (unless contraindicated)
Consider GP2b3a inhibitor (IV eptifibatide or t irofiban) in addit ion to aspirin and clopidogrel i f considered at high
risk of MI or death
If symptoms or ST-segment changes persist despite optimal  pharmacological intervention, inform cardiologist
with a view to angiography and possible angioplasty or surgery.
Key trial
Yusuf S for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of
clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl
J Med. 2001; 345:494–502
Heart failure—assessment
Impaired abi l i ty of the heart to supply adequate oxygen and nutrients to meet the demands of the body's
metabolising t issues.
Major causes
Myocardial  infarction/ischaemia
Drugs e.g. β-blockers, cytotoxics
Tachy- or bradyarrhythmias
Valve dysfunction
Sepsis
Septal  defect
Cardiomyopathy/myocarditis
Pericardial tamponade
Clinical features
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Decreased forward flow leading to poor tissue perfusion
Muscle fatigue leading ultimately to hypercapnia and collapse
Confusion, agitation, drowsiness, coma
Oliguria
Increasing metabol ic acidosis, arterial hypoxaemia and dyspnoea
Increased venous congestion secondary to right heart failure
Peripheral oedema
Hepatic congestion
Splanchnic ischaemia
Raised intracranial pressure
Increased pulmonary hydrostatic pressure secondary to left heart failure
Pulmonary oedema, dyspnoea
Hypoxaemia
Investigations
Test Diagnosis
ECG Myocardial ischaemia/infarction, arrhythmias
CXR With left heart failure: pulmonary oedema (interstitial perihilar (‘bat's wing’)
shadowing, upper lobe blood diversion, Kerley B lines, pleural effusion) ±
cardiomegaly
Pulmonary artery
catheter
Low cardiac output and stroke volume, low mixed venous oxygen saturation
(<60%), raised PAWP (with left heart failure), raised RAP (with right heart
failure). V waves with mitral or tricuspid regurgitation
Blood tests Low SaO2, variable PaCO2, base deficit >2mmol/l, hyperlactataemia, low
venous O2 (mixed or central venous), raised cardiac enzymes, troponin, BNP,
thyroid function (if indicated)
Echocardiogram Poor myocardial contractility, pericardial effusion, valve
stenosis/incompetence
Notes
Peripheral oedema implies total body salt and water retention but not necessari ly intravascular fluid overload.
See also:
ECG monitoring, p108; Blood pressure monitoring, p110; Central  venous catheter—use, p114; Central venous
catheter—insertion, p116; Pulmonary artery catheter—use, p118; Pulmonary artery catheter—insertion, p120; Cardiac
output—thermodi lution, p122; Cardiac output—other invasive, p124; Cardiac output—non-invasive (1), p126; Cardiac
output—non-invasive (2), p128; Hypotension, p312; Tachyarrhythmias, p316; Bradyarrhythmias, p318; Acute
coronary syndrome (1), p320; Heart fai lure—management, p326
Heart failure—management
Basic measures
Determine l ikely cause and treat as appropriate, e.g. antiarrhythmic1.
Oxygen—to maintain SaO2≥98%2.
GTN spray SL then commence IV nitrate infusion t itrated rapidly unti l good cl inical effect. Beware hypotension
which, at low dosage, is suggestive of left ventricular underfi l l ing, e.g. hypovolaemia, tamponade, mitral
stenosis, pulmonary embolus
3.
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If patient is agitated or in pain, give diamorphine IV.4.
Consider early CPAP, BiPAP and/or IPPV to reduce work of breathing and provide good oxygenation. Cardiac
output wil l  often improve. Do not delay unti l the patient is in extremis.
5.
Furosemide is rarely needed as first l ine therapy unless intravascular fluid overload is causative. Init ial
symptomatic rel ief is provided by its prompt vasodi lating action; however, subsequent diuresis may result in
marked hypovolaemia leading to compensatory vasoconstriction, increased cardiac work and worsening
myocardial  function. Diuretics may be indicated for acute-on-chronic fai lure, especial ly if the patient is on long
term diuretic therapy but should not be used if hypovolaemic. If furosemide is required, start at low doses then
reassess.
6.
Directed management
Adequate monitoring (e.g. pulmonary artery catheterisation) and investigation (echocardiography).1.
If evidence exists for hypovolaemia, give 100–200ml col loid fluid chal lenges to achieve optimal stroke volume.2.
If vasoconstriction persists (SVR >1400dyn/s/cm5), t itrate ni trate infusion further to optimise stroke volume
and, ideal ly, reduce SVR <1300dyn/s/cm5.  If hypovolaemia is suspected (i.e. stroke volume fal ls), fluid
chal lenges should be given to re-optimise the stroke volume. Within 24h of nitrate infusion, commence ACE
inhibi tion, initial ly at low dose but rapidly increased to appropriate long-term doses.
3.
Inotropes are indicated if evidence of t issue hypoperfusion, hypotension or vasoconstriction persists despi te
optimal  fluid loading and nitrate dosing. Consider epinephrine, dobutamine or mil rinone; while epinephrine may
sometimes cause excessive constriction, dobutamine and mi lrinone may excessively vasodi late. Levosimendan
increases cardiac output though not at the expense of increased cardiac work.
4.
Intra-aortic balloon counterpulsation augments cardiac output, reduces cardiac work and improves coronary
artery perfusion.
5.
Angioplasty or surgical  revascularization are beneficial i f performed early after myocardial  infarct. Surgery may
also be necessary for mechanical defects, e.g. acute mitral regurgitation.
6.
Treatment end-points
BP and cardiac output adequate to maintain organ perfusion (e.g. no oliguria, confusion, dyspnoea nor metabolic
acidosis). A mean BP of 60mmHg is usually sufficient but may need to be higher, especial ly if premorbid blood
pressures are high.
1.
A mixed venous oxygen saturation ≥60%. Excessive inotropes should be avoided as myocardial oxygen demand
is increased.
2.
Symptomatic rel ief.3.
Drug dosage
GTN 2–40mg/h IV or 0.4–0.8mg by SL spray
Isosorbide dinitrate 2–40mg/h IV
Nesiritide 2µg/kg bolus followed by infusion of 0.01–0.03µg/kg/min.
Sodium
nitroprusside
20–400µg/min IV
Captopril 6.25mg PO test dose increasing to 25mg tds
Enalapril 2.5mg PO test dose increasing to 40mg od
Lisinopril 2.5mg PO test dose increasing to 40mg od
Epinephrine Infusion starting from 0.05µg/kg/min
Dobutamine 2.5–25µg/kg/min IV
Dopamine 2.5–25µg/kg/min IV
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
153 из 254 07.11.2006 1:04
Milrinone Loading dose of 50µg/kg IV over 10min followed by infusion from
0.375–0.75µg/kg/min.
Enoximone Loading dose of 0.5–1mg/kg IV over 10min followed by infusion from
5–20µg/kg/min.
Levosimendan 12–24µg/kg over 10min followed by 0.1µg/kg/min for 24h
Diamorphine 2.5mg IV. Repeat every 5min as necessary
Furosemide 10–20mg IV bolus. Repeat or increase as necessary
Key trials
Cotter G, et al . Randomised trial  of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose
furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998; 351:389–93
Cuffe MS, et al.  Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous
mil rinone for exacerbations of chronic heart fai lure. Am Heart J 2000; 139:15–22
Fol lath F, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output
heart fai lure (the LIDO study): a randomised double-bl ind trial . Lancet 2002; 360:196–202
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; Posi tive end expiratory pressure (1), p22; Posi tive end
expiratory pressure (2), p24; Continuous posi tive airway pressure, p26; Inotropes, p196; Vasodi lators, p198;
Vasopressors, p200; Antiarrhythmics, p204; Chronotropes, p206; Basic resuscitation, p270; Fluid challenge, p274;
Heart fai lure—assessment, p324
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Renal Disorders
Oliguria
Defined as a urine output <0.5ml/kg/h and caused by:
Post-renal—urinary tract obstruction, e.g. blocked catheter, ureteric trauma, prostatism, raised intra-abdominal
pressure, blood clot, bladder tumour.
Renal—established acute renal fai lure, acute tubular necrosis, glomerulonephritis.
Pre-renal—hypovolaemia, low cardiac output, hypotension, inadequate renal  blood flow.
Obstruction and pre-renal causes of ol iguria must be excluded before resorting to diuretics.
Urinary tract obstruction
A full  bladder should be excluded by palpation. Ensure a patent catheter is present. If obstruction is due to blood clot
the bladder should be irrigated. If obstruction is suspected higher in the renal tract an ultrasound scan is required for
diagnosis and possible urological intervention (e.g. nephrostomies). Raised intra-abdominal pressure may cause
oliguria by impeding renal  venous drainage (particularly if >20mmHg). Relief of the high pressure often promotes a
diuresis.
Hypovolaemia
Once renal tract obstruction is excluded, i t i s mandatory to correct hypovolaemia by fluid chal lenge. Oliguria in
hypovolaemic patients may be a physiological response or due to a reduced renal  blood flow.
Inadequate renal blood flow and/or pressure
If cardiac output remains low despi te correction of hypovolaemia, correction with vasodilators and/or inotropes wil l
be necessary. If the blood pressure remains low after improving the cardiac output, vasopressors may be needed to
achieve a mean blood pressure of at least 60mmHg. In elderly patients and others with pre-existing hypertension, a
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higher mean blood pressure may be necessary to maintain urine output.
Persistent oliguria
Attempts to increase urine output with diuretics may fol low the above measures if ol iguria persists. Furosemide is
given in a dose of 5–10mg intravenously with higher increments at 30min intervals to a maximum of 250mg. Higher
doses may be needed if the patient has previously received diuretic therapy. A low dose infusion may be started
(1–5mg/h IV). Mannitol  (20g intravenously) may be considered although fai lure to promote a diuresis may increase
oedema formation. Failure to re-establish urine output may require renal  support in the form of dialysis or
haemofi ltration. There is no point in continuing diuretic therapy i f i t i s not effective; loop diuretics in particular may
be nephrotoxic. Indications for renal support include fluid overload, hyperkalaemia, metabol ic acidosis, creation of
space for nutri tion or drugs, persistent renal  fai lure with rising urea and creatinine, and symptomatic uraemia.
Biochemical assessment
 Pre-renal cause Renal cause
Urine osmolality (mOsmol/kg) >500 <400
Urine Na (mmol/l) <20 >40
Urine:Plasma creatinine >40 <20
Fractional Na excretion* <1 >2
*
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Peritoneal dialysis, p66; Blood pressure monitoring,
p110; Urea & creatinine, p144; Urinalysis, p166; Colloid osmotic pressure, p172; Crystalloids, p176; Col loids, p180;
Diuretics, p212; Dopamine, p214; Basic resuscitation, p270; Fluid challenge, p274; Hypotension, p312; Acute renal
fai lure—diagnosis, p332; Acute renal  fai lure—management, p334; Bowel perforation and obstruction, p348;
Abdominal  sepsis, p350; Pancreatit is, p354; Acute l iver fai lure, p360; Hyperkalaemia, p420; Sepsis and septic
shock—treatment, p486; Malaria, p490; Mult iple trauma (1), p500; Multiple trauma (2), p502; Burns—fluid
management, p510; Rhabdomyolysis, p528; Post-operative intensive care, p534
Acute renal failure—diagnosis
Renal fai lure is defined as renal  function inadequate to clear the waste products of metabolism despite the absence of
or correction of haemodynamic or mechanical causes. Renal  fai lure is suggested by:
Uraemic symptoms (drowsiness, nausea, hiccough, twitching)
Raised plasma creatinine (>200µmol/l)
Hyperkalaemia
Hyponatraemia
Metabol ic acidosis
Persistent ol iguria may be a feature of acute renal  fai lure but non-ol iguric renal fai lure is not uncommon; 2–3l of poor
quali ty urine per day may occur despite an inadequate glomerular fi ltration rate. The prognosis is better i f urine
output is maintained. Cl inical features may suggest the cause of renal fai lure and dictate further investigation. Acute
tubular necrosis is a common aetiology in the crit ical ly i l l  (e.g. fol lowing hypovolaemia, extensive burns) but other
causes must be borne in mind. In sepsis, the kidney often has a normal  histological appearance. Anaemia impl ies
chronic renal fai lure.
Post-operative renal failure
Risk factors include hypovolaemia, haemodynamic instabil i ty (particularly hypotension), major abdominal surgery in
those >50 years, major surgery in jaundiced patients and bil iary and other sepsis. Surgical procedures (particularly
gynaecological) may be compl icated by damage to the lower urinary tract with an obstructive nephropathy.
Abdominal  aortic aneurysm surgery may be associated with renal arterial  disruption and should be investigated
urgently with renography and possible arteriography or re-exploration.
Other causes
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Nephrotoxins—may cause renal  fai lure via acute tubular necrosis, interstit ial  nephrit is or renal tubular
obstruction. Al l potential  nephrotoxins should be withdrawn.
Rhabdomyolysis—suggested by myoglobinuria and raised CPK in patients who have suffered a crush injury, coma
or seizures.
Glomerular disease—red cell  casts, haematuria, proteinuria and systemic features (e.g. hypertension, purpura,
arthralgia, vascul it is) are al l suggestive of glomerular disease. Renal  biopsy or specific blood tests (e.g.
Goodpasture's syndrome, vascul itis) are required to confi rm diagnosis and appropriate treatment.
Haemolytic uraemic syndrome—suggested by haemolysis, uraemia, thrombocytopenia and neurological
abnormali ties.
Crystal  nephropathy—suggested by the presence of crystals in the urinary sediment. Microscopic examination of
the crystals confi rms the diagnosis (e.g. urate, oxalate). Release of purines and urate are responsible for acute
renal fai lure in the tumour lysis syndrome.
Renovascular disorders—loss of vascular supply may be diagnosed by renography. Complete loss of arterial
supply may occur in abdominal trauma or aortic disease (particularly dissection). More commonly, the arterial
supply is partial ly compromised (e.g. renal artery stenosis) and blood flow is further reduced by haemodynamic
instabil i ty or local ly via drug therapy (e.g. NSAIDs, ACE inhibi tors). Renal vein obstruction may be due to
thrombosis or external compression (e.g. raised intra-abdominal  pressure).
Nephrotoxins
The fol lowing are some common nephrotoxins:
Allopurinol Aminoglycosides
Amphotericin Cephalosporins
Dextran 40 Furosemide
Heavy metals Herbal medicines
Narcotics NSAIDs
Organic solvents Paraquat
Penicillins Pentamidine
Phenytoin Radiographic contrast
Sulphonamides Tetracyclines
Thiazides Vancomycin
See also:
Urinalysis, p166; Fluid challenge, p274; Hypotension, p312; Oliguria, p330; Acute renal fai lure—management, p334;
Bowel perforation and obstruction, p348; Abdominal sepsis, p350; Pancreatitis, p354; Acute l iver fai lure, p360;
Haemolysis, p404; Platelet disorders, p406; Sepsis and septic shock—treatment, p486; Malaria, p490; Rheumatic
disorders, p492; Vascul itides, p494; Multiple trauma (1), p500; Multiple trauma (2), p502; Burns—fluid management,
p510; Burns—general management, p512; Post-operative intensive care, p534
Acute renal failure—management
Identi fication and correction of reversible causes of renal  fai lure is crucial.  Al l cases require careful  attention to fluid
management and nutrit ional support. Dialysis and/or fi ltration techniques wi l l  make space for adequate fluid and
nutri tional  intake.
Urinary tract obstruction
Lower tract obstruction requires the insertion of a catheter (suprapubic if there is urethral  disruption) to al low tract
decompression. Ureteric obstruction requires urinary tract decompression by nephrostomy or stent. A massive
diuresis is common after decompression so it is important to ensure adequate circulating volume to prevent
secondary pre-renal fai lure.
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Haemodynamic management
Pre-renal  fai lure is reversible before it becomes establ ished. Careful fluid management to ensure an adequate
ci rculating volume and any necessary inotrope or vasopressor support may establish a diuresis. If ol iguria persists
after pre-renal  factors have been corrected, the use of diuretics (furosemide, mannitol) may establish a diuresis.
Metabolic management
Hyperkalaemia may be l ife-threatening (>6.5mmol/l  or ECG changes) and may be prevented by potassium restriction,
early dialysis or haemo(dia)fi ltration. Hypocalcaemia and hyponatraemia are best treated with dialysis and/or
haemo(dia)fi l tration, al though calcium supplementation may be used. Hyponatraemia is usual ly due to water excess
although sal t-losing nephropathies (acute tubular necrosis, other renal  tubular disorders) may require sodium
chloride supplements. Hyperphosphataemia may be treated with dialysis, f i l tration or aluminium hydroxide orally.
Metabolic acidosis (not due to tissue hypoperfusion) may be corrected with dialysis, fi ltration or 1.26% sodium
bicarbonate infusion.
Nephrotoxins and crystal nephropathies
Al l nephrotoxic agents should be withheld if possible. All  necessary drugs should have their dosage modi fied
according to the GFR. In some cases urinary excretion of nephrotoxins and crystals may be encouraged by urinary
alkalinisation to maintain their solubil ity wi th an induced diuresis (rhabdomyolysis, acidic crystals). Dialysis may
also be useful.
Glomerular disease
Immunosuppressive therapy may be useful  after diagnosis has been confi rmed. Dialysis is often required for the more
severe forms of glomerulonephritis despite steroid responsiveness.
Urgent treatment of hyperkalaemia
10–20ml calcium chloride 10% by slow intravenous injection.
100ml 8.4% sodium bicarbonate intravenously.
Glucose (50g) and insulin (10–20IU) intravenously with careful blood glucose monitoring and urgent
haemodialysis.
Renal replacement therapy
Continuous haemofi ltration forms the mainstay of replacement therapy in cri tical ly i l l  patients who often cannot
tolerate haemodialysis due to haemodynamic instabil ity. Peri toneal  dialysis is not commonly used today. Acute renal
fai lure in the critical ly i l l  usually recovers within 1–6 weeks; permanent renal fai lure is rare.
General indications for dialysis or haemo(dia)filtration
Fluid excess (e.g. pulmonary oedema)
Hyperkalaemia (>6.0mmol/l)
Metabol ic acidosis (pH <7.2) due to renal fai lure
Clearance of dialysable nephrotoxins and other drugs
Creatinine rising >100µmol/l/day
Creatinine >300–600µmol/l
Urea rising >16–20mmol/l /day
To create space for nutri tion or drugs
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Peritoneal dialysis, p66; Crystalloids, p176; Colloids,
p180; Diuretics, p212; Dopamine, p214; Basic resuscitation, p270; Fluid challenge, p274; Oliguria, p330; Acute renal
fai lure—diagnosis, p332; Hyperkalaemia, p420; Hyponatraemia, p418; Hypocalcaemia, p428; Metabol ic acidosis, p434
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Vomiting/gastric stasis
Whi le vomiting per se  is relatively rare in the ICU patient, large volume gastric aspirates are commonplace and
probably represent the major reason for fai lure of enteral nutrition.
Ileus
Ileus affects the stomach more frequently than the rest of the gastrointestinal tract. Abdominal surgery, drugs
(particularly opiates), gut dysfunction as a component of multi -organ dysfunction, hypoperfusion and prolonged
starvation may all  contribute to gastric i leus. Early and continued use of the bowel  for feeding appears to maintain
forward propulsive action. Management consists of treating the cause where possible, the use of moti l i ty stimulants
such as metoclopramide or erythromycin and, in resistant cases, bypassing the stomach with a
nasoduodenal/nasojejunal tube or a jejunostomy.
Upper bowel obstruction
Relatively unusual; apart from primary surgical  causes such as neoplasm or adhesions, the predominant cause in the
ICU is gastric outlet obstruction. This may be related to long-standing peptic ulcer disease or may occur in the short
term from pyloric and/or duodenal  swell ing consequent to gastri tis or duodeni tis. This can be diagnosed
endoscopical ly and treated by bowel rest plus an H2 antagonist, proton pump inhibi tor or sucralfate.
Gastric irritation
Drugs or chemicals—either accidental or adverse reaction (e.g. steroids, aspirin), intentional  (e.g. alcohol, bleach) or
therapeutic (e.g. ipecacuanaha syrup) may induce vomiting. Treatment, where appropriate, may comprise (i) removal
of the cause, (i i) di lution with copious amounts of fluid (i i i) neutralisation with alkal i and/or H2 antagonist or proton
pump inhibi tor and (iv) administration of anti-emetic (e.g. metoclopramide).
Neurological
Stimulation of the emetic centre may fol low any neurological  event (e.g. trauma, CVA), drug therapy (e.g.
chemotherapy), pain and metabol ic disturbances. Management is by treating the cause where possible and by
judicious use of anti -emetics, init ial ly metoclopramide or prochlorperazine. Consider ondansetron or granisetron i f
these are unsuccessful.
See also:
Enteral nutrit ion, p80; Electrolytes
, p146; Opioid analgesics, p234; Anti -emetics, p224; Gut moti l ity agents, p226; Bowel perforation and obstruction,
p348; Electrolyte management, p414; Poisoning—general principles
Diarrhoea
The definition of diarrhoea in the ICU patient is problematic as the amount of stool  passed daily is diff icult to
measure. Frequency and consistency may also vary signi ficantly. Loose/watery and frequent (≥ 4 × day) stool wil l
often require investigation and/or treatment.
Commoner ICU causes
Infection—Clostridium difficile, gastroenteri tis (e.g. Salmonella, Shigella), rarer tropical causes (e.g. cholera,
dysentry, giardiasis, tropical sprue).
Drugs, e.g. antibiotics, laxatives.
Gastrointestinal—feed (e.g. lactose intolerance), coel iac disease, other malabsorption syndromes, inflammatory
bowel disease, diverticulit is, pelvic abscess, bowel obstruction with overflow. Enteral feed is often implicated
but rarely causative.
For bloody diarrhoea consider infection, ischaemic or inflammatory bowel  disease.
Diagnosis
Rectal examination to rule out impaction with overflow. Consider sigmoidoscopy if col it is or C. difficile suspected
(pseudomembrane seen).
Stool sent to laboratory for MC & S, C. difficile toxin.
Fat estimation (malabsorption) is rarely necessary in the ICU patient
If ischaemic or inflammatory bowel  disease suspected, perform a supine abdominal X-ray and inspect for di lated
loops of bowel (NB toxic megacolon), thickened wal ls (increased separation between loops) and ‘thumbprinting’
(suggestive of mucosal  oedema). Fluid levels seen on erect or lateral abdominal X-ray may be seen in diarrhoea
or paralytic i leus and do not necessari ly indicate obstruction. Diarrhoea is often but not always bloody.
If abscess suspected, perform ultrasonography or CT scan
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Management
Treat cause where possible e.g. for C. difficile, metronidazole plus cholesytramine (binds the toxin).1.
Consider temporary (12–24h) cessation of enteral feed if very severe. Consider change in feed if appropriate,
e.g. coeliac disease, lactose intolerance.
2.
Consider stopping antibiotics.3.
Give antidiarrhoeal i f infection excluded.4.
Careful  attention to fluid and electrolyte balance (in particular Na+, K+,  Mg2+).5.
Request surgical opinion if infarcted or inflamed bowel or abscess suspected.6.
See also:
Enteral nutrit ion, p80; Antidiarrhoeals, p228; Antimicrobials, p260; Abdominal sepsis, p350; Infection—diagnosis,
p480
Failure to open bowels
Commoner ICU causes
Prolonged i leus/decreased gut moti l i ty (e.g. opiates, post-surgery)
Lack of enteral nutri tion
Bowel obstruction—this is a relatively uncommon secondary event and is mainly seen post-operatively, ei ther
after a curative procedure or with development of adhesions
Management
Clinically exclude obstruction and confirm presence of stool  per rectum.1.
Ensure adequate hydration.2.
Anticonstipation therapy may be given, usually starting with laxatives (e.g. lactulose or, for more urgent
response, magnesium sulphate), then proceeding to glycerine supposi tories and, final ly, enemata i f gentler
measures prove unsuccessful .
3.
Consider reducing/stopping dose of opiate i f possible.4.
See also:
Anticonstipation agents, p230; Opioid analgesics, p234; Bowel  perforations and obstruction, p348; Abdominal  sepsis,
p350
Upper gastrointestinal haemorrhage
Causes
Peptic ulceration
Oesophagi tis/gastrit is/duodeni tis
Varices
Mallory–Weiss lower oesophageal  tear
Neoplasms
Pathophysiology
Peptic ulceration is related to protective barrier loss leading to acid or bi l iary damage of the underlying mucosa and
submucosa. Barrier loss occurs secondary to critical  i l lness, alcohol , drugs, e.g. non-steroidals, poisons including
corrosives. Direct damage, especial ly at the lower oesophagus, may occur from feeding tubes. Mucosal  damage
(‘stress ulcers’) may also occur as a consequence of t issue hypoperfusion. Gastric hypersecretion is uncommon in
critical ly i l l  patients; indeed, gastric acid content and secretion is often reduced.
Prophylaxis
Smal l-bore feeding tubes
Nasogastric enteral nutrit ion (nasojejunal  and parenteral  feeding has also been shown to reduce the incidence of
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stress ulcer bleeding)
Adequate t issue perfusion (flow and pressure)
The role of prophylactic drug therapy including H2 antagonists, proton pump inhibi tors and sucralfate is
controversial. Evidence suggests that enteral  nutrition alone is as effective and there are claims that loss of the
acid environment in the stomach predisposes the patient to nosocomial  infection. Patients at highest risk are
those requiring prolonged mechanical  venti lat ion or wi th a concurrent coagulopathy.
Treatment of major haemorrhage
Fluid resuscitation with colloid and blood with blood products as appropriate to correct any coagulopathy.
Maintain haemoglobin between 7–10g/dl  and have adequate cross-matched blood available should further large
haemorrhages occur.
If possible, discontinue any on-going anticoagulation, e.g. heparin.
Urgent diagnostic fibreoptic endoscopy. Local  injection of epinephrine or a sclerosant into (or thermal sealing of)
a bleeding peptic ulcer base may halt further bleeding. Likewise, banding or sclerosant injection may arrest
bleeding varices.
If oesophageal varices are known or highly suspected, consider vasopressin or terl ipressin ± a Sengstaken-type
tube for severe haemorrhage, ei ther as a bridge to endoscopy or i f banding/injection is unsuccessful . Remember
that sources of bleeding other than varices may be present, e.g. peptic ulcer.
For peptic ulceration and general ised inflammation commence an H2 antagonist or proton pump inhibi tor. Give
intravenously to ensure effect. Enteral  antacid may also be beneficial .
Surgery is rarely necessary but should be considered i f bleeding continues, e.g. >6–10 uni t transfusion
requirement. Inform a surgeon promptly of any patient with major bleeding.
See also:
Endotracheal  intubation, p36; Sengstaken-type tube, p72; Upper gastrointestinal endoscopy, p74; Coagulation
monitoring, p156; Colloids, p180; Blood transfusion, p182; H2 blockers and proton pump inhibitors, p218; Sucral fate,
p220; Antacids, p222; Coagulants and antifibrinolytics, p254; Basic resusci tation, p270; Fluid challenge, p274;
Vomiting/gastric stasis, p338; Bleeding varices, p346; Bleeding disorders, p396; Systemic inflammation/multiorgan
fai lure, p484
Bleeding varices
Varices develop fol lowing a prolonged period of portal  hypertension, usual ly related to l iver cirrhosis. Approximately
one third wi l l  bleed. They are commonly found in the lower oesophagus but, occasional ly, in the stomach or
duodenum. Torrential haemorrhage may occur. Approximately 50% of patients die within 6 weeks of presentation of
their fi rst bleed; each subsequent bleed carries a 30% mortali ty.
Management
If airway and/or breathing are compromised, perform endotracheal  intubation and insti tute mechanical
venti lation. This faci l i tates Sengstaken-type tube placement and endoscopy but may be associated with severe
hypotension secondary to covert hypovolaemia. If possible, ensure adequate intravascular fi l l ing before
intubation.
1.
Fluid resuscitation with colloid and blood with blood products as appropriate to correct any coagulopathy. Ensure
good venous access (at least two 14G cannulae). Group-speci fic or O-negative blood may be needed for
emergency use. Maintain haemoglobin >10g/dl  and have at least 4 units of cross-matched blood available for
urgent transfusion. There is a theoretical  risk that over-transfusion may precipitate further bleeding by raising
portal  venous pressure. Cardiac output monitoring should be considered i f the patient remains haemodynamical ly
unstable or there is a history of heart disease.
2.
If bleeding is torrential,  insert a Sengstaken-type tube and commence administration of IV
vasopressin/terl ipressin (q.v.).
3.
Gentle placement of a large-bore nasogastric tube is a reasonably safe procedure that faci l itates drainage of
blood, lessens the risk of aspiration and can be used to assess continuing blood loss.
4.
Perform urgent fibreoptic endoscopy to exclude other sources of bleeding. This also permits variceal banding or
local injection of a sclerosing agent. Bleeding is arrested in up to 90% of cases. Endoscopy may be impossible in
the short term if bleeding is too severe. It may have to be delayed for 6–24h unti l  a period of tamponade by the
Sengstaken-type tube ± vasopressin has enabled some control  of the bleeding.
5.
Either octreotide, vasopressin or terl ipressin can be administered for severe bleeding, or prophylaxis against
fresh bleeding. Vasopressin controls bleeding in approximately 60% of cases and i ts efficacy and safety appears
to be enhanced by concurrent GTN. The side-effect profi le of terl ipressin is lower as i t does not appear to
precipitate as much mesenteric, cardiac or digi tal  ischaemia, Octreotide is a somatostatin analogue but
longer-acting than its parent compound; l ike somatostatin, i t i s probably as effective as vasopressin but without
6.
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the side-effects.
If bleeding continues after prolonged balloon tamponade (2–3 days) and repeated endoscopy, consider
transjugular intrahepatic portosystemic stented shunt (TIPSS). This can be performed quickly and carries a
relatively low mortal ity compared to surgery although the risk of encephalopathy is increased.
7.
The tradi tional  al ternative to TIPSS is oesophageal  transection (now performed with a staple gun) with or
without devascularisation. Mortal ity in the acute situation is of the order of 30%.
8.
Drug dosages
Octreotide 50µg bolus then 50µg/h infusion
Vasopressin 20 units over 20min then 0.4 units/min infusion
Also give glyceryl trinitrate 2–20mg/h to counteract myocardial and mesenteric
ischaemia
Terlipressin 2mg IV followed by 1–2mg IV 4–6-hrly until bleeding controlled for up to 72h
See also:
Endotracheal  intubation, p36; Sengstaken-type tube, p72; Upper gastrointestinal endoscopy, p74; Coagulation
monitoring, p156; Colloids, p180; Blood transfusion, p182; Basic resusci tation, p270; Fluid challenge, p274; Upper
gastrointestinal haemorrhage, p344; Acute l iver fai lure, p360; Chronic l iver fai lure, p364
Bowel perforation and obstruction
Patients with bowel perforation or obstruction may be admitted to the ICU after surgery, for pre-operative
resuscitation and cardiorespiratory optimisation, or for conservative management. Although rarely occurring de novo
in the ICU patient, these conditions may be diff icult to diagnose because of sedation ± muscle relaxation. Consider
when there is:
Abdominal  pain, tenderness, peritonism
Abdominal  distension
Agitation
Increased nasogastric aspirates, vomiting
Increasing metabol ic acidosis
Signs of hypovolaemia or sepsis
A firm diagnosis is often not made unti l laparotomy al though supine and either erect or lateral  abdominal X-ray may
reveal  ei ther free gas in the peritoneum (perforation) or di lated bowel loops with multiple fluid levels (obstruction).
Ultrasound is usually unhelpful though faecal f luid may occasionally be aspirated from the peri toneum fol lowing
perforation.
It may be di fficul t to dist inguish bowel obstruction from a paralytic i leus as (i) bowel sounds may be present or
absent in ei ther and (i i ) X-ray appearances may be simi lar.
Management
Correct fluid and electrolyte abnormali ties. Resuscitation should be prompt and aggressive and usually consists
of colloid replacement plus blood to maintain Hb >7g/dl . Inotropes or vasopressors may be required to restore
an adequate circulation, particularly fol lowing perforation. Early cardiac output monitoring should be considered
if the ci rculatory status remains unstable or vasoactive drugs are required.
1.
The surgeon should be informed early. A conservative approach may be adopted, e.g. with upper smal l bowel
perforation; however, surgery is usually required for large bowel perforation. Small  or large bowel  obstruction
may sometimes be managed conservatively as spontaneous resolution may occur, e.g. adhesions. Prompt
exploration should be encouraged i f the patient shows signs of systemic toxici ty.
2.
Both conservative and post-operative management of perforation and obstruction usually require continuous
nasogastric drainage to decompress the stomach, nil  by mouth and parenteral  nutri tion.
3.
Pain rel ief should not be withheld.4.
Broad spectrum antibiotic therapy should be commenced for bowel perforation after appropriate specimens have
been taken for laboratory analysis. Therapy usual ly comprises aerobic and anaerobic Gram negative cover (e.g.
2nd or 3rd generation cephalosporin, quinolone or carbapenem, plus metronidazole ± aminoglycoside).
5.
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Post-operative management of bowel perforation may involve repeated laparotomies to exclude collections of pus
and bowel ischaemia/infarction; surgery should be expedited i f the patient's condi tion deteriorates.
Alternatively, regular imaging ± drainage of col lections may be needed.
6.
See also:
Parenteral nutrit ion, p82; Fai lure to open bowels, p342; Abdominal sepsis, p350; Pancreatitis, p354; Metabol ic
acidosis, p434; Systemic inflammation/multiorgan failure, p484; Post-operative intensive care, p534
Lower intestinal bleeding and colitis
Causes of lower gastrointestinal bleeding
Bowel ischaemia/infarction
Inflammatory bowel disease (ulcerative coli tis, Crohn's disease)
Infection, e.g. Shigella, Campylobacter,  amoebic dysentry
Upper gastrointestinal source, e.g. peptic ulceration
Angiodysplasia
Neoplasm
Although relatively rare, massive lower gastrointestinal haemorrhage can be l i fe-threatening.
Ischaemic/infarcted bowel
Can occur fol lowing prolonged hypoperfusion or, occasionally, secondary to a mesenteric embolus. It usual ly presents
with severe abdominal  pain, bloody diarrhoea and signs of systemic toxicity including a rapidly increasing metabolic
acidosis. Plasma phosphate levels may also be elevated. X-ray appearances of thickened, oedematous bowel  loops
(‘thumb printing’) wi th an increased distance between bowel loops are suggestive. Treatment is by restoration of
tissue perfusion, blood transfusion to maintain haemoglobin >7g/dl  and, if cl inical  features fail to settle promptly,
laparotomy with a view to bowel  excision.
Inflammatory bowel disease
Presents with weight loss, abdominal  pain and diarrhoea which usually contains blood. Complications of ulcerative
col it is include perforation and toxic megacolon while compl ications of Crohn's disease include fistulae, abscesses and
perforations.
Management involves:
Fluid and electrolyte replacement.1.
Blood transfusion to maintain haemoglobin >7g/dl.2.
High dose steroids IV and, if distal  bowel  involvement, by enema.3.
Nutrit ion (often parenteral).4.
Regular surgical review. Surgery may be indicated i f symptoms fail  to settle after 5–7 days, for toxic megacolon,
perforation, abscesses or obstruction.
5.
Antidiarrhoeal  drugs should be avoided.6.
Angiodysplasia
Usually presents as fresh bleeding per rectum and this may be considerable. It is due to an arteriovenous
mal formation and commoner in the elderly. Localisation and embolisation by angiography may be curative during
active bleeding, Surgery may be required i f bleeding fai ls to settle on conservative management and, occasional ly,
‘bl ind’ laparoscopic embol isation of a mesenteric vessel . However, localisation of the lesion may be diff icult at
laparotomy, necessitating extensive bowel resection.
See also:
Col loids, p180; Blood transfusion, p182; Coagulants and antif ibrinolytics, p254; Basic resusci tation, p270; Fluid
challenge, p274; Bowel perforation and obstruction, p348; Bleeding disorders, p396
Abdominal sepsis
This is a common but difficul t to diagnose condi tion in intensive care patients. A proportion of such patients are
admitted fol lowing laparotomy but others may develop abdominal sepsis de novo or as a secondary complication
fol lowing abdominal surgery, in particular after bowel resection. Sepsis may either be local ised to an organ, e.g.
cholecystit is, or the peri toneal  cavity (abscess); al ternatively, there may be a generalised peritoni tis. Non-bowel
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infection or inflammation can present in a simi lar manner, e.g. pancreatit is, cholecysti tis, gynaecological infection,
pyelonephrit is.
Clinical features
Non-specific signs including pyrexia (especial ly swinging), neutrophil ia, fal l ing platelet count, increasing
metabol ic acidosis, circulatory instabil ity
Abdominal  distension ± localised discomfort, peritonism
Abdominal  mass, e.g. gall  bladder, pseudocyst, abscess
Failure to tolerate enteral  feed/large nasogastric aspirates
Pleural effusion (i f subdiaphragmatic sepsis)
Diarrhoea (i f pelvic sepsis)
Diagnosis
Ultrasound
CT scan
Laparotomy
Gal l ium white cell  scans are occasional ly useful  for identi fication of abscesses.
Samples should be taken for microbiological analysis from blood, urine, stool , abdominal drain fluid and vaginal
discharge i f present. A sample of pus is preferred to a swab. Hyperamylasaemia may suggest pancreati tis though
amylase levels can also be elevated with other intra-abdominal pathologies.
Treatment
Antibiotic therapy providing Gram negative and anaerobic cover (e.g. 2nd or 3rd generation cephalosporin,
quinolone or carbapenem, plus metronidazole ± aminoglycoside). Treatment can be amended depending on
cul ture results and patient response.
Ultrasonic or CT-guided drainage of pus.
Laparotomy with removal of pus, peritoneal lavage, etc.
A negative laparotomy should be viewed as a useful means of excluding intra-abdominal  sepsis rather than an
unnecessary procedure. Laparotomy should be encouraged if the patient deteriorates and a high suspicion of
abdominal  pathology persists.
Cholecystit is, wi th or without (acalculous) gal lstones, may present with signs of infection. There is a characteristic
ultrasound appearance of an enlarged organ with a thickened, oedematous wall  surrounded by fluid. Treatment is
often conservative with antibiotics (as above) and percutaneous, ul trasound-guided drainage via a pigtail  catheter.
Cholecystectomy is rarely necessary in the acute si tuation unless the gall  bladder has perforated, though some
authorit ies argue that this is the treatment of choice for acalculous cholecystitis.
See also:
Parenteral nutrit ion, p82; Bacteriology, p158; Colloids, p180; Inotropes, p196; Vasopressors, p200; Antimicrobials,
p260; Basic resuscitation, p270; Fluid chal lenge, p274; Bowel  perforation and obstruction, p348; Pancreatit is, p354;
Infection—diagnosis, p480; Infection—treatment, p482; Systemic inflammation/multiorgan fai lure, p484; Sepsis and
septic shock treatment, p550; Pain, p532; Post-operative intensive care, p534
Pancreatitis
Inflammation of the pancreas and surrounding retroperi toneal  t issues. The appearance of the pancreas may range
from mildly oedematous to haemorrhagic and necrotising. A pseudocyst may develop which can become infected and
the bi le duct may be obstructed causing bi l iary obstruction and jaundice. Though mortality is quoted at 5–10%, this
is much higher (approx. 40%) in those with severe pancreatit is requiring intensive care.
Causes
Alcohol
Gal lstones
Miscel laneous, e.g. ischaemia, trauma, viral,  hyperl ipidaemia
Part of the multiple organ fai lure syndrome
Diagnosis
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Non-specific features include central, severe abdominal pain, pyrexia, haemodynamic instabi l i ty, vomiting, i leus.
Discolouration around the umbi l icus (Cullen's sign) or flanks (Grey Turner's sign) is rarely seen.
Plasma enzymes—elevated levels of amylase (usually >1000IU/ml) and pancreatic l ipase are suggestive but
non-specific. Levels may be normal , even in severe pancreatit is.
Ultrasound
CT scan
Laparotomy
Complications
Multi-organ dysfunction syndrome
Infection/abscess formation
Hypocalcaemia
Diabetes mel l itus
Bleeding
Management
General  measures including fluid resuscitation, maintaining Hb at 7–10g/dl , respiratory support, analgesia, and
anti-emetics. Routine antibiotic therapy is of unproved benefit.
Adequate monitoring should be instituted, including cardiac output monitoring i f cardiorespiratory instabil ity is
present.
The patient is conventional ly kept ni l by mouth with continuous NG drainage, and nutrit ion and vitamins
provided IV. However, recent studies show safety and efficacy of distal  nasojejunal—and even
nasogastric—enteral feeding.
Gal lstone obstruction should be rel ieved either endoscopically or surgically.
Hypocalcaemia, i f symptomatic, should be treated by intermittent slow IV injection (or, occasionally, infusion) of
10% calcium chloride.
Hyperglycaemia should be controlled by a continuous insul in infusion.
No specific treatment is routinely used.
The role and extent of surgery remains controversial ; Some advocate percutaneous drainage of infected and/or
necrotic debris while surgery frequently consists of regular (often dai ly) laparotomy with debridement of necrotic
tissue and peri toneal  lavage. Pseudocysts may resolve or require drainage ei ther percutaneously or into the
bowel.
Ranson's signs of severity in acute pancreatitis
On hospital admission:
Age >55 years old
Blood glucose >11mmol/l
Serum lactate dehydrogenase (LDH) >300U/l
Serum aspartate aminotransferase (AST) >250U/l
White blood count >16×109/l
At 48 h after admission:
Haematocri t fal l >10%
Blood urea ni trogen rise >1mmol/l
Serum calcium <2mmol/l
PaO2 <8kPa
Arterial  base defici t >4mmol/l
Estimated fluid sequestration >6000ml
Pancreatitis severe if more than 2 criteria met within 48h of admission
Imrie scoring system
White blood count >15 × 109/l
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Blood glucose >10mmol/l
Blood urea nitrogen >16mmol/l
LDH >600IU/l
AST >200IU/l
Albumin <32g/dl
Plasma calcium <2mmol/l
PaO2 <8kPa
Pancreatitis severe if more than 2 criteria met within 48h of admission
APACHE II scoring system
Pancreatitis severe if APACHE II score>8
See also:
Venti latory support—indications, p4; Enteral nutri tion, p80; Parenteral nutrit ion, p82; Basic resuscitation, p270; Fluid
challenge, p274; Respiratory fai lure, p282; Acute respiratory distress syndrome (1), p292; Acute respiratory distress
syndrome (2), p294; Hypotension, p312; Oliguria, p330; Abdominal  sepsis, p350; Metabolic acidosis, p434; Systemic
inflammation/multiorgan fai lure, p484; Sepsis and septic shock—treatment, p486; Pain, p532
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Hepatic Disorders
Jaundice
Jaundice is a cl inical diagnosis of yellow pigmentation of sclera and skin resul ting from a raised plasma bil irubin. It is
usually visible when the plasma bil irubin exceeds 30–40µmol/l.
Commoner causes seen in the ICU
Pre-hepatic—intravascular haemolysis (e.g. drugs, malaria, haemolytic uraemic syndrome), Gilbert's syndrome.
Hepatocellular—cri tical  i l lness, viral (hepati tis A, B, C, Epstein–Barr), alcohol , drugs (e.g. paracetamol,
halothane), toxoplasmosis, leptospirosis.
Cholestatic—cri tical  i l lness, intrahepatic causes (e.g. drugs such as chlorpromazine, erythromycin and isoniazid,
primary bil iary ci rrhosis), extrahepatic causes (e.g. bi l iary obstruction by gallstones, neoplasm, pancreatit is).
Diagnosis
Urinalysis—unconjugated bil irubin does not appear in the urine.
Measurement of conjugated and unconjugated bil i rubin—conjugated bil irubin predominates in cholestatic
jaundice, unconjugated bi l i rubin in pre-hepatic jaundice, and a mixed picture is often seen in hepatocellular
jaundice.
Plasma alkaline phosphatase is usual ly markedly elevated in obstructive jaundice while prothrombin times,
aspartate transaminase and alanine aminotransferase are elevated in hepatocellular jaundice.
Ultrasound or CT scan wil l  diagnose extrahepatic bi l iary obstruction.
Management
Identi fy and treat cause. Where possible, discontinue any drug that could be impl icated. If extrahepatic,
consider percutaneous transhepatic drainage, bi le duct stenting or, rarely, surgery.
1.
Liver biopsy is rarely necessary in a jaundiced ICU patient unless the diagnosis is unknown and the possibi l ity
exists of l iver involvement in the underlying pathology, e.g. malignancy.
2.
Non-obstructive jaundice usual ly settles with conservative management as the patient recovers.3.
An antihistamine and topical calamine lotion may provide symptomatic rel ief for pruritus if troublesome.
Cholestyramine 4g tds PO may be helpful in obstructive jaundice.
4.
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See also:
Liver function tests, p152; Acute l iver fai lure, p360; Chronic l iver fai lure, p364; Haemolysis, p404; Infection
control—general principles, p476; Infection—diagnosis, p480; Infection—treatment, p482; Systemic
inflammation/multiorgan fai lure, p484; HELLP syndrome, p540
Acute liver failure
This condit ion resul ts from massive necrosis of l iver cells leading to severe l iver dysfunction and encephalopathy.
Survival  rates for l iver fai lure with Grade 3 or 4 hepatic encephalopathy vary from 10–40% on medical therapy alone,
to 60–80% with orthotopic l iver transplantation.
Major causes
Alcohol
Drugs, particularly paracetamol overdose
Viral hepati tis, particularly hepatit is B, hepati tis C
Poisons, e.g. carbon tetrachloride
Acute decompensation of chronic disease, e.g. fol lowing infection
Diagnosis
Should be considered in any patient presenting with jaundice, general ised bleeding, encephalopathy or marked
hypoglycaemia.
Abnormal l iver function tests, in particular, prolonged PT or INR and hyperbi l irubinaemia. In severe l iver fai lure,
plasma enzyme levels may not be elevated.
Management
General  measures include fluid resusci tation and blood transfusion to keep Hb 7–10g/dl. The circulation is
usually hyperdynamic and di lated; vasopressors may be needed to maintain an adequate BP.
Correction of coagulopathy is often withheld as this provides a good guide to recovery or the need for
transplantation. Use of fresh frozen plasma is restricted to patients who are bleeding or are about to undergo an
invasive procedure.
Adequate monitoring should be instituted i f cardiorespiratory instabil ity is present.
Mechanical  venti lation may be necessary if the ai rway is unprotected or respiratory fai lure develops. Lung shunts
are frequently present, causing hypoxaemia.
Infection is commonplace and is frequently ei ther Gram posit ive or fungal. Clinical  signs are often absent.
Samples of blood, sputum, urine, wound sites, drain fluid, intravascular catheter sites and ascites should be sent
for regular microbiological surveil lance. Systemic antimicrobial  therapy, wi th or without selective gut
decontamination, has been shown to reduce the infection rate. Fungal  infections are also wel l recognised. Some
Liver Uni ts give prophylactic antifungal therapy.
Hypoglycaemia is a common occurrence. It should be frequently monitored and treated with ei ther enteral  (or
parenteral) nutrit ion, or a 10–20% glucose infusion to maintain normoglycaemia.
Renal fai lure occurs in 30–70% of cases and may necessi tate renal replacement therapy. The incidence may be
reduced by careful maintenance of intravascular volume. Vasopressin/terl ipressin has also been used
successfully for hepatorenal syndrome.
Upper gastrointestinal bleeding is more common due to the associated coagulopathy. Prophylactic H2 blockers or
proton pump inhibi tors may be of benefit.
N-acetylcysteine and/or epoprostenol improves O2 consumption. Though tissue hypoxia may be reduced by these
drugs, particularly when vasopressor drugs are needed, outcome benefit remains unproved.
Corticosteroids, prostaglandin E and charcoal  haemoperfusion have not been shown to have any outcome benefit.
See also:
Venti latory support—indications, p4; Liver function tests, p152; Coagulation monitoring, p156; Hepatic
encephalopathy, p362; Paracetamol poisoning, p456
Hepatic encephalopathy
Grading
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Confused, altered mood1.
Inappropriate, drowsy2.
Stuporose but rousable, very confused, agitated3.
Coma, unresponsive to painful stimuli4.
The risk of cerebral oedema is far higher at Grades 3 and 4 (50–85%) and is the leading cause of death. Suggestive
signs include systemic hypertension, progressive heart rate slowing and increasing muscle rigidi ty. These occur at
intracranial pressures >30mmHg.
Management
Correct/avoid potential aggravating factors, e.g. gut haemorrhage, over-sedation, hypoxia, hypoglycaemia,
infection, electrolyte imbalance.
Consider early intracranial  pressure (ICP) monitoring. CT and cl inical features correlate poorly with ICP though
no control led studies have yet been performed to show outcome benefi t from ICP monitoring which carries its
own complication rate (bleeding, infection).
Maintain patient in sl ight head-up posi tion (20–30°).
Regular lactulose, e.g. 20–30ml qds PO, to achieve 2–3 bowel motions/day.
Dietary restriction of protein is now not encouraged as this promotes endogenous protein uti l isation.
Hyperventi lation to achieve a PaCO2 of 3.5–4kPa is often attempted but is frequently unsuccessful in achieving
improvement. It may also compromise cerebral blood flow.
Mannitol (0.5–1mg/kg over 20–30min) if serum osmolali ty <320mOsmol/kg and either a raised ICP or cl inical
signs of cerebral oedema persist. If severe renal  dysfunction is present, use renal replacement therapy in
conjunction with mannitol.
Sodium benzoate (2g tds PO) may be considered i f the patient is severely hyperammonaemic.
If no response to above, consider barbiturate administration, e.g. thiopental infusion at 1–5mg/kg/h, ideally
with ICP monitoring.
If sti l l  no response, consider urgent l iver transplantation.
Exercise caution with concomitant drug usage.
Identification of patients unlikely to survive without transplantation
Prothrombin time >100s
Or any three of the fol lowing:
Age <10 or >40 years
Aetiology is hepatitis C, halothane, or other drug reaction
Duration of jaundice pre-encephalopathy >2 days
Prothrombin time >50s
Serum bil irubin >225µmol/l
If paracetamol-induced:
pH <7.3 or prothrombin time >100s and creatinine >200µmol/l plus Grade 3 or 4 encephalopathy.
As only 50–85% of patients identi fied as requiring transplantation wil l  survive long enough to receive one, the
Regional Liver Uni t should be informed soon after diagnosis of al l  possible candidates.
See also:
Venti latory support—indications, p4; Intracranial pressure monitoring, p134; Liver function tests, p152; Coagulation
monitoring, p156; Sedatives, p238; Jaundice, p358; Chronic l iver fai lure, p364; Paracetamol poisoning, p456
Chronic liver failure
Patients admitted to intensive care with chronic l iver fai lure may develop speci fic associated problems:
Acute decompensation—this may be secondary to infection, sedation, hypovolaemia, hypotension, diuretics,
gastrointestinal haemorrhage, excess dietary protein and electrolyte imbalance.
Infection—the patient may transmit infection, e.g. hepati tis A, B or C and, by being immunosuppressed, is also
more prone to acquiring infections such as TB and fungi.
Drug metabol ism—as many drugs are al l  or part-metabolised by the l iver and/or excreted into the bile, the drug
action may be prolonged or slowed depending on whether the metabol ites are active or not. Inparticular,
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sedatives may have a greatly prolonged duration of action.
Portal  hypertension—results in asci tes, varices and splenomegaly. Ascites may produce diaphragmatic spl inting
and is at risk of becoming infected. Drainage may incur a considerable protein loss. Varices may bleed while
splenomegaly may resul t in thrombocytopenia. Renal fai lure is also recognised due to high intra-abdominal
pressure.
Bleeding—an increased risk is present due to decreased production of clott ing factors (II, VII, IX, X), varices and
splenomegaly related thrombocytopenia.
Alcohol—the most frequent cause of ci rrhosis in the western world; acute withdrawal may lead to deli rium
tremens with severe agitation, hal lucinations, seizures and cardiovascular disturbances.
2° hyperaldosteronism—resul ts in ol iguria, sal t and water retention.
Increased tendency to jaundice, especial ly during crit ical i l lness.
Management
Ascites
Take specimens for microbiological  analysis (including TB), protein and cytology. If WBC > 250 per high
power field, give Gram negative antibiotic cover.
If present in large quantity, (i) decrease sodium and water intake, (i i ) commence spironolactone PO (or
potassium canrenoate IV) ± furosemide. Paracentesis ± colloid replacement, or asci tic reinfusion (i f
uninfected/non-pancreatit ic in origin) may be considered, particularly i f diaphragmatic splinting occurs.
1.
Coagulopathy:
Vitamin K 10mg/day slow IV bolus for 2–3 days.
Fresh frozen plasma, platelets as necessary.
2.
Hypoglycaemia—should be prevented by adequate nutrit ion or a 10% or 20% glucose infusion.3.
Adequate nutrit ion and vitamin supplementation.4.
Acute decompensation—avoid any precipitating causes, e.g. infection, sedation, hypovolaemia, electrolyte
imbalance.
5.
Drug administration—review type and dose regularly.6.
See also:
Liver function tests, p152; Sedatives, p238; Jaundice, p358; Acute l iver fai lure, p360
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Neurological Disorders
Acute weakness
Severe acute weakness may require urgent intubation and mechanical  venti lat ion if the FVC <1l or gas exchange
deteriorates acutely.
Investigation
Metabol ic myopathies—exclude and treat hypophosphataemia, hypokalaemia, hypocalcaemia and
hypomagnesaemia.
Prolonged effects of muscle relaxants—a prolonged effect of suxamethonium wil l usually be cl inically obvious and
should prompt assessment of pseudocholinesterase levels. Suxamethonium effects wil l  also be prolonged in
myasthenics. Prolonged effects of non-depolarising muscle relaxants are suggested by a response to an
anticholinesterase (neostigmine 0.5 mg by slow IV bolus with an antichol inergic). This should not be attempted
if paralysis is complete. Patients with myasthenia gravis wi l l  also respond.
Gui l lain–Barré syndrome—a lumbar puncture should be performed to confirm raised CSF protein with normal
cel ls. If these features are not found but suspicion is strong, nerve conduction studies may demonstrate
segmental demyel ination with slow conduction veloci ties.
Myasthenia gravis—fatigueable weakness or ptosis suggests myasthenia gravis; response to IV edrophonium
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(Tensilon test) and a strongly posit ive acetylcholine receptor antibody titre confi rm this diagnosis. A myasthenic
syndrome associated with mal ignancy (Eaton–Lambert syndrome) involves pelvic and thigh muscles
predominantly, tending to spare the ocular muscles.
Other diagnoses are made largely on the basis of cl inical  suspicion and speci fic special ised tests.
General management
FVC should be monitored 2–4-hrly and intubation and mechanical venti lation should fol low if FVC <1l. Other
indices of respiratory function are less sensit ive. In particular, arterial blood gases may be maintained up to the
point of respiratory arrest.
Weak respiratory muscles lead to progressive basal atelectasis and sputum retention. Chest infection is a
significant risk; regular chest physiotherapy with intermittent positive pressure breathing are required for
prevention where mechanical venti lat ion is not necessary.
Patients who are immobile are at risk of venous stasis and deep venous thrombosis. Prophylaxis with
subcutaneous heparin is reasonable. Immobi le patients also require attention to posture to prevent pressure
sores and contractures.
Weak bulbar muscles may compromise swallowing with consequent malnutri tion or pulmonary aspiration. Enteral
nutrit ional support via a nasogastric tube is necessary.
In cases with coexistent autonomic neuropathy enteral nutrit ion may be impossible, necessi tating parenteral
nutrit ional support. These patients may also suffer arrhythmias and hypotension requiring appropriate support.
Causes of severe weakness
Common in ICU
Metabolic myopathies
Prolonged effects of muscle relaxants
Cri tical  i l lness neuropathy or myopathy
Gui l lain–Barré syndrome
Myasthenia gravis
Pontine CVA
Substance abuse (especial ly benzene ring compounds)
Uncommon in ICU
Chronic relapsing polyneuritis
Endocrine myopathies
Sarcoid neuropathy
Pol iomyel it is
Diphtheria
Carcinomatous neuropathy
Porphyria
Botul ism
Famil ial  periodic paralysis
Multiple sclerosis
Lead poisoning
Organophosphorus poisoning
See also:
Venti latory support—indications, p4; IPPV—assessment of weaning, p18; Enteral nutrit ion, p80; Parenteral  nutrition,
p82; Pulmonary function tests, p94; Electrolytes
, p146; Calcium, magnesium and phosphate, p148; Muscle relaxants, p240; Respiratory failure, p282; Guil lain–Barré
syndrome, p384; Myasthenia gravis, p386; ICU neuromuscular disorders, p388
Agitation/confusion
In the ICU, agi tation and/or confusion are predominantly related to sepsis, cerebral  hypoperfusion drugs or drug
withdrawal. ‘ICU psychosis’, with loss of day–night rhythm and inabil ity to sleep, is a common occurrence in the
patient recovering from severe i l lness.
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Commoner ICU causes
Infection—including general ised sepsis, chest, cannula sites, urinary tract. Cerebral  infection such as meningi tis,
encephali tis and malaria are relatively rare but should always be considered.
Drug-related—(i) adverse reaction (particularly affecting the elderly), e.g. sedatives, analgesics, diuretics; (i i)
withdrawal , e.g. sedatives, analgesics, ethanol; (i i i) abuse, e.g. opiates, amphetamines, alcohol , hallucinogens.
Metabol ic—e.g. hypo- or hyperglycaemia, hypo- or hypernatraemia, hypercalcaemia, uraemia, hepatic
encephalopathy, hypo- or hyperthermia, dehydration.
Respiratory—infection, hypoxaemia, hypercapnia.
Neurological—infection (meningo-encephal it is, malaria), post-head injury, space-occupying lesion (including
haematoma), post-ictal , post-cardiac arrest.
Cardiac—low output state, hypotension, endocardit is.
Pain—full  bladder (blocked Foley catheter), abdominal pain.
Psychosis—‘ICU psychosis’, other psychiatric states.
Principles of management
Examine for signs of (i) infection (e.g. pyrexia, purulent sputum, catheter sites, neutrophil ia, fal l ing platelet
count, CXR, meningism), (i i) cardiovascular instabi l i ty (hypotension, increasing metabolic acidosis, ol iguria,
arrhythmias), (i i i ) covert pain, particularly abdominal and lower l imbs (e.g. compartment syndrome, DVT), (iv)
focal neurological  signs (e.g. meningism, unequal pupi ls, hemiparesis), (v) respiratory failure (arterial blood
gases), (vi) metabol ic derangement (biochemical  screen). If any of the above are found, treat as appropriate.
Psychosis should not be assumed unti l treatable causes are excluded.
1.
Reassure and calm the patient. Maintain quiet atmosphere and reduce noise levels. Attempt to restore day–night
rhythm, e.g. by changing ambient l ighting and use of oral hypnotic agents.
2.
Consider starting, changing or increasing dose of sedative or major tranqui l l iser to control  the patient. If highly
agi tated and l ikely to endanger themselves, rapid short term control can be achieved by a slow IV bolus of
sedative. Consider propofol,  a benzodiazepine, haloperidol  or chlorpromazine in the smallest possible dose to
achieve the desi red effect; observe for hypotension, respiratory depression, arrhythmias and extra-pyramidal
effects. Opiates may be needed, especial ly if pain or wi thdrawal  is a factor. An ethanol  infusion can be
considered for del irium tremens result ing from alcohol withdrawal .
3.
Sedation can be maintained by continuous infusion or intermittent injection, either regularly or as required. The
less agitated patient may respond to IM injections of a major tranquil l i ser, though these should be avoided with
concurrent coagulopathy.
4.
Drug dosages for severe agitation
•Chlorpromazine—12.5 mg by slow IV bolus. Repeat, doubling dose, every 10–15 until effect. May
need up to 100 mg. For regular prescription, give qds.
•Haloperidol—2.5 mg by slow iIV bolus. Repeat, doubling dose, every 10–15 minutes until effect.
For regular prescription, give qds.
•Midazolam/diazepam—2–5 mg by slow IV bolus.
•Propofol—30–100 mg by slow IV bolus.
•Morphine—2.5–5 mg by slow IV bolus.
NB beware excessive central and respiratory depression with the above agents
See also:
IPPV—failure to tolerate venti lation, p12; Toxicology, p162; Sedatives, p238; Acute l iver fai lure, p360; Chronic l iver
fai lure, p364; Thyroid emergencies, p446; Poisoning—general principles, p452; Amphetamines including Ecstasy,
p462; Cocaine, p464; Infection—diagnosis, p480; Systemic inflammation/multiorgan fai lure, p484; Head injury (1),
p504; Head injury (2), p506; Pyrexia (1), p518; Pyrexia (2), p520; Pain, p532
Generalised seizures
Control of seizures is necessary to prevent ischaemic brain damage, to reduce cerebral  oxygen requirements and to
reduce intracranial pressure. Where possible correct the cause and give specific treatment. A CT scan may be
necessary to identify structural  causes. Common causes include:
Hypoxaemia
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Hypoglycaemia
Hypocalcaemia
Space-occupying lesions
Metabol ic and toxic disorders
Drug withdrawal , e.g. alcohol, benzodiazepines, anticonvulsants
Infection, especial ly meningoencephalit is
Trauma
Idiopathic epilepsy
Most seizures are sel f-l imiting, requiring no more than protection from injury (coma posi tion, protect head and do not
force anything into the mouth).
Specific treatment
Hypoxaemia should be corrected with oxygen (FIO2 0.6–1.0).
Intubation and venti lation if the ai rway is unprotected or SpO2<90%.
Blood glucose should be measured urgently and hypoglycaemia corrected with IV 50 ml 50% glucose.
Anticonvulsant levels should be corrected in known epi leptics.
Cerebral oedema should be managed with sedation, induced hypothermia, control led hyperventi lat ion and
osmotic diuretics.
In patients with a known tumour, arterit is or parasitic infection, high dose dexamethasone may be given.
Thiamine 100 mg IV should be given to alcoholics.
Consider surgery for space-occupying lesions, e.g. blood clot, tumour.
Anticonvulsants
Anticonvulsants are necessary where there are repeated seizures, a single seizure lasts >30 min or there is cyanosis.
A benzodiazepine (e.g. lorazepam, diazepam) is the usual f irst l ine treatment.
Phenytoin—a loading dose should be given intravenously if the patient has not previously received phenytoin.
Phenytoin may not provide immediate control  of seizures within the first 24 h.
If seizures continue appropriate anticonvulsants include:
Magnesium sulphate.
Clonazepam, which is particularly useful for myoclonic seizures.
Thiopental  or propofol  infusion in severe intractable epi lepsy.
With all  anticonvulsants care should be taken to avoid hypoventi lation and respiratory failure. However, mechanical
venti lat ion wi l l  certainly be required i f thiopental  is used, and probably to maintain oxygenation in cases of continued
seizures.
Other supportive treatment
Muscle relaxants prevent muscular contraction during seizures but wil l  not prevent continued seizures. They may be
necessary to faci l itate mechanical venti lation but continuous EEG monitoring should be used to judge seizure control.
Correction of circulatory disturbance is required to maintain optimal cerebral  blood flow.
Drug dosages
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Lorazepam 4 mg IV.
Diazepam Initially 2.5–5 mg IV or PR.
Further increments as necessary to a maximum of 20 mg.
Midazolam Initially 2.5–5 mg IV or PR.
Further increments as necessary to a maximum of 20 mg.
Phenytoin Loading dose 18 mg/kg IV at a rate <50 mg/min with continuous ECG
monitoring. Maintenance at 300–400 mg/day IV, IM or PO adjusted according to
levels.
Magnesium
sulphate
Initially 20 mmol over 3–5 min followed by 5–10 mmol/h by infusion as
necessary.
Clonazepam 1 mg/h IV.
Thiopental 1–3 mg/kg IV followed by lowest dose to maintain control.
Propofol 0.5–2 mg/kg IV followed by 1–3 mg/kg/h.
Key trial
Treiman VA for the Veterans Affai rs Status Epilepticus Cooperative Study Group. A comparison of four treatments
for generalized convulsive status epilepticus. N Engl  J Med. 1998; 339:792–8
Meningitis
This is a l i fe-threatening condi tion demanding prompt treatment. As the classical presentation of meningism may be
absent, suspect in those presenting with obtundation, agitation, seizures or focal neurology. Signs may be subtle or
present insidiously in neutropenics and the elderly. Meningococcaemia presents with a prominent rash in 30% of
cases whi le Listeria monocytogenes may cause early seizures and focal  neurological defects.
Diagnosis
Bacterial  meningit is is primari ly diagnosed by CSF examination. This is unnecessary with a classical
meningococcal  rash where the organism can be often cultured from the skin lesions. Lumbar puncture (LP)
samples should be sent for urgent microscopy and cul ture, PCR, antigen vi rology, protein and glucose estimation
(with concurrent plasma sample). Normal or lymphocytic CSF may be found in early pyogenic meningit is,
especial ly L. monocytogenes.
Raised ICP is common; unless confidently excluded, delay lumbar puncture (LP) but not antibiotics unti l  after CT
scanning. A normal  CT scan does not completely exclude raised ICP.
Empiric antibiotic therapy with concurrent steroids should be commenced immediately after taking blood
cul tures. The choice should be based on the patient's age. CSF cultures are posit ive in 50% i f antibiotics are
given compared to 60–90% in untreated cases.
CSF bacterial  antigen testing is available for most infecting organisms; sensi tivity varies from 50–100% whi le
specifici ty is high.
Management
Antibiotic therapy, usually for ≥10 days, though recent studies suggest equal efficacy with shorter courses.1.
Dexamethasone 10 mg qds for 4 days should be commenced with or just before the fi rst dose of antibiotic,
particularly for pneumococcal meningit is.
2.
General  measures include attention to fluid and electrolyte replacement, adequate gas exchange, nutrit ion, and
skin care.
3.
Management of raised intracranial  pressure if present.4.
Give oral  ciprofloxacin (adults only) or rifampicin to family and close social  contacts of meningococcal and
haemophilus meningi tis. The index case should also receive this treatment before discharge home.
5.
Aseptic meningitis
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No organisms are identi fied by routine CSF analysis despi te a high neutrophil  and/or lymphocyte count. Causes
include viruses (e.g. mumps, measles), Lyme disease, fungi , leptospirosis, l i steriosis, brucel losis, atypical TB,
sarcoidosis, SLE.
Encephalitis
Presenting features include drowsiness, coma, agitation, pyrexia, seizures and focal signs; meningism need not
necessari ly be present.
Causes:
Bacterial  (as for meningitis)
Viruses (in particular, herpes simplex and post-measles, chicken pox, mumps infection). Herpes simplex
classical ly affects the temporal lobe and can be diagnosed by EEG. Give aciclovir 10 mg/kg tds IV for 10 days.
Rarer causes include leptospirosis and brucellosis; the CSF reveals no organisms but a high lymphocyte count is
present. If indicated, send CSF for acid fast stain (TB) and India Ink stain (Cryptococcus).
Typical CSF values in meningitis
 Pyogenic Viral Tuberculosis
Classical appearance turbid clear fibrin web
Predominant cell type polymorphs lymphocytes lymphocytes
Cell count/mm3 >1000 <500 50–1500
Protein (g/l) >1 0.5–1 1–5
CSF:blood glucose <60% >60% <60%
Organisms and empiric starting antibiotic therapy
Organism Patients often
affected
Antibiotic and dosage regimen
(alternatives in brackets)
Neisseria meningitidis
(Meningococcus)
young adults ceftriaxone 2–4 g IV od (cefotaxime 50 mg/kg
IV 8-hrly) (benzylpenicillin 1.2 g IV 2–4-hrly)
(chloramphenicol 12.5 mg/kg IV 6-hrly)
Streptococcus
pneumoniae
(Pneumococcus)
older adults ceftriaxone 2–4 g IV od (cefotaxime 50 mg/kg
IV 8-hrly) (chloramphenicol 12.5 mg/kg IV
6-hrly)
Haemophilus
influenzae
children ceftriaxone 20–50 mg/kg IV od (cefotaxime
50 mg/kg IV 8-hrly) (chloramphenicol 12.5
mg/kg IV 6-hrly)
Listeria
monocytogenes
elderly,
immuno-compromised
ampicillin 1g IV 4–6-hrly plus gentamicin 120
mg IV stat, then 80 mg 8–12-hrly (adjust by
plasma levels)
Mycobacterium
tuberculosis  
quadruple therapy (rifampicin/isoniazid/
ethambutol /pyrazinamide)
Cryptococcus
neoformans
immuno-compromised amphotericin B starting at 250 µg/kg IV od +
flucytosine 50 mg/kg IV 6-hrly
Staph. aureus  flucloxacillin 2 g IV 6-hrly
Key papers
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de Gans J, et al . Dexamethasone in adults with bacterial meningitis. N Engl  J Med 2002; 347:1549–56.
van de Beek D, et al. Corticosteroids in acute bacterial  meningit is. Cochrane Database Syst Rev 2003; (3):CD004305.
Review.
See also:
Bacteriology, p158; Virology, serology and assays, p160; Antimicrobials, p260; Steroids, p262; Basic resuscitation,
p270; Hypotension, p312; General seizures, p372; Raised intracranial pressure, p382; Infection control—general
principles, p476; Infection—diagnosis, p480; Infection—treatment, p482; Sepsis and septic shock—treatment, p486;
Pyrexia (1), p518; Pyrexia (2), p520
Intracranial haemorrhage
Extradural haemorrhage
Usually presents acutely after head injury. Characterised by fall ing Glasgow Coma Score progressing to coma, focal
signs (lateral ising weakness or anaesthesia, pupil lary signs), visual disturbances and seizures. Treatment by random
burr holes has been supplanted by di rected drainage fol lowing CT scan local isation.
A conservative approach may be adopted for small haematomata but increasing size (assessed by regular CT scanning
or cl inical  deterioration) are indications for surgical drainage.
Subdural haemorrhage
Classically presents days to weeks fol lowing head trauma with a fluctuating level  of consciousness (35%), agi tation,
confusion, seizures and signs of raised intracranial  pressure, localising signs, or a slowly evolving stroke. Diagnosis
is made by CT scan. Treatment is by surgical drainage.
Intracerebral haemorrhage
Causes include hypertension, neoplasm, vascul it is, coagulopathy and mycotic aneurysms associated with bacterial
endocardi tis.
Clinical  features include sudden onset coma, drowsiness and/or neurological deficit. Headache usually occurs only
with cortical and intraventricular haemorrhage. The rate of evolution depends on the size and size of the bleed. The
area affected is the putamen (55%), thalamus (10%), cerebral cortex (15%), pons (10%) and cerebel lum (10%).
Diagnosis
CT scan is the defini tive test. A coagulation and vascul itis blood screen may be indicated. Angiography is indicated i f
surgical  repair is contemplated though not for drainage of blood clot.
Treatment
Bed rest
Supportive (e.g. hydration, nutri tion, analgesia, venti latory support)
Physiotherapy
Blood pressure control (maintain systol ic BP <220–230 mmHg)
Correct any coagulopathy
Control  raised intracranial pressure
Surgery—contact Regional  Centre, e.g. for evacuation of haematoma, repair/cl ipping of aneurysm
Steroid therapy is ineffective
See also:
Venti latory support—indications, p4; Blood pressure monitoring, p110; Intracranial pressure monitoring, p134;
Coagulation monitoring, p156; Neuroprotective agents, p244; Basic resusci tation, p270; Hypertension, p314;
Generalised seizures, p372; Subarachnoid haemorrhage, p378; Raised intracranial  pressure, p382; Bleeding
disorders, p396; Vascul itides, p494; Head injury (1), p504; Head injury (2), p506; Brain stem death, p548;
Withdrawal and witholding treatment, p550; Care of the potential organ donor, p552
Subarachnoid haemorrhage
Pathology
In 15% no cause is found; of the remainder, 80% are due to a ruptured aneurysm, 5% to arteriovenous
malformations and 15% fol low trauma.
The anterior part of the Circle of Wi l l is is affected in 85–90% of caseswhile 10–15% affect the vertebrobasilar
system.
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There is a 30% risk of rebleeding for which the mortali ty is 40%. Those surviving a month have a 90% chance of
surviving a year.
Cerebral vasospasm occurs in 40–70% of patients at 4–12 days after the bleed. This is the most important cause
of morbidi ty and mortali ty.
Hydrocephalus, seizures, hyponatraemia and inappropriate ADH secretion are recognised complications.
Clinical features
SAH may be preceded by a prodrome of headache, dizziness and vague neurological symptoms.
Often there is rapid onset (minutes to hours) presentation including col lapse, severe headache ± meningism.
Cranial  nerve palsies, drowsiness and hemiplegia may also occur.
Diagnosis
Diagnosis is usually made by CT scan; i f there is no evidence of raised intracranial  pressure, a lumbar puncture may
be performed reveal ing blood-stained CSF with xanthochromia.
Management
Bed rest.
Maintain adequate hydration, nutrition, analgesia, sedation.
Cerebral vasospasm is prevented by nimodipine infusion and maintenance of a ful l  intravascular volume.
Systemic hypertension should only be treated if severe (e.g. systol ic pressure >220–230 mmHg) and prolonged.
Surgery—the timing is controversial  wi th either early or delayed (7–10 days) intervention being advocated. The
Regional Neurosurgical Centre should be consulted for local pol icy.
Antifibrinolytic therapy (e.g. tranexamic acid) reduces the incidence of rebleeding but has no beneficial  effect on
outcome.
Key trial
Al len GS, et al. Cerebral arterial  spasm—a control led trial of nimodipine in patients with subarachnoid hemorrhage. N
Engl J Med 1983; 308:619–24
See also:
Venti latory support—indications, p4; Blood pressure monitoring, p110; Intracranial pressure monitoring, p134;
Coagulation monitoring, p156; Neuroprotective agents, p244; Basic resusci tation, p270; Hypertension, p314;
Generalised seizures, p372; Intracranial haemorrhage, p376; Raised intracranial  pressure, p382; Bleeding disorders,
p396; Brain stem death, p548; Withdrawal  and witholding treatment, p550; Care of the potential organ donor, p552
Stroke
Pathology
Haemorrhage, embolus or thrombosis.
‘Secondary’ stroke may occur with meningit is, bacterial endocardi tis, subarachnoid haemorrhage and vasculit is.
Dissection and cerebral venous thrombosis need to be considered, as anticoagulation is indicated for both
(unless a large infarct is establ ished, as there is an increased risk of bleeding). Dissection should be suspected
in younger patients, often presenting with severe headache or neck pain ± Horner's syndrome ± seizures after
trauma or neck manipulation. Cerebral  venous thrombosis may mimic stroke, tumour, subarachnoid haemorrhage
or meningo-encephal itis and may present with headache, seizures, focal  signs or obtundation.
Urgent CT scan
Indicated when the diagnosis is in doubt, for continuing deterioration, suspicion of subarachnoid haemorrhage,
hydrocephalus or trauma, or for patients who are anticoagulated or who have a bleeding tendency.
Aims of treatment
To protect the penumbra with close attention to oxygenation, hydration, glycaemic control, and avoidance of
pyrexia.
Blood pressure control is needed for severe hypertension (e.g. >200/120 mmHg) and hypotension.
Drug therapy including thrombolysis and aspirin. The evidence for anticoagulation remains contentious as there
is an increased risk of bleeding and no consistent subgroup benefi t has been shown. Early anticoagulation is
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probably beneficial for intracranial  stenosis, a stroke-in-evolution, complete vessel occlusion with minimal
defici t and in low risk patients with a high probabil i ty of recurrence (secondary prevention).
For thrombolysis the extent of reperfusion depends on the aetiology with basi lar > middle cerebral artery >
internal carotid, and embol ic > thrombotic. Pooled studies with rt-PA (0.9 mg/kg) given within 3 h of stroke
onset (and tight blood pressure control) showed a favourable outcome. However, there was a 6-fold increase in
haemorrhage (to 5.9%), of whom 60% died. This was more common in the elderly, and with more severe stroke.
Neurosurgical intervention may be considered for cerebellar haematoma, cerebel lar infarction and the malignant
middle cerebral  artery syndrome (for massive infarction on the non-dominant side).
Key paper
Hacke W, et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS
rt-PA stroke trials. Lancet 2004; 363:768–74
See also:
Venti latory support—indications, p4; Blood pressure monitoring, p110; Neuroprotective agents, p244; Basic
resuscitation, p270; Hypertension, p314; Generalised seizures, p372; Intracranial haemorrhage, p376; Subarachnoid
haemorrhage, p378; Raised intracranial pressure, p382
Raised intracranial pressure
Clinical features
Headache, vomiting, dizziness, visual disturbance
Seizures, focal  neurology, papil loedema
Increasing blood pressure, bradycardia (late responses)
Agi tation, increasing drowsiness, coma
Slow deep breaths, Cheyne–Stokes breathing, apnoea
Ipsilateral progressing to bi lateral pupi l lary di latation
Decorticate progressing to decerebrate posturing
Diagnosis
CT scan or MRI
Intracranial  pressure (ICP) measurement >20 mmHg
Lumbar puncture should be avoided because of the risk of coning.
Nei ther CT scan nor absence of papil loedema wi l l  exclude a raised ICP.
Causes
Space-occupying lesion (e.g. neoplasm, blood clot, abscess)
Increased capil lary permeabil i ty (e.g. trauma, infection, encephalopathy)
Cell  death (e.g. post-arrest hypoxia)
Obstruction (e.g. hydrocephalus)
Management
Bed rest, 20–308 head-up ti l t,  sedation, quiet environment, minimal suction and noise. Sedation is often
necessary to overcome a hyperadrenergic state but sedative-induced hypotension should be avoided. The tape
tethering the endotracheal tube in place should not occlude jugular venous drainage.
1.
Venti late if GCS ≤8, airway unprotected or excessively agi tated.2.
Maintain PaCO2 at 4–4.5 kPa and avoid rapid rises. CSF bicarbonate levels re-equil ibrate within 4–6 h, negating
any benefi t from hyperventi lation.
3.
If possible, monitor ICP. Aim to maintain ICP <20 mmHg and cerebral  perfusion pressure (CPP=MAP-ICP) ≥70
mmHg. Vasopressors may be needed. Do not treat systemic hypertension unless very high (e.g. systol ic
>220–230 mmHg).
4.
Jugular bulb venous saturation (SjO2) and lactate may be useful monitoring techniques though do not detect
regional ischaemia.
5.
Give mannitol  0.5 mg/kg over 15 min. Repeat 4-hrly depending on CPP measurements and/or cl inical  signs of6.
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deterioration. Stop when plasma osmolal ity reaches 310–320 mOsmol/kg.
Avoid severe alkalosis as cerebral vascular resistance rises and cerebral ischaemia increases.7.
Consider specific treatment, e.g. for meningo-encephali tis, malaria, hepatic encephalopathy, surgery. Some
neurosurgeons decompress the cranium for general ised oedema by removing a skull  flap. Seek local advice.
Dexamethasone 4–16 mg qds IV is beneficial for oedema surrounding a tumour or abscess and for herpes simplex
encephali tis.
8.
Acute deterioration/risk of imminent coning
Mechanical ly venti late to PaCO2 3.0–3.5 kPa for 10–20 min.1.
Give mannitol  0.5 g/kg IV over 15 min. Repeat 4-hrly as necessary while plasma osmolal ity <310–320
mOsmol/kg. Consider furosemide.
2.
If no response in ICP, CPP and/or cl inical features, give thiopental (successful in 50% of resistant cases).3.
Consider repeat CT scan and refer for urgent surgery if a surgical ly amenable space-occupying lesion is
diagnosed.
4.
See also:
Venti latory support—indications, p4; Blood pressure monitoring, p110; Intracranial pressure monitoring, p134;
Diuretics, p212; Neuroprotective agents, p244; Basic resusci tation, p270; Hypertension, p314; General ised seizures,
p372; Intracranial haemorrhage, p376; Subarachnoid haemorrhage, p378; Stroke, p380; Head injury (1), p504; Head
injury (2), p506; Brain stem death, p548; Withdrawal  and witholding treatment, p550; Care of the potential organ
donor, p552
Guillain–Barré syndrome
This is an immunologically-mediated, acute demyelinating polyradiculopathy. Viral infections and immunisations are
common antecedents. The syndrome includes a progressive, areflexic motor weakness (often symmetrical , ascending
and involving cranial nerves including facial,  bulbar and extraocular) with progression over days to weeks. There are
often minor sensory disturbances (e.g. paraesthesiae). Autonomic dysfunction is not unusual. There is no increase in
cel l count on CSF examination but protein levels usual ly rise progressively (>0.4 g/l). Nerve conduction studies show
slow conduction velocit ies with prolonged F waves. Other features include muscle tenderness and back pain. The
major contributors to morbidi ty and mortality are respiratory muscle weakness and autonomic dysfunction
(hypotension, hypertension, arrhythmias, i leus and urinary retention).
Differential diagnosis
Other causes of acute weakness must be excluded before a diagnosis of Gui l lain–Barré syndrome can be made.
Specific treatment
Intravenous gammaglobulin (0.4 g/kg/day for 5 days) or plasma exchange (five 50 ml/kg exchanges over 8–13
days) is effective if started within 14 days of onset of symptoms.
Steroids have not been shown to be beneficial.
Supportive treatment
Respiratory care
Regular chest physiotherapy and spirometry are required. Mechanical venti lation is needed if FVC <1l or PaCO2 is
raised. An early tracheostomy is useful since mechanical  venti lat ion is l ikely to continue for several weeks. Patients
with bulbar involvement or inadequate cough should undergo tracheotomy, even if spontaneous breathing continues.
Cardiovascular care
Continuous cardiovascular monitoring is required due to the effects of autonomic involvement. Arrhythmias are
particularly l ikely with anaesthesia (especial ly with suxamethonium). Hypertensive and hypotensive responses are
generally exaggerated with vasoactive drugs.
Nutritional support
Parenteral nutrit ion wi l l  be required in cases where there is i leus. Enteral  nutrition is preferred, i f possible, even
though energy and fluid requirements are reduced in Guil lain–Barré syndrome.
Analgesia
Analgesia is required for muscle, abdominal and back pain. Although NSAIDs may be useful,  opiates are often
required.
Other support
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Particular attention is required to pressure areas and deep vein thrombosis prophylaxis.
Key trials
Plasma Exchange/Sandoglobul in Gui l lain-Barre Syndrome Trial  Group. Randomised trial of plasma exchange,
intravenous immunoglobul in, and combined treatments in Guil lain-Barré syndrome. Lancet 1997; 349:225–30
van Koningsveld R, for the Dutch GBS study group. Effect of methylprednisolone when added to standard treatment
with intravenous immunoglobul in for Guil lain–Barre syndrome: randomised trial. Lancet 2004; 363:192–6
See also:
Venti latory support—indications, p4; Blood pressure monitoring, p110; Neuroprotective agents, p244; Basic
resuscitation, p270; Hypertension, p314; Generalised seizures, p372; Intracranial haemorrhage, p376; Subarachnoid
haemorrhage, p378; Raised intracranial pressure, p382
Myasthenia gravis
Myasthenia gravis is associated with painless weakness which is worse after exertion with deterioration during stress,
infection or trauma.
Tendon reflexes are normal. It is an autoimmune disease associated with acetylcholine receptor and, rarely,
anti-striated muscle antibodies.
There is also an association with other autoimmune diseases (e.g. thyroid disease, SLE, rheumatoid arthritis).
Younger (<45 years), predominantly female patients may have a thymoma which, i f resected, may provide remission.
Severe weakness may be the result of a myasthenic or cholinergic (e.g. sweating, salivation, lacrimation, colic,
fasciculation, confusion, ataxia, smal l pupi ls, bradycardia, hypertension, seizures) crisis.
Diagnosis of myasthenia
Edrophonium is a short acting antichol inesterase used in the diagnosis of myasthenia in patients with no previous
history of myasthenia gravis. In myasthenic patients with an acute deterioration the test may dist inguish a
myasthenic from a cholinergic crisis. In cholinergic crisis there is a possibi l i ty of further deterioration and atropine
and faci l it ies for urgent intubation and venti lation should be available. An initial dose of 2 mg IV is given. If there
are no cholinergic side-effects a further 8 mg may be given. A posi tive test is judged by improvement of weakness
within 3 min of injection. The test may be combined with objective assessment of respiratory function by measuring
the FVC response or by assessing the response to repetitive stimulation with an EMG.
Maintenance treatment
Antichol inesterase drugs provide the mainstay of symptomatic treatment but steroids, immunosuppressives and
plasma exchange may provide pharmacological  remission.
Myasthenic crisis
New myasthenics may present in crisis and treatment should be started with steroids, azathioprine and
pyridostigmine. Plasma exchange may be useful to reduce the antibody load. In known myasthenics an increased dose
of pyridostigmine and steroids wi l l  be required. If the condit ion deteriorates drug therapy should be stopped; plasma
exchange may be l ife saving. Anticholinesterases may produce improvement in some muscle groups and chol inergic
deterioration in others due to differential sensit ivity. As with any case of acute weakness mechanical  venti latory
support is required if FVC <1l  or the PaCO2 is raised.
Cholinergic crisis
Cholinergic symptoms are usual ly at their most severe 2 h after the last dose of anticholinesterase. It is common to
give atropine prophylactical ly in the treatment of myasthenia which may mask some of the cholinergic symptoms. If a
deterioration of myasthenia fai ls to respond to edrophonium all  drugs should be stopped and atropine given (1 mg IV
every 30 min to a maximum of 8 mg). The edrophonium test should be repeated every 2 h and anticholinesterases
reintroduced when the test is posit ive. Mechanical  venti lat ion is required i f FVC <1l or the PaCO2 is raised.
Drug dosages
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Prednisolone 80 mg/day orally
Azathioprine 2.5 mg/kg/day orally
Pyridostigmine 60–180 mg 6-hrly orally
Atropine 0.6 mg 6-hrly orally
Drugs causing a deterioration in myasthenia
Aminoglycosides
Streptomycin
Tetracycl ines
Local  anaesthetics
Muscle relaxants
Opiates
See also:
Venti latory support—indications, p4; Endotracheal intubation, p36; Special support surfaces, p86; Plasma exchange,
p68; Pulmonary function tests, p94; Steroids, p262; Respiratory fai lure, p282; Hypotension, p312; Tachyarrhythmias,
p316; Bradyarrhythmias, p318; Acute weakness, p368
ICU neuromuscular disorders
Neuromuscular disorders in the cri tical ly i l l  have long been recognised, particularly in those being mechanical ly
venti lated. First suspicions are often raised when patients fai l to wean from mechanical venti lation or l imb weakness
is noted on stopping sedation. Disuse atrophy, catabol ic states and drug therapy (e.g. high dose steroids, muscle
relaxants) are probably responsible for some cases but do not explain al l. A neuromyopathic component of
multi -organ dysfunction syndrome may be implicated.
Critical illness neuropathy
Neurophysiological studies have demonstrated an acute idiopathic axonal  degeneration in patients with a flaccid
weakness fol lowing a prolonged period of intensive care. Nerve conduction velocit ies are normal indicating no
demyel ination. CSF is normal unlike Gui l lain–Barré syndrome. The neuropathy is self-l imiting but prolongs the
recovery phase of cri tical  i l lness. Recovery may take weeks to years. Pyridoxine (100–150 mg daily PO) has been
used in the treatment.
Critical illness myopathy
Drug induced myopathy is not uncommon in crit ical ly i l l  patients. Steroid induced myopathy is less common as the
indications for high dose steroids have been reduced. Muscle relaxants may have a prolonged effect and may be
potentiated by β2 agonists. Muscle histological  studies have demonstrated abnormali ties (fibre atrophy, mitochondrial
defects, myopathy and necrosis) which could not be associated with steroid or muscle relaxant therapy. Myopathy
may cause renal  damage via myoglobinuria. Crit ical i l lness myopathy is associated with various forms of muscle
degeneration but is usually self-l imit ing. Recovery may take weeks to years.
See also:
Venti latory support—indications, p4; IPPV—assessment of weaning, p18; Special support surfaces, p86; Pulmonary
function tests, p94; Respiratory fai lure, p282; Acute weakness, p368; Gui l lain–Barré syndrome, p384
Tetanus
The cl inical syndrome is caused by the exotoxin tetanospasmin from the anaerobe Clostridium tetani in contaminated
or devitalised wounds. Tetanospasmin ascends intra-axonal ly in motor and autonomic nerves, blocking release of
inhibitory neurotransmitters. The disease may be modi fied by previous immunisation, thus milder or localised
symptoms occur with heavier toxin loads.
Clinical features
Gradual onset of st iffness, dysphagia, muscle pain, hypertonia, rigidity and muscle spasm.
Laryngospasm often fol lows dysphagia.
Muscle spasm is often provoked by minor disturbance, e.g. laryngospasm may be provoked by swallowing.
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Onset of symptoms within 5 days of injury impl ies a heavy toxin load and severe disease.
The disease is sel f-l imiting so treatment is supportive but may need to continue for several weeks.
Management of the wound
If a contaminated wound is present, it should be debrided surgical ly to remove the source of the toxin.
Benzylpenici l l in 1.2 g 6-hrly and metronidazole 500 mg 8-hrly IV are appropriate antibiotics.
Passive immunisation
Human tetanus immunoglobulin 1000–1500 uni ts IM may shorten the course of the disease by removing ci rculating
toxin. Rapid fixation of the toxin to tissues l imits the usefulness of this approach.
Mild tetanus
Patients with mild symptoms, no respiratory distress and a delayed onset of symptoms should be nursed in a quite
environment with mild sedation to prevent tetanic spasms.
Severe tetanus
Intubate and venti late since asphyxia may occur due to prolonged respiratory muscle spasm.
Sedation may be achieved with diazepam (20 mg 4–6-hrly NG and 5 mg IV as necessary).
Muscle rigidity is best treated with magnesium sulphate 20 mmol/h IV ± chlorpromazine 25–75 mg 4-hrly IV or
NG, with muscle relaxants i f necessary.
Autonomic hyper-reactivi ty is a feature (arrhythmias, hypotension, hypertension and myocardial ischaemia). It is
minimised by sedation, anaesthesia and treated by atropine 1–20 mg/h IV, propranolol 10 mg 8-hrly IV or NG,
and magnesium sulphate 20 mmol/h IV.
Tetanus toxoid prophylaxis
The disease confers no immunity so patients must be immunised prior to hospital discharge.
Last dose of tetanus toxoid >5 years no further dose
Last dose of tetanus toxoid <10 years 1 dose
No previous immunisation 3 doses
See also:
Venti latory support—indications, p4; Sedatives, p238; Muscle relaxants, p240; Antimicrobials, p260; Respiratory
fai lure, p282; Hypotension, p312; Hypertension, p314; Tachyarrhythmias, p316; Bradyarrhythmias, p318
Botulism
An uncommon, lethal disease caused by the exotoxins of the anaerobe Clostridium botulinum. Botulism is most
commonly a food-borne disease, especial ly associated with canned foods. It may be contracted by wound
contamination with aquatic soi ls. The toxin is carried in the blood to cholinergic neuromuscular junctions where i t
binds irreversibly. Symptoms begin between 6 h and 8 days after contamination and are more severe with earl ier
onset. Botul ism is diagnosed by isolating Clostridium botulinum from the stool or by mouse bioassay (survival of
immunised mice and death of non-immunised mice when infected serum is injected).
Clinical features
Symptoms include gastrointestinal disturbance, sore throat, fatigue, dizziness, paraesthesiae, cranial
involvement and a progressive, descending flaccid weakness.
Parasympathetic symptoms are common.
The disease is usually self-l imit ing within several weeks.
Respiratory care
Regular spirometry and mechanical  venti lation i f FVC <1l. Patients with bulbar palsy need intubation for ai rway
protection.
Toxin removal
If there is no i leus the use of non-magnesium containing cathartics may remove the toxin load. Magnesium may
enhance the effect of the toxin.
Antitoxin
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May shorten the course of the disease i f given early and the toxin type is known (seven have been identif ied). There
is a high risk of anaphylactoid reactions.
Wound botulism
Surgical  debridement and penici l l in are the mainstay of treatment for contaminated wounds.
See also:
Venti latory support—indications, p4; Antimicrobials, p260; Respiratory failure, p282; Bradyarrhythmias, p318
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Haematological Disorders
Bleeding disorders
A common problem in the cri tical ly i l l , this may be due to (i) large vessel bleeding—usually ‘surgical ’  or fol lowing a
procedure (e.g. chest drain, tracheostomy, accidental  arterial  puncture, removal  of intravenous or intra-arterial
catheter); peptic ulcer bleeding is now relatively uncommon due to improved attention to perfusion and nutri tion; (i i )
around vascular catheter sites or from intubated/instrumented lumens and orif ices—usually related to severe
multisystem il lness or excess anticoagulant therapy, including thrombolytics; (i i i) smal l vessel  bleeding, e.g. skin
petechiae, gastric erosions—usually related to anticoagulation or severe general ised i l lness including disseminated
intravascular coagulation.
A fal l ing platelet count is often an early sign of sepsis and cri tical  i l lness. Recovery of the count usual ly coincides
with overall  patient recovery.
Common ICU causes
Decreased platelet production, e.g. sepsis- or drug-induced
Decreased production of coagulation factors, e.g. l iver fai lure
Increased consumption, e.g. DIC, major trauma, bleeding, heparin-induced thrombocytopenia, antiplatelet
antibodies, extracorporeal circuits
Impaired or deranged platelet function
Drugs, e.g. heparin, aspirin
Decreased protease inhibitors, e.g. antithrombin III, Protein S and Protein C deficiency (fol lowing sepsis)
Principles of management
An International Normalised Ratio (INR) between 1.5–2.5 and/or platelet count of (20–40) ×  109/l  do not usually
require correction i f the patient is not bleeding or at high risk e.g. active peptic ulcer, recent cerebral
haemorrhage, undergoing an invasive procedure. 5–10 uni ts of platelets wi l l  raise the count by only 10–20 ×
109/l. The effect is often transient (<24 h) and the increment reduces with repetit ive dosing. Treatment of
symptomatic thrombocytopenia aims to increase the count >50 ×  109/l.  A target INR <1.5 is acceptable. Vi tamin
K is given for l iver fai lure and considered for warfarin overdosage. 1 mg Vi tamin K wil l  reverse warfarin effects
within 12 h while 10 mg wil l  saturate l iver stores, preventing warfarin activity for some weeks. Fresh frozen
plasma (FFP) is given for short term control.
1.
If bleeding and INR = 1.5–2, give 2–3 uni ts FFP. If INR >2, give 4–6 uni ts FFP. If not bleeding (or high risk),
general ly only correct i f INR >2.5–3. Repeat clotting screen 30–60 min after FFP infused. Give more FFP i f
bleeding continues and/or INR >3.
2.
For bleeding related to thrombolysis, (i) stop the drug infusion, (i i ) give ei ther aprotinin 500,000 units over 10
min, then 200,000 units over 4 h or tranexamic acid 10 mg/kg repeated 6–8-hrly (i i i ) give 4 uni ts FFP.
3.
Cryoprecipitate is rarely needed. Consider when the thrombin time is elevated, e.g. with DIC. Similarly, factor
VIII is general ly used for haemophil iacs only.
4.
If aspirin has been taken within the past 1–2 weeks, platelet function may be deranged. Give fresh platelets,
even though count may be adequate.
5.
Factor VIIa may be useful  for severe, intractable bleeding but more studies are needed to confi rm its efficacy.6.
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Management of major bleeding
If external, di rect occlusion/deep suture.1.
Urgent expert opinion—e.g. for surgery, endoscopy + injection, etc.2.
Correct coagulopathy.3.
Management of vascular catheter or percutaneous drain site bleeding
Direct pressure/occlusive dressing.1.
Correct coagulopathy; consider use of aprotinin or tranexamic acid.2.
Surgical intervention is rarely necessary al though perforation/laceration of local  artery/vein should be
considered i f bleeding fai ls to stop or becomes significant.
3.
See also:
Coagulation monitoring, p156; Blood transfusion, p182; Blood products, p252; Coagulants and antifibrinolytics, p254;
Aprotinin, p256; Haemoptysis, p304; Upper gastrointestinal haemorrhage, p344; Lower intestinal  bleeding and coli tis,
p348; Acute l iver fai lure, p360; Chronic l iver fai lure, p364; Platelet disorders, p406; Systemic
inflammation/multiorgan fai lure, p484; Post-operative intensive care, p534
Clotting disorders
Uncommon as a secondary event in crit ical ly i l l  patients as they tend to be auto-anticoagulated. The risk of major
venous thrombosis increases with long term immobil ity and paralysis, and in specific pro-thrombotic condit ions such
as pregnancy, thrombotic thrombocytopenic purpura, SLE (lupus anticoagulant), sickle cel l crisis, hyperosmolar
diabetic coma.
Disseminated intravascular coagulation is associated with microvascular clotting, a consumption coagulopathy and
increased fibrinolysis.
Clotting of extracorporeal ci rcuits, e.g. for renal replacement therapy, may be due to (i) mechanical obstruction to
flow, e.g. kinked catheter, (i i ) inadequate anticoagulation or (i i i) in severe i l lness, a decrease in endogenous
anticoagulants (e.g. antithrombin III); this may resul t in circuit blockage despite a coexisting thrombocytopenia
and/or coagulopathy.
Axi l lary vein or subclavian vein thrombosis may resul t from indwell ing intravenous catheters.
Management
If the patient is not auto-anticoagulated, prophylactic low molecular weight heparin (5000 IU od SC) should be given
for long term immobil ity/paralysis and to high risk patients (e.g. previous DVT, femoral fractures).
For pulmonary embol ism or deep vein thrombosis give 200 IU/kg SC daily (or 100 IU/kg bd i f at risk of bleeding).
Partial thromboplastin times (PTT) should be checked regularly if giving unfractionated heparin and maintained at
approximately 2–3 × normal. Monitoring is not necessary for LMW heparin though anti-Factor Xa levels can be used.
Intra-arterial  clot can be treated with local infusion of thrombolytics, usually fol lowed by heparinisation. Seek
vascular surgical  advice.
Axi l lary vein or subclavian vein thrombosis should be managed by elevation of the affected arm, e.g. in a Bradford
sl ing, and heparinisation.
Speci fic condi tions may require speci fic therapies, e.g. plasma exchange for SLE and TTP, whole blood exchange for
sickle cell  crisis.
Warfarinisation should generally be avoided unti l shortly before ICU discharge because of the risk of continued
bleeding fol lowing routine invasive procedures such as central  venous catheterisation.
See also:
Coagulation monitoring, p156; Anticoagulants, p248; Thrombolytics, p250; Blood products, p252; Pulmonary embolus,
p308
Anaemia
Defined as a low haemoglobin due to a decreased red cel l mass, i t may also be ‘physiological’ due to di lution from an
increased plasma volume, e.g. pregnancy, vasodilated states.
Major causes in the ICU patient
Blood loss, e.g. haemorrhage, regular blood sampl ing
Severe i l lness—analogous to the ‘anaemia of chronic disease’, there is decreased marrow production and,
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possibly, a decreased l i fespan
Rarer causes include:
Microcytic anaemia—predominantly iron deficiency
Normocytic
Chronic disease
Bone marrow fai lure (idiopathic, drugs, neoplasm, radiation)
Haemolysis
Renal fai lure
Macrocytic—vitamin B12 and folate deficiency, alcoholism, ci rrhosis, sideroblastic anaemia, hypothyroidism
Congenital  diseases—sickle cel l, thalassaemia
Management
Treatment of the cause where possible.1.
Blood transfusion:
The ideal haemoglobin level for optimal oxygen carriage and viscosity remains contentious. A recent
multicentre trial showed improved outcomes if a trigger of 7 g/dl was used. A higher transfusion threshold,
e.g. 9–10 g/dl , may be needed in those with cardiorespiratory disease.
Transfusion is usually given as packed cells with or wi thout a smal l dose of furosemide to maintain fluid
balance. This may need to be given rapidly during active blood loss, or slowly for correction of a gradually
fal l ing haemoglobin level .
Rarely, patients admitted with a chronically low haemoglobin, e.g. <4–5 g/dl, which often fol lows long term
malnutrition or vi tamin deficiency, wil l  need a much slower elevation in haemoglobin level to avoid
precipi tating acute heart fai lure. An init ial target of 7–8 g/dl is often acceptable. Obviously, this may need
to be al tered in the l ight of any concurrent acute i l lness where elevation of oxygen delivery is deemed
necessary.
Erythropoeitin reduces the need for blood transfusion in long-term ICU patients and may be useful in those
with multiple antibodies or declining transfusion for rel igious reasons.
2.
Key trial
Hebert PC, et al  for the Transfusion Requirements in Critical  Care Investigators, Canadian Cri tical  Care Trials
Group. A multicenter, randomized, control led cl inical trial of transfusion requirements in crit ical care. N Engl J
Med 1999; 340:409–17
Sickle cell disease
A chronic, heredi tary disease almost enti rely confined to the black population where the gene for Hb S is inherited
from each parent. The red blood cells lack Hb A; when deprived of oxygen these cells assume sickle and other bizarre
shapes resul ting in erythrostasis, occlusion of blood vessels, thrombosis and tissue infarction. After stasis, cel ls
released back into the circulation are more fragile and prone to haemolysis. Occasionally, there may be bone marrow
fai lure.
Chronic features
Patients with sickle cell disease are chronical ly anaemic (7–8 g/dl) wi th a hyperdynamic circulation. Splenomegaly is
common in youth but, with progressive episodes of infarction, splenic atrophy occurs leading to an increased risk of
infection, particularly pneumococcal.
Chronic features include skin ulcers, renal fai lure, avascular bone necrosis (± supervening osteomyel itis, especial ly
Salmonella), hepatomegaly, jaundice and cardiomyopathy. Sudden cardiac death is not uncommon, usually before the
age of 30.
Sickle cell crises
Crises are precipitated by various triggers, e.g. hypoxaemia (air travel, anaesthesia, etc.), infection, cold,
dehydration and emotional stress.
Thrombotic crisis
Occurs most frequently in bones or joints but also affects chest and abdomen giving rise to severe pain. Neurological
symptoms (e.g. seizures, focal  signs), haematuria or priapism may be present. Pulmonary crises are the commonest
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
183 из 254 07.11.2006 1:04
P.403
P.404
reason for ICU admission; secondary chest infection or ARDS may supervene, worsening hypoxaemia and further
exacerbating the crisis.
Aplastic crisis
Related to parvovirus infection, it is suggested by worsening anaemia and a reduction in the normal ly elevated
reticulocyte count (10–20%).
Haemolytic crisis
Intravascular haemolysis with haemoglobinuria, jaundice and renal  fai lure sometimes occurs.
Sequestration crisis
Rapid hepatic and splenic enlargement due to red cell trapping with severe anaemia. This condition is particularly
serious.
Management
Prophylaxis against crises includes avoidance of hypoxaemia and other known precipitating factors, prophylactic
penici l l in and pneumococcal vaccine, and exchange transfusions.
Painful  crises usually require prompt opiate infusions. Although psychological dependence is high, analgesia
should not be withheld.
1.
Give oxygen to maintain SaO2 at 100%.2.
Rehydrate with intravenous fluids and keep warm.3.
If infection is suspected, antibiotics should be given as indicated.4.
Transfuse blood if haemoglobin level drops or central nervous system or lung compl ications present.5.
Lower proportion of sickle cel ls to <30% by exchange transfusion.6.
Mechanical  venti lation may be necessary for chest crises.7.
See also:
Oxygen therapy, p2; Pulse oximetry, p90; Full blood count, p154; Bacteriology, p158; Acute chest infection (1),
p288; Acute chest infection (2), p290; Acute renal fai lure—diagnosis, p332; Acute renal fai lure—management, p334;
Jaundice, p358; Anaemia, p400; Haemolysis, p404
Haemolysis
Shortening of erythrocyte l i fespan below the expected 120 days. Marked intravascular haemolysis may lead to
jaundice and haemoglobinuria.
Causes
Blood transfusion reactions
Haemolytic uraemic syndrome (microangiopathic haemolytic anaemia)
Trauma (cardiac valve prosthesis)
Malaria
Sickle cell haemolytic crisis
Drugs—e.g. high-dose penici l l in, methyl  dopa
Autoimmune (cold- or warm antibody-mediated)—may be idiopathic or secondary, e.g. lymphoma, SLE,
mycoplasma
Glucose-6-phosphate dehydrogenase deficiency—oxidative crises occur fol lowing ingestion of fava beans,
primaquine, sulphonamides leading to rapid onset anaemia and jaundice
Diagnosis
Unconjugated hyperbil i rubinaemia, increased urinary urobil inogen (increased RBC breakdown)
Reticulocytosis (increased RBC production)
Splenic hypertrophy (extravascular haemolysis)
Methaemoglobinaemia, haemoglobinuria, free plasma haemoglobin (intravascular haemolysis), reduced serum
haptoglobins
RBC fragmentation (microangiopathic haemolytic anaemia)
Coombs' test (immune-mediated haemolysis)
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Other (including haemoglobin electrophoresis, bone marrow biopsy)
Management
Identi fication and speci fic treatment of the cause where possible.1.
Blood transfusion to maintain haemoglobin >7g/dl2.
Massive intravascular haemolysis may lead to acute renal fai lure. Maintain a good diuresis and haemo(dia)fi lter
if necessary.
3.
See also:
Ful l blood count, p154; Blood transfusion, p182; Acute renal  fai lure—diagnosis, p332; Acute renal
fai lure—management, p334; Jaundice, p358; Anaemia, p400; Sickle cel l disease, p402; Platelet disorders, p406;
Malaria, p490; Vascul it ides, p494; HELLP syndrome, p540
Platelet disorders
Thrombocytopenia
Rarely symptomatic unti l  the platelet count <50 × 109/l ; spontaneous bleeding is more l ikely <20 ×  109/l. Al though
bleeding is often minor, e.g. skin petechiae, oozing at intravascular catheter sites, it may be massive or
l i fe-threatening, e.g. haemoptysis, intracranial haemorrhage.
Causes
Sepsis—in the ICU this is the commonest cause of a low platelet count; often provides a good barometer of
recovery or deterioration
Disseminated intravascular coagulation
Drugs
Related to antiplatelet antibody production, e.g. heparin (heparin-induced thrombocytopenia syndrome, ‘HITS’),
sulphonamides, quinine
Result ing in bone marrow suppression, e.g. chemotherapy agents
Others, e.g. aspirin, chlorpromazine, prochlorperazine, digoxin
Following massive bleeding and multiple blood transfusions
Bone marrow fai lure, e.g. tumour infi ltration, drugs
Splenomegaly
Thrombotic thrombocytopenic purpura (TTP), haemolytic uraemic syndrome (HUS)
Idiopathic thrombocytopenic purpura (ITP)
Specific infections, e.g. measles, infectious mononucleosis, typhus
Collagen vascular diseases, e.g. SLE
Management
Directed at the cause, e.g. antibiotics for sepsis, stopping offending drugs, plasma exchange for TTP,
splenectomy and steroids for ITP.
1.
Platelet support
Given routinely (e.g. 6–10 units/day) when counts <10–20 × 109/l
6–10 units given if <50 × 109/l and either symptomatic or due to undergo surgery or another invasive
procedure
2.
Unless actively bleeding, avoid platelet transfusions in TTP or HUS.3.
Deranged platelet function
Function may be deranged, albei t with normal counts, e.g. fol lowing aspirin within past 1–2 weeks, epoprostenol ,
uraemia. Fresh platelets may be required i f the patient is symptomatic. In uraemia, one dose of vasopressin (20µg IV
over 30 min) may be useful before surgery.
Thrombocythaemia
Rare in ICU patients; platelet counts often exceed 800 × 109/l .
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Causes
Prolonged low-level bleeding, post-splenectomy, myeloprol iferative disorders. Essential (idiopathic)
thrombocythaemia is unusual .
Management
As the major risk is thrombosis, management is based upon mobil ising the patient and administration of either
prophylactic aspirin (150 mg bd PO) or LMW heparin (5000 IU od SC). Dipyridamole (300–600 mg tds PO) is
occasionally used.
See also:
Plasma exchange, p68; Ful l blood count, p154; Blood transfusion, p182; Anticoagulants, p248; Blood products, p252;
Intracranial haemorrhage, p376; Abdominal sepsis, p350; Bleeding disorders, p396; Haemolysis, p404; Systemic
inflammation/multiorgan fai lure, p484; Vascul itides, p494
Neutropenia
Neutropenia is defined as a neutrophil count <2 × 109/l.  Li fe threatening infections may develop below 1 ×109/l  and
more commonly below 0.5 ×  109/l . Absolute numbers of neutrophils are more relevant than percentages as the total
white cel l count may be either decreased, normal  or increased.
Clinical features
Usually asymptomatic unti l infection supervenes
Causes
Systemic inflammation resul ts in margination and aggregation of neutrophils in vital organs, e.g. lung, l iver,
gut. Predominantly seen in the first 24 h after severe infection or trauma, it is often a precursor of multiple
organ dysfunction
Haemopoietic diseases, e.g. leukaemia, lymphoma, myeloma or as a consequence of chemotherapy or radiation
Nutrit ional deficiencies, e.g. folate, vitamin B12, malnutrit ion
Adverse drug reaction, e.g. carbimazole, sulphonamides
Part of aplastic anaemia, e.g. idiopathic, drugs, infection
Specific infections, e.g. brucel losis, typhoid, vi ral , protozoal
Hypersplenism
Antineutrophil  antibodies, e.g. systemic lupus erythematosis
Infections
Ini tial infections are with common organisms such as pneumococci, staphylococci and col iforms.
With recurrent infections or after repeated courses of antibiotics, more unusual  and/or antibiotic-resistant
organisms may be responsible, e.g. pseudomonas, fungi (particularly Candida and Aspergil lusspp.),
pneumocystis, cytomegalovirus, TB.
Management
If no diagnosis has been made, urgent investigations including a bone marrow aspiration are indicated.1.
Any implicated drugs should be immediately discontinued.2.
If the neutrophi l count fal ls below 1 × 109/l, the patient should be protectively isolated in a cubicle with strict
infection control procedures. Consider laminar flow ai r condit ioning if available.
3.
Minimise invasive procedures.4.
Maintain good oral hygiene. Apply topical treatment as necessary, e.g. nystatin mouthwashes for oral  fungal
infection.
5.
Clotrimazole cream for fungal skin infection.6.
Antibiotic therapy
For suspected infection use aggressive, parenteral antibiotics (broad spectrum if no organism has been
isolated).
Have a high index of suspicion for atypical infections such as fungi.
Although prophylactic broad-spectrum antibiotics are often prescribed, this encourages antibiotic
7.
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resistance. Another al ternative is to maintain strict infection control  wi th regular survei l lance and to treat
infections aggressively as indicated by l ikely sites and lab resul ts. Avoid uncooked foods, e.g. salads
(pseudomonas risk) and bottled pepper (aspergil lus).
Granulocyte-colony stimulating factor (G-CSF) is frequently given to stimulate a bone marrow response.8.
Neutrophi l infusions are short-l ived, expensive and often induce a pyrexial  response. Their role remains
controversial.
9.
See also:
Ful l blood count, p154; Bacteriology, p158; Antimicrobials, p260; Infection control—general principles, p476;
Infection—diagnosis, p480; Infection—treatment, p482
Leukaemia
Such patients may present acutely to an ICU with compl ications arising from ei ther the disease or the therapy.
Complications arising from the disease
Decreased resistance to infection
Hyperviscosi ty syndrome—drowsiness, coma, focal neurological  defects
Central  nervous system involvement
Anaemia, thrombocytopenia, bleeding tendency, DIC
Complications arising from the therapy
Tumour lysis syndrome—hyperkalaemia, hyperuricaemia and acute renal  fai lure may fol low rapid destruction of a
large white cel l mass
Neutropenia and immune compromise with an increased risk of infection
Anaemia
Thrombocytopenia leading to spontaneous bleeding, usual ly from intravascular catheter sites, skin, lung, gut and
brain
Lung fibrosis, e.g. fol lowing radiotherapy, bleomycin
Myocardial  fai lure, e.g. fol lowing mitozantrone
Graft versus host disease (GVHD)—features include mucosit is, hepatit is, jaundice, diarrhoea, abdominal pain,
rash and pneumonitis
Management
Tumour lysis syndrome can be prevented by adequate hydration, maintaining a good diuresis and administering
allopurinol. Once establ ished, haemo(dia)fi ltration and other measures to lower serum potassium levels may be
necessary.
1.
The raised white cell  mass may be reduced by leucophoresis.2.
Frequent blood transfusions to maintain Hb levels >7 g/dl3.
Platelet transfusions are required i f counts remain <10–20 ×  109/l, or if <50 × 109/l and remaining symptomatic
or undergoing an invasive procedure.
4.
Give fresh frozen plasma and other blood products as needed.5.
Neutropenia management, including protective isolation, appropriate antibiotic therapy, ± granulocyte colony
stimulating factor.
6.
GVHD is managed by supportive treatment and parenteral  nutri tion. Prostaglandin E1 and immunosuppression
may be helpful.
7.
Psychological support for both patient and family is vital.8.
Respiratory failure
Maintenance of gas exchange. Mortal ity is high (>60%) if mechanical venti lation is necessary. Non-invasive
techniques including CPAP and BiPAP can prove highly effective in avoiding the need for intubation.
1.
Where possible, treat the cause. Infection (including atypical  organisms), fluid overload, ARDS and a
pneumonitis/fibrosis secondary to chemo- or radiotherapy should be considered.
2.
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See also:
Venti latory support—indications, p4; Continuous positive airway pressure, p26; Non-invasive respiratory support,
p32; Acute respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2), p294; Heart
fai lure—assessment, p324; Heart fai lure—management, p326; Acute renal fai lure—diagnosis, p332; Acute renal
fai lure—management, p334; Diarrhoea, p340; Jaundice, p358; Anaemia, p400; Platelet disorders, p406; Neutropenia,
p408; Hyperkalaemia, p420; Infection—diagnosis, p480; Infection—treatment, p482
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Metabolic Disorders
Electrolyte management
A balance must be achieved between electrolyte intake and output. Consider:
Altered intake
Impaired renal excretion
Increased body losses
Body compartment redistribution (e.g. increased capil lary leak, secondary hyperaldosteronism)
As wel l as Na+ and K+,  consider Mg2+,  Ca2+,  Cl - and PO43- balance.
Plasma electrolyte values are poorly reflective of whole body stores; however, excessively high or low plasma levels
may induce symptoms and deleterious physiological and metabolic sequelae.
Water balance must also be taken into account; depletion or excess repletion may respectively concentrate or di lute
electrolyte levels.
The usual  daily requirements of Na+ and K+ are 60–80 mmol.
Gravi tational peripheral oedema implies increased total  body Na+ and water, though intravascular sal t and water
depletion may coexist.
Electrolyte losses
•Large nasogastric aspirate, vomiting Na+, Cl-
•Sweating Na+, Cl-
•Polyuria Na+, Cl-, K+, Mg2+
•Diarrhoea Na+, Cl-, K+, Mg2+
•Ascitic drainage Na+, Cl-, K+
Principles of management
Establ ish sources and degree of fluid and electrolyte losses.1.
Assess patient for signs of (i ) intravascular fluid depletion—hypotension (e.g. fol lowing changes in posture,
PEEP, vasodilating drugs) ol iguria, increasing metabol ic acidosis, thi rst, (i i) total  body NaCl  and water
overload—i.e. gravi tational  oedema.
2.
Measure urea, creatinine, osmolal ity and electrolyte content of plasma and urine.3.
As appropriate, ei ther replace estimated fluid and electrolyte deficit or increase excretion (with diuretics,
haemofi ltration). For rate of f luid and specific electrolyte replacement see individual  sections.
4.
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See also:
Electrolytes
, p146; Urinalysis, p166; Hypernatraemia, p416; Hyponatraemia, p418; Hyperkalaemia, p420; Hypokalaemia, p422;
Hypomagnesaemia, p424; Hypercalcaemia, p426; Hypocalcaemia, p428; Hypophosphataemia, p430
Hypernatraemia
Clinical features
Thirst, lethargy, coma, seizures, muscular tremor and rigidity, and an increased risk of intracranial haemorrhage.
Thirst usually occurs when the plasma sodium rises 3–4 mmol/l above normal. Lack of thi rst is associated with
central nervous system disease.
Treatment
Depends upon the cause and whether total  body sodium stores are normal , low or elevated and body water is normal
or low.
Rate of correction
If hyperacute (<12 h), correction can be rapid.
Otherwise, aim for gradual correction of plasma sodium levels (over 1–3 days), particularly in chronic cases (>2
days' duration), to avoid cerebral  oedema through sudden lowering of osmolali ty. A rate of plasma sodium
lowering <0.7 mmol/h has been suggested.
Hypovolaemia
If hypovolaemia is accompanied by haemodynamic alterations, use colloid init ial ly to restore the ci rculation.
Otherwise, use isotonic sal ine.
Artifi cial col loid solutions consist of hydroxyethyl  starches (e.g. Hespan, EloHAES) or gelatins (e.g. Gelofusin,
Haemaccel) dissolved in isotonic sal ine.
Normal total body Na (water loss)
Water replacement either PO (addit ion to enteral  feed) or as 5% glucose IV. Up to 5l/day may be necessary.
If cranial diabetes insipidus (CDI): restrict salt and give thiazide diuretics. Complete CDI wi l l  require
desmopressin (10µg bd intranasally or 1–2µg bd IV) whereas partial  CDI may require desmopressin but often
responds to drugs that increase the rate of ADH secretion or end-organ responsiveness to ADH, e.g.
chlorpropamide, hydrochlorthiazide
If nephrogenic DI: manage by a low sal t diet and thiazides. High dose desmopressin may be effective. Consider
removal  of causative agents, e.g. l ithium, demeclocycline.
Low total body Na (Na and water losses)
Treat hyperosmolar non-ketotic diabetic crisis, uraemia as appropriate.
Otherwise consider 0.9% sal ine or hypotonic (0.45%) sal ine. Up to 5 l/day may be needed.
Increased total body Na (Na gain)
Water replacement either PO (addit ion to enteral  feed) or as 5% glucose IV. Up to 5l/day may be necessary.
In addi tion, furosemide 10–20 mg IV prn may be necessary.
Causes of hypernatraemia
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Type Aetiology Urine
Low total body Na Renal losses: diuretic excess,
osmotic diuresis (glucose, urea,
mannitol)
[Na+] >20 mmol/l iso-
or hypotonic
Extra-renal losses: excess
sweating
[Na+] <10 mmol/l
hypertonic
Normal total body Na Renal losses: diabetes insipidus [Na+] variable hypo-,
iso- or hypertonic
Extra-renal losses: respiratory
and renal insensible losses
[Na+] variable
hypertonic
Increased total body Na Conn's syndrome, Cushing's
syndrome, excess NaCl, hypertonic
NaHCO3
[Na+] >20 mmol/l iso-
or hypertonic
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Enteral  nutri tion, p80; Parenteral nutrit ion, p82;
Electrolytes
, p146; Urinalysis, p166; Crystal loids, p176; Col loids, p180; Diuretics, p212; Electrolyte management, p414; Diabetic
ketoacidosis, p442; Hyperosmolar diabetic emergencies, p444
Hyponatraemia
Clinical features
Nausea, vomiting, headache, fatigue, weakness, muscular twitching, obtundation, psychosis, seizures and coma.
Symptoms depend on the rate as wel l as the magnitude of fal l in the plasma [Na+].
Treatment
Rate and degree of correction
In chronic hyponatraemia correction should not exceed 0.5 mmol/l /h in the fi rst 24 h and 0.3 mmol/l/h
thereafter.
In acute hyponatraemia the ideal rate of correction is controversial though elevations in plasma Na+ can be
faster, but <20 mmol/l /day.
A plasma Na+ of 125–130 mmol/l is a reasonable target for ini tial correction of both acute and chronic states.
Attempts to achieve normo- or hypernatraemia rapidly should be avoided.
Neurological  compl ications, e.g. central pontine myel inolysis, are related to the degree of correction and (in
chronic hyponatraemia) the rate. Premenopausal  women are more prone to these complications.
Extracellular fluid (ECF) volume excess
If symptomatic (e.g. seizures, agi tation), and not oedematous, 100 ml aliquots of hypertonic (1.8%) saline can
be given, checking plasma levels every 2–3 h.
If symptomatic and oedematous, consider furosemide (10–20 mg IV bolus prn), mannitol (0.5g/kg IV over 15–20
min), and replacement of urinary sodium losses with al iquots of hypertonic sal ine. Check plasma levels every
2–3 h. Haemofi ltration or dialysis may be necessary if renal  fai lure is establ ished.
If not symptomatic, restrict water to 1–1.5 l /day. If hyponatraemia persists, consider inappropriate ADH (SIADH)
secretion.
If SIADH likely, give isotonic saline and consider demeclocycl ine.
If SIADH unl ikely, consider furosemide (10–20 mg IV bolus prn), mannitol  (0.5 g/kg IV over 15–20 min), and
replacement of urinary sodium losses with al iquots of hypertonic saline.
Check plasma levels regularly. Haemofi ltration or dialysis may be necessary if renal  fai lure is establ ished.
Extracellular fluid volume (ECF) depletion
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If symptomatic (e.g. seizures, agi tation), give isotonic (0.9%) sal ine. Consider hypertonic (1.8%) saline.
If not symptomatic, give isotonic (0.9%) saline.
General points
Equations that calculate excess water are unreliable. It is safer to perform frequent estimations of plasma
sodium levels.
Hypertonic saline may be dangerous in the elderly and those with impaired cardiac function. An alternative is to
use furosemide with replacement of urinary sodium (and potassium) losses each 2–3 h. Thereafter, simple water
restrict ion is usual ly sufficient.
Many patients achieve normonatraemia by spontaneous water diuresis.
Use isotonic solutions for reconsti tuting drugs, parenteral  nutrition, etc.
Hyponatraemia may intensi fy the cardiac effects of hyperkalaemia.
A true hyponatraemia may occur with a normal osmolal ity in the presence of abnormal  solutes e.g. ethanol ,
ethylene glycol , glucose.
Causes of hyponatraemia
Type Aetiology Urine
[Na+]
ECF volume depletion Renal losses: diuretic excess, osmotic diuresis (glucose,
urea, mannitol), renal tubular acidosis, salt-losing nephritis,
mineralocorticoid deficiency
>20
mmol/l
Extra-renal losses:
vomiting, diarrhoea,
burns, pancreatitis
<10
mmol/l
Modest ECF volume
excess (no oedema)
water intoxication (NB post-operative, TURP syndrome),
inappropriate ADH secretion, hypothyroidism, drugs (e.g.
carbamazepine, chlorpropamide), glucocorticoid deficiency,
pain, emotion.
>20
mmol/l
acute and chronic renal
failure
>20
mmol/l
ECF volume excess
(oedema)
nephrotic syndrome, cirrhosis, heart failure <10
mmol/l
Causes of inappropriate ADH secretion
Neoplasm, e.g. lung, pancreas, lymphoma
Most pulmonary lesions
Most central  nervous system lesions
Surgical and emotional stress
Glucocorticoid and thyroid deficiency
Idiopathic
Drugs, e.g. chlorpropamide, carbamazepine, narcotics
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Enteral  nutri tion, p80; Parenteral nutrit ion, p82;
Electrolytes
, p146; Urinalysis, p166; Crystal loids, p176; Col loids, p180; Diuretics, p212; Acute renal fai lure—diagnosis, p332;
Acute renal  fai lure—management, p334; Electrolyte management, p414; Diabetic ketoacidosis, p442; Hyperosmolar
diabetic emergencies, p444
Hyperkalaemia
Plasma potassium depends on the balance between intake, excretion and the distribution of potassium across cell
membranes. Excretion is normal ly controlled by the kidneys.
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Causes
Reduced renal  excretion (e.g. chronic renal  fai lure, adrenal  insufficiency, diabetes, potassium sparing diuretics)
Intracellular potassium release (e.g. acidosis, rapid transfusion of old blood, cel l lysis including rhabdomyolysis,
haemolysis and tumour lysis, K+ channel openers (nicorandi l))
Potassium poisoning
Clinical features
Hyperkalaemia may cause dangerous arrhythmias including cardiac arrest. Arrhythmias are more closely related to
the rate of rise of potassium than the absolute level. Cl inical  features such as paraesthesiae and areflexic weakness
are not clearly related to the degree of hyperkalaemia but usual ly occur after ECG changes (tall ‘T’ waves, f lat ‘P’
waves, prolonged PR interval  and wide QRS).
Management
Potassium restriction is needed for al l cases and haemodiafi ltration or haemodialysis may be needed for resistant
cases.
Cardiac arrest associated with hyperkalaemia
Sodium bicarbonate (8.4%) 50–100 ml should be given in addit ion to standard CPR and other treatment detailed
below.
Potassium >7 mmol/l
Calcium chloride (10%) 10 ml should be given urgently in addition to treatment detai led below. Although calcium
chloride does not reduce the plasma potassium, i t stabil ises the myocardium against arrhythmias.
Clinical features of hyperkalaemia or potassium >6 mmol/l with ECG changes
Glucose (50 ml 50%) and soluble insulin (10 iu) should be given IV over 20 min. Blood glucose should be monitored
every 15 min and more glucose given i f necessary. In addit ion, calcium resonium 15 g qds PO or 30 g bd PR can be
considered.
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Enteral  nutri tion, p80; Parenteral nutrit ion, p82;
Electrolytes
, p146; Urinalysis, p166; Crystal loids, p176; Diuretics, p212; Cardiac arrest, p272; Bradyarrhythmias, p318; Acute
renal fai lure—diagnosis, p332; Acute renal  fai lure—management, p334; Electrolyte management, p414;
Rhabdomyolysis, p528
Hypokalaemia
Plasma potassium depends on the balance between intake, excretion and the distribution of potassium across cell
membranes. Excretion is normal ly controlled by the kidneys.
Causes
Inadequate intake
Gastrointestinal losses (e.g. vomiting, diarrhoea, fistula losses)
Renal losses (e.g. diabetic ketoacidosis, Conn's syndrome, secondary hyperaldosteronism, Cushing's syndrome,
renal tubular acidosis, metabolic alkalosis, hypomagnesaemia, drugs including diuretics, steroids, theophyll ines)
Haemofi ltration losses
Potassium transfer into cel ls (e.g. acute alkalosis, glucose infusion, insulin treatment, famil ial  periodic
paralysis)
Clinical features
Arrhythmias (SVT, VT and Torsades de Pointes)
ECG changes (ST depression, ‘T’ wave flattening, ‘U’ waves)
Metabol ic alkalosis
Constipation
Ileus
Weakness
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Management
Wherever possible, the cause of potassium loss should be treated.
Potassium replacement should be intravenous with ECG monitoring when there is a cl inically significant
arrhythmia (20 mmol over 30 min, repeated according to levels).
Slower intravenous replacement (20 mmol over 1 h) should be used where there are cl inical  features without
arrhythmias.
Oral supplementation (to a total intake of 80–120 mmol/day, including nutrit ional  input) can be given where
there are no cl inical  features.
See also:
Enteral nutrit ion, p80; Parenteral nutrition, p82; Electrolytes
, p146; Urinalysis, p166; Crystal loids, p176; Diuretics, p212; Steroids, p262; Cardiac arrest, p272;
Tachyarrhythmias, p316; Electrolyte management, p414; Metabol ic alkalosis, p436; Diabetic ketoacidosis, p442;
Post-operative intensive care, p534
Hypomagnesaemia
Causes
Excess loss, e.g. diuretics, other causes of polyuria (including poorly controlled diabetes mel l i tus), severe
diarrhoea, prolonged vomiting, large nasogastric aspirates
Inadequate intake, e.g. starvation, parenteral  nutrition, alcoholism, malabsorption syndromes
Clinical features
Magnesium is primari ly an intracellular ion involved in the production and uti l isation of energy stores and in the
mediation of nerve transmission. Low plasma levels, which do not necessari ly reflect ei ther intracellular or whole
body stores, may thus be associated with features related to these functions:
Confusion, irri tabil ity
Seizures
Muscle weakness, lethargy
Arrhythmias
Symptoms related to hypocalcaemia and hypokalaemia which are resistant to calcium and potassium
supplementation respectively
Normal  plasma levels range from 0.7–1.0 mmol/l ; severe symptoms do not usual ly occur unti l levels drop below 0.5
mmol/l .
Management
Where possible, identify and treat the cause.
For severe, symptomatic hypomagnesaemia, 10 mmol of magnesium sulphate can be given IV over 3–5 min. This
can be repeated once or twice as necessary.
In less acute situations or for asymptomatic hypomagnesaemia, 10–20 mmol MgSO4 solution can be given over
1–2 h and repeated as necessary, or according to repeat plasma levels.
A continuous IV infusion (e.g. 3–5 mmol MgSO4 solution/h) can be given; however, this is usually reserved for
therapeutic indications where supranormal  plasma levels (1.5–2 mmol/l ) of magnesium are sought, e.g.
treatment of supraventricular and ventricular arrhythmias, pre-eclampsia and eclampsia, bronchospasm.
Oral magnesium sulphate has a laxative effect and may cause severe diarrhoea.
High plasma levels of magnesium may develop in renal fai lure; caution should be applied when administering IV
magnesium.
See also:
Enteral nutrit ion, p80; Parenteral nutrition, p82; Calcium, magnesium and phosphate, p148; Diuretics, p212;
Asthma—general  management, p296; Tachyarrhythmias, p316; Electrolyte management, p414; Generalised seizures,
p372; Pre-eclampsia and eclampsia, p538
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
193 из 254 07.11.2006 1:04
P.427
Hypercalcaemia
Causes
Malignancy (e.g. myeloma, bony metastatic disease, hypernephroma)
Hyperparathyroidism
Sarcoidosis
Excess intake of calcium, vi tamin A or D
Drugs, e.g. thiazides, l ithium
Immobil isation
Rarely, thyrotoxicosis, Addison's disease
Clinical features
Usually become apparent when total  (ionised and un-ionised) plasma levels >3.5 mmol/l (normal range 2.2–2.6
mmol/l ). Symptoms depend on the patient's age, the duration and rate of increase of plasma calcium, and the
presence of concurrent medical  condi tions.
Nausea, vomiting, weight loss, pruri tus
Muscle weakness, fatigue, lethargy
Depression, mania, psychosis
Drowsiness, coma
Abdominal  pain, constipation
Acute pancreati tis
Peptic ulceration
Polyuria, renal  calculi , renal  fai lure
Arrhythmias
Management
Identi fy and treat cause where possible.1.
Careful ly monitor haemodynamic variables, urine output, and ECG morphology with frequent estimations of
plasma Ca2+,  PO43- , Mg2+, Na+ and K+.
2.
Intravascular volume repletion—this inhibits proximal  tubular reabsorption of calcium and often lowers the
plasma calcium by 0.4–0.6 mmol/l. It should precede diuretics or any other therapy. Either colloid or 0.9%
sal ine should be used, depending on the presence of hypovolaemia-related features.
3.
Calciuresis—after adequate intravascular volume repletion, a forced diuresis with furosemide plus 0.9% saline
(6–8 l/day) may be attempted. An effect is usual ly seen within 12 h. Loop diuretics inhibit calcium reabsorption
in the ascending l imb of the loop of Henlé.  More aggressive furosemide regimens can be attempted but can
potential ly result in compl ications. Thiazides should not be used as tubular reabsorption may be reduced and
hypercalcaemia worsened.
4.
Dialysis/haemofi ltration—may be indicated at an early stage if the patient is in establ ished oligo-anuric renal
fai lure ± fluid overloaded.
5.
Steroids can be effective for hypercalcaemia related to haematological  cancers (lymphoma, myeloma), vitamin D
overdose and sarcoidosis.
6.
Calcitonin has the most rapid onset of action with a nadir often reached within 12–24 h. Its action is usual ly
short-l ived and rebound hypercalcaemia may occur. It generally does not drop the plasma level more than 0.5
mmol/l.
7.
Biphosphonates (e.g. pamidronate) and IV phosphate should only be given after special ist advice is taken in
view of their toxicity and potential  compl ications.
8.
Drug dosage
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Diuretics Furosemide 10–40 mg IV 2–4 h (may be increased to 80–100 mg IV every 1–2 h)
Steroids Hydrocortisone 100 mg qds IV or prednisolone 40–60 mg PO for 3–5 days
Pamidronate 15–60 mg slow IV bolus
Calcitonin 3–4 U/kg IV followed by 4 U/kg SC bd
See also:
Calcium, magnesium and phosphate, p148; Diuretics, p212; Steroids, p262; Acute renal fai lure—diagnosis, p332;
Acute renal  fai lure—management, p334; Pancreatit is, p354; Electrolyte management, p414; Diabetic ketoacidosis,
p442; Thyroid emergencies, p446; Hypoadrenal crisis, p448
Hypocalcaemia
Causes
Associated with hyperphosphataemia:
Renal  fai lure
Rhabdomyolysis
Hypoparathyroidism (including surgery), pseudohypoparathyroidism
Associated with low/normal phosphate:
Crit ical i l lness including sepsis, burns
Hypomagnesaemia
Pancreatit is
Osteomalacia
Over-hydration
Massive blood transfusion (citrate-binding)
Hyperventi lation and the resul ting respiratory alkalosis may reducethe ionised plasma calcium fraction and
induce cl inical  features of hypocalcaemia
Clinical features
These usually appear when total  plasma calcium levels <2 mmol/l and the ionised fraction is <0.8 mmol/l .
Tetany (including carpopedal  spasm)
Muscular weakness
Hypotension
Perioral and peripheral parasthesiae
Chvostek & Trousseau's signs
Prolonged QT interval
Seizures
Management
If respiratory alkalosis is present, adjust venti lator sett ings or, if spontaneously hyperventi lating and agi tated,
calm ± sedate. Rebreathing into a bag may be beneficial.
1.
If symptomatic, give 5–10 ml 10% calcium chloride solution over 2–5 min. Repeat as necessary.2.
Correct hypomagnesaemia or hypokalaemia i f present.3.
If asymptomatic and in renal  fai lure or hypoparathyroid, consider enteral/parenteral  calcium supplementation
and vitamin D analogues.
4.
If hypotensive or cardiac output is decreased fol lowing administration of a calcium antagonist, give 5–10 ml 10%
calcium chloride solution over 2–5 min.
5.
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See also:
Enteral nutrit ion, p80; Parenteral nutrition, p82; Calcium, magnesium and phosphate, p148; Diuretics, p212; Acute
renal fai lure—diagnosis, p332; Acute renal  fai lure—management, p334; Hypotension, p312; Pancreati tis, p354;
Electrolyte management, p414; Rhabdomyolysis, p528
Hypophosphataemia
Causes
Cri tical i l lness
Inadequate intake
Loop diuretic therapy (including low dose dopamine)
Parenteral  nutrition—levels fal l  rapidly during high dose intravenous glucose therapy, especial ly wi th insulin
Alcoholism
Hyperparathyroidism
Clinical effects
Hypophosphataemia is associated with muscle weakness; however, this is rarely cl inical ly apparent, even in patients
with severe hypophosphataemia where plasma levels may drop <0.1 mmol/l.
Treatment
Phosphate supplements (5–10 mmol) should be given by intravenous infusion over 6 h and repeated according to the
plasma phosphate level.
See also:
Enteral nutrit ion, p80; Parenteral nutrition, p82; Calcium, magnesium and phosphate, p148; Diuretics, p212; Acute
weakness, p368
General acid–base management
Increased intake, altered production or impaired/excessive excretion of acid or base leads to derangements in blood
pH. Augmented renal excretion of H+ ions may result from hypokalaemia. With time, respiratory and renal
adjustments correct the pH towards normali ty by altering the plasma level of PCO2 or HCO3-.
Increased intake
Acid: aspirin overdose
Base: NaHCO3 administration, antacid abuse, buffered replacement fluid (haemofi ltration)
Altered production
Increased acid production: lactic acidosis (usually secondary to hypoperfusion), diabetic ketoacidosis
Increased base production: chronic hypercapnic respiratory fai lure, permissive hypercapnia
Decreased base production: chronic hyperventi lat ion
Altered excretion
Increased acid loss: vomiting, large gastric aspirates, diuretics, hyperaldosteronism, corticosteroids
Increased base loss: diarrhoea, smal l bowel  fistula, urethroenterostomy, proximal  renal  tubular acidosis
Decreased acid loss: renal fai lure, distal  renal  tubular acidosis, acetazolamide
Decreased base loss: chronic hypercapnic respiratory fai lure, permissive hypercapnia
Principles of management
Correct (where possible) the abnormal ity, e.g. hypoperfusion
Consider addi tion of ‘substrate’ and physiological corrective functions
NaCl  infusion for vomiting-induced alkalosis; insul in, Na+ and K+ in diabetic ketoacidosis
Correct pH in specific circumstances only, e.g. NaHCO3 in renal fai lure
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See also:
Blood gas analysis, p100; Lactate, p170; Sodium bicarbonate, p178; Respiratory fai lure, p282; Chronic ai rflow
limitation, p286; Metabolic acidosis, p434; Metaboloic alkalosis, p436
Metabolic acidosis
A subnormal  arterial  blood pH with a base defici t >2 mmol/l.  Outcome in cri tical ly i l l  patients has been l inked to the
severi ty and duration of metabolic acidosis and hyperlactataemia.
Causes
Tissue hypoperfusion, e.g. heart fai lure, hypovolaemia, sepsis. The anion gap is related to production of lactic
and other organic acids. Anaerobic metabol ism contributes in part to this metabolic acidosis although other
cel lular mechanisms are involved.
Tissue necrosis, e.g. bowel , muscle.
Hyperchloraemia, e.g. excessive saline infusion.
Ketoacidosis—high levels of β-hydroxybutyrate and acetoacetate related to uncontrolled diabetes mell itus,
starvation and alcohol ism.
Renal fai lure—accumulation of organic acids, e.g. sulphuric.
Drugs—in particular, aspirin (salicyl ic acid) overdose, acetazolamide (carbonic anhydrase inhibit ion), ammonium
chloride. Vasopressor agents may be implicated, possibly by inducing regional  ischaemia or, in the case of
epinephrine, accelerated glycolysis.
Ingestion of poisons, e.g. paraldehyde, ethylene glycol , methanol.
Bicarbonate loss, e.g. severe diarrhoea, smal l bowel  fistulae, large i leostomy losses.
Type B lactic acidosis—no evidence of t issue hypoperfusion.
Causes of type B lactic acidosis
Acute infection
Diabetes mel l i tus
Drugs, e.g. phenformin, metformin, alcohols
Glucose-6-phosphatase deficiency
Haematological mal ignancy
Hepatic fai lure
Pancreati tis
Renal fai lure
Short bowel syndrome (D-lactate)
Thiamine deficiency
Clinical features
Dyspnoea
Haemodynamic instabil ity
A rapidly increasing metabolic acidosis (over minutes to hours) is not due to renal  fai lure. Other causes,
particularly severe t issue hypoperfusion, sepsis or t issue necrosis should be suspected when there is associated
systemic deterioration
Management
The underlying cause should be identified and treated where possible rather than administering alkali  or
manipulating minute volume to normalise the arterial pH.
1.
Urgent haemo(dia)fi ltration may be necessary i f ol iguria persists.2.
Reversal of the metabol ic acidosis (other than simple buffering with bicarbonate) is generally an indication of
successful therapy. An increasing base defici t suggests that the therapeutic manoeuvres in operation are ei ther
inadequate or wrong.
3.
The benefi ts of buffers such as Carbicarb and THAM (tris-hydroxy-methyl-aminomethane) remain unproved and
are not generally avai lable.
4.
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Metabolic alkalosis
A supranormal arterial blood pH with a base excess >2 mmol/l caused ei ther by loss of (non-carbonic) acid or
gain of base. As the kidney is usually efficient at excreting large quantit ies of bicarbonate, persistence of a
metabol ic alkalosis usually depends on either chronic renal  fai lure or a diminished extracel lular fluid volume
with severe depletion of K+.
The patient is usually asymptomatic though, i f spontaneously breathing, wil l  hypoventi late.
A metabolic alkalosis wi l l  cause a left shift of the oxyhaemoglobin curve, reducing oxygen availabil ity to the
tissues.
Causes
Loss of total  body fluid, Na+, Cl+,  K+ usual ly due to:
diuretics
large nasogastric aspirates, vomiting
Secondary hyperaldosteronism with potassium depletion
Use of haemofi ltration replacement fluid containing excess buffer (e.g. lactate)
Renal compensation for chronic hypercapnia. This can develop within 1–2 weeks. Although more apparent when
the patient hyperventi lates, or is hyperventi lated to normocapnia, an overcompensated metabolic alkalosis can
occasionally be seen in the chronic state (i.e. a raised pH in an otherwise stable long term hypercapnic patient)
Excess administration of bicarbonate
Excess administration of ci trate (large blood transfusion)
Drugs, including laxative abuse, corticosteroids
Rarely, Cushing's, Conn's, Bartter's syndrome
Management
Replacement of fluid, sodium, chloride (i.e. give 0.9% sal ine) and potassium losses are often sufficient to
restore acid–base balance.
1.
With distal renal causes related to hyperaldosteronism, addition of spi ronolactone (or potassium canrenoate) can
be considered.
2.
Active treatment is rarely necessary. If so, give ammonium chloride 5 g tds PO. Hydrochloric acid has been used
on occasion for severe metabolic alkalosis (pH >7.7). It should be given via a central  vein in a concentration of
1 mmol HCl  per ml water at a rate not exceeding 1 mmol/kg/h.
3.
Compensation for a long-standing respiratory acidosis, fol lowed by correction of that acidosis, e.g. wi th
mechanical  venti lation, wil l  lead to an uncompensated metabol ic alkalosis. This usually corrects with time
though treatments such as acetazolamide can be considered. Mechanical ‘hypoventi lation’, i .e. maintaining
hypercapnia, can also be considered.
4.
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Blood gas analysis, p100; Sodium bicarbonate, p178;
Blood transfusion, p182; Acute renal  fai lure—diagnosis, p332; Acute renal  fai lure—management, p334;
Vomiting/gastric stasis, p338; Hypokalaemia, p422; General  acid–base management, p432
Hypoglycaemia
Causes
Inadequate intake of carbohydrate
Excess insul in or sulphonylurea
Liver fai lure with depletion of glycogen stores
Alcohol
Hypoadrenalism (including Addison's disease), hypopituitarism
Quinine, aspirin
Clincal features
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Nausea, vomiting
Increased sympathetic activity, e.g. sweating, tachycardia
Altered behaviour and conscious level
Seizures, focal  neurological signs
Management
Monitor careful ly with regular bedside estimations. The frequency should be increased in condit ions known to
precipitate hypoglycaemia, e.g. insulin infusion, l iver fai lure, quinine treatment of malaria.
1.
Administer 25 ml 50% glucose solution i f the blood glucose is:
≤ 3 mmol/l or
≤ 4 mmol/l and the patient is symptomatic or
Within the normal range but the patient is symptomatic (usual ly long-standing poorly controlled diabetics)
Repeat as necessary every few minutes unti l symptoms abate and the blood glucose level has normal ised.
2.
If the blood glucose is 3–4 mmol/l  and the patient is non-symptomatic, ei ther reduce the rate of insulin infusion
(if present), or increase calorie intake (enteral ly or parenterally). In insul in dependent diabetes mell i tus, the
insulin should continue with adequate glucose intake.
3.
A continuous parenteral infusion of 10%, 20% or 50% glucose solution varying from 10–100 ml/h may be
required, depending on the degree of continuing hypoglycaemia and the patient's fluid balance/urine output. 5%
glucose solution only contains 20Cal/100 ml and should not be used to prevent or treat hypoglycaemia.
4.
In the rare instance of no venous access, hypoglycaemia may be temporari ly reversed by glucagon 1 mg given
either IM or SC.
5.
Continuing hypoglycaemia in the face of adequate treatment and lack of symptoms should be confirmed with a
formal laboratory blood sugar estimation to exclude mal functioning of the bedside testing equipment.
6.
See also:
Nutri tion—use and indications, p78; Enteral nutrit ion, p80; Parenteral  nutrition, p82; Crystal loids, p176; Acute l iver
fai lure, p360; General ised seizures, p372; Hypoadrenal crisis, p448; Paracetamol  poisoning, p456
Hyperglycaemia
Causes
A common occurrence in crit ical ly i l l  patients due to a combination of impaired glucose tolerance, insulin
resistance, high circulating levels of endogenous catecholamines and corticosteroids, and regular administration
of such drugs which antagonise the effect of insulin
Pancreati tis resul ting in islet cel l damage
Clinical features
None in the short term, other than polyuria from the osmotic diuresis. The patient may complain of thi rst or show
signs of hypovolaemia if fluid balance is al lowed to become too negative.
Metabolic effects
Relative lack of insulin prevents cellular glucose uptake and uti l isation resul ting in:
Increased l ipolysis
Altered cellular metabol ism
Increased risk of infection (decreased neutrophi l action)
Prognostic significance
Strict maintenance of glycaemic control (approx. 4–7 mmol/l) resul ted in significant outcome improvement in a
surgical  ICU population. Whether this is related to prevention of hyperglycaemia and/or an effect related to addit ional
administration of insul in remains uncertain.
Management
Treatment should be given if blood glucose elevations persist (>7–8 mmol/l).1.
A short-acting insul in infusion (e.g. actrapid) should be used and ti trated to maintain normoglycaemia (4–72.
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mmol/l). Usually 1–4Units/h are required though may need to be much higher in diabetics who become critically
i l l . Regular bedside monitoring of blood sugar should be performed; this should be undertaken hourly i f unstable.
Oral hypoglycaemic agents should be general ly avoided in the ICU patient because of their prolonged duration of
action and unpredictable absorption.
3.
Key trial
Van den Berghe G, et al. Intensive insulin therapy in cri tical ly i l l  patients. N Engl  J Med 2001; 345:1359–67
Diabetic ketoacidosis
This may occur de novo in a previously undiagnosed diabetic or fol low an acute insul t (e.g. infection) in a known
diabetic patient.
Clinical features
Excess fat metabolism to fatty acids with ketone production
An osmotic diuresis with large losses of f luid (up to 6–10l), sodium (400–800 mmol), potassium (250–800 mmol)
and magnesium
Symptoms resul t from hypovolaemia, metabol ic acidosis and electrolyte imbalance with polyuria. Hyperventi lation is
a prominent feature.
Coma need not necessari ly be present for l i fe to be threatened.
Plasma amylase commonly exceeds 1000U/l but does not indicate pancreatitis. If suspected, perform an abdominal
ultrasound.
Monitoring
Adequate invasive monitoring is essential , particularly if the patient has circulatory instabil ity or cardiac dysfunction.
Urine output, blood gases and plasma electrolytes should also be monitored frequently.
Fluid and electrolyte management
Fluid and electrolyte repletion should be tai lored to individual needs. Tradi tional  regimens (e.g. 3–4 l  wi thin the
first 3–4 h) increase the risk of cerebral  oedema, cardiac and/or renal fai lure.
1.
Colloid fluid chal lenges should be given to restore the circulating blood volume in tissue hypoperfusion.2.
Fluid replacement with 0.9% sal ine should be given at a rate of 200 ml/h unti l the sal t and water debt has been
replenished.
3.
Hypotonic (0.45%) saline resuscitation may be appropriate in the non-shocked patient if the plasma sodium is
rising rapidly (shift of water and potassium into cells and sodium out).
4.
Substi tute 5% glucose solution (100–200 ml/h) after replacing the sodium debt; usual ly when the blood sugar
fal ls to <10 mmol/l .
5.
Careful ly monitor K+ replacement. Both acidosis and excessive K+ administration cause hyperkalaemia whi le
fluid and insul in wil l  produce hypokalaemia. Check levels frequently to maintain normokalemia. Infusion of
10–40 mmol/h KCl  wil l  be needed.
6.
Careful ly monitor magnesium replacement: 3–5 mmol/h MgSO4 is usual ly sufficient.7.
Hyperglycaemia
Correct slowly at a rate of 2–4 mmol/h by adjusting the short acting insulin infusion (usually 1–5U/h). Monitor blood
glucose hourly. Continue IV insulin (with glucose after achieving normoglycaemia) unti l heavy ketonuria has
disappeared and the base deficit normal ised.
Other aspects of managing ketoacidosis
Seek a precipitating cause and treat as indicated. Approximately 50% are related to underlying disease, e.g.
sepsis, myocardial  infarction, stroke, infective gastroenterit is.
1.
Only give antibiotics for proved or highly suspected infection.2.
Abdominal  pain should not be dismissed as part of the syndrome.3.
A nasogastric tube should be inserted, as gastric emptying is often delayed and acute gastric di latation is
common.
4.
Avoid bicarbonate, even for severe acidosis (pH <7.0). It causes an increased intracellular acidosis and5.
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depressed respiration due to a relative CSF alkalosis. Sodium overload may also occur.
Low molecular weight heparin 5000U SC od is indicated in immobi le or comatose patients.6.
See also:
Central venous catheter—use, p114; Central  venous catheter—insertion, p116; Electrolytes
, p146; Bacteriology, p158; Urinalysis, p166; Crystalloids, p176; Fluid chal lenge, p274; Anticoagulants, p248;
Antimicrobials, p260; Ol iguria, p330; Vomiting/gastric stasis, p338; Abdominal sepsis, p350; Hyperkalaemia, p420;
Hypokalaemia, p422; Hypomagnesaemia, p424; Hyperglycaemia, p440; Metabolic acidosis, p434;
Infection—diagnosis, p480; Infection—treatment, p482
Hyperosmolar diabetic emergencies
This is more common in elderly, non-insul in dependent diabetics though can present de novo in young adul ts.
Precipitating factors are similar to ketoacidosis, e.g. sepsis, myocardial infarction
Clinical features
Fluid depletion is greater, blood glucose levels often higher, coma more frequent and mortali ty much higher than
in diabetic ketoacidosis.
Confusion, agitation and drowsiness that may persist for 1–2 weeks.
A metabolic acidosis may be present but is not usually profound; ketoacidosis is not a major feature.
Hyperosmolal ity may predispose to thrombotic events; this is the major cause of mortality. Severe
hyperosmolal ity does not always occur.
Focal neurological  signs and disseminated intravascular coagulation are occasionally recognised.
Management
As for diabetic ketoacidosis; however:
Unless the patient shows signs of hypovolaemia and tissue hypoperfusion, in which case colloid challenges
should be given for prompt resuscitation, fluid replacement should be more gradual as the risk of cerebral
oedema is higher. This can be with ei ther 0.9% saline or, if the plasma sodium is high, 0.45% sal ine at a rate of
100–200 ml/h.
1.
The plasma sodium rises with treatment, even with 0.45% saline, and can often increase in the first few days to
160–170 mmol/l before gradually declining thereafter. Aim to correct slowly.
2.
Serum phosphate and magnesium levels fal l rapidly with this condit ion; replacement may be needed as guided
by frequently taken plasma levels.
3.
Patients may be hypersensitive to insul in and require lower doses.4.
Unless otherwise contraindicated, these patients should be ful ly heparinised unti l ful l recovery (which may take
≥5 days).
5.
See also:
Electrolytes
, p146; Bacteriology, p158; Urinalysis, p166; Crystalloids, p176; Anticoagulants, p248; Antimicrobials, p260; Fluid
challenge, p274; Oliguria, p330; Vomiting/gastric stasis, p338; Abdominal  sepsis, p350; Hypernatraemia, p416;
Hyponatraemia, p418; Hyperkalaemia, p420; Hypokalaemia, p422; Hypomagnesaemia, p424; Hypophosphataemia,
p430; Hyperglycaemia, p440; Diabetic ketoacidosis, p442; Infection—diagnosis, p480; Infection—treatment, p482
Thyroid emergencies
Thyrotoxic crisis
Presents as an exacerbation of the cl inical features of hyperthyroidism (e.g. pyrexia, hyperdynamic ci rculation, heart
fai lure, confusion). There is usual ly a precipi tating factor such as infection, surgery, ketoacidosis, myocardial
infarction or chi ldbirth. It may present with exhaustion in the elderly with few features of hyperthyroidism. The
diagnosis is confirmed by standard thyroid function tests.
Management
Pyrexia should be control led by surface cooling (avoid aspirin which displaces thyroxine from plasma proteins).
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Catecholamine effects should be reduced by β blockade (e.g. propranolol  1–5 mg IV then 20–80 mg qds PO).
These should be used with caution if there is acute heart fai lure.
Blockade of thyroxine synthesis is achieved by potassium iodide 200–600 mg IV over 2 h then 2 g/day PO and
carbimazole 60–120 mg/day PO.
Blockade of peripheral  T4 to T3 conversion is achieved by dexamethasone 2 mg qds IV.
Careful  fluid and electrolyte management is essential.
Myxoedema coma
Presents as an exacerbation of the features of hypothyroidism (e.g. hypothermia, coma, bradycardia, metabol ic and
respiratory acidosis, anaemia). There may be a precipi tating factor (e.g. cold, infection, surgery, myocardial
infarction, CVA, central nervous system depressant drugs). Diagnosis is confirmed by thyroid function tests.
Management
Treatment of the compl ications of severe hypothyroidism (e.g. hypotension, heart fai lure, hypothermia,
bradycardia, seizures) is more important than thyroid hormone replacement.
Thyroxine replacement should be with low doses (0.1–0.2 mg PO or PR unless ischaemic heart disease is
possible, then start at 0.25 mg).
There are no defini te advantages to using T3 replacement, high dose replacement regimens or intravenous
treatment.
Steroids (hydrocortisone 100 mg qds IV) should be given since coexisting hypoadrenal ism is masked by
myxoedema.
Sick euthyroid/low T3 syndrome
This is a frequent compl ication of cri tical  i l lness with low T3 and T4 and high reverse T3 (rT3) levels. These correlate
with the severi ty of disease and a poor outcome. There is both reduced TSH secretion and al tered peripheral thyroid
metabolism. A trial of thyroxine administration in crit ical ly i l l  patients produced a negative outcome al though those
suffering from the sick euthyroid syndrome were not identified. Treatment of this syndrome thus remains unknown.
See also:
Hypotension, p312; Tachyarrhythmias, p316; Bradyarrhythmias, p318; Acute coronary syndrome (1), p320; Acute
coronary syndrome (2), p322; Heart fai lure—assessment, p324; Heart fai lure—management, p326; Diarrhoea, p340;
Fai lure to open bowels, p342; Acute weakness, p368; General ised seizures, p372; Hypercalcaemia, p426; Diabetic
ketoacidosis, p442; Hypoadrenal  crisis, p448; Systemic inflammation/multi -organ failure, p484; Hypothermia, p516;
Pyrexia (1), p518; Pyrexia (2), p520
Hypoadrenal crisis
Clinical features
Primary hypoadrenalism
Glucocorticoid deficiency (e.g. weakness, vomiting, diarrhoea, abdominal  pain, hypoglycaemia)
Mineralocorticoid deficiency (e.g. dehydration, hyponatraemia, weight loss, postural  hypotension,
hyperkalaemia)
Skin pigmentation due to ACTH excess
Secondary hypoadrenalism
May be due to critical  i l lness, steroid withdrawal  after 2 weeks' treatment, hypopituitarism or etomidate use
No skin pigmentation
Features of mineralocorticoid deficiency may be absent
Diagnosis
Diagnosis is confirmed by plasma cortisol , ACTH levels and a negative Tetracosactrin (ACTH analogue) test, although
treatment should begin on cl inical suspicion. A dose of 250µg IV should produce a >200 nmol/l rise in plasma
cortisol . In primary hypoadrenal ism levels remain below 600 nmol/l. However, basl ine levels may be normal  or
elevated in the relative adrenal deficiency seen in sepsis and other critical  i l lnesses. Dexamethasone may be used for
steroid replacement for 48 h before an ACTH test is performed since other steroid treatments are detected in the
plasma cortisol assay.
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Management
Salt and water deficiency should be corrected urgently. Init ial f luid replacement should be with colloid i f there is
hypotension, or evidence of poor t issue perfusion. Otherwise 4–5l/day 0.9% saline wil l  be needed for several
days.
Fluid management should be careful ly monitored to ensure adequate replacement without fluid overload.
Glucocorticoid replacement should be with hydrocortisone 50–100 mg tds IV on day 1 then 20–50 mg tds on days
2–3. Hydrocortisone may be changed to equivalent doses of dexamethasone before the ACTH test has been
performed.
The relative hypoadrenalism related to sepsis can be treated with hydrocortisone 50 mg qds for 7 days, and then
a reducing dose over the next 5–7 days. Studies have shown more rapid resolution of shock and an improved
outcome in those showing a suboptimal  response to synthetic ACTH, despite raised baseline levels.
See also:
Blood presure monitoring, p110; Central venous catheter—use, p114; Electrolytes
, p146; Calcium, magnesium and phosphate, p148; Crystal loids, p176; Col loids, p180; Steroids, p262; Fluid
challenge, p274; Hypotension, p312; Diarrhoea, p340; Hyponatraemia, p418; Hypercalcaemia, p426; Hypoglycaemia,
p438
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Poisoning—general principles
Poisoning should be considered in patients presenting with altered consciousness, respiratory or cardiovascular
depression, vomiting, hypothermia or seizures. The history usually makes diagnosis obvious although cl inical signs
may be confused due to ingestion of mult iple poisons or absent i f effects are delayed. It should be remembered that
poisons may enter the body via routes other than ingestion, e.g. inhalation or transdermal ly. Salicylate and
paracetamol are extremely common agents in sel f-poisoning and patients often present with no alteration of
consciousness.
Investigation
Al l patients require urea and electrolyte, blood glucose and blood gas estimations. Rapid bedside kits detect the
presence of common agents such as paracetacol, aspirin, and several recreational drugs. Urine samples and gastric
aspirate should be saved for possible later toxicology analysis. Sal icylate and paracetamol levels are necessary due
to the common lack of early signs and to al low speci fic early treatment. Other drug levels may help in diagnosis but
treatment is often supportive. Early support from the local  Poisons Information Service should be sol ici ted.
Supportive treatment
Treatment of cardiovascular and respiratory compromise and neurological  disturbance is by standard methods
outl ined elsewhere in the book. In the unconscious patient, opiates and benzodiazepines may be reversed temporari ly
to al low assessment of underlying neurological status.
Gastric elimination
Consider gastric emptying if the poison is not a corrosive or hydrocarbon and has been ingested <4h previously. If
sal icylates or tricycl ics have been ingested gastric emptying is useful for 12h after ingestion. There are no clear
advantages for forced emesis (ipecacuanaha 30ml in 200ml water) or gastric lavage. Forced emesis may be delayed
for 30min and then may be intractable. Aspiration is a serious risk with either form of gastric emptying therapy; the
patient should be intubated for airway protection i f consciousness is at all impaired.
Activated charcoal
Activated charcoal is probably more effective than gastric emptying to prevent drug absorption. A charcoal:poison
weight ratio of 10:1 is required. Poisons may be el iminated after absorption via the small  bowel  with activated
charcoal  50–100g fol lowed by 12.5g/h NG. Activated charcoal is particularly useful for benzodiazepines,
anticonvulsants, tricycl ics, theophyl l ine, phenothiazines and antihistamines.
Forced diuresis and dialysis
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Forced diuresis wi th appropriate urinary acidi fication or alkalinisation (see table) is useful  for water-soluble poisons
which are distributed predominantly extracel lularly. Forced diuresis should not be used if renal function is abnormal .
Small  molecules may also be removed by haemodialysis (e.g. ethylene glycol, methanol, oxalic acid, formic acid).
Forced alkaline diuresis
Used for soluble acidic drugs (e.g. sal icylates)
Furosemide or mannitol  to maintain urine output >200ml/h
Intravenous crystalloid to prevent hypovolaemia
Avoid excessive posit ive fluid balance
Use 1.26% bicarbonate to maintain urinary pH >7
Stop bicarbonate i f arterial pH >7.5 and use 0.9% saline
Alternate bicarbonate/saline with 5% glucose
Monitor and replace potassium and magnesium carefully
Forced acid diuresis
Used for soluble basic drugs (e.g. amphetamines, quinine, phencyclidine)
Furosemide or mannitol  to maintain urine output >200ml/h
Intravenous crystalloid to prevent hypovolaemia
Avoid excessive posit ive fluid balance
Use 750g NH4Cl in each 500ml 5% glucose to maintain urinary pH <7.0
Alternate 0.9% sal ine with 5% glucose
Monitor and replace potassium and magnesium carefully
See also:
Venti latory support—indications, p4; Endotracheal intubation, p36; ECG monitoring, p108; Blood pressure monitoring,
p110; Toxicology, p162; Respiratory stimulants, p188; Basic resuscitation, p270; Respiratory failure, p282;
Hypotension, p312; Tachyarrhythmias, p316; Bradyarrhythmias, p318; Sal icylate poisoning, p454; Paracetamol
poisoning, p456; Sedative poisoning, p458; Tricycl ic antidepressant poisoning, p460; Amphetamines including
Ecstasy, p462; Cocaine, p464; Inhaled poisons, p466; Household chemicals, p468; Methanol and ethylene glycol,
p470; Organophosphate poisoning, p472; Rhabdomyolysis, p528
Salicylate poisoning
Serious, l i fe-threatening toxici ty is l ikely after ingestion of >7.5g sal icylate. Aspirin is the most common form
ingested though salicyl ic acid and methylsal icylate are occasionally impl icated.
Loss of consciousness is rare but metabol ic derangements are complex (e.g. respiratory alkalosis due to respiratory
centre stimulation, dehydration due to salt and water loss, renal  bicarbonate excretion and hyperthermia,
hypokalaemia, metabolic acidosis due to interference with carbohydrate, l ipid and amino acid metabolism,
hyperthermia due to uncoupl ing of oxidative phosphorylation and increased metabol ic rate).
There may also be pulmonary oedema due to capil lary leak, and bleeding due to reduced prothrombin levels.
Al though gastric erosions are common with aspirin treatment, bleeding from this source is rare in acute poisoning.
Management
Gastric elimination
Due to delayed gastric emptying gastric el imination is worthwhile for up to 24h after ingestion. Activated charcoal
(12.5g/h) should be given NG to adsorb salicylate remaining in the bowel and adsorb any sal icylate back- diffusing
across the bowel mucosa. Insoluble aspirin may form a gastric mass that is di ffi cul t to remove by gastric lavage.
Salicylate levels
Repeated levels should be taken since these may continue to rise as absorption continues. Levels taken after 12h
may underestimate the degree of toxicity due to t issue binding. If salicylate levels are <3.1mmol/l  after 1h of
ingestion and there is no metabol ic derangement then observation, fluids and repeat levels are all that is required.
Urine alkalinization is required i f levels are >3.1mmol/l or there is metabol ic derangement but no renal  fai lure.
Levels >6.2mmol/l (or >3.1mmol/l with renal  fai lure) require haemodialysis.
Alkaline diuresis
The alkal inisation rather than the forced diuresis is more important for sal icylate excretion. Urinary pH must be >7.0
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without arterial alkalosis (pH <7.5). Potassium loss wil l  occur with the bicarbonate infusion, due to the diuresis and
as a toxic effect of the sal icylate. Potassium levels must be monitored and corrected in a high dependency
environment. Alkal inization, if successful,  should continue unti l sal icylate levels <3.1mmol/l . Calcium levels may
drop with prolonged alkalinization.
Haemodialysis
Indications include sal icylate levels >6.2mmol/l or renal fai lure.
See also:
Blood gas analysis, p100; Toxicology, p162; Hypokalaemia, p422; Metabol ic acidosis, p434; Poisoning—general
principles, p452
Paracetamol poisoning
Serious, l i fe-threatening toxici ty is l ikely after ingestion of >15g paracetamol, particularly wi th co-ingestion of
enzyme-inducing drugs (e.g. anticonvulsants, anti-TB therapy) and/or alcohol.
Paracetamol is rapidly absorbed from the stomach and upper smal l bowel  and is metabol ised by conjugation in the
liver. Hepatic necrosis occurs due to the toxicity of an alkylating metabolite that is normally removed by conjugation
with glutathione; glutathione is rapidly depleted with overdose and may already be low in starvation, alcoholics and,
possibly, HIV disease, thus predisposing these groups to an increased risk of toxicity.
Toxici ty is usual ly asymptomatic for 1–2 days al though laboratory assessment of l iver function may become abnormal
after 18h.
Hepatic fai lure, if mani fest, develops after 2–7 days, an earl ier onset being associated with more severe toxicity.
Management
If ingestion has occurred <4h previously, gastric el imination techniques should be employed. Paracetamol  levels may
be taken to confirm ingestion but should not be interpreted for toxicity unti l after 4h from ingestion. The mainstay of
treatment is wi th N-acetylcysteine to restore hepatic glutathione levels by increasing intracel lular cysteine levels.
N-acetylcysteine
Treatment is most effective if started within 10h of ingestion but is currently advised for up to 36h of ingestion.
Treatment is required i f the paracetamol levels are in the toxic range (see figure) or >15g paracetamol  has been
ingested. It should be continued unti l  paracetamol  is not detected in the blood. N-acetylcysteine is given by
continuous IV infusion (150mg/kg over 15min, 50mg/kg in 500ml 5% glucose over 4h then 50mg/kg in 500ml 5%
glucose 8-hrly).
Complications
The major compl ication is hepatic (± renal) fai lure. A rise in prothrombin time, INR and bil irubin are early warning
signs of signi ficant hepatic damage and this should prompt early referral to a special ist centre.
Guidelines for referral to a specialist liver centre
Arterial  pH <7.3
INR >3 on day 2 or >4 thereafter
Oliguria and/or rising creatinine
Altered conscious level
Hypoglycaemia
Guidelines for liver transplantation
Arterial  pH <7.3
Plus al l of the fol lowing:
PT >100, INR >6.5
Creatinine >300µmol/l
Grade 3–4 encephalopathy
High lactate levels (>3.5mmol/l  at 4 and 12h) and low factor V levels are also associated with a poor outcome i f
not transplanted.
Graph for predicting treatment requirement
Treatment is required at lower levels if the patient is a known alcoholic, protein-depleted, HIV posi tive, or is taking
enzyme-inducing drugs, e.g. phenytoin.
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Figure. No Caption Available.
See also:
Liver function tests, p152; Coagulation monitoring, p156; Toxicology, p162; Acute renal fai lure—diagnosis, p332;
Acute renal  fai lure—management, p334; Acute l iver fai lure, p360; Hepatic encephalopathy, p362; Poisoning—general
principles, p452
Sedative poisoning
Patients present with al teration of consciousness, respiratory failure and, in some cases, cardiovascular disturbance.
After prolonged immobil ity the possibi l i ty of rhabdomyolysis should be considered. In most cases treatment is
supportive.
Benzodiazepine poisoning
Benzodiazepines are common agents used for sel f-poisoning but severe features are uncommon, except at
extremes of age.
Flumazenil  may be used as a specific antidote (0.2–1.0mg IV given in 0.1mg increments).
Flumazenil  i s short acting so benzodiazepine reversal  may be temporary.
Rapid reversal of benzodiazepines may lead to anxiety attacks or seizures.
Opioid poisoning
Treatment is supportive with attention particularly to respiratory depression and cardiovascular disturbance.
Naloxone may be used as an antidote (0.2–0.4mg IV) although rapid reversal  is not desi red in abusers.
Naloxone is short acting so reversal  may be temporary.
Consider HIV infection and endocardi tis in IV drug abusers.
In iatrogenic poisoning naloxone wil l  reverse the pain rel ief that opioids were given for. In these cases
respiratory depression is better reversed by the non-specific respiratory stimulant doxapram (1.0–1.5mg/kg over
30s IV fol lowed by 1.5–4.0mg/min).
Barbiturates
Treatment is supportive with particular attention to respiratory and cardiovascular depression. Vasodi latation may be
extreme requiring fluid support and, in some cases, inotropic support. Phenobarbital may be eliminated by forced
alkaline diuresis.
See also:
Venti latory support—indications, p4; Blood gas analysis, p100; Blood pressure monitoring, p110; Toxicology, p162;
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Respiratory stimulants, p188; Opioid analgesics, p234; Sedatives, p238; Basic resuscitation, p270;
Poisoning—general  principles, p452; Rhabdomyolysis, p528
Tricyclic antidepressant poisoning
Tricycl ic antidepressants are prescribed to patients who are at greatest risk of a suicide attempt. They are rapidly
absorbed from the gastrointestinal tract, al though gastric emptying is delayed.
Clinical features
Anticholinergic effects (di lated pupils, dry mouth, i leus, retention of urine).
Arrhythmias (particularly associated with prolonged QT interval and QRS waves).
Hypotension related to arrhythmias and/or cardiac depression through Na+ channel  blockade.
Hyper-reflexia with extensor plantars, visual  hallucinations, coma and seizures. Drug levels do not correlate with
severi ty.
Metabol ism is usually rapid and improvement can be expected within 24h.
Management
There is no specific treatment for tricycl ic antidepressant poisoning.1.
Patients require ECG monitoring during the fi rst 24h and unti l  ECG changes have disappeared for 12h.2.
Gastric el imination is worthwhile for 24h after ingestion since tricycl ics slow gastric emptying.3.
Activated charcoal  via a nasogastric tube wil l  adsorb tricycl ics remaining in the bowel.4.
Cardiac arrhythmias are more common i f there is acidosis. Bicarbonate should be used to achieve an arterial pH
of 7.5 urgently. If arrhythmias occur with no acidosis and fai l  to respond to treatment with amiodarone or
phenytoin, bicarbonate (25–50ml 8.4% IV) may sti l l  be useful.
5.
Seizures are best managed with benzodiazepines and phenytoin.6.
See also:
Venti latory support—indications, p4; Blood gas analysis, p100; ECG monitoring, p108; Blood pressure monitoring,
p110; Toxicology, p162; Sodium bicarbonate, p178; Basic resusci tation, p270; Tachyarrhythmias, p316; Generalised
seizures, p372; Poisoning—general  principles, p452
Amphetamines including Ecstasy
Amphetamines, including 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) and
3,4-methylenedioxyethamphetamine (‘Eve’), are stimulants taken predominantly for recreational use, or as appetite
suppressants. These drugs are hal lucinogenic at higher doses. MDMA has been shown to cause rapid decreases in
central nervous system 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid levels and increases in dopamine
release.
Clinical features of overdose
Agitation, hyperactivity, hypertension, hallucinations, paranoia fol lowed by exhaustion, coma, convulsions and
hyperthermia.
Idiosyncratic responses to Ecstasy and Eve are more common, with numerous reports of mortality and major
morbidity fol lowing ingestion of just 1–2 tablets. These appear related to ingestion in hot environments, e.g.
nightclubs, and concurrent dehydration. Features include profound hyperthermia (>40°C), agitation, seizures, muscle
rigidity, hypertension, tachycardia, sweating, coma, disseminated intravascular coagulation and rhabdomyolysis.
These complications lead to hypovolaemia, electrolyte imbalance (particularly hyperkalaemia) and a metabol ic
acidosis.
Some patients taking Ecstasy or Eve have been admitted with water intoxication and acute hyponatraemia fol lowing
ingestion of large amounts of water.
Management
Supportive care including airway protection, fluid resusci tation, electrolyte correction and, if needed, mechanical
venti lation.
1.
Early stages of amphetamine poisoning can often be control led with tepid sponging, chlorpromazine, β-blockade.
Forced acid diuresis to increase urinary excretion is rarely needed.
2.
Severe complications should be managed as they arise, e.g. rapid cooling for hyperpyrexia, anticonvulsants for
seizures, forced alkaline diuresis ± fasciotomies for rhabdomyolysis, platelet and fresh frozen plasma infusions
for coagulopathy.
3.
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Dantrolene may be given to treat the hyperpyrexia at a dose of 1mg/kg IV, repeated to a cumulative maximum
dose of 10mg/kg, particularly i f the temperature is >40°C.
4.
See also:
Venti latory support—indications, p4; Blood gas analysis, p100; ECG monitoring, p108; Blood pressure monitoring,
p110; Toxicology, p162; Basic resuscitation, p270; Hypertension, p314; Tachyarrhythmias, p316; General ised
seizures, p372; Poisoning—general  principles, p452; Hyperthermia, p522
Cocaine poisoning
Modes of action
Blocks reuptake of dopamine (causing euphoria, hyperactivi ty) and noradrenal ine (causing vasoconstrict ion and
hypertension)
Blocks Na+ channels, result ing in a local anaesthetic action and myocardial  depression
Platelet activation
Complications
Chest pain related to myocardial ischaemia or infarction. Local  chest pain guidel ines should be fol lowed. ECG
abnormali ties often resolve within 12h. Arrhythmias should be treated conventionally, though avoiding
β-blockers.
Heart fai lure from myocardial depression or a cardiomyopathy
Seizures
Cerebrovascular accidents
Pneumothorax
Rhabdomyolysis
Premature labour—abruption
Agitated del irium, hyperthermia
Thermal  injury from smoke inhalation
Management
Oxygen1.
Diazepam for agi tation, del irium, chest pain2.
Aspirin for chest pain, CVA3.
Nitrates for chest pain, heart fai lure4.
Sodium bicarbonate and forced diuresis for rhabdomyolysis5.
β-blockers should be avoided6.
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; Blood gas analysis, p100; ECG monitoring, p108; Blood
pressure monitoring, p110; Toxicology, p162; Basic resuscitation, p270; Hypertension, p314; Tachyarrhythmias,
p316; Acute coronary syndrome (1), p320; Acute coronary syndrome (2), p322; General ised seizures, p372; Stroke,
p380; Poisoning—general principles, p452; Hyperthermia, p522; Rhabdomyolysis, p528
Inhaled poisons
Carbon monoxide
Carbon monoxide poisoning should be considered in anyone found in a smoke fi l led, enclosed space. Carbon monoxide
displaces oxygen from haemoglobin, to which i t has 200 times greater affini ty and thus prevents oxygen carriage.
There is also a di rect toxic effect on mitochondrial oxidative phosphorylation as i t competes with oxygen for the same
binding site on cytochrome oxidase.
Clinical features
Fatigue, headache, vomiting, dizziness, confusion, dyspnoea.
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A cherry red appearance of the skin and mucosae are classical  but not common.
PaO2 wi l l  be normal  unless there is respiratory depression and pulse oximetry is misleading.
The hal f l i fe of carboxyhaemoglobin is 4h when breathing room air and 50min when breathing 100% oxygen.
Management
Carboxyhaemoglobin levels should be measured by a co-oximeter and treatment started immediately with
oxygen at the maximum concentration that can be delivered (FIO2 1.0 if venti lated and 0.6–1.0 i f
sel f-venti lating).
If carboxyhaemoglobin levels >25% or carbon monoxide poisoning is associated with mental  disturbance, the
optimal  treatment is hyperbaric oxygen at 3 atmospheres for 30min, repeated 6-hrly if levels remain >25%.
Death is l ikely with carboxyhaemoglobin levels >60%.
High concentration oxygen treatment should continue unti l  carboxyhaemoglobin levels <10%.
Cyanide
Severe cyanide poisoning has an extremely rapid onset and occurs in some cases of smoke inhalation. Survival
may be associated with anoxic brain damage.
Diagnosis must be made cl inically since a blood cyanide level takes >3h to perform.
Clinical features
Clinical  features include anxiety, agi tation, hyperventi lat ion, headache, loss of consciousness, dyspnoea, weakness,
dizziness and vomiting. The skin remains pink and hypotension may be severe. An unexplained metabolic acidosis is
suggestive.
Management
High concentration oxygen should be given, but is only truly effective when given at hyperbaric pressures.
In mild cases rapid, natural detoxification reduces cyanide levels by 50% within 1h, al lowing supportive therapy
only.
Sodium thiosulphate (150mg/kg intravenously fol lowed by 30–60mg/kg/h) converts cyanide to thiocyanate and
should be used i f there is unconsciousness. It is, however, slow-acting.
Nitrites produce methaemoglobinaemia and may potential ly worsen cyanide toxicity.
Dicobalt edetate (300mg IV) is the speci fic antidote to cyanide but is severely toxic (vomiting, urticaria,
tachycardia, hypotension, dyspnoea, chest pain) in the absence of cyanide. It is therefore best avoided unless
cyanide toxicity is l ikely.
Key trial
Weaver LK, et al . Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl  J Med 2002; 347:1057–67
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; Blood gas analysis, p100; ECG monitoring, p108; Blood
pressure monitoring, p110; Toxicology, p162; Basic resuscitation, p270; Inhalation injury, p306; Metabolic acidosis,
p434; Poisoning—general principles
Household chemicals
Corrosives
Strong acids and alkalis are increasingly available in the household and ingestion may lead to shock and bowel
perforation. Gastric el imination techniques must be avoided since aspiration of corrosives may cause severe lung
damage. Early surgical repair of perforation may be necessary.
Petroleum
Although not strictly a household chemical, access to petroleum in the home is easy.
Clinical features
Gastrointestinal ingestion and absorption gives cl inical features similar to those of alcohol  intoxication with more
severe central nervous system depression.
Management
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Gastric el imination techniques must be avoided since a few drops of petroleum spi l l ing into the lungs can lead to
a severe pneumonitis. This is due to the low surface tension and vapour pressure of petroleum allowing rapid
spread through the lungs.
Treatment involves supportive therapy and 250ml l iquid paraffin orally.
Paraquat
Paraquat is widely available as a selective weedkil ler which is inactivated on contact with the soi l.  A dose of 2–3g is
usually fatal (equivalent to 80–120g of granules or 10–15ml of industrial l iquid concentrate).
Clinical features
Very l itt le of the ingested paraquat is absorbed from the gut but a large dose wil l  lead rapidly to shock with
widespread tissue necrosis.
A burning sensation in the mouth and abdomen is more common in poisoning, as is the development of painful
mouth ulcers and, after several  days, a relentless, proli ferative alveol itis causing death by pulmonary fibrosis.
Management
Treatment should begin on cl inical grounds in view of the severity of toxicity and the t ime taken for laboratory
confirmation.
Urgent gastric emptying is required with insti l lation of 500ml water containing 150g Fuller's earth and 25g
magnesium sulphate afterwards.
Severe diarrhoea may ensue requiring careful fluid management.
If paraquat poisoning is confi rmed 200–500ml of 30% Ful ler's earth is given 2-hrly for 24h via a nasogastric
tube.
A forced diuresis should be started to encourage renal  excretion.
Pulmonary fibrosis is more severe when breathing high oxygen concentrations; if oxygen is required the lowest
concentration possible should be given accepting a low PaO2. Liposomal superoxide dismutase and glutathione
peroxidase have been used experimental ly.
See also:
Toxicology, p162; Poisoning—general principles, p452
Methanol and ethylene glycol
Methanol
Toxici ty mainly arises due to oxidation of methanol  to formic acid and formaldehyde. The oxidative pathway is an
enzymatic process involving alcohol  dehydrogenase but proceeds at 20% of the rate of ethanol oxidation.
Clinical features
Clinical  features of poisoning include bl indness (due to concentration of methanol in the vi treous humour), severe
metabolic acidosis, headache, nausea, vomiting and abdominal  pain.
Management
Metabol ism of methanol  is slow so treatment wi l l  need to be prolonged (several days).
Treatment includes gastric emptying (within 4h of ingestion), sodium bicarbonate titrated to correct arterial  pH
and ethanol to saturate the oxidative pathway.
On presentation 1ml/kg ethanol (50%) is given oral ly fol lowed by 0.5ml/kg 2-hrly for 5 days.
Alternatively, metabolism can be blocked by 4-methyl  pyrazole (fomepizole) which can be infused or injected
12-hrly.
If methanol levels are >1000mg/l  haemodialysis is used unti l levels are <250mg/l.
Ethylene glycol
Ethylene glycol  is partial ly metabolised by alcohol dehydrogenase to oxalic acid which is responsible for a severe
metabolic acidosis, renal fai lure and seizures.
Clinical features
Clinical  suspicion is aroused by odourless drunkenness, oxalate crystals in the urine or blood and the severe acidosis.
As l i ttle as 50ml can be fatal .
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Management
Treatment is as for methanol.
See also:
Urinalysis, p166; Toxicology, p162; Sodium bicarbonate, p178; Acute renal fai lure— management, p334;
Vomiting/gastric stasis, p338; Metabolic acidosis, p434; Poisoning—general principles, p452
Organophosphate poisoning
Organophosphate pesticides are the major cause of suicidal poisoning in developing countries and are used as nerve
agents in terrorist attacks (e.g. Sarin, Tabun, VX, GF). Their mode of action is via chol inergic toxici ty.
Cholinergic (anticholinesterase) syndrome
Sal ivation, lacrimation
Vomiting, diarrhoea
Bradycardia
Bronchospasm
Meiosis
Management
Atropine—antagonises acetylcholine at muscarinic receptors. A dose of 2mg should be given every 15min unti l
the mouth is dry
Pral idoxime—reactivates inhibi ted enzymes if given before the agent permanently binds to the enzyme
Diazepam—neuroprotection
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; ECG monitoring, p108; Toxicology, p162; Bronchodilators,
p186; Chronotropes, p206; Bradyarrhythmias, p318; Vomiting/gastric stasis, p338; Diarrhoea, p340;
Poisoning—general  principles, p452
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Infection and Inflammation
Infection control—general principles
Infection acquired within the ICU is a major cause of mortal ity, morbidi ty and increased duration of stay. There are
remarkable variations in practice for which the lack of a good evidence base is chiefly responsible. Examples include
different policies with regard to patient isolation, microbiological survei l lance, handwashing procedures, use of
impregnated vascular catheters, the duration of indwel l ing catheters, and frequency of change of disposables such as
intravenous giving sets and fi lters. It is nevertheless accepted that adequate handwashing before and after patient
contact and strict aseptic technique when performing procedures are mandatory.
ICU design
Ample wash hand basins with elbow operated mixer taps, soap and antiseptic dispensers
Separate clean-treatment and sluice areas
Some isolation cubicles with posi tive/exhaust ai r f low faci l ity
Ample space around bed areas
Staff measures
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Remove watches and jewel lery, remove long-sleeve white coats and jackets, rol l  shirt sleeves up to elbow
Hand and forearm washing before and after touching patient
Wear disposable aprons and gloves if in contact with patient
Wear gloves and aprons when handling any body fluid and eyeprotection when any danger of fluid or droplet
splash
Strict aseptic technique for invasive procedures (e.g. central  venous catheter insertion) and clean technique for
basic procedures, e.g. endotracheal suction, changing venti lator circui ts or drug infusions
Previous immunisation against hepati tis B, tuberculosis
Stethoscopes should be cleaned between patients
Clear sign-posting of precautions to be taken on cubicle doors
Visitors
Non-ICU medical and paramedical  staff, relatives and friends should adhere to the guidel ines in force regarding
the patient being visited, e.g. hand washing, gowns and gloves as di rected.
Traffic through the ICU should be minimised.
Cross-infection
Inform the Infection Control  nurse should cross-infection arise with more than one patient infected by the same
strain of bacteria.
Affected patients should generally be source isolated, especial ly if the organism is mult iresistant; treated with
antibiotics and topical  antiseptics if necessary; and barrier-nursed.
If cross-infection persists/spreads, other sources should be sought, e.g. taps, sinks, reusable equipment
(rebreathing bags, venti lators).
Protective isolation
Some patients carry potential ly contagious or infective organisms and require source isolation, e.g. tuberculosis.
Immunosuppressed patients, e.g. when neutropenic fol lowing chemotherapy, are at risk of acquiring infection.
Microbiological surveillance
Pol icies vary; some ICUs routinely screen sputum, bronchoalveolar lavage, blood, urine and drain fluid every 3–7
days while others screen only when indicated, e.g. deteriorating cardiorespiratory status, pyrexia, neutrophi l ia. Send
samples promptly to the lab for analysis.
See also:
Bacteriology, p158; Virology, serology and assays, p160; Antimicrobials, p260; Acute chest infection (1), p288; Acute
chest infection (2), p290; Infection—diagnosis, p480; Infection—treatment, p482; ICU layout, p566
Routine changes of disposables
Care of intravascular catheters
Sites should be covered with transparent semipermeable dressings to allow observation and prevent secretions
from accumulating.
Routine changes of intravascular catheters are no longer recommended. As the risk of infection does increase
considerably after a week in situ, catheters should be removed as soon as cl inical ly feasible.
Catheters can be changed over a guidewire i f the site looks clean but signs suggestive of mi ld to moderate
infection are present elsewhere, (e.g. pyrexia or unexplained neutrophil ia) but wi thout major cardiorespiratory
disturbance.
Catheters should be changed to a fresh site if:
the old si te appears infected
the patient shows signs of severe infection
a posit ive growth is obtained from a blood culture drawn through the catheter or from the tip of the
previous catheter
Routine changes of disposables
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 Frequency
Ventilator circuit (if using bacterial filters) Between patients unless soiled
Ventilator circuit (if using water bath humidifier) Daily
Endotracheal tube catheter mount and bacterial filter Between patients unless soiled
Disposable oxygen masks Between patients unless soiled
CPAP circuits Between patients unless soiled
Rebreathing bags and masks Between patients unless soiled
Intravenous infusion giving sets 48h
Parenteral nutrition giving sets Daily
Enteral feeding giving sets Daily
Arterial/venous pressure transducer sets 48h
Wound dressings Depends on type of dressing
Tracheostomy site As necessary
Urinary catheter bags Weekly
Infection—diagnosis
Infection is both a common cause of admission to intensive care and the major secondary complication. Crit ical ly i l l
patients are predisposed to further nosocomial infections as many of their natural barriers and defence mechanisms
have been lost, al tered or penetrated. They are often heavi ly instrumented, sedated and immobi le. They often
develop immune hyporesponsiveness as part of their cri tical  disease process, notwithstanding any therapeutic
immune suppression they may have received. The high antibiotic load given to these sick patients encourages
colonisation by pathogenic organisms and subsequent development of infections by multidrug resistant and/or
atypical  (e.g. fungi) organisms.
Sepsis is defined as the systemic response to an insult of proven or high l ikelihood of infection. Whereas infection
can be applied to a localised phenomenon, sepsis initiates a systemic inflammatory response thereby affecting distant
organs.
Diagnosis
Often problematic in the critically i l l  patient as focal  signs may be lacking and/or camouflaged by concurrent
disease (e.g. venti lator-associated pneumonia on top of ARDS). Symptoms are often notforthcoming due to the
patient's mentally incompetent state.
In addi tion, al l of the tradit ional cl inical  and biochemical markers of infection are non-speci fic. These include
pyrexia, neutrophi l ia and altered sputum. Furthermore, the frequent presence of colonising organisms e.g. MRSA
on skin, Pseudomonas aeruginosa in the respiratory tract, does not imply concomitant infection. As a
consequence, many patients are over-treated with antibiotics, enhancing the risk ofovergrowth of
resistant/atypical  organisms.
Markers of inflammation (C-reactive protein, procalcitonin) may be useful , though studies have produced
confl icting resul ts as to their specificity/sensi tivity in diagnosing underlying infection.
The value of routine screening (microbiological survei l lance) is not proven, though this may help to identify
infecting organisms earl ier.
For cases of suspected infection, appropriate samples should be taken for analysis including blood, sputum,
wound swabs, drainage fluid, aspirated pus, catheter tips, cerebrospinal  fluid, etc. These shouldgeneral ly be
taken before new antibiotics are commenced.
Consider less common causes of infection such as endocardi tis or osteomyeli tis, particularly if the patient fai ls
to sett le after a standard course of therapy.
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Differential diagnosis of pyrexia
Infection
Non-infective causes of inflammation, e.g. trauma, surgery, burns, myocardial infarction, vascul itis, hepati tis,
acalculous cholecysti tis, pancreati tis
Adverse drug reactions
Excessive ambient heating
Miscel laneous causes, e.g. neoplasm
Definitions
Infection
Microbial phenomenon characterised by an inflammatory response to the presence of micro-organisms or the invasion
of normal ly steri le host t issue by those organisms
Bacteraemia
The presence of viable bacteria in the blood.
Sepsis
The systemic response to infection. Defini tion as for SIRS but as a result of infection.
Sites of infection before and after admission to an ICU
Organ Primary site of infection needing
admission to ICU
Secondary site of infection
acquired while in ICU
Brain + +
Sinuses - +
Cannula/wound sites ++ +++++
Other skin and soft
tissue
++ +
Chest ++++ ++++
Urogenital tract ++ +
Abdomen ++++ ++
Bone + +
Heart valves + +
Key paper
American Col lege of Chest Physicians/Society of Cri tical  Care Medicine Consensus Conference: definit ions for sepsis
and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864–74.
See also:
Bacteriology, p158; Virology, serology and assays, p160; Pyrexia (1), p518; Pyrexia (2), p520
Infection—treatment
Treatment
Drain pus
Change cannula sites i f necessary
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Appropriate antibiotic therapy after laboratory specimens taken—though this may not be necessary for mild
infections where the cause has been removed, e.g. an infected catheter
Radiological  and/or surgical intervention if indicated
Regular input from microbiological ± infectious disease special ists isrecommended to advise on best options for
empiric therapy and for possible modifications based on early communication of laboratory resul ts (including
antibiotic sensit ivity patterns).
Empiric antibiotic therapy is guided on the severi ty of i l lness of the patient, l ikely site of infection and l ikely
infecting organism(s), whether the infection is community-acquired or nosocomial  (including ICU-acquired), patient
immunosuppression, and known antibiotic resistance patterns of hospi tal  and local community organisms. In general ,
critical ly i l l  patients should receive parenteral antibiotics at appropriate dosage, taking into account any impaired
hepatic or renal clearance, or concurrent renal  replacement therapy. Broad-spectrum therapy may be initial ly needed,
with refinement, cessation or change after 2–3 days depending on cl inical response and organisms subsequently
isolated. The duration of treatment remains highly contentious. Apart from speci fic condi tions such as endocardi tis,
tuberculosis and meningitis, where prolonged therapy is probably advisable, i t may be sufficient to stop within 3–5
days provided the patient has shown adequate signs of recovery. Alternatively, patients not responding or
deteriorating should be considered to be either treatment fai lures or inappropriately treated (i.e. no infection was
present in the first place).As described earl ier, commonly accepted markers of infection are poorly specific in the
intensive care patient. Indeed, pyrexia may settle on stopping antibiotic treatment. Cessation or change of antibiotic
therapy must be considered on individual meri ts according to the patient's condi tion and any subsequent laboratory
resul ts. An advantage of ceasing therapy is the abi l i ty to take further specimens for cul ture in an antibiotic-free
environment.
It may be necessary to remove indwell ing pacemakers, tunnelled vascular catheters, prosthetic joints, plates,
implants, grafts and stents i f these are the suspected cause of infection. This should be done in consultation with
microbiologists and the appropriate special ist as individual  risk and benefi t needs to be careful ly weighed up.
Specimen antibiotic regimens (organism unknown)
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Sepsis of unknown origin 2nd/3rd generation cephalosporin OR quinolone OR carbapenem OR
piptazobactam
± aminoglycoside (if Gram negative suspected)
± metronidazole (anaerobic cover)
± glycopeptide or linezolid (if MRSA suspected)
Pneumonia—community
acquired
2nd/3rd generation cephalosporin + macrolide
Pneumonia—nosocomial 3rd generation cephalosporin OR quinolone OR carbapenem OR
piptazobactam ± aminoglycoside (if Gram negative suspected)
+ teicoplanin, vancomycin
+ rifampicin or linezolid (if MRSA likely)
Skin and soft tissue Flucloxacillin (if MSSA likely)
Glycopeptide or linezolid (if MRSA likely)
Benzyl penicillin or clindamycin (if Streptococcus suspected)
Abdominal 2nd/3rd generation cephalosporin OR quinolone OR carbapenem OR
piptazobactam
± aminoglycoside
± metronidazole
Gynaecological 2nd/3rd generation cephalosporin OR quinolone OR carbapenem OR
piptazobactam
± aminoglycoside
+ metronidazole
Nephrourological 2nd/3rd generation cephalosporin OR quinolone OR carbapenem OR
piptazobactam
± aminoglycoside
See also:
Blood pressure monitoring, p110; Bacteriology, p158; Antimicrobials, p260; Acute chest infection (1), p288; Acute
chest infection (2), p290; Hypotension, p312; Abdominal  sepsis, p350; Meningi tis, p374; Tetanus, p390; Botul ism,
p392; Neutropenia, p408; Systemic inflammation/multi-organ fai lure, p484; Sepsis and septic shock—treatment,
p486; HIV related disease, p488; Malaria, p490; Pyrexia (1), p518; Pyrexia (2), p520; Post-operative intensive care,
p534
Systemic inflammation/multi-organ failure
Exposure to an exogenous insul t can result in an exaggerated, general ised and often inappropriate inflammatory
response. This is described as ‘SIRS’—the systemic inflammatory response syndrome. Stimulation of inflammatory
pathways leads to activation of macrophages, endothelium, neutrophi ls, platelets, coagulation, fibrinolytic and
contact systems with release of inflammatory mediators and effectors (e.g. cytokines, prostanoids, free oxygen
radicals, proteases, ni tric oxide, endothelin). This resul ts in microvascular obstruction and occlusion, blood flow
redistribution, interstit ial oedema and fibrosis, and cellular mitochondrial dysfunction. The consequences of this may
be organ dysfunction, varying from ‘mild’ to severe, and affecting single or mult iple organs, resulting in
cardiovascular collapse, gastrointestinal fai lure, renal fai lure, hepatic fai lure, encephalopathy, neuropathy,
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myopathy, and/or disseminated intravascular coagulation. Acute respiratory distress syndrome (ARDS) is the
respiratory component of this pathophysiological response.
Causes include:
Infection
Trauma, burns
Pancreati tis
Inhalation injuries
Massive blood loss/transfusion
Miscel laneous including drug-related (including overdose), myocardial infarction, drowning, hyperthermia,
pulmonary embolus
Treatment
Largely supportive, though the cause should be removed/treated if at al l  possible. Treatment includes antibiotics,
drainage of pus, f ixation of femoral/ pelvic fractures and debridement of necrotic t issue.
An important facet of organ support is to minimise iatrogenic trauma. It is sufficient to maintain survival with
relative homeostasis unti l  recovery takes place rather than attempting to achieve normal physiological or biochemical
target values. An example of this is permissive hypercapnia.
Speci fic treatment regimens remain contentious due to a lack of adequately powered studies showing optimal
haemodynamic goals, inotropic/ pressor agents, antibiotic regimens, etc. Local policies may favour the use of one or
more of a range of eclectic therapies that may offer a reasonable theoretical basis for administration, or anecdotal
success, though theseal l remain essential ly unproven. Examples include antioxidants, protease inhibi tors,
immunonutri tion, plasmapheresis, vasodilators, and immunoglobulins. It is generally agreed that rapid resuci tation
and restoration of oxygen delivery, glycaemic control and prompt removal  of any treatable cause is desi rable in
preventing the onset of SIRS.
Because of non-standardisation of definitions, outcome data are confl ict ing, though single organ ‘fai lure’ carries an
approximate 20–30% mortality while ≥3 organ ‘fai lures’ lasting ≥3 days carries a mortal ity in excess of 50%.
Recovery is often complete in survivors, though recent studies are revealing long term physical  and psychological
sequelae in a significant proportion of patients.
Current UCL Hospitals principles of management
Respiratory SaO2>90–95% (may have to settle for lower) Permissive hypercapnia
Cardiovascular Maintain cardiac output/oxygen delivery and blood pressure compatible
with adequate organ perfusion (e.g. no metabolic acidosis)
Renal Maintain adequate metabolic and fluid homeostasis by intravascular
filling, diuretics, vasoactive agents, and/or haemo(dia)filtration
Haematological Maintain haemoglobin >7g/dl (unless cardiorespiratory problems),
platelets >20–40 × 109/l, INR <1.5–2.5
Gastrointestinal Stress ulcer prophylaxis (generally by enteral nutrition), pancreatitis,
acalculous cholecystitis
Infection Antibiotics, pus drainage, good infection control
Nutrition Preferably early and by enteral route
Pressure
area/mouth/joint care
Frequent turns, low pressure support surfaces, nursing care and
physiotherapy
Psychological Support to both patient and family
Definitions
Systemic inflammatory response syndrome (SIRS)
Two or more of:
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Temperature >38°C or <36°C
Heart rate >90bpm
Respiratory rate > 20 breaths/min or PaCO2 <32mmHg (4.3kPa)
WBC >12,000 cells/mm3,  <4000/mm3, or >10% immature forms
Sepsis
The systemic response to infection. Defini tion as for SIRS but as a result of infection.
Severe sepsis
Sepsis associated with organ dysfunction, hypoperfusion or hypotension. These may include, but are not l imited to,
lactic acidosis, ol iguria or an acute al teration in mental  status.
Septic shock
Sepsis wi th hypotension, despite adequate fluid resuscitation, plus presence of perfusion abnormal it ies.
Multi-organ dysfunction syndrome (MODS)
Presence of altered organ function in an acutely i l l  patient such that homeostasis cannot be maintained without
intervention. Multiple organ fai lure (MOF) has not achieved worldwide uniformity of defini tion.
See also:
Venti latory support—indications, p4; Blood pressure monitoring, p110; Bacteriology, p158; Antimicrobials, p260;
Acute respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2), p294; Inhalation injury,
p306; Hypotension, p312; Abdominal  sepsis, p350; Pancreati tis, p354; Infection control—general  principles, p476;
Sepsis and septic shock—treatment, p486; Multiple trauma (1), p500; Multiple trauma (2), p502; Burns—fluid
management, p510; Burns—general management, p512; Pyrexia (1), p518; Pyrexia (2), p520
Sepsis and septic shock—treatment
Principles of treatment
As for other causes of MODS, outcome in sepsis improves with:
Prompt diagnosis and treatment of the underlying cause1.
Rapid resuscitation to prevent prolonged tissue hypoxia2.
Good glycaemic control3.
Strict infection control4.
Recogni tion and appropriate treatment of secondary infections5.
Adequate nutrit ion6.
Recogni tion that ‘normal ’ physiological/biochemical  levels do not necessari ly need to be attained while the
patient is crit ical ly i l l , provided he/she is not compromised: e.g. a mean BP of 55–60mmHg is often acceptable
unless evidence of poor perfusion or ischaemia suggests higher levels should be sought
7.
Avoidance of preventable mishaps, e.g. prolonged hypotension, pressure sores, thromboembolism8.
Temperature control in the range 36–38.5°C.9.
Prevention of contractures, early mobil isation, etc.10.
Specific treatments (see below)11.
Specific treatments for severe sepsis/septic shock
Activated protein C significantly improves outcome in patients with ≥2 organ dysfunctions if commenced within
48h of onset of severe sepsis. The PROWESS study mainly included patients presenting from the community and
had numerous exclusion criteria, particularly related to those at increased risk of bleeding. Subsequent studies
revealed <15% of septic patients presenting to ICUs meet both inclusion and exclusion criteria.
1.
‘Low-dose’ hydrocortisone (50mg qds) given for 7 days improved outcomes if commenced within 8h of septic
shock presentation, though only in the subset with an abnormal cortisol response to synthetic ACTH. Our current
practice is to start hydrocortisone after performing a Synacthen test and to discontinue this therapy if the test is
normal .
2.
For norepinephrine (NEPI)-resistant septic shock, i .e. high-output severe hypotension not responding to
adequate fluid loading and a NEPI dose >0.4µg/kg/min, we consider careful administration of terl ipressin or
methylthioninium chloride. Unti l  more data are forthcoming, these agents should be viewed as rescue therapies
rather than a straight alternative for NEPI.
3.
We occasional ly use plasmapheresis, prostaglandins or high-output haemofi ltration for resistant cases of septic4.
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shock, particularly those with low cardiac outputs. We readi ly acknowledge the evidence base for these therapies
is sl ight and our use is based on anecdotal  success.
Figure. No Caption Available.
Key paper
Del l inger RP et al . Surviving Sepsis Campaign guidelines. Crit Care Med 2004; 32:858–73
Key trials
Bernard GR, for the PROWESS study group. Efficacy and safety of recombinant human activated protein C for severe
sepsis. N Engl  J Med; 344:699–709
Annane D, et al . Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortali ty in patients
with septic shock. JAMA 2002; 288:862–71
See also:
Oxygen therapy, p2; Venti latory support—indications, p4; Haemo(dia)fi ltration (1), p62; Haemo(dia)fi l tration (2),
p64; Plasma exchange, p68; Enteral  nutrition, p80; Parenteral  nutri tion, p82; Blood gas analysis, p100; Blood
pressure monitoring, p110; Cardiac output—thermodilution, p122; Cardiac output—other invasive, p124; Cardiac
output—non-invasive (1), p126; Cardiac output—non-invasive (2), p128; Bacteriology, p158; Lactate, p170;
Inotropes, p196; Vasopressors, p200; Anticoagulants, p248; Antimicrobials, p260; Steroids, p262; Novel therapies in
sepsis, p266; Fluid chal lenge, p274; Acute chest infection (1), p288; Acute chest infection (2), p290; Acute
respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2), p294; Hypotension, p312; Acute
renal fai lure—diagnosis, p332; Acute renal  fai lure—management, p334; Abdominal sepsis, p350; Infection—diagnosis,
p480; Infection—treatment, p482; Pyrexia (1), p518; Pyrexia (2), p520
HIV related disease
Affected patients may present electively after diagnostic biopsies of brain or lung, or where elective venti lation is
needed postoperatively. Other cases present with compl ications of HIV related disease, especial ly pulmonary
infection (e.g. Pneumocystis carinii, CMV) or seizures (e.g. cerebral  lymphoma, cerebral  abscess, meningi tis). HIV
related diseases are now considered to be chronic manageable condi tions with an often good short term prognosis. It
is therefore reasonable that intensive care should be offered.
Infection control
The protection of staff from transmission of HIV fol lows basic measures. Body fluids should not be handled (wear
gloves) and the face and eyes should be protected where there is a risk of splash contamination.
Needles should be disposed of in appropriate bins without re-sheathing. Any fluid spil lages should be cleaned up
immediately. Robust procedures are adhered to where a patient is known HIV posi tive; the real risk is in the patient
of unknown HIV status. Remember that patients presenting with non-HIV related i l lness may be unknown posit ives. It
fol lows that precautions should be taken for al l  patients.
Pneumocystis carinii pneumonia
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This is the commonest respiratory disorder affecting HIV posit ive patients. The majori ty survive their f irst attack
but prognosis is not as good in those requiring mechanical venti lation. Intensive, early support with CPAP and
appropriate chemotherapy may avert the need for venti latory support.
Treatment is usual ly started without waiting for laboratory confirmation.
First l ine treatment is with high-dose co-trimoxazole or pentamidine with adjuvant high-dose steroids.
Co-trimoxazole has a faster onset of effect and a broader spectrum of antibacterial  activity covering the common
secondary pathogens. Pentamidine is usually used where co-trimoxazole fai ls or where patients cannot take
co-trimoxazole.
Methylprednisolone is used to suppress peribronchial fibrosis andalveolar infi l trate. It is usual for there to be an
ini tial deterioration on treatment lasting several  days.
Respiratory support is provided with CPAP (5–10cmH2O) if hypoxaemic despite high FIO2.  Lower CPAP pressures
should be used where possible as these patients are at risk of pneumothorax.
Mechanical  venti lation is reserved for those who have a rising with deteriorating gas exchange and fatigue
despite CPAP.
CXR changes respond very slowly.
Lactic acidosis
Nucleoside reverse transcriptase inhibitors (NRTIs) are frequently used anti -retroviral agents. However, an
associated mitochondrial impairment can cause a severe lactic acidosis and a high mortali ty. Anecdotal use of
L-carnit ine is reported to be of benefi t.
IV drug abusers
IV drug abusers are at high risk for HIV related disease, though present more commonly for other reasons (e.g. drug
withdrawal syndromes, overdose, sepsis, endocarditis, hepatitis B or C, rhabdomyolysis).
Drug dosages
Co-trimoxazole 120mg/kg/day in divided doses IV for 10–14 days then PO to complete 21
days
Pentamidine 4mg/kg/day IV
Methylprednisolone 1g/day for 3 days
See also:
Venti latory support—indications, p4; Endotracheal intubation, p36; Continuous posi tive airway pressure, p26;
Bacteriology, p158; Virology, serology and assays, p160; Antimicrobials, p260; Steroids, p262; Acute chest infection
(1), p288; Acute chest infection (2), p290; Pneumothorax, p300; Infection control—general principles, p476
Malaria
Malaria should be suspected in any patient returning from endemic areas with a febri le i l lness which may have
cerebral , abdominal, lung or renal features. Rarely, people l iving near ai rports may be bi tten by a transported
Anopheles mosquito. There may be considerable delay (weeks to months) between the mosquito bi te and signs of
infection. It is caused by protozoal  infection with the Plasmodium genus. The most severe form is P. falciparum which
causes malignant, tertian malaria. Other forms (P. malariae, P. vivax, P. ovale) rarely cause significant l i fe
threatening disease and wil l  not be discussed further.
Pathophysiology
P. falciparum invades erythrocytes regardless of age. High levels of parasi taemia >5% are considered severe in
non-immune travellers. The cel ls may haemolyse or be destroyed in l iver or spleen. Anaemia may be severe.
Increased vascular permeabi l i ty, cytokine release, red cell  agglutination and intravascular coagulation (DIC) may also
occur.
Clinical features
Symptoms include headache, fever with rigors, myalgia, abdominal  pain, vomiting and diarrhoea. Signs include
splenomegaly, jaundice, tender hepatomegaly and anaemia. Hyponatraemia is common.
Only a minority of patients with P. falciparumhave paroxysms of fever with ‘cold’ and ‘hot’ stages.
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If >5% parasi taemia, features include:
Cerebral malaria, causing coma, deli rium, seizures or focal  deficits.
Cough and haemoptysis or acute respiratory distress
Blackwater fever is associated with massive intravascular haemolysis, jaundice, haemoglobinuria, collapse and
renal fai lure
Acute renal dysfunction occurs in a thi rd of adult ICU patients
Acute cardiovascular col lapse (‘algid malaria’) and metabolic acidosis
Thrombocytopenia, DIC and spontaneous bleeding
Diagnosis
Plasmodia seen in RBC in thick or thin smears of peripheral blood. The parasitaemia intensity may vary from
hour to hour and may be scanty in number. The smear should be carefully scrutinised and repeated if doubt
persists.
Leucocytosis is not a feature of malaria
Splenomegaly is almost invariable during the second week of i l lness
Treatment
Early IV quinine infusion is the mainstay of treatment of severe malaria. Levels should be monitored daily and
dosage adjusted as appropriate. Compl ications include hypoglycaemia and tinnitus. Artemether should be
considered in cases of l ikely quinine resistance.
1.
A 2–3l  exchange transfusion should be considered if the patient is severely i l l  or i f parasi taemia levels
>10–20%.
2.
Careful  attention must be paid to fluid and electrolyte balance and management of renal fai lure.3.
Treatment of hypoglycaemia, renal fai lure, coagulopathy, metabol ic acidosis, seizures, ARDS, anaemia and
hyperpyrexia fol low conventional l ines
4.
Steroids are not recommended for cerebral oedema.5.
Suspect coincident Gram negative infection with ci rculatory collapse.6.
Drug dosage
First line
Quinine 20mg quinine salt/kg IV over 4h, then 10mg/kg infusion over 4h,
repeated 8-hrly until the patient can swallow, then tablets (10mg
quinine salt/kg 8-hrly) to complete 7 days' treatment.
Halve maintenance dose to 5mg salt/kg 8-hrly if continuing
parenteral therapy for >48h.
Artemether 3.2mg/kg IM followed by 1.6mg/kg daily
Second line after asexual parasites eliminated
Sulfadoxine
500mg/pyramethamine
25mg
3 tablets once
Doxycycline 200mg then 100mg daily for 7 days
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Blood transfusion, p182; Fluid chal lenge, p274; Ol iguria,
p330; Acute renal fai lure—diagnosis, p332; Acute renal  fai lure—management, p334; General ised seizures, p372;
Jaundice, p358; Anaemia, p400; Haemolysis, p404; Platelet disorders, p406; Infection—diagnosis, p480;
Infection—treatment, p482; Pyrexia (1), p518;Pyrexia (2), p520
Rheumatic disorders
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Rheumatoid arthritis
A debi l i tating arthrit is that may present to intensive care through pulmonary involvement or through compl ications of
treatment (e.g. renal  fai lure, immunosuppression, bleeding disorders). Pleuro-pulmonary involvement may precede
the arthrit ic symptoms and is more common in those with active rheumatoid disease and middle aged men. Care is
required when intubating patients with rheumatoid arthri tis since the neck joints may sublux.
Rheumatoid pleurisy
Rheumatoid pleurisy, often with effusion, is most common and is usually asymptomatic. However, effusions may be
recurrent or chronic and may impede respiratory function. The effusion is an exudate, low in glucose and often high
in cholesterol .
Rheumatoid lung
Rheumatoid lung is a diffuse interstit ial  pneumonitis wi th bi-basal fibrotic changes on the CXR. The condit ion may be
difficul t to dist inguish from idiopathic pulmonary fibrosis and produces a restrictive pulmonary defect. The mainstay
of treatment is early systemic steroid therapy, al though chronic cases do not respond.
Systemic lupus erythematosis (SLE)
A non-organ specific autoimmune disease characterised by antinuclear antibodies with high ti tres of
antidouble-stranded DNA antibodies. A vascul it is is prominent, although cutaneous and central nervous system
involvement are not vasculi tic. SLE may present to intensive care through pulmonary, renal or central  nervous
system involvement.
Renal failure
Renal fai lure is vascul itic in origin and may progress to end stage renal fai lure requiring long term dialysis. Early
treatment with systemic steroids and immunosuppressives may hal t disease progress.
Lupus pleurisy and pericarditis
Unl ike rheumatoid pleurisy the pleural  involvement in SLE is often painful  and associated with large pleural effusions.
Pulmonary haemorrhage
Pulmonary haemorrhage is associated with renal fai lure and may be l ife threatening. Plasma exchange may be
helpful.
Interstitial pneumonitis
Intersti tial pneumonitis is uncommon in SLE. It is more l ikely that parenchymal  infi ltrates are infective in origin
secondary to immunosuppressive therapy.
Pulmonary thromboembolic disease
Patients typically have a prolonged activated partial  thromboplastin time due to ci rculating lupus anticoagulant. but
are more prone to thrombotic episodes. Lupus anticoagulant is associated with anticardiol ipin antibodies and a false
posit ive VDRL. Recurrent pulmonary emboli  may be associated with chronic pulmonary hypertension. Treatment is
long term anticoagulation.
See also:
Endotracheal  intubation, p36; Plasma exchange, p68; Non-opioid analgesics, p236; Steroids, p262; Haemoptysis,
p304; Acute renal fai lure—diagnosis, p332; Acute renal  fai lure—management, p334; Upper gastrointestinal
haemorrhage, p344; Vasculit ides, p494
Vasculitides
Vasculit is should be suspected in any patient with multisystem disease, especial ly involving the lungs and kidneys.
Wegener's granulomatosis
A systemic vascul itis characterised by necrotising granulomas of the upper and lower respiratory tract,
glomerulonephritis and small vessel  vasculi tis. Wegener's granulomatosis is associated with posi tive core
antineutrophil  cytoplasmic antibodies (c-ANCA), particularly granular with central attenuation on
immunofluorescence. Intensive care admission is usual ly because of renal  and/or pulmonary involvement.
Renal failure
Focal necrotising glomerulonephritis leads to progressive renal fai lure. Treatment with steroids and
cyclophosphamide may give complete remission.
Upper airway disease
Most patients wil l  have nasal symptoms including epistaxis, nasal  discharge and septal  perforation. Intensive care
admission may be required rarely for severe epistaxis. Ulcerating lesions of the larynx and trachea may cause
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
222 из 254 07.11.2006 1:04
P.495
P.496
P.497
subglott ic stenosis. This is usual ly insidious but may present problems on attempted intubation.
Pulmonary involvement
Usually associated with haemoptysis, dyspnoea and cough with rounded opacit ies on the CXR. There may be
cavitation. Nodules may be sol itary. Alveolar haemorrhage may be l ife threatening. The mainstay of treatment is
steroids and cyclophosphamide which may produce complete remission. Plasma exchange may be helpful.
Polyarteritis nodosa (PAN)
PAN is a necrotising vasculit is affecting smal l and medium sized muscular arteries. Intensive care admission may be
provoked by renal fai lure, ischaemic heart disease, hypertensive crisis and bronchospasm, al though true pulmonary
involvement is uncommon. Diagnosis may be confirmed by mesenteric angiography or renal biopsy. Treatment
involves renal replacement therapy, high dose steroids and cyclophosphamide.
Goodpasture's syndrome
Antiglomerular basement membrane (anti-GBM) antibodies bind at the glomerulus and alveolus. Patients present with
a prol iferative glomerulonephrit is and haemoptysis. Diagnosis is confi rmed by posi tive anti -GBM antibodies and renal
biopsy. Treatment is with immunosuppressive therapy and plasma exchange.
See also:
Plasma exchange, p68; Airway obstruction, p280; Steroids, p262; Haemoptysis, p304; Acute renal  fai lure—diagnosis,
p332; Acute renal fai lure—management, p334; Rheumatic disorders, p492
Anaphylactoid reactions
Minor reactions to al lergens (itching, urticaria) are common before a severe reaction occurs; any such history should
be taken seriously and potential al lergens avoided. Most reactions are acute in onset and clearly related to the
causative al lergen. However, some complement-mediated reactions may take longer to develop.
Clinical features
Respiratory—laryngeal  oedema, bronchospasm, pulmonary oedema, pulmonary hypertension
Cardiovascular—hypotension, tachycardia, general ised oedema
Other—urticaria, angio-oedema, abdominal  cramps, rigors
Management
Stop al l infusions and blood transfusions and withhold any potential drug or food al lergen. Blood and blood
products should be returned to the laboratory for analysis.
1.
Start oxygen (FIO2 0.6–1.0). If there is evidence of persistent hypoxaemia consider urgent intubation and
mechanical  venti lation.
2.
If there is laryngeal  obstruction, bronchospasm or facial  oedema give IM or nebul ised epinephrine and IV
hydrocortisone. If there is not rapid rel ief of airway obstruction, consider urgent intubation or, in extremis,
emergency cricothyroidotomy or tracheostomy. Persistent bronchospasm may require an epinephrine infusion,
aminophyll ine infusion or assisted expiration (manual chest compression).
3.
Hypotension should be treated with epinephrine IV/IM and rapid col loid infusion. Large volumes of colloid may be
required to replace the plasma volume deficit in severe anaphylaxis.
Severe oedema may coexist with hypovolaemia.
Plasma volume has not been adequately replaced i f the haemoglobin is higher than normal .
Hetastarch is the most appropriate fluid for col loid resusci tation unless the reaction is due to a
hydroxyethyl starch.
4.
Persistent hypotension should be treated with further epinephrine, hydrocortisone and col loid infusion guided by
central venous pressure ± cardiac output monitoring. An epinephrine infusion may be required to overcome
myocardial  depression. The use of mil itary antishock trousers or norepinephrine should be considered to divert
blood centrally and increase peripheral  resistance.
5.
Urticaria requires chlorphenamine IV or PO depending on the severi ty of the reaction.6.
After control of the anaphylactoid reaction, advice should be sought from the immunology laboratory and
appropriate samples taken for confirmation.
7.
Reactions to long-acting drugs or fluids wil l  require continued support (perhaps for many hours).8.
Drug dosages
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Laryngeal oedema and bronchospasm
 Initial dose Continued treatment
Epinephrine 0.3–0.5mg IM or 0.5mg nebulised Start at 0.05µg/kg/min
Hydrocortisone 200mg IV
Hypotension
 Initial dose Continued treatment
Epinephrine 0.5–1.0mg IM or 0.05–0.2mg IV Start at 0.05µg/kg/min
Hetastarch 6% 500ml According to response
Hydrocortisone 200mg IV 200mg IV qds
Chlorphenamine  10mg IV tds
Urticaria
Chlorphenamine 10mg IV tds or 4mg PO tds
Hydrocortisone 50–100mg IV tds
Prednisolone 20mg PO daily
See also:
Venti latory support—indications, p4; Endotracheal intubation, p36; Col loids, p180; Blood transfusion, p182;
Inotropes, p196; Blood products, p252; Steroids, p262; Basic resuscitation, p270; Fluid chal lenge, p274
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Trauma and Burns
Multiple trauma (1)
Such patients are admitted ei ther after surgery or for close observation and medical management. The principles of
management are to:
Maintain or quickly restore adequate tissue perfusion and gas exchange
Control  pain
Secure haemostasis and correct any coagulopathy
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Provide adequate nutri tion
Monitor closely and deal  promptly with any complications
Circulatory management
Patients are often cold and vasoconstricted on admission. This serves to camouflage concurrent hypovolaemia
and compromise t issue perfusion.
Adequate monitoring must be insti tuted at an early stage.
Development of a persisting tissue oxygen debt has been shown to lead to subsequent multiple organ
dysfunction which may not become cl inically apparent for 3–7 days. Therefore, adequate perfusion must be
restored promptly by repeated fluid challenges. Addition of a vasodilating agent, e.g. glyceryl trini trate, may be
beneficial.
An increasing metabol ic acidosis should prompt suspicion of inadequate resuscitation, covert haemorrhage or
tissue necrosis. Myocardial  depression or fai lure may also be impl icated.
Respiratory management
Consider the possibi l ity of a fractured, unstable neck, especial ly in unconscious patients. This should be
excluded by appropriate radiology and an expert opinion. Unti l then the neck should be immobil ised.
If venti lated, ensure haemodynamic stabi l i ty, removal of any metabol ic acidosis, adequate rewarming and
satisfactory gas exchange before attempting to wean. If the patient remains unstable, it is advisable to delay
extubation in case urgent surgery is required.
If spontaneously breathing, give supplemental  oxygen to provide adequate arterial oxygenation, encourage deep
breathing to prevent atelectasis and secondary infection, and ensure sufficient analgesia, albei t not too much to
suppress venti latory drive.
Haematological management
Maintain haemoglobin >7g/dl (higher with cardiorespiratory disease) to assist oxygen transport. Cross-matched
blood should be readily avai lable for secondary haemorrhage.
Correct any coagulopathy with fresh frozen plasma, ± platelets, and, occasional ly, other blood products (e.g.
cryoprecipitate) or activated factor VII.
Peripheries
Injury to the l imb may result in nerve injuries, obstruction of the vascular supply, or muscle damage which may lead
to compartment syndrome and rhabdomyolysis. A high level of suspicion should be held and corrective surgery
undertaken promptly i f necessary.
See also:
Venti latory support—indications, p4; Chest drain insertion, p42; Nutri tion—use and indications, p78; Blood gas
analysis, p100; Blood pressure monitoring, p110; Ful l blood count, p154; Coagulation monitoring, p156; Lactate,
p170; Crystalloids, p176; Colloids, p180; Blood transfusion, p182; Coagulants and anti fibrinolytics, p254; Basic
resuscitation, p270; Fluid challenge, p274; Pneumothorax, p300; Haemothorax, p302; Hypotension, p312; Anaemia,
p400; General acid–base management, p432; Metabol ic acidosis, p434; Infection—diagnosis, p480;
Infection—treatment, p482; Multiple trauma (2), p502; Head injury (1), p504; Head injury (2), p506;
Rhabdomyolysis, p528
Multiple trauma (2)
Analgesia
Adequate analgesia is imperative to avoid circulatory instabil ity and decreased chest wal l excursion, especial ly
fol lowing chest, abdominal or spinal  trauma.
Increased use of regional  techniques (depending on absence of infection and coagulopathy) and
patient-control led analgesia has faci l i tated pain rel ief and weaning.
Opiates are recommended for ini tial analgesia. Non-steroidals are particularly effective for bony pain though
may occasionally precipi tate coagulopathies, stress ulceration and renal fai lure.
Agi tation may be due to causes other than pain, e.g. infection, intracranial lesion.
Nutrition
Early nutri tion has been shown to reduce post-operative complications. This should ideally be enteral , an approach
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which has been demonstrated to be safe, even after abdominal laparotomy for trauma.
Infection
Depending on the si te of trauma, the type of wound (open/closed, clean/dirty), and the need for surgery,
prophylactic tetanus and antibiotic cover varying from 1 dose to 1–2 weeks may be needed.
The trauma patient is at high risk of developing secondary infection, in particular chest, wound si tes,
intravascular catheter insertion si tes, post-abdominal trauma, intra-abdominal abscesses. Preventive measures
and strict infection control should be undertaken.
Intravascular catheters inserted during emergency resuscitation under non-steri le condit ions should be replaced.
Prophylaxis
Attention should be paid to pressure areas; this may involve the use of special ised mattresses or support beds.
Clear instructions should be obtained from the surgeon regarding care of the wound and drain sites.
Especial ly after orthopaedic procedures on the pelvis and lower l imb, or if the patient wi l l  remain immobil ised,
heparin prophylaxis against deep venous thrombosis should be insti tuted.
Review
Regular review of the patient is necessary to ensure compl ications are detected and deal t with promptly. This
may require repeat laparotomy, ultrasound or CT scanning.
Later complications include pancreatit is, acalculous cholecystit is, and multiple organ dysfunction (including
ARDS).
See also:
Nutri tion—use and indications, p78; Special support surfaces, p86; Opioid analgesics, p234; Non-opioid analgesics,
p236; Anticoagulants, p248; Antimicrobials, p260; Acute respiratory distress syndrome (1), p292; Acute respiratory
distress syndrome (2), p294; Infection—diagnosis, p480; Infection—treatment, p482; Multiple trauma (1), p500;
Head injury (1), p504; Head injury (2), p506; Pain, p532
Head injury (1)
The head may be injured with or wi thout signi ficant trauma to other parts of the body. Priori ty in management of the
multiply injured patient must be placed on securing adequate gas exchange and circulatory resuscitation, and deal ing
with any l ife-threatening injury, e.g. an arterial injury, before defini tive treatment for head injury.
The patient wil l  usually be admitted to the ICU after CT scanning has identified the extent of injury. The neck should
also be imaged by CT, particularly i f the patient is venti lated. It is also l ikely that surgery wi l l  have been undertaken
for any significant space-occupying lesion or for elevation of a depressed fracture.
General management
An unstable neck fracture should be assumed unti l excluded by an expert opinion and appropriate investigations.
Most head injury patients admitted to non-neurosurgical  ICUs wil l  have di ffuse or local brain injury for which a
non-operative approach has been adopted. The Regional  Neurosurgery Centre should be contacted i f raised
intracranial  pressure is present as local  policy may encourage early bone flap decompression or referral  for
invasive monitoring (e.g. intracranial pressure, jugular venous bulb O2 saturation).
If a basal  skull  fracture is suspected (e.g. X-rays, rhinorrhoea, otorrhoea), avoid nasal insertion of feeding or
endotracheal  tubes.
Deterioration in conscious level , developing neurological deficits or focal signs (e.g. unilateral pupi l lary
dilatation) should prompt urgent repeat CT scanning for late compl ications, e.g. subdural haematoma.
Complications
Actively manage raised intracranial  pressure.
Actively treat seizures with anticonvulsants to prevent further hypoxaemic cerebral  damage, reduce cerebral
oxygen requirements and ICP. The patient should be loaded with IV phenytoin as prophylaxis against further fi ts.
Consider addi tional causes such as hypoglycaemia, development of a new space-occupying lesion, recreational
drugs and infection.
Diabetes insipidus suggests hypothalamic injury and carries a poor prognosis. Desmopressin 1–4µg IV should be
given daily to maintain urine output of 100–150ml/h.
Actively manage hyperpyrexia. Some studies show long-term benefi t from induced hypothermia but this needs to
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be aggressively insti tuted as early as possible after the injury to be effective.
Actively manage hyperglycaemia with insulin, and avoid hypoglycaemia.
Key papers
Rovlias A, Kotsou S. The influence of hyperglycemia on neurological outcome in patients with severe head injury.
Neurosurgery 2000; 46:335–42 Cl ifton GL, Mil ler ER, Choi SC et al.  Lack of effect of induction of hypothermia after
acute brain injury. N Engl  J Med 2001; 344:556–63
See also:
Anticonvulsants, p242; Neuroprotective agents, p244; Generalised seizures, p372; Intracranial haemorrhage, p376;
Raised intracranial pressure, p832; Mult iple trauma (1), p500; Mult iple trauma (2), p520; Head injury (2), p506;
Spinal cord injury, p508
Head injury (2)
Analgesia
Adequate analgesia (usual ly opiates) must be given to the head-injured patient as pain and agitation wil l
increase intracranial pressure, thereby causing a secondary insul t.
Short-acting sedation should be used as this enables rapid assessment of the underlying conscious level and any
focal neurological  deficit.
Respiratory management
Aggressive hyperventi lat ion is no longer recommended apart from short-term management of raised intracranial
pressure. If venti lated, aim to maintain the PaCO2 at 3.5–4kPa.
Face or neck injuries may have required emergency cricothyroidotomy or tracheostomy to obtain a patent
airway. If orotracheal ly intubated, ensure local  swell ing has subsided (nasendoscopy, air leak around deflated
cuff) before extubation.
Severe agi tation and confusion may last for several weeks; this wil l  often delay weaning and extubation.
Judicious sedation, e.g. with chlorpromazine, may be necessary.
Circulatory management
Hypotension should be avoided with adequate fluid resuscitation ± vasopressor therapy.
Elevated blood pressures may be tolerated unless excessive.
β-blockers may be useful in reducing the myocardial effects of excessive catecholamine levels.
Other drug therapy
Antibiotic prophylaxis is not routinely recommended.
High-dose steroid therapy has not yet been shown to be beneficial .
Trials of other neuroprotective agents, e.g. free radical  scavengers, have also failed to show benefi t.
Indications for consideration of intracranial pressure monitoring
Indications
GCS ≤8 and any abnormal ity on CT scan
GCS ≤8 and a normal  CT scan but any two of the fol lowing:
Age >40 years
Hypotension
Decerebrate posturing
GCS >8 but:
Requiring general anaesthesia for treatment of other injuries
Requiring treatment l ikely to increase ICP, e.g. high levels of PEEP
Contraindications
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Coagulopathy
Infection?
ICP monitoring should be continued:
As long as the ICP is elevated
During active management of ICP
For up to 3 days in the absence of signi ficant elevation
See also:
Venti latory support—indications, p4; Endotracheal intubation, p36; Intracranial pressure monitoring, p134; Jugular
venous bulb saturation, p136; Hypotension, p312; Raised intracranial pressure, p382; Pain, p532
Spinal cord injury
Spinal injury, wi th or without damage to the cord, may be apparent soon after admission to hospital; however,
deterioration may occur, requiring a high index of suspicion and careful monitoring.
Immobilisation
The spine should be immobil ised unti l a senior surgical/orthopaedic opinion has confirmed that no unstable
fracture is present, both radiological ly and cl inical ly.
Place a hard cervical  collar i f a neck fracture is possible. This does not stabi l ise the spine; ei ther skul l traction
or operative stabi l isation wil l  be needed for an unstable fracture.
Move the patient by ‘log-rol l ing’ or straight-l i fting, using at least four staff members. Exercise care with neck
manipulation; intubation should be performed by an experienced operator.
Circulatory instability
So-cal led ‘spinal shock’ may occur with marked hypotension due to sympathetic outflow disturbance.
Hypovolaemia should be excluded fi rst. Consider damage to other organs/vessels, e.g. spleen, aorta.
Vasopressor therapy may be necessary if evidence of t issue hypoperfusion persists, e.g. ol iguria, metabol ic
acidosis.
Postural hypotension and ci rculatory instabi l ity (including symptomatic bradycardia) is commonplace for the fi rst
few weeks. Autonomic dysfunction affects 50% of cervical  and high thoracic cord injuries.
Respiratory management
High cervical cord injury above C5 results in loss of diaphragmatic function, whereas above C8 can result in loss
of intercostal function. This may compromise or prevent breathing and weaning from IPPV.
When able, the patient should be managed in an upright posture.
Atelectasis is common and requires regular physiotherapy.
Early tracheostomy may faci l itate support and comfort.
General measures
Careful ly monitor neurological  function to enable early detection of spinal  cord compression and referral  for
urgent remedial  surgery.
Give LMW heparin SC for thromboembolism prophylaxis.
The incidence of stress ulceration is high. Ideally, enteral nutrit ion should be instituted at an early stage though
this may prove unsuccessful . Drugs (e.g. sucralfate, H2 blockers) may be needed.
Enteral feeding may be di fficul t to institute init ial ly as gastric distension and paralytic i leus is common fol lowing
spinal  cord injury. A NG tube should be inserted for gastric decompression. An enterostomy may eventually be
needed to enable long-term feeding.
Bowel and bladder function may be deranged. Long-term si lastic bladder catheters and regular laxative and
enema therapy should be instituted at an early stage.
Special care is needed to prevent pressure sores.
Institute regular exercises to prevent contractures.
Psychological support for patient and fami ly is crucial,  particularly if long-term disabil i ty is l ikely.
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High-dose steroid therapy may be beneficial  i f started within 8h, though this sti l l  remains controversial.
Hyperbaric oxygen therapy is of unproved benefi t.
After spinal  injury, muscle relaxants may cause severe hyperkalaemia.
Steroids have been shown to be useful  but this remains controversial.
Key trial
Bracken MB, et al.  Administration of methylprednisolone for 24 or 48 hours or ti ri lazad mesylate for 48 hours in the
treatment of acute spinal cord injury. Results of the Third National  Acute Spinal Cord Injury Randomized Controlled
Trial . National Acute Spinal  Cord Injury Study. JAMA. 1997; 277:1597–604
See also:
Special support surfaces, p86; Blood pressure monitoring, p110; H2 blockers and proton pump inhibitors, p218;
Sucralfate, p220; Anticoagulants, p248; Steroids, p262; Fluid challenge, p274; Hypotension, p312; Acute weakness,
p368; Metabol ic acidosis, p434; Mult iple trauma (1), p500; Multiple trauma (2), p502; Head injury (1), p504; Head
injury (2), p506
Burns—fluid management
Major thermal injuries (i.e. >20% body surface area) are admitted to an intensive care unit, usually special ising in
the management of burns, for meticulous attention to fluid resusci tation, prevention of infection, and the frequent
need for mechanical venti lation.
Monitoring
The fluid loss from major burns requires careful  assessment of intravascular volume status. The tradit ional
markers of fluid resusci tation in burns of central  venous pressure, urine output and haematocri t are general ly
inadequate.
Either invasive or non-invasive cardiac output monitoring is needed for accurate titration of fluid. This is
particularly appl icable in the presence of a hyperdynamic, vasodilated circulation which often commences within
1–2 days. Al though infection is not necessari ly present, vasopressor therapy may be needed to maintain
adequate systemic blood pressures.
Pulmonary artery and central  venous catheters should not be inserted through affected skin areas if at al l
possible.
Insertion of intravascular catheters, urinary catheters and NG tubes should be carried out soon after admission
as rapid onset swel l ing within a few hours may make these procedures impossible.
Fluid management
The extent of injury wi l l  have been estimated by plastic surgeons who wil l  also determine the proportion of ful l
thickness dermal injury to calculate the approximate fluid resuscitation required.
Fluid resuscitation in the UK often fol lows the Mount Vernon (albumin-based) formula while the Parkland
(crystalloid-based) formula is often used in the US. Colloids may reduce oedema at non-burn sites and restore
blood volume faster than crystalloids.
These formulae only provide an approximate guide and frequently underestimate losses both into the interstitial
spaces and through the lost skin barrier. Evaporative losses are approximately 2ml/kg/h. Water losses may be
increased if wounds are not covered. Losses increase further with inhalation injury.
Overzealous fluid infusion should be avoided to minimise oedema.
The increased permeabi l i ty and fluid leak phase lasts approximately 1–2 days. After 2–5 days, a diuretic phase
usually commences when excess t issue fluid is lost and the body swell ing reduces.
Electrolyte levels (especial ly K+ and Mg2+) can fluctuate widely in both periods requiring monitoring and
replacement as necessary.
Though some haemolysis may occur, blood transfusion requirements are usually low, but debridement wi l l  resul t
in major blood loss often requiring major transfusion (>8–10 uni ts). A coagulopathy wil l  often occur, in part due
to a di lutional  effect of the albumin infusion.
Fluid resuscitation regimen (adapted from Mount Vernon formula)
Note: this regimen should be used as a guide only.
Divide fi rst 36h from the t ime of burn into six consecutive periods of 4, 4, 4, 6, 6 and 12h. For each period give
0.5ml 4.5–5% albumin ×  body wt [kg] × %burn
1.
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Give blood as necessary to maintain haemoglobin >10g/dl .2.
Commence enteral  nutri tion as soon as possible3.
Give 1.5–2ml/kg/h 5% glucose4.
Reassess cardiorespiratory variables and urine output at frequent intervals to determine whether volume
replacement is inadequate or excessive. Adjust fluid input as necessary.
5.
See also:
Blood pressure monitoring, p110; Central  venous catheter—use, p114; Col loid osmotic pressure, p172; Crystal loids,
p176; Col loids, p180; Basic resuscitation, p270; Fluid chal lenge, p274; Hypotension, p312; Oliguria, p330;
Burns—general management
Burns—general management
Surgery
Escharotomy may be needed on hospital admission to affected l imbs, as well  as to the neck and/or chest if a
circumferential  burn is present.
Debridement of necrotic tissue is often begun within the first few days as early grafting is associated with
improved outcome.
Coverage is obtained using either spl it skin grafts from the patient's own unaffected skin, donor skin grafts or
even experimental ‘skin’.
Blood loss may be rapid and massive, e.g. 100ml per 1% of body surface grafted.
Wound care
Early appl ication of dressings and Flamazine (si lver sulphadiazine) cream which has anti-bacterial  properties
against Gram negative bacteria may usefully prevent secondary infection.
Early grafting often takes place within the fi rst 2–3 days to provide a skin protective barrier.
Nutrition
Enteral nutrition should be commenced soon after admission as studies have shown that early enteral nutri tion
improves outcome.
Target intake is protein of 1g/kg + 2g/%burn and a calorie intake of 20Cal/kg + 50Cal/%burn.
Infection
Prophylactic antibiotics are often not given to burn patients.
Body temperature rises on day 1–2 as high as 40°C, may persist for several days and does not indicate
secondary infection.
Likely infecting agents include streptococci , staphylococci  and Gram negative bacteria such as Pseudomonas.
Appropriate antibiotic treatment should be given as indicated.
Other considerations
Any suspected inhalation injury should be diagnosed and treated.
Ensure adequate analgesia (opiates). Ketamine is a useful anaesthetic as i t has analgesic properties in addit ion.
Tetanus toxoid should be given soon after hospital admission.
Reduce heat and fluid losses by placing the patient on a heated air fluidised bed and by early coverage of burnt
skin through application of occlusive dressings and placement of affected l imbs in transparent plastic bags.
Stress ulceration can usual ly be avoided through prompt resuscitation and early enteral nutrit ion.
Pressure sores and contractures should be prevented by careful nursing and physiotherapy.
Suxamethonium should be avoided from 5–150 days' post-burn because of the risk of rapid and severe
hyperkalaemia.
Increasing resistance to non-depolarising muscle relaxants may be seen.
β-blockade has been associated with outcome improvement in chi ldren sustaining burn injury.
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See also:
Enteral nutrit ion, p80; Special support surfaces, p86; Opioid analgesics, p234; Non-opioid analgesics, p236; Muscle
relaxants, p240; Antimicrobials, p260; Hyperkalaemia, p420; Infection control—general  principles, p476;
Infection—diagnosis, p480; Infection—treatment, p482; Burns—fluid management, p510; Pyrexia (10; Pyrexia (2),
p520; Rhabdomyolysis, p528; Pain, p532
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Physical Disorders
Hypothermia
Clinical features
Above 33°C—shivering is usually marked in an attempt to correct body temperature.
Below 33°C—neurological signs of dysarthria and slowness appear.
Below 31°C—hypertonicity and sluggish reflexes with cardiovascular dysfunction become l ife threatening.
Below 28°C—arterial pulses often become impalpable. Hypothermic rigidity is diff icult to distinguish from death.
Prognosis depends on the degree and duration of hypothermia.
ECG changes
Sinus bradycardia is fol lowed by atrial f lutter and fibri l lat ion with ventricular ectopics. The PR interval, QRS complex
and QT interval  are prolonged. Atrial activi ty eventually ceases. The ‘J’ wave is most often seen <31°C and
ventricular fibri l lation is common <30°C, giving way to asystole <28°C.
Complications
Hypoxaemia is common due to hypoventi lat ion and venti lation–perfusion mismatch. Hypovolaemia and metabol ic
acidosis are common. Renal tubular damage may result from renal blood flow reduction. Acute pancreatit is,
rhabdomyolysis and gastric erosions are common.
Management
Oxygen (FIO2 0.6–1.0) to maintain SaO2 >95%.1.
Fluid replacement with careful  monitoring.2.
Rewarming—Al l hypothermic patients with no evidence of other fatal disease should be assumed fully
recoverable. In the event of cardiac arrest ful l  resuscitation should continue unti l the patient is normothermic
(ventricular fibri l lation is resistant to defibri l lation between 28 and 30°C). The technique used for rewarming
depends on the core temperature (measured with a low reading rectal thermometer) and the cl inical
circumstance.
3.
Rapid central rewarming
In cases where the temperature is <28°C (<33°C with acute exposure hypothermia), or where there is cardiac arrest,
rapid rewarming may be achieved by peri toneal  dialysis, gastric or bladder lavage with warmed fluids. These
techniques may achieve rewarming rates of 1–5°C/h. Active surface rewarming with a heated blanket or warm air
blanket can achieve rates of 1–7°C/h and is less invasive. Haemodynamic changes may be dramatic during active
rewarming, requiring careful monitoring and support. If extracorporeal  rewarming is avai lable, rates of 3–15°C/h may
be achieved with the addi tion of cardiovascular support.
Spontaneous rewarming
Spontaneous rewarming proceeds at a rate inversely proportional  to the duration of hypothermia. With good
insulation (space blanket), rewarming rates of 0.1–0.7°C/h can be achieved. Core temperature may fal l  during
spontaneous rewarming as cold blood is returned from the periphery to the central  ci rculation.
Causes of hypothermia
Coma and immobil ity
Cold water immersion
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Exposure
Hypothyroidism
Hypopitui tarism
Sepsis
Erythroderma
See also:
Venti latory support—indications, p4; Endotracheal intubation, p36; Defibri l lat ion, p45; Peritoneal dialysis, p66; ECG
monitoring, p108; Basic resuscitation, p270; Cardiac arrest, p272; Fluid chal lenge, p274; Tachyarrhythmias, p316;
Bradyarrhythmias, p318; Pancreati tis, p354; Thyroid emergencies, p446; Rhabdomyolysis, p528
Pyrexia (1)
Mechanisms underlying a rise in temperature are poorly understood. It reflects the balance between heat loss and
heat production. There may be inabil ity to lose heat (e.g. high ambient temperature), ‘thermostat’ dysregulation
within the hypothalamus or increased heat generation (e.g. due to mitochondrial uncoupl ing). There is some
laboratory evidence that a raised temperature may be beneficial  in terms of white cel l response, heat shock protein
activation and mitochondrial protection. Septic patients presenting with a low temperature have a poorer prognosis.
An excessive temperature may be unpleasant to the patient (e.g. rigors), wil l  increase metabol ic rate and therefore
oxygen demand, may induce excessive vasodilatation and sal t and water loss. At very high temperatures, biochemical
function is disrupted with al tered enzyme function and increased cel l breakdown (e.g. rhabdomyolysis).
Causes
Infection
The commonest cause in the ICU patient, though over-diagnosed. Main si tes are chest and intravascular catheter
si tes. Urinary tract infections are di fficult to diagnose in the presence of a urethral catheter. Similarly, the
respiratory tract is routinely colonised with bacteria within a few days of ICU admission; differentiation between
colonising and pathogenic bacteria is difficul t. Seek malaria in patients who have visited endemic areas. Antibiotic
therapy may itself be a cause of pyrexia.
Inflammation
Inflammation unrelated to infection wil l  usually generate a pyrexic response, e.g. systemic inflammatory response
syndrome, post-cardiac surgery, post-burns, post-myocardial  infarction, vasculi tis, glomerulonephri tis, hepatit is,
acalculous cholecystitis. Other than specific therapy, e.g. immnosuppression for vasculi tis, management is general ly
symptom-orientated to include cooling.
Adverse drug reaction
Numerous drugs may induce an idiosyncratic pyrexia, including antibiotics, sedatives, paralysing agents, and
amphetamines. Usually removal of the offending drug is sufficient but more active measures may have to be taken,
including active cooling and dantrolene.
Adverse reaction to blood transfusion
This may be related to an immunological  reaction to one of the cellular consti tuents, or to contamination with an
organism, bacterial cel l products or other pyrogen.
Ambient heating
Excessive heating or prevention of heat loss may cause pyrexia. Consider strong sunl ight, excess temperature control
settings on special ised beds or mattresses, and heat-retaining bed clothing.
Miscellaneous
Other causes of pyrexia include neoplasm and post-cerebral insult (e.g. head injury, cerebrovascular accident).
Key paper
Circiumaru B, et al. A prospective study of fever in the intensive care uni t. Intensive Care Med 1999; 25:668–73.
Pyrexia (2)
At present, the optimal  temperature to target in disease states is not known, other than cerebral insults where
normo- or even hypothermia appears to offer neuroprotection by reducing cerebral metabol ic rate. In other condi tions
it seems reasonable to accept mild pyrexia provided this is tolerated by the patient.
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Principles of management
Diagnose then remove or treat the offending cause. For example, seek and treat infection, stop blood infusion
and send discontinued bag to laboratory for analysis, use anti-inflammatory ± immunosuppressive agents for
vascul itis.
1.
Cool ing aids symptomatic recovery, reduces metabolic rate and lowers pressor requirements:
Increase evaporative losses, e.g. tepid sponging, wet sheets, ice packs
Increase convective losses, e.g. fanning to improve air ci rculation
Antipyretics, e.g. paracetamol, aspirin, chlorpromazine
More aggressive cool ing i f temperature >40°C
Aim to lower temperature to <38.5°C then reassess.
2.
See also:
Bacteriology, p158; Virology, serology and assays, p160; Blood transfusion, p182; Antimicrobials, p260; Acute chest
infection (1), p288; Acute chest infection (2), p290; Abdominal sepsis, p350; Infection—diagnosis, p480;
Infection—treatment, p482; Systemic inflammation/multi -organ failure, p484; Malaria, p490; Vascul itides, p494;
Burns—general management, p512; Pyrexia (1), p518; Hyperthermia, p522; Post-operative intensive care, p534
Hyperthermia
Hyperthermia is defined as a core temperature above 41°C.
Clinical features
Del irium and seizures are associated with temperatures of 40–42°C
Coma is associated with temperatures above 42°C
Tachycardia
Tachypnoea
Salt water depletion
Rhabdomyolysis
Disseminated intravascular coagulation
Heart fai lure with ST depression and ‘T’ wave flattening
Causes
Hyperthermia may be an extreme form of pyrogen-induced fever associated with infection, inflammation,
neoplasm or cerebrovascular accident.
Heat stroke is associated with severe exercise in high environmental temperatures and humidity. There may be
excess clothing or hypovolaemia reducing the body's abi l i ty to dissipate heat production.
Malignant hyperthermia is a drug-induced myopathy associated with a hereditary calcium transfer defect in
patients receiving volati le anaesthetics, muscle relaxants, antidepressants, alcohol or Ecstasy. Heat production
is increased by muscle catabol ism, spasm and peripheral vasoconstriction.
The neuroleptic mal ignant syndrome is a drug-induced hyperthermic syndrome secondary to phenothiazines or
butyrophenones. It is associated with muscle rigidity, akinesia, impaired consciousness and autonomic
dysfunction and continues for 1–2 weeks.
Management
Rapid cool ing should be instituted when temperatures exceed 41°C.1.
Supportive treatment includes fluid replacement and seizure control.2.
Clothing should be removed and patients should be nursed in a cool environment.3.
Surface cool ing may be achieved with a fan, tepid sponging, wet sheets, ice packs or a cool bath.4.
Handling should be minimised and active cooling measures should be stopped when the core temperature is
<39°C.
5.
Internal cooling may be considered by gastric lavage or peri toneal  lavage using cooled fluids.6.
Phenothiazines may be used to reduce temperature and prevent shivering (not in neuroleptic mal ignant
syndrome).
7.
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Muscle relaxants should be used i f the patient is venti lated.8.
For mal ignant hyperthermia the offending drug should be stopped and dantrolene 1mg/kg given IV every 5min to
a maximum dose of 10mg/kg.
9.
Mechanical  venti lation with high FIO2 and treatment of hyperkalaemia are required.10.
The neuroleptic mal ignant syndrome is treated by stopping the offending drug, giving dantrolene as above, and
dopamine agonists (e.g. L-dopa or bromocriptine).
11.
See also:
Venti latory support—indications, p4; Blood pressure monitoring, p110; Coagulation monitoring, p156; Colloids, p180;
Sedatives, p238; Muscle relaxants, p240; Basic resuscitation, p270; Fluid challenge, p274; Hypotension, p312;
Agi tation/confusion, p370; Generalised seizures, p372; Metabolic acidosis, p434; Thyroid emergencies, p446;
Amphetamines including Ecstasy, p462; Pyrexia (1), p518; Pyrexia (2), p520; Rhabdomyolysis, p528; Post-operative
intensive care, p534
Electrocution
The effects of electrocution are due to the effects of the current and the conversion of electrical energy to heat
energy on passage through the t issues. Important factors are:
Energy del ivered—heat = amperage2 × resistance × time, i.e. the amperage is the most important determinant
of heat production.
Resistance to current flow–tissues are resistant to current flow in the fol lowing decreasing order: bone, fat,
tendon, skin, muscle, blood vessels, nerves. A high skin resistance and short duration of contact concentrate the
effects local ly. However, skin contaminants, moisture and burning reduce resistance.
Type of current—alternating current is more dangerous than direct current. Tetanic muscle contractions may
prevent the vict im from releasing the current source whereas the single, strong muscle contraction with direct
current often throws the victim clear. Al ternating current is more l ikely to reach central tissues with consequent
sustained apnoea and ventricular fibri l lation (with as l itt le as 50–100mA for 1–10ms).
Current pathway—cardiorespiratory arrest is more l ikely the closer the contact is with the chest and heart.
Lightening strike di ffers from contact electrocution in that high intensi ty, ultra-short duration of current may produce
cardiac arrest wi th l ittle t issue destruction.
Clinical features
Tachyarrhythmias—including ventricular tachycardia and fibri l lat ion.
Asystole—more l ikely with high current (>10A).
Myocardial  injury—heat injury, coronary artery spasm, arrhythmias, myocardial spasm.
Respiratory arrest—tetanic contraction of the diaphragm, arrhythmias, cerebral medullary dysfunction.
Trauma—tetanic muscle contraction, fal l ing or being thrown clear.
Burns—to skin and internal tissues.
Management
Most severe electrical injuries require urgent field treatment prior to hospital admission.
The first priority is to ensure that the source of the electrical  injury is not a hazard to rescuers.1.
Management of cardiorespiratory arrest.2.
Prevention of further injury, e.g. spinal protection, removal  of smouldering clothes3.
After hospi tal  admission and restoration of the ci rculation management is di rected towards the compl ications.
Maintain venti latory support.1.
Management of hypovolaemia associated with burn injury. Fluid requirements are usually greater than for
victims of thermal  burns and require close monitoring.
2.
Check cardiac enzymes for degree of myocardial injury. Treat heart fai lure and/or arrhythmias as indicated.3.
Management of rhabdomyolysis and covert compartment syndrome.4.
Surgical debridement of necrotic tissue and fixation of bony injury.5.
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See also:
Venti latory support—indications, p4; Endotracheal intubation, p36; Defibri l lat ion, p52; Cardiac function tests, p150;
Basic resuscitation, p270; Cardiac arrest, p272; Fluid challenge, p274; Tachyarrhythmias, p316; Acute coronary
syndrome (1), p320; Acute coronary syndrome (2), p322; Burns—fluid management, p510; Burns—general
management, p512; Rhabdomyolysis, p528
Near-drowning
Fol lowing near-drowning the major complications are lung injury, hypothermia and the effects of prolonged hypoxia.
Al though hypothermia bestows protective effects against organ damage, rewarming carries particular hazards.
Pathophysiology
Prolonged immersion usually results in inhalation of fluid; however, 10–20% of patients develop intense
laryngospasm leading to so-cal led ‘dry drowning’. Tradit ionally, fresh water drowning was considered to lead to rapid
absorption of water into the circulation with haemolysis, hypo-osmolali ty and possible electrolyte disturbance
whereas inhalation of hypertonic fluid from sea water drowning produced a marked flux of fluid into the alveol i.  In
practice, there seems to be l i tt le distinction between fresh and sea water as both cause loss of surfactant and severe
inflammatory disruption of the alveolar-capil lary membrane leading to an ARDS-type picture. Ini tial ly, haemodynamic
instabil ity is often minor. A simi lar picture often develops after ‘dry drowning’ and subsequent endotracheal
intubation.
Acute hypothermia often accompanies near-drowning with loss of consciousness and haemodynamic alterations.
Management
Oxygen—FIO2 0.6–1 should be given, ei ther by face mask i f the patient is spontaneously breathing, or via
mechanical  venti lation. Comatose patients should be intubated. Early CPAP or PEEP may be useful .
1.
Bronchospasm is often present and may require nebulised β2 agonists, and ei ther nebulised or SC epinephrine.2.
Fluid replacement should be di rected by appropriate monitoring. Inotrope therapy may be necessary i f
hypoperfusion persists after adequate fluid resusci tation. Intravascular fluid overload is uncommon and the role
of early diuretic therapy with a view to lowering intracranial pressure is controversial.  Haemolysis may occur
and require blood transfusion.
3.
Arrhythmias may arise secondary to myocardial  hypoxia, hypothermia and electrolyte abnormal it ies. These
should be treated conventionally.
4.
Metabol ic acidosis may be profound, but sodium bicarbonate therapy is rarely indicated as the acidosis wi l l
usually correct on restoration of adequate tissue perfusion.
5.
Electrolyte abnormali ties are usual ly minor and should be managed conventional ly.6.
Rewarming fol lows conventional practice; cardiopulmonary bypass may be considered if core temperature is
<30°C. Cardiopulmonary resusci tation including cardiac massage should be continued unti l normothermia is
achieved.
7.
Cerebral protection usually fol lows raised intracranial pressure protocols though, as mentioned above, the role of
diuretic therapy and fluid restrict ion is controversial . Signs of brain damage such as seizures may become
apparent and should be treated as they arise.
8.
Antibiotic therapy (e.g. cl indamycin, or cefuroxime plus metronidazole) should be given if strong evidence of
aspiration exists. Otherwise, take specimens and treat as indicated.
9.
Decompress the stomach using a nasogastric tube to lessen any risk of aspiration. Enteral feeding can be
ini tiated afterwards.
10.
See also:
Venti latory support—indications, p4; Endotracheal intubation, p36; Positive end expiratory pressure (1), p22; Posit ive
end expiratory pressure (2), p24; Continuous posi tive airway pressure, p26; Bronchodi lators, p186; Antiarrhythmics,
p204; Antimicrobials, p260; Acute respiratory distress syndrome (1), p292; Acute respiratory distress syndrome (2),
p294; Metabol ic acidosis, p434; Hypothermia, p516
Rhabdomyolysis
Breakdown of striated muscle which may result in compartment syndrome, acute renal fai lure and electrolyte
abnormali ties (hyperkalaemia, hypocalcaemia, hyperphosphataemia).
Causes
Trauma, especial ly crush injury
Prolonged immobi l isation, e.g. after fal l,  drug overdose
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Drugs, e.g. opiates, Ecstasy
Hyperpyrexia
Vascular occlusion (including lengthy vascular surgery)
Infection
Burns/electrocution
Congenital  myopathy (rare)
Diagnosis
Suggested by disproportionately high serum creatinine compared to urea (usual ratio is approximately
10µmol:1mmol).
Raised creatine kinase (usually >2000IU/l).
Myoglobinuria—this produces a positive urine dipstick to blood; laboratory analysis is required to confi rm
myoglobin rather than blood or haemoglobin. The urine is usually red or black but may appear clear despite
significant rhabdomyolysis.
General management
Prompt fluid resuscitation.
Hypocalcaemia should not be treated unless the patient is symptomatic; administered calcium may form crystals
with the high circulating phosphate.
Hyperkalaemia may be resistant to medical management and require urgent haemodialysis or
haemo(dia)fi l tration.
Compartment syndrome
Suspect i f l imb is tender or painful  and peripheries are cool. Loss of peripheral pulses and tense muscles are late
signs.
Manometry in muscle compartments reveal pressures >20–25mmHg.
Arm, legs and buttock compartments may be affected.
Management involves ei ther prophylactic fasciotomies i f at high risk or close monitoring (including regular
manometry) with decompression i f pressures exceed 20–25mmHg.
Fasciotomies may resul t in major blood loss.
Renal failure
Renal fai lure is thought to be produced by a combination of free radical injury, hypovolaemia, hypotension and,
possibly, myoglobin blocking the renal tubules.
Renal fai lure may be prevented by prompt rehydration and a forced alkal ine diuresis wi th 6–10l  0.9% sal ine/day
for 3–5 days, aiming to produce an equivalent amount of urine. The urinary pH should be maintained ≥6 and
blood pH <7.5 using up to 500ml/h 1.24% sodium bicarbonate solution to increase urinary excretion of
myoglobin. Furosemide and/or mannitol  may be needed to avoid fluid overload and potassium, sodium, calcium
and magnesium levels regularly monitored and managed as appropriate.
If renal fai lure is established, dialysis or fi ltration techniques wil l  be required, usual ly for a period of 6–8 weeks.
Key paper
Better OS, Stein JH. Early management of shock and prophylaxis of acute renal fai lure in traumatic rhabdomyolysis. N
Engl J Med 1990; 322:825–9
See also:
Haemo(dia)fi l tration (1), p62; Haemo(dia)fi ltration (2), p64; Peritoneal dialysis, p66; Urinalysis, p166; Sodium
bicarbonate, p178; Diuretics, p212; Oliguria, p330; Acute renal fai lure—diagnosis, p332; Acute renal
fai lure—management, p334; Poisoning—general principles, p452; Amphetamines including Ecstasy, p462; Cocaine,
p464; Multiple trauma (1), p500; Mult iple trauma (2), p502; Burns—fluid management, p510; Burns—general
management, p512; Hyperthermia, p522; Electrocution, p524
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Pain
Pain results from many insults, e.g. trauma, invasive procedures, speci fic organ disease and inflammatory processes.
Pain rel ief is necessary for physiological and psychological reasons:
Anxiety and lack of sleep.
Increased sympathetic activity contributing to an increased metabolic demand.
The capaci ty of the ci rculation and respiratory system to meet the demands of metabol ising tissues may not be
adequate.
Myocardial  ischaemia is a significant risk.
The endocrine response to injury is exaggerated with consequent sal t and water retention.
Physiological attempts to l imit pain may include immobil ity and muscle spl inting and consequent reductions in
venti latory function and cough.
Pain perception
The degree of tissue damage is related to the magnitude of the pain stimulus. The site of injury is also important;
thoracic and upper abdominal injury is more painful  than injury elsewhere. However, the perception of pain is
dependent on other factors, e.g. simultaneous sensory input, personal ity, cul tural background and previous
experiences of pain.
Management of pain
Systemic analgesia
Opioid analgesics form the mainstay of analgesic drug treatment in intensive care.
Smal l,  frequent IV doses or a continuous infusion provide the most stable blood levels. Since the degree of
analgesia is dependent on blood levels i t i s important that they are maintained.
Higher doses are required to treat rather than prevent pain.
The dose of drug required for a particular individual depends on their perception of pain and whether tolerance
has bui lt up to previous analgesic use.
The use of non-opioid drugs may avoid the need for or reduce the dose required of opioid drugs. This includes
paracetamol and non-steroidals, ketamine and α2-agonists such as clonidine and dexmedetomidine.
Regional analgesia
Regional techniques reduce respiratory depression but require experience to ensure procedures are performed
safely.
Epidural analgesia may be achieved with local anaesthetic agents or opioids.
Opioids avoid the vasodi latation and hypotension associated with local anaesthetic agents but do not produce as
profound analgesia.
The combination of opioid and local anaesthetic is synergist ic.
Intravenous opioids should be avoided or close monitoring should continue for 24h after cessation of epidural
opioids due to the potential  for late respiratory fai lure. Sample regimens are shown opposite.
Local anaesthetic agents may be used to block superficial  nerves, e.g. intercostal nerve block with 3–5ml 0.5%
bupivacaine plus adrenal ine.
Non-pharmacological techniques
Adequate explanation, posit ioning and physical techniques may all  reduce drug requirements.
Regimens for epidural analgesia
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Lumbar LA 10–15ml 0.5% bupivacaine followed by an infusion of 5–20ml/h 0.125% bupivacaine
Thoracic
LA
4–6ml 0.5% bupivacaine followed by an infusion of 6–10ml/h 0.125% bupivacaine
Opioid 5mg morphine gives up to 12h analgesia
Combined An infusion of 3–4ml/h 0.125% bupivacaine with 0.3–0.4mg/h morphine or
25–50µg/h fentanyl
See also:
Opioid analgesics, p234; Non-opioid analgesics, p236; Mult iple trauma (1), p500; Multiple trauma (2), p502; Head
injury (1), p504; Head injury (2), p506; Burns—general  management, p512; Post-operative intensive care, p534
Post-operative intensive care
Patients may be admitted to the ICU after surgery, either electively (see opposite) or after unexpected peri-operative
complications.
General care
Ensure surgical  and anaesthetic plan has been agreed, e.g. overnight venti lation, special precautions (e.g. wire
cutters i f mandible wired), movement al lowed, haemodynamic targets, etc.
Provide adequate analgesia.
Ensure adequate rewarming.
Maintain euglycaemia.
Provide appropriate thrombosis prophylaxis.
Blood gas, electrolyte and haemoglobin monitoring.
Post-operative respiratory problems
Common in those with pre-existing respiratory disease, especial ly wi th a reduced vital  capacity or peak flow rate.
Problems include:
Exacerbation of chronic chest disease
Retained secretions
Basal atelectasis
Pneumonia
Upper airway problems, e.g. laryngeal  oedema
Anaesthesia and surgery (especial ly upper abdominal  surgery) reduce functional residual capacity, thoracic
compliance and cough. There is reduced macrophage function and systemic inflammatory activation with infection and
acute lung injury as possible consequences.
Therapeutic aims
Pre-operative preparation may help avoid some of the problems:
Cessation of smoking for >1 week
Bronchodi latation
Respiratory muscle training
Chest physiotherapy
Avoidance of hypovolaemia in the ni l-by-mouth period
Post-operative clearance of secretions and maintenance of basal lung expansion are very important. These require
effective analgesia and chest physiotherapy. Consider early use of non-invasive venti lat ion if spontaneously breathing
but requiring high FIO2. Mechanical  venti lat ion assists basal  expansion and secretion clearance where anaesthetic
recovery is expected to be prolonged or where surgery ± pre-existing disease increase the risk of secretion retention
and atelectasis. Ensure a patent airway prior to extubation where intubation was difficult or after upper ai rway
surgery.
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Post-operative circulatory problems
Prevention of hypovolaemia is crucial  in avoiding inflammatory activation and, therefore, many post-operative
complications.
Haemorrhage is usually obvious and managed by resuscitation, correction of coagulation disturbance and
surgery.
Subclinical  hypovolaemia is common postoperatively. Hypothermia and high catecholamine levels help to
maintain CVP and BP despi te continuing hypovolaemia. Avoiding reduced stroke volume or metabol ic acidosis are
the best indicators of adequate resusci tation.
Post-operative fluid management requires a high degree of suspicion of hypovolaemia; fluid chal lenges with
col loid should be used to confi rm and treat hypovolaemia where there is any circulatory disturbance, metabol ic
acidosis or ol iguria.
Reasons for elective ICU admission
Airway monitoring: e.g. major oral , head and neck surgery
Respiratory monitoring: e.g. cardiothoracic surgery, upper abdominal  surgery, prolonged anaesthesia, previous
respiratory disease
Cardiovascular monitoring: e.g. cardiac surgery, vascular surgery, major abdominal surgery, prolonged
anaesthesia, previous cardiovascular disease
Neurological  monitoring: e.g. neurosurgery, cardiac surgery with circulatory arrest
Elective venti lation: e.g. cardiac surgery, major abdominal surgery, prolonged anaesthesia, previous respiratory
disease
See also:
Venti latory support—indications, p4; Endotracheal intubation, p36; Non-invasive respiratory support, p32; Chest
physiotherapy, p48; Pulse oximetry, p90; Blood gas analysis, p100; ECG monitoring, p108; Blood pressure
monitoring, p110; Central  venous catheter—use, p114; Central venous catheter—insertion, p116; Cardiac
output—thermodi lution, p122; Cardiac output—other invasive, p124; Cardiac output—non-invasive (1), p126; Cardiac
output—non-invasive (2), p128; Electrolytes
, p146; Full  blood count, p154; Coagulation monitoring, p156; Col loids, p180; Blood transfusion, p182;
Bronchodilators, p186; Respiratory stimulants, p188; Opioid analgesics, p234; Non-opioid analgesics, p236;
Sedatives, p238; Muscle relaxants, p240; Anticoagulants, p248; Coagulants and anti fibrinolytics, p254; Fluid
challenge, p274; Respiratory fai lure, p282; Atelectasis and pulmonary collapse, p284; Chronic airflow l imitation,
p286; Hypotension, p312; Ol iguria, p330; Metabolic acidosis, p434; Hypothermia, p516; Pain, p532
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Obstetric Emergencies
Pre-eclampsia and eclampsia
The hallmark of pre-eclampsia is hypertension with proteinuria. It is considered mi ld if proteinuria is 0.25–2g/l and
severe if >2g/l . Eclampsia is the same condit ion associated with seizures. They are associated with cerebral  oedema
and, in some cases, haemorrhage. A reduced plasma volume, raised peripheral  resistance and disseminated
intravascular coagulation all  impair tissue perfusion, with possible renal and hepatic fai lure. Pulmonary oedema may
occur secondary to increased peripheral resistance and low col loid osmotic pressure.
Management
Hypertensive crises and convulsions may continue for 48h post-partum, during which time close monitoring in a high
dependency or intensive care area is essential.
Circulatory management
High blood pressure is due to arteriolar vasospasm so controlled plasma volume expansion is essential as the
first l ine treatment.
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A standard fluid chal lenge regimen may be used in the intensive care area with l i ttle risk of fluid overload.
Oliguria may coexist with reduced plasma volume; controlled volume expansion is usual ly more appropriate than
diuretic therapy.
If plasma volume expansion fails to control  hypertension, anti-hypertensives such as labetalol , nifedipine or
hydralazine may be used.
Convulsions
Convulsions are best avoided by good blood pressure control.
Ini tial seizure control  may be achieved with small doses of benzodiazepines.
Magnesium sulphate is the treatment of choice for eclamptic convulsions. Magnesium levels should be monitored
and kept between 2.5–3.75mmol/l.  Above 3.75mmol/l toxici ty with possible cardiorespiratory arrest may be
seen.
Prophylactic anticonvulsant therapy with magnesium may also be considered in pre-eclampsia.
Excess sedation should be avoided due to the risk of aspiration although continued seizures may require elective
intubation, mechanical hyperventi lat ion and further anticonvulsant therapy.
Early fetal delivery
The definitive treatment for eclampsia is fetal del ivery but the needs of the fetus must be balanced against those of
the mother. If fetal maturi ty has been reached immediate delivery after control  of seizures and hyper-tension is
necessary.
Drug dosages
Labetalol Start at 2mg/min IV or quicker if a rapid response is required. Labetalol is usually
effective once 200mg has been given after which a maintenance infusion of
5–50mg/h may be continued.
Nifedipine 10mg SL is an often effective alternative, given every 20min if necessary.
Hydralazine 5–10mg by slow IV bolus, repeat after 20–30min. Alternatively, by infusion starting
at 200–300µg/min and reducing to 50–150µg/min.
Magnesium 4g over 20min followed by 1–1.5g/h by intravenous infusion until seizures have
stopped for 24h.
Key papers
Magpie Trial  Collaboration Group. Do women with pre-eclampsia, and their babies, benefi t from magnesium sulphate?
The Magpie Trial: a randomised placebo-controlled trial.  Lancet 2002; 359:1877–90
Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial.  Lancet 1995;
345:1455–63
See also:
Venti latory support—indications, p4; Blood pressure monitoring, p110; Central venous catheter—use, p114; Central
venous catheter—insertion, p116; EEG/CFM monitoring, p138; Coagulation monitoring, p156; Colloid osmotic
pressure, p172; Col loids, p180; Hypotensive agents, p202; Anticonvulsants, p242; Fluid challenge, p274;
Hypertension, p314; General ised seizures, p372
HELLP syndrome
HELLP syndrome is a pregnancy related disorder associated with haemolysis, elevated l iver function tests and low
platelets. Cri teria used for the diagnosis of HELLP are shown below.
Microangiopathic haemolysis resul ts from destruction of red cells as they pass through damaged smal l vessels.
Hepatic dysfunction is characterised by periportal  necrosis and hyal ine deposits in the sinusoids. In some cases
hepatic necrosis may proceed to hepatic haemorrhage or rupture.
Thrombocytopenia resul ts from increased platelet consumption, although prothrombin time and activated partial
thromboplastin time are normal , unlike in DIC.
Clinical features
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Epigastric or right upper quadrant pain with malaise.
Nausea and vomiting.
General ised oedema is usual  but hypertension is less common. Presentation may occur post-partum.
Criteria for diagnosis of HELLP syndrome
Haemolysis
Abnormal blood fi lm
Hyperbi l irubinaemia
LDH >600U/l
Elevated l iver enzymes
AST >70U/l
Thrombocytopenia
Platelets <100 × 109/l
Management
Priori ties for management include basic resusci tation and exclusion of hepatic haemorrhage or ruptured l iver. In
the latter case an early Caesarean section and definitive surgical  repair are urgent.
Microangiopathic haemolysis and thrombocytopenia may respond to plasma exchange and fresh frozen plasma
infusion.
Platelet transfusions should be avoided unless there is active bleeding.
See also:
Plasma exchange, p68; Liver function tests, p152; Full blood count, p154; Coagulation monitoring, p156; Blood
products, p252; Basic resusci tation, p270; Vomiting/gastric stasis, p338; Haemolysis, p404; Platelet disorders, p406
Post-partum haemorrhage
Usually due to incomplete uterine contraction after delivery, but may be due to retained products. The magnitude of
haemorrhage may be severe and l ife threatening.
Resuscitation
The principles of resuscitation are the same as those applying to any haemorrhagic condit ion. Blood transfusion
requirements may be massive and there may therefore be a need to replace coagulation factors. There may be
signi ficant retroplacental  bleeding which may lead to underestimation of blood volume loss. It is safer to manage
fluid and blood replacement with haemodynamic monitoring.
Aortic compression
Temporary reduction of haemorrhage may be achieved by compressing the aorta with a fist pushed firmly above the
umbil icus, using the pressure between the fist and vertebral column to achieve compression. This manoeuvre may
buy time whi le defini tive surgical repair is organised.
Stimulated uterine contraction
Prostaglandin F2α injected locally into the uterus or IM is an effective method of st imulating uterine contraction and
may avoid the need for surgery.
Arterial occlusion
Angiographic embolisation or internal  i l iac artery l igation may avoid the need for hysterectomy in some cases. The
disadvantages of these procedures include a significant delay in organisation and, in the latter case, the high fai lure
rate.
See also:
Blood pressure monitoring, p110; Central  venous catheter—use, p114; Central venous catheter— insertion, p116; Ful l
blood count, p154; Coagulation monitoring, p156; Blood transfusion, p182
Amniotic fluid embolus
An uncommon but dangerous compl ication of childbirth.
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There is a high early mortal ity associated with acute pulmonary hypertension.
The ini tial response of the pulmonary vasculature to the presence of amniotic f luid is intense vasospasm
result ing in severe pulmonary hypertension and hypoxaemia.
Right heart function is ini tial ly compromised severely but returns to normal with a secondary phase during which
there is severe left heart fai lure and pulmonary oedema.
Amniotic fluid contains l ipid-rich particulate material  which stimulates a systemic inflammatory reaction. In this
respect the progress of the condi tion is simi lar to other causes of mult iple organ fai lure with associated capil lary
leak and disseminated intravascular coagulation.
Diagnosis is supported by amniotic f luid and fetal cel ls in pulmonary artery blood and urine, though this finding
is not speci fic for embolus.
Management
Management is enti rely supportive. If amniotic f luid embolism occurs prior to delivery urgent Caesarean section must
be performed to prevent further embol isation.
Respiratory support
Oxygen (FIO2 0.6–1.0) must be provided. In many cases CPAP or mechanical venti lation wil l  be required.
Cardiovascular support
Standard resuscitation principles apply with control led fluid loading and inotropic support being started as required.
Haematological management
Management of the coagulopathy requires blood product therapy guided by laboratory assessment of coagulation
times. In addit ion, some cases improve after treatment with cryoprecipi tate, possible due to the effects of fibronectin
replacement.
See also:
Venti latory support—indications, p4; Continuous positive airway pressure, p26; Pulmonary artery catheter—use,
p118; Pulmonary artery catheter—insertion, p120; Fluid challenge, p274; Pulmonary embolus, p308; Heart
fai lure—assessment, p324; Heart fai lure—management, p326; Systemic inflammation/multiorgan fai lure, p484
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Death and the Dying Patient
Brain stem death
The correct diagnosis of brain stem death allows discontinuation of futi le venti lat ion and enables potential retrieval  of
organs for donation. Diagnosis of brain stem death is usually fol lowed by asystole within a few days. Before brain
stem function testing can be performed to confirm the diagnosis the patient must have an underlying diagnosis
compatible with brain stem death. They must be comatose and non-responsive for at least 6h and there should be a
minimum of 2h fol lowing a cardiac arrest. There must be no hypothermia (temperature >35°C), evidence or suspicion
of depressant drugs, signi ficant metabolic abnormality or muscle relaxant effect. The performance of brain stem
death tests should not proceed unti l  relatives and al l medical  and nursing staff involved with the patient have had a
chance to take part in discussions, al though the test itsel f does not require consent. Cessation of mechanical
venti lat ion is seen by many lay people as the final point of death. Clearly, this final step is easier if al l are aware
that i t i s to happen. If organ donation is considered, the transplant coordinator should be involved at an early stage.
Brain stem death testing
Procedures vary international ly. In the UK cl inical assessment of brain stem reflexes must be performed by 2 doctors
who have been registered for >5 years. An EEG is required in other countries.
Pupillary light reflex
Pupils should appear fixed in size and fai l to respond to a l ight st imulus.
Corneal reflexes
These should be absent bi laterally
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Pain response
There should be no cranial response to supraorbi tal pain.
Vestibulo-ocular reflexes
After confi rming that the tympanic membranes are clear and unobstructed 20ml iced water is syringed into the ear.
The eyes would normally deviate toward the opposi te direction. Absence of movement to bi lateral cold stimulation
confirms an absent reflex.
Oculo-cephalic reflexes
Also cal led ‘doll 's eye’ reflexes. With the eyelids held open, brisk lateral  rotation of the head normal ly produces
opposi te rotation of the eyebal l as if to fix the gaze on an object. This rotation is lost in brain stem death.
Gag reflex
The gag reflex is absent in brain stem death. However, the gag reflex is often lost in patients who are intubated.
Apnoea test
Whi le the reflex assessments are being performed the patient should be pre-oxygenated with 100% oxygen. The
venti lator is disconnected and 6l/min oxygen is passed into the trachea via a catheter. Apnoeic oxygenation can
sustain SaO2 for prolonged periods but there is an inevitable rise in PaCO2 which should stimulate respiratory effort.
After 3-15min of disconnection blood gas analyses are performed unti l  PaCO2 >6.7 kPa. Any respiratory effort negates
the diagnosis of brain stem death.
See also:
Blood gas analysis, p100; EEG/CFM monitoring, p138; Urea and creatinine, p144; Electrolytes
, p146; Toxicology, p162; Opioid analgesics, p234; Non-opioid analgesics, p236; Sedatives, p238; Muscle relaxants,
p240; Cardiac arrest, p272; Hypoglycaemia, p438; Hypothermia, p516; Care of the potential organ donor, p552
Withdrawal and withholding treatment
This is arguably the most difficult and stressful  decision that has to be made for the critically i l l  patient. Withdrawal
involves reduction or cessation of vasoactive drugs and/or respiratory support. In some ICUs the patient is heavily
sedated and disconnected from the venti lator. Withholding involves non-commencement or non-escalation of
treatment, e.g. applying an upper threshold dose for an inotrope and/or not starting renal  replacement therapy.
Before approaching the patient/family, there should ideal ly be a consensus among medical  and nursing staff that
quanti ty and/or quali ty of l i fe are significantly compromised and unl ikely to recover. Often, the patient's viewpoint is
very well -defined and the carers may rue the fact that the discussion was not init iated earl ier.
Ethnic, cul tural and rel igious factors wil l  influence both doctor and patient/fami ly in the timing and frequency of such
decisions. In some societies doctors have a more paternal istic approach with l ittle involvement of patient and/or
family in the decision-making process. Others are overly inclusive, sometimes to the point of excessively acquiescing
to the family's demands despite obvious futi l ity in continuing care. Clearly, a balance needs to be struck that serves
the best interests of the patient. Although potential ly awkward, the mental ly competent patient should be involved in
the most important decision affecting their l i fe. This should be done as considerately as possible, avoiding
unnecessary distress. A series of discussions over several  days may be needed, al lowing time to contemplate.
Consensus is reached with >95% of patients/famil ies by the third discussion.
It should be stressed to the patient and fami ly that care is not  being withdrawn/withheld but that pain rel ief,
comfort, hydration and general  nursing care are to be continued. Likewise, no decision is binding but can be amended
depending on the patient's progress, e.g. moving from withholding to withdrawal, or re-insti tution of ful l treatment. A
‘negotiated settlement’ is often a useful interim compromise for fami l ies unable to accept a withdrawal decision,
whereby l imitation of treatment is instituted and subsequently reviewed
Relatives can sometimes be very distraught and, occasionally, i rrational on discussing withdrawal/withholding. For
many, this wil l  be their fi rst experience of the dying process in a loved fami ly member. A number of other factors
including guil t,  anger and within-fami ly disagreements may also surface. It should be stressed that the
withdraw/withhold decision should not be left to the fami ly alone as this is an unfair burden for them to carry.
Rather, i t i s their passive agreement with a medical recommendation that is being sought. The emphasis of the
discussion is to inform them of the l ikely outcome and to seek their view of what the patient would want. They need
to be dealt with both sensi tively and honestly, and they should not feel pressured to give instant decisions.
Discussions should involve the patient's nurse and other involved carers as appropriate. It should be accurately
documented in the case notes to ensure good communication between caregivers and act as source data should
subsequent complaints surface.
See also:
Communication, p564
Ovid: Oxford Handbook of Critical Care file:///C:/Documents%20and%20Settings/MVP/Application%20Data/Mozilla/Firefox/Profiles/2...
243 из 254 07.11.2006 1:04
P.553
Care of the potential organ donor
Patients with suspected brain stem death should be considered candidates for organ donation unless there is evidence
of:
Cancer (except primary central nervous system)
HIV or hepatitis surface antigen posit ive
High risk for HIV
Uncontrol led sepsis
Significant systemic disease
Slow virus infection
The transplant co-ordinator should be contacted early (before the fami ly are approached) to confi rm l ikely suitabi l ity.
If the family are amenable, the transplant co-ordinator wi l l  then ini tiate organ donation procedures. Do not reject
those brain dead potential donors who, for example, have ful ly treated infections or acute renal fai lure without
consul tation with the transplant co-ordinator.
Management
Confirm brain stem death with appropriate testing.1.
Laboratory tests for blood group, HIV and hepati tis status and electrolytes.2.
Confirm organ donation is permissible by the coroner (or equivalent).3.
Maintain optimal cardiorespiratory status with fluid ± inotropes, optimal venti lat ion and physiotherapy. Diabetes
insipidus should be treated with DDAVP.
4.
Contact surgical and anaesthetic teams.5.
Organ suitability
Kidneys—Age 4–70, acceptable U&E and creatinine
Heart—Age 0–50, acceptable CXR and ECG
Lungs—Age 0–50, acceptable CXR and blood gases
Liver—Age 0–55, no alcohol or drug abuse, acceptable LFTs
Corneas—Age 0–100, no previous intraocular surgery
The transplant co-ordinator wi l l  advise on other organ and tissue suitabil ity, e.g. pancreas, trachea, bowel, skin.
See also:
Blood gas analysis, p100; Urea and creatinine, p144; Electrolytes
, p146; Colloids, p180; Inotropes, p196; Vasopressors, p200; Fluid chal lenge, p274; Hypotension, p312
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ICU Organisation and Management
ICU layout
The intensive care unit should be easily accessible by departments from which patients are admitted and close to
departments which share engineering services. It is desi rable that cri tical ly i l l  patients are separated from those
requiring coronary care or high dependency care where a quieter environment is often needed. It is possible to
provide intensive care and high dependency care in the same uni t so long as patients can be separated within the
uni t. However, the di ffering requirements of these patients may l imit such flexibi l ity. The floor sizes given below
represent a minimum guide.
Size
Intensive care bed requirements depend on the activity of the hospital with addit ional beds required for regional
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specialt ies such as cardiothoracic surgery or neurosurgery. Very smal l (<6 beds) or very large (>14 beds) units may
be difficul t to manage although larger uni ts may be divided operationally and allow better concentration of resources.
Patient areas
Patient areas must provide unobstructed passage around the bed with a floor space of 26m2per bed. Curtains or
screens are required for privacy.
Floors and ceil ings must be constructed to support heavy equipment (some pieces may weigh 1000kg).
Doors must al low for passage of bulky equipment as well as wide beds.
Every bed should have access to a wash hand basin.
The speci fication should include 1 cubicle per 2 beds with 26m2floor area for isolation. Ai r condit ioning should
allow for posit ive and negative pressure control  in cubicles and temperature and humidi ty control.
Services must include adequate electricity supply (at least 28 sockets per bed) with emergency back-up supply.
Oxygen (4), medical  ai r (2) and suction (2) outlets must be available for every bed.
The bed areas should have natural dayl ight and patients and staff should ideally have an outside view.
Communications systems include an adequate number of telephones to avoid all telephones being in use at once,
intercom systems to al low bed to bed communication and a system to control  entry to the department.
Computer networks should enable communication with central  hospi tal  administration and laboratory systems.
Other areas
Other areas include adequate storage space, dirty uti l ity, clean uti l i ty, offices, laboratory, seminar room, cleaners'
room, staff rest room, locker room, toi lets, relatives' area, bedroom and interview room.
ICU staffing (medical)
Intensive care has evolved from the early success in simple mechanical venti lation of the lungs of pol io victims to the
present day where patients admitted to intensive care wil l  usually have fai lure or dysfunction of one or more organ
systems requiring mechanical support and monitoring. The intensive care unit should have dedicated consultant
sessions with addi tional al location for management, teaching and audi t activi ties. These sessions should be divided
between several  intensive care special ists. In addition, the intensive care special ist should be supported by junior
doctors in training who can provide 24h per day cover on a rota which provides adequate rest.
Required skills of intensive care medical staff
Management
Senior intensive care medical  staff, assisted by senior nursing and pharmacy col leagues, command the primary
responsibi l ity for the financial  management of the intensive care uni t. It is through their actions that treatment of the
critical ly i l l  i s ini tiated and perpetuated; they are ultimately responsible for the activity of the unit and patient
outcome.
Decision making
In the ICU most decisions are ult imately made by team consensus. Cl inical decisions in the intensive care unit can be
thought of under three categories: (i) decisions relating to common or routine problems for which a unit pol icy
exists; (i i) decisions relating to uncommon problems requiring discussion with al l  ICU and non-ICU staff currently
involved and (i i i) decisions of an urgent nature taken by intensive care staff without delay.
Practical skills
Expertise in the management of complex equipment, monitoring procedures and performance of invasive procedures
are required.
Clinical experience
Medical staff require experience in the recogni tion, prevention and management of critical  i l lness, infection control,
anaesthesia and organ support.
Technical knowledge
The intensive care special ist has an important role in the choice of equipment used in the intensive care unit.
Pharmacological knowledge
Drug therapy regimens are clearly open to the problems of drug interactions and, in addit ion, pharmacokinetics are
often severely altered by the effects of major organ system dysfunction, particularly involving the l iver and kidneys.
Teaching and training
The modern intensive care special ist has acquired a number of skil ls that cannot be gained outside the intensive care
uni t. It is therefore necessary to be able to provide this education to junior doctors in training for intensive care.
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ICU staffing (nursing)
Cri tical ly i l l  patients require close nursing supervision. Many wi l l  require high-intensi ty nursing throughout a 24h
period while others are of a lower dependency and can share nurses. In addit ion to the bedside nurses, the
department needs addi tional  staff to manage the day to day operation of the unit, to assist in l i fting and handl ing of
patients, to rel ieve bedside nurses for rest periods and to collect drugs and equipment. These additional nurses (or
nurse assistants) can be termed the ‘fixed nursing establ ishment’ and the nature of their duties is such that they wil l
usually be higher grade nurses. The bedside nurses are a ‘variable establishment’ and their numbers are dependent
on activi ty such that more patients require higher numbers. Most departments fix their variable establishment by
assuming an average activity.
Fixed establishment
In the UK providing 1 nurse per shift continuously requires 5.5 nurses. In addit ion staff handover, annual leave, study
leave and sickness are usually calculated at 22% such that 1 addit ional nurse is required. Thus, the provision of 1
nurse in charge of each shi ft and 1 nurse to support the bedside nurses requires 11 nurses. In larger units there may
be a need for addit ional  support nurses.
Variable establishment
The same principles apply for the provision of bedside nurses. Thus, to provide 1:1 nursing for a bed requires 5.5
nurses and to provide 1:2 nursing requires 2.75 nurses. The total  number required depends on the occupancy and the
nurse to patient ratio for each occupied bed. One of the difficult ies in staffing an intensive care unit relates to the
variable dependency and occupancy. An average dependency weighted occupancy (average occupancy ×  average
nurse to patient ratio) should be used to set the establishment of bedside nurses with additional nurses being drafted
in from a bank or agency to cover peak demands.
Skill mix
Nursing ski l l  mix is the subject of much controversy as the need for economy is balanced against the need for quali ty.
As stated above the fixed nursing wi l l  usual ly be of higher grade since the role incorporates the administration of the
uni t and supervisory nursing. The bedside nurses wil l  be made up of those who have received post-qualif ication
training in intensive care and those who have not. The ratio of trained to untrained intensive care nurses should be of
the order of 3:1 to faci l itate in-service teaching.
Fire safety
Fires affecting the ICU are rare but are particularly di ffi cul t in that patients are not easily evacuated, yet their l ives
depend on services which fi re may disrupt. Smoke, while dangerous to staff and the less critical ly i l l  patients who
may be breathing spontaneously, is less of a problem to those on mechanical venti lation since their fresh gas supply
is from outside the affected environment. It therefore fol lows that, in the event of fire, the priority is to ensure
safety and means of escape for the staff first.
Control of smoke
Smoke and toxic gases are a common association with fire and may, in themselves, be flammable, particularly in
association with high concentrations of oxygen. The main techniques for control of smoke include containment (e.g.
fire-resist ing walls, doors and seals) and dispersal (e.g. positive pressure air conditioning), the latter being used in
patient areas. The possibi l ity of flammable or toxic fumes should be considered when equipping and furnishing the
intensive care uni t.
Escape from fire
Escape routes should be well  marked and unobstructed.
The nature of crit ical i l lness is such that not al l patients can be evacuated.
The staff should escape first by proceeding to the nearest exit away from the fi re.
Patients should be evacuated in the order of the least sick first.
Evacuation of patients should be managed by someone trained in the use of breathing apparatus; in most cases
this wil l  be the fire brigade.
If patients are to be evacuated they should be moved to a place of safety on the same floor as the intensive care
uni t. Patients should not be moved downstai rs.
In the majori ty of fires containment wil l  reduce the need for ful l evacuation.
Preventing fire
Automatic smoke or heat alarms should be provided in al l areas.
Cooking areas and laboratory areas must be separated from patient areas by fi re doors.
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Fire doors are provided to protect staff and patients and should not be wedged open.
If a closed door would compromise the care given to patients but is essential to separate fire compartments then
an electro-mechanical  device should hold the door open and be disabled by the fi re alarm.
Fire extinguishers of the appropriate types should be readily avai lable and staff should be properly trained in
their use.
Communication
Good communication is essential to the smooth running of the ICU. This includes communication between the ICU
staff,  patients, visi ting professionals and relatives.
Patient communication
Cri tical ly i l l  patients may sti l l  be able to hear conversation despite sedation or apparent unconsciousness. Bedside
discussions should take this into account and all procedures should be explained to the patient in simple terms before
starting. The patient who is not competent to consent to treatment may appreciate verbal  discussion or explanation.
Doctor–nurse communication
It is essential that the multidiscipl inary approach to intensive care involves medical and nursing staff in decision
making. Ward rounds are a forum for such interdiscipl inary communication and the consultant leading the round
should ensure that al l present are truly involved. The plan for the day can be set on the ward round but is more l ikely
to succeed i f al l involved in effecting the plan are involved in sett ing i t. Similarly, al l  changes from the plan, whether
due to unforeseen emergencies or due to fai lure of the patient to respond, should be ful ly discussed.
Communication with visiting teams
The intensive care staff should be responsible for the day to day care of crit ically i l l  patients, including coordinating
the input from various non-ICU professionals involved in the management of patients and affecting the treatment
plan. The admitting team should be involved in major decisions. Visi ting medical  staff should not see patients without
being accompanied by a member of the intensive care medical staff.
Communication with relatives
Relatives are often overwhelmed by the environment of an intensive care unit, are worried about the patient and are
easily confused by the information they are given about crit ically i l l  patients. Most communication should be face to
face, avoiding lengthy discussions on the telephone. Where several  people are imparting information, differences in
emphasis or content destroy any chance of effective communication. It is essential that the bedside nurse is present
when relatives are spoken to since there are often questions and concerns which crop up later and are directed to the
nurse; it i s worth remembering that the relatives have greater contact with the nurses and often build up a
relationship with them. Where admitting teams need to communicate with relatives about a specific aspect of the
il lness the bedside nurse and, ideally, a member of the intensive care medical  staff, should be present. Most
interviews with relatives should be away from the bedside al though it is often helpful to impart simple information at
the bedside, particularly to demonstrate particular issues. Again i t must be remembered that the patient may hear
the conversation. Whi le it is helpful to interview al l relatives together this is not always practical , ei ther because
they cannot al l  be present at once or because they do not relate to each other. Information often changes when
del ivered second hand so it is better to communicate directly with various relatives separately in these
ci rcumstances.
Medicolegal aspects
The intensive care unit is a source of many medicolegal problems. Patients are often not competent to consent to
treatment. They may be admitted fol lowing trauma, violence or poisoning, al l  of which may involve a legal process.
Admission may also fol low complications of treatment or medical  mishaps occurring elsewhere in the hospi tal . The
nature of crit ical i l lness is such that complications are common and l itigation may fol low.
Consent and agreement
Many procedures in intensive care are invasive or involve signi ficant risk. The patient is often not competent to
consent for such treatment and, in many countries, surrogate consent or assent cannot be legally given by the
next-of-kin. It is important that the risks and benefi ts of the procedure are explained to the next-of-kin and that this
discussion is documented in the case records. For major decisions, particularly those involving withdrawal  or
withholding of l i fe-prolonging treatments, the patient should ideally be involved in discussions. If not feasible,
relatives should be asked to give their view of what the patient would want in this situation.
Research presents consent problems in the critical ly i l l  and requires close ethical committee supervision.
Note-keeping
It is impossible to record everything that happens in intensive care in the patient's notes. The 24h observation chart
provides the most detailed record of what has happened but summary notes are essential. Such notes must be factual
without unsubstantiated opinions about the patient or about previous treatment. All  entries must be t imed and
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signed. Records of ward rounds must record the name of the consultant leading the round. It must be remembered
that the notes may be used later in legal proceedings. They may be used against you but, if wel l kept, wil l  usual ly
form the best defence. In the event of a medical mishap the episode should be clearly documented after witnessed
explanation to relatives.
Dealing with the police
Most police enquiries relate to patients who are admitted after suspicious ci rcumstances. While there is a duty to
patient confidential ity it may be in the patient's interests to impart information about them. This may be with the
consent of the patient or the next of kin. Wri tten statements or verbal information may be requested. Any information
given should avoid opinion and be strictly factual .
Dealing with the Coroner
The Coroner must be informed of any death where a death certif icate cannot be issued. Death certif icates can be
issued where the death is due to a natural  cause and the patient has been seen professional ly by the doctor wi thin 14
days prior to death. The table documents the condit ions requiring the Coroner to be informed. Where there is any
doubt the Coroner should be informed.
Deaths which must be informed to the Coroner
Unidentif ied body
No doctor attending within prior 14 days
Death without recovery from anaesthesia
Sudden or unexplained death
Medical  mishap
Industrial accident or disease
Violence, accident or misadventure
Suspicious circumstances
Alcoholism
Poisoning
Death in custody
Clinical governance
Clinical  governance is a framework through which healthcare organizations are accountable for continuously
improving the qual ity of their services and safeguarding high standards of care by creating an environment in which
excellence in cl inical care wil l  f lourish. For the ICU cl inical  governance requires the culture, the systems and the
support mechanisms to achieve good cl inical performance and ensuring that qual ity improvement is embedded into
the unit's routine. This includes action to ensure risks are managed, adverse effects are rapidly detected, openly
investigated and lessons learned, good practice is rapidly disseminated and systems are in place to ensure
continuous improvements in cl inical  care. There must be systems to ensure all  cl inicians have the right education,
training, skil ls and competencies to deliver the care needed by patients. There must be systems in place to recognise
and act on poor performance.
Essential components of clinical governance
Clear management arrangements
Eveyone must know who they are accountable to, the l imits of their decision making and who must be informed in the
decision making process.
Quality improvement
Through the process of cl inical audit the standard of practice is monitored and changes effected to improve quali ty.
Clinical effectiveness
Evidence based practice is essential where evidence exists to support cl inical decisions. Protocols and guidelines
standardise practice.
Risk assessment and management
A register of cl inical  risks should be kept, to which new risks are appended as they are assessed. An action plan
should be developed for managing each risk.
Staff and organisational development
Including continued professional  education, cl inical  supervision and professional  regulation.
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Patient input
Complaints monitoring should be used to learn lessons and improve practice within ICU. Patient and relative surveys
can be used to adapt qual ity init iat ives to the needs of patients.
See also:
Audit, p570
Audit
Audit has become an essential part of medical  practice. The main purpose is to improve quali ty of care which, in the
intensive care uni t, must involve al l members of the multidiscipl inary team. Change in practice in one discipl ine wil l
inevitably have a knock-on effect in others. Audi t may involve a review of activity, performance against
predetermined indicators or cost-effectiveness. Audit may focus on specific topics or may encompass the performance
of several intensive care units. Successful audit requires commitment from senior staff to ensure practice is defined,
data are col lected and change is effected where necessary. Where change is suggested by audit a further review is
required to ensure that such change has occurred.
Data collection
Ideally, a basic data set should be common to al l  intensive care units nationally to al low meaningful comparisons to
be made. This requires the data set to be detailed enough to answer questions posed but not so detai led that
col lection becomes unsustainable. Resources must be provided in terms of computer databases and staff to col lect
and analyse data. Those collecting the data should be provided with regular summary reviews to ensure that
enthusiasm continues, and qual ity control  is maintained. Methods of data entry should consider the time involved and
the fact that most of those col lecting data are not keyboard experts. Typographical mistakes destroy the value of
col lected data such that error trapping and data validation must form part of the housekeeping in any database used.
Some audi t topics require data collection that is not part of the basic data set. Collecting appropriate data requires
clari ty in setting the question to be answered and care in choosing data i tems that wil l  truly answer the question.
Audit meetings
Regular audi t meetings should fol low a predefined t imetable. This helps to ensure maximum staff attendance and also
sets target dates for data col lection and analysis. Audi t meetings should be chaired and have defined aims.
Discussion of the topic being audited must lead to recommended changes in practice and these must be fol lowed
through after the meeting. It is clear that al l  staff cannot attend all  meetings. Dissemination of information prior to
implementing proposed changes is necessary to stand some chance of carrying them through.
See also:
Clinical  governance, p568
ICU scoring systems
Various ICU scoring systems have evolved to provide:
An index of disease severity, e.g. APACHE, SAPS.
An index of workload and consumption of resources, e.g. TISS.
A means of comparison for
(i) Audit ing performance—either in the same ICU or between ICUs.
(i i ) Research, e.g. evaluation of new products or treatment regimens.
Patient management objectives, e.g. sedation, pressure area care.
Other than the Glasgow Coma Score, there is no universal system practised by every ICU. Whi le APACHE is the
predominant system used in the USA and UK for scoring disease severity, SAPS is more popular in mainland Europe.
Interpretation of the same system can also be highly variable.
TISS (Therapeutic Intervention Scoring System)
This system attaches a score to procedures and techniques performed on an individual  patient (e.g. use and
number of vasoactive drug infusions, renal replacement therapy, administration of enteral nutrit ion).
It has been used by some ICUs to develop a means of costing individual patients by attaching a monetary value
to each TISS point scored.
It is also used as an index of workload activi ty.
A discharge TISS score can be used to estimate the amount of nursing interventions required for a patient in
step-down faci l i ties (e.g. a high dependency unit) or on the general  ward.
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TISS does not accurately measure nursing workload activity as i t fai ls to cater for tasks and duties such as
coping with the irritable or confused patient, deal ing with grieving relatives, etc.
Glasgow Coma Scale
First described by Teasdale and Jennett in 1974, it uti l ises eye opening, best motor response and best verbal
response to categorise neurological  status. It is the only system used universal ly in ICUs, though l imitations exist in
mechanically venti lated, sedated patients. It can be used for prognostication and is also frequently used for
therapeutic decision making, e.g. elective venti lation in patients presenting with a GCS <8.
Sedation
A variety of systems gauge and record the level of sedation in a mechanically venti lated patient. This assists the
staff to titrate the dose of sedative agents to avoid either over- or under-sedation. The forerunner developed in 1974
was the Ramsay Sedation Score which consists of a 6-point scoring system separated into 3 awake and 3 asleep
levels where the patient responds to a tap or loud audi tory stimulus with either brisk, sluggish or no response at all .
The main problem l ies in achieving reproducibi l ity of the tap or loud audi tory stimulus. We currently use an 8-point
system developed in-house.
Glasgow Coma Scale
Score Eyes open Best motor response Best verbal response
6 — obeys commands —
5 — localises pain orientated
4 spontaneously flexion withdrawal confused
3 to speech decerebrate flexion inappropriate words
2 to pain decerebrate extension incomprehensible sounds
1 never no response silent
UCLH Sedation Score
3 Agitated and restless
2 Awake and uncomfortable
1 Aware but calm
0 Roused by voice, remains calm
-1 Roused by movement
-2 Roused by noxious or painful stimuli
-3 Unrousable
A Natural sleep
ICU scoring systems—APACHE II
APACHE (Acute Physiology And Chronic Health Evaluation)
Devised by Knaus et al , this system uti l ises a point score derived from the degree of abnormal ity of readi ly
obtainable physiological  and laboratory variables in the first 24h of ICU admission, plus extra points for age and
chronic i l l  health.
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The summated score provides a measure of severi ty whi le the percentage risk of subsequent death can be
computed from speci fic coefficients applied to a wide range of admission disorders (excluding burns and cardiac
surgery).
APACHE I, fi rst described in 1981, uti l ised 34 physiological and biochemical  variables.
A simplif ied version (APACHE II) uti l i sing just 12 variables was published in 1985 and extensively validated in a
number of countries.
A further refinement published in 1990, APACHE III, claims to improve upon the statist ical predictive power by
adding five new physiological variables (albumin, bi l i rubin, glucose, urea, urine output).
Changing thresholds and weighting of existing variables.
Comparing both admission and 24h scores.
Incorporating the admission source (e.g. ward, operating theatre).
Reassessing effects of age, chronic heal th and speci fic disease category. Wide acceptance of APACHE III may be
limited as i ts risk strati fication system is proprietary and has to be purchased.
Key paper
Knaus WA, et al.  APACHE II: a severity of disease classification system. Cri t Care Med 1985; 13:818–29
Acute physiology score
 +4 +3 +2 +1 0 +1 +2
Core temperature
(°C)
≥41 39–40.9  38.2–38.9 36–38.4 34–35.9 32–33.9 3
Mean BP (mmHg) ≥160 130–159 110–129  70–109  50–69  
Heart rate (/min) ≥180 140–179 110–139  70–109  55–69 4
Respiratoryrate
(/min)
≥50 35–49  25–34 12–24 10–11 6–9  
If
FIO2≥0.5:A-aDO2
(mmHg)
≥500 350–499 200–349 <200     
If FIO2<0.5:PO2
(mmHg)
   >70  61–70  5
Arterial pH ≥7.7 7.6–7.69  7.5–7.59 7.33–7.49  7.25–7.32 7
Serum
Na+(mmol/l)
≥180 160–179 155–159 150–154 130–149
 
120–129 1
Serum
K+(mmol/l)
≥7 6–6.9
 
5.5–5.9 3.5–5.4 3–3.4 2.5–2.9
 
Serum creatinine (µmol/l)NB double points score if acute renal failure
 ≥300 171–299 121–170  50–120  <50  
Haematocrit (%) ≥60  50–59.9 46–49.9 30–45.9  20–29.9  
Leukocytes
(/mm3)
≥40
 
20–39.9 15–19.9 3–14.9
 
1–2.9
 
Neurological points= 15 - Glasgow coma score
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Age points:
Years ≤44 45–54 55–64 65–74 ≥75
Points 0 2 3 5 6
Chronic health points
2 points for elective post-operative admission or 5 points i f emergency operation or non-operative admission, i f
patient has either:
Biopsy proven cirrhosis, portal hypertension or previous hepatic fai lure
Chronic heart fai lure (NYHA Grade 4),
Chronic hypoxia, hypercapnia, severe exercise l imitation, 2° polycythaemia or pulmonary hypertension
Dialysis-dependent renal  disease
Immunosuppression by disease or drugs
ICU scoring systems—SAPS II
Has a simi lar role to APACHE II, but more widely uti l i sed in mainland Europe, the Simplif ied Acute Physiology
Score (SAPS) was devised by LeGall  et al  in 1984 (SAPS I) and modified by the same group in 1993 (SAPS II). A
SAPS III score is in development.
As for APACHE II, burns and cardiac surgical  patients are excluded from analysis.
The original  version used 14 readily measured cl inical and biochemical variables while the updated version, SAPS
II, comprises 12 physiology variables, age, type of admission (medical , scheduled or unscheduled surgical) and
three underlying disease variables.
A point score is based on the degree and prognostic importance of derangement of these variables in the fi rst
24h fol lowing ICU admission. The point scoring was assigned fol lowing logistic regression model l ing of data
obtained from 8369 patients in 137 adult ICUs in both Europe and North America and validated in a further 4628
patients.
The claimed advantage of this system is that i t estimates the risk of death without having to specify a primary
diagnosis.
Key paper
Le Gal l JR, et al. A new Simpli fied Acute Physiology Score (SAPS II) based on a European/North American
multicenter study. JAMA 1993;270: 2957–63
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Point score in brackets
Age <40 (0); 40–59 (7); 60–69 (12); 70–74 (15); 75–79
(16);≥80 (18)
Heart rate (bpm) <40 (11); 40–69 (2); 70–119 (0); 120–159 (4);≥160 (7)
Systolic BP (mmHg) <70 (13); 70–99 (5); 100–199 (0); ≥200 (2)
Body temp (°C) <39 (0); ≥39 (3)
PaO2/FIO2 (kPa) only if ventilated or
on CPAP
<13.3 (11); 13.3–26.5 (9); ≥26.6 (6)
Urine output (l/day) <0.5 (11); 0.5–0.999 (4); ≥1 (0)
Serum urea (mmol/l) <10 (0); 10–29.9 (6); ≥30 (10)
White cell count (/mm3) <1 (12); 1–19.9 (0); ≥20 (3)
Serum K+ (mmol/l) <3 (3); 3–4.9 (0); ≥5 (3)
Serum Na+ (mmol/l) <125 (5); 125–144 (0); ≥145 (1)
Serum HCO3- (mmol/l) <15 (6); 15–19 (3); ≥20 (0)
Serum bilirubin (µmol/l) <68.4 (0); 68.4–102.5 (4); ≥102.6 (9)
Glasgow Coma Score <6 (26); 6–8 (13); 9–10 (7); 11–13 (5); 14–15 (0)
Chronic disease metastatic cancer (9), haematological malignancy (10),
AIDS (17)
Type of admission scheduled surgical (0); medical (6); unscheduledsurgical
(8)
ICU scoring systems—SOFA
A l imitation of the APACHE and SAPS scoring systems is that they were designed and val idated on data obtained
during the first 24 hours of intensive care admission. Various systems have been developed to enable daily scoring
(e.g. Sequential Organ Failure Assessment (SOFA), Riyadh Intensive Care Program (RIP) score, Mult iple Organ
Dysfunction Score, etc.) to al low a better assessment of change in the patient's condit ion.
As the physiological  and biochemical status of the patient is determined in part by the disease severity, but also by
the degree of medical  intervention, these sequential scoring systems incorporate the use of various therapies and
procedures.
The SOFA system was init ial ly designed to improve patient characterisation for mult icentre drug trials in sepsis
(SOFA ini tial ly stood for Sepsis Organ Failure Assessment) but has subsequently been appl ied to intensive care
patients in general, wi th ‘Sequential ’  being substituted for ‘Sepsis’.
Al though it has not been validated in the sense that a point score denoting severity of dysfunction in one organ
system does not translate directly to an equivalent severity in another organ, i t has been used successfully to
prognosticate and to fol low changes in patient status throughout their intensive care stay.
Point score in brackets
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 0 1 2 3 4
Respiratory
PaO2:FIO2 ratio
(mmHg)
>400 ≤400 ≤300 ≤200* <100*
Renal Creatinine
(mg/dl) or Urine
output (ml/d)
<1.2 1.2–1.9 2.0–3.4 3.5–4.9 or
<500ml/d
≥5.0 or
<200ml/d
Hepatic Bilirubin
(mg/dl)
<1.2 1.2–1.9 2.0–5.9 6.0–11.9 ≥12.0
Cardiovascular
Mean arterial
pressure (mmHg)
No
hypo-tension
MAP
>70
Dopamine≤5
or
dobutamine
(any dose)†
Dopamine>5 or
epinephrine≤0.1
epinephrine≤0.1†
Dopamine>15 or
epinephrine>0.1
epinephrine>0.1†
Haematological
Platelet
count(×103/mm3)
>150 ≤150 ≤100 ≤50 ≤20
Neurological
Glasgow Coma
Score
15 13–14 10–12 6–9 <6
*With ventilatory support
†Adrenergic agents administered for at least 1 h (doses in µg/kg/min)
Conversion factors:
PaO2:FIO2 to KPa: divide by 7.5
Creatinine to µmol/l: multiply by 88
Bil irubin to µmol/l: multiply by 17.1
Key paper
Moreno R, Vincent JL, Matos R, et al. The use of maximum SOFA score to quantify organ dysfunction/fai lure in
intensive care. Resul ts of a prospective, mult icentre study. Working Group on Sepsis related Problems of the
ESICM. Intensive Care Med 1999; 25:686-96
ICU scoring systems—trauma
Scoring systems have been developed in trauma for:
Rapid field triage to di rect the patient to appropriate levels of care
Qual ity assurance
Developing and improving trauma care systems by categorising patients and identifying problems within the
systems
Making comparisons between groups from different hospitals, in the same hospital over time, and/or undergoing
different treatments
The Injury Severity Score (ISS) is a severity scoring system patients based on the anatomical  injuries sustained. The
Revised Trauma Score (RTS) uti l ises measures of physiological abnormality to predict survival. A combination of ISS
and RTS—TRISS—was developed to overcome the shortcomings of anatomical  or physiological  scoring alone. The
TRISS methodology uses ISS, RTS, patient age and whether the injury was blunt or penetrating to provide a measure
of the probabil ity of survival .
Injury Severity Score
Use AIS90 (Abbreviated Injury Score 1990) dictionary to score injury1.
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Identi fy highest abbreviated injury scale score for each of the fol lowing:
Head and neck
Abdomen and pelvic contents
Bony pelvis and l imbs
Face
Chest
Body surface
2.
Add together the squares of the three highest area scores.3.
Revised trauma score
 Measure Coded value × = Score weighting
Respiratory rate (breaths/min) 10–29 4
>29 3
6–9 2 0.2908
1–5 1
0 0
Systolic blood pressure (mmHg) >89 4
76–89 3
50–75 2 0.7326
1–49 1
0 0
Glasgow Coma Score 13–15 4
9–12 3
6–8 2 0.9368
4–5 1
3 0
 Total = revised trauma score
